text
stringlengths 46
525k
| url
stringlengths 24
420
| crawl_date
timestamp[us, tz=UTC]date 2022-04-01 00:01:42
2022-09-25 07:27:13
| id
stringlengths 24
420
| label
bool 2
classes |
|---|---|---|---|---|
WASHINGTON — Does the country need a national law guaranteeing the right to gay marriage? Some in Congress say yes, and a vote could happen in the Senate as early as this week.
Senator Chuck Schumer (D-NY), who leads Democrats in the Senate, has promised a vote soon.
HISTORY OF GAY MARRIAGE
After centuries of laws banning the practice, the last two decades have seen gay rights expand greatly across the United States.
In 2004, San Francisco started issuing marriage licenses in the city.
That same year, Massachusetts became the first state to offer them.
In 2012, President Barack Obama became the first president to endorse gay marriage.
In 2015, the Supreme Court made it a constitutional right and the law across the United States.
Since then, thousands of Americans have celebrated their love in ceremonies around the country.
RECENT ABORTION RULING
However, the recent abortion ruling at the Supreme Court has some on Capitol Hill wondering if gay rights could be the next to change.
The reasoning? One sentence by Justice Clarence Thomas on page 119 of the opinion document.
In Thomas' concurring opinion, he wrote, " [...] we should reconsider all of this court's substantive due process precedents, including Griswold, Lawrence, and Obergefell."
Obergefell is the landmark case that legalized gay marriage.
Justice Thomas' issue appears to be the same one he had with abortion, believing state lawmakers should decide who can marry, not lawyers in a courtroom.
UNCERTAINTY ACROSS STATES
If, for some reason, gay marriage would ever be overturned by the high court, it could mean uncertainty across the country, similar to abortion rights.
Poynter, a non-profit committed to investigative journalism, reports gay marriage would be illegal in 25 to 32 states if the Supreme Court overturned Obergefell.
SENATE TO TAKE ACTION
The Senate could move as early as this week to protect gay marriage. The Respect for Marriage Act would require the federal government to recognize any marriage if it was valid in the state where it was performed.
It would also repeal the federal law that gave states the authority not to recognize same-sex marriages.
The bill already passed the House of Representatives this summer.
47 Republicans joined every Democrat to pass it.
In the Senate, 60 votes will be needed.
Currently, at least three Republican senators, including Senator Rob Portman of Ohio, have signaled support, telling reporters they are close to getting 10 Republicans to join 50 democrats.
But don't expect unanimous approval.
Some conservatives clarified this issue to the states and that Democratic leaders are simply trying to create an unnecessary political debate weeks before an election.
|
https://www.kxxv.com/news/national-politics/heres-why-a-historic-vote-on-same-sex-marriage-is-expected-in-congress-soon
| 2022-09-12T11:20:51Z
|
https://www.kxxv.com/news/national-politics/heres-why-a-historic-vote-on-same-sex-marriage-is-expected-in-congress-soon
| false
|
CORAL GABLES, Fla., Sept. 12, 2022 /PRNewswire/ -- MasTec, Inc. (NYSE: MTZ) (the "Company") today announced its amendment of the terms of its private exchange offer to certain Eligible Holders (as defined herein) (the "Exchange Offer") for any and all outstanding 6.625% Senior Notes due August 15, 2029 (the "IEA Existing Notes") issued by IEA Energy Services LLC (the "IEA Issuer"), a subsidiary of Infrastructure and Energy Alternatives, Inc. ("IEA"), for up to an aggregate principal amount of $300,000,000 of new 6.625% MasTec Senior Notes due August 15, 2029 issued by the Company (the "MTZ Exchange Notes"). The Company has amended the Exchange Offer to extend (i) the Consent Deadline, (ii) the Early Tender Date and (iii) the Expiration Date (each as defined herein). Except as otherwise described in this press release, the terms and conditions of the Exchange Offer set forth in the Offering Memorandum (as defined herein) remain unchanged.
The Exchange Offer and Consent Solicitation are being conducted in connection with, and are conditioned upon the completion of, the previously announced merger in which IEA would become a wholly owned subsidiary of the Company (the "Merger"), which is currently expected to close in October 2022, subject to customary closing conditions, regulatory approvals and approval by the stockholders of IEA.
As part of the Exchange Offer, the Company is soliciting consents (the "Consent Solicitation") with respect to the IEA Existing Notes, to eliminate or modify certain of the covenants, restrictive provisions and events of default (the "Proposed Amendments") in the indenture, dated as of August 17, 2021, governing the IEA Existing Notes. The Proposed Amendments require the valid consent of the holders of not less than a majority in principal amount of IEA Existing Notes, excluding IEA Existing Notes held by certain affiliated holders of IEA (the "Requisite Consents").
The Company has amended the Early Tender Date to be 5:00 p.m., New York City time, on September 23, 2022 (such date and time, as the same may be further extended, the "Early Tender Date"). In addition, the Company has amended the Consent Deadline to be the earlier of (i) 5:00 p.m., New York City time, on September 23, 2022 and (ii) 5:00 p.m., New York City time, on the date the Requisite Consents are obtained (such date and time, as the same may be further extended, the "Consent Deadline"). The Company has also extended the date on which the Exchange Offer and Consent Solicitation will expire to 5:00 p.m., New York City time, on October 14, 2022 (such date and time, as the same may be further extended, the "Expiration Date").
As of 5:00 p.m. New York City time, on September 9, 2022, holders of approximately 25.8% of the outstanding aggregate principal amount of the IEA Existing Notes have validly tendered and not validly withdrawn their IEA Existing Notes.
Subject to applicable law, the Company expressly reserves the right, in its sole discretion, to amend the Exchange Offer and Consent Solicitation in any respect, including to (i) extend the Early Tender Date without extending the Consent Deadline, (ii) extend the Consent Deadline or (iii) provide that the Early Tender Premium (as defined in the Offering Memorandum) will be payable only to Eligible Holders who validly tender and do not validly withdraw IEA Existing Notes at or prior to the Consent Deadline.
At any time before the Expiration Date, if the Company receives the Requisite Consents, the IEA Issuer has agreed that the IEA Issuer, IEA and the trustee of the IEA Existing Notes will execute and deliver a supplemental indenture relating to the Proposed Amendments, which will be effective upon execution on the date the Requisite Consents are obtained but will only become operative upon the settlement date of the Exchange Offer. An Eligible Holder that validly tenders (and does not validly withdraw) its IEA Existing Notes and validly delivers a consent prior to the Consent Deadline, but validly withdraws such IEA Existing Notes after the Consent Deadline but prior to the Expiration Date, will receive the Consent Payment (as defined in the Offering Memorandum), even if such Eligible Holder is no longer the beneficial owner of such IEA Existing Notes at the Expiration Date, but will not receive the Early Tender Premium or the Exchange Consideration (as defined in the Offering Memorandum).
The Company, at its option, may complete the Exchange Offer even if the Requisite Consents are not received. Any amendment or waiver of the terms of or conditions with respect to the Exchange Offer by the Company will automatically amend or waive such terms or conditions with respect to the Consent Solicitation unless expressly stated otherwise.
The Exchange Offer and Consent Solicitation are being made pursuant to the terms and subject to the conditions set forth in the offering memorandum, dated August 8, 2022, as amended by the Offering Memorandum Supplement, dated August 22, 2022 (as so amended, the "Offering Memorandum"), as such terms and conditions are amended by this press release, and are conditioned upon the closing of the Merger, which condition may not be waived by the Company, and certain other conditions that may be waived by the Company. The Exchange Offer and Consent Solicitation will expire on the Expiration Date, unless extended or terminated.
Tenders of IEA Existing Notes may be validly withdrawn by Eligible Holders at any time prior to the Expiration Date; however, a valid withdrawal of tendered IEA Existing Notes before the Expiration Date will not be deemed a valid revocation of the related consent delivered by such Eligible Holder, and such consent will continue to be deemed delivered. Any consents to the Proposed Amendments delivered prior to the Consent Deadline (including any consents delivered prior to the date hereof) may not be revoked.
Documents relating to the Exchange Offer and Consent Solicitation will only be distributed to persons who certify that they are (a) a "Qualified Institutional Buyer," as that term is defined in Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), or (b) a person that is not a U.S. person (as defined in Regulation S under the Securities Act) (such persons, "Eligible Holders"). The complete terms and conditions of the Exchange Offer and Consent Solicitation are described in the Offering Memorandum, copies of which may be obtained by contacting D.F. King & Co., Inc., the exchange agent and information agent in connection with the Exchange Offer and Consent Solicitation, by telephone at (800) 549-6864 (U.S. toll-free) or (212) 269-5550 (banks and brokers), or by email at mastec@dfking.com. The eligibility certification may be completed at www.dfking.com/mastec or is also available by contacting D.F. King & Co., Inc. using the information above.
The MTZ Exchange Notes have not been, and will not be, registered with the Securities and Exchange Commission (the "SEC") under the Securities Act, or any state or foreign securities laws. The MTZ Exchange Notes may not be offered or sold in the United States or to any U.S. person except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.
This press release is provided for informational purposes only and does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders or consents with respect to, any security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation or sale would be unlawful. The Exchange Offer and Consent Solicitation are being made solely pursuant to the Offering Memorandum and only to such persons and in such jurisdictions as are permitted under applicable law.
MasTec is a leading infrastructure construction company operating mainly throughout North America across a range of industries. MasTec's primary activities include the engineering, building, installation, maintenance and upgrade of communications, energy, utility and other infrastructure, such as: power delivery services, including transmission and distribution, wireless, wireline/fiber and customer fulfillment activities; power generation, primarily from clean energy and renewable sources; pipeline infrastructure, including natural gas pipeline and distribution infrastructure; heavy civil; and industrial infrastructure. MasTec's customers are primarily in these industries. The information contained on the Company's website is not incorporated into this press release.
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, the anticipated results and execution of the Exchange Offer and Consent Solicitation and the actions that the Company may take with respect thereto; statements relating to expectations regarding the future financial and operational performance of the Company or IEA; the projected impact and benefits of IEA on the Company's operating or financial results; expectations regarding the Company's or IEA's business or financial outlook; expectations regarding the Company's plans, strategies and opportunities; expectations regarding opportunities, technological developments, competitive positioning, future economic conditions and other trends in particular markets or industries; the potential strategic benefits and synergies expected from the acquisition of IEA; the development of and opportunities with respect to future projects, including renewable and other projects designed to support transition to a carbon-neutral economy; the Company's ability to successfully integrate the operations of IEA; the expected closing of, and financing sources for, the acquisition of IEA; the impact of inflation on the Company's costs and the ability to recover increased costs, as well as other statements reflecting expectations, intentions, assumptions or beliefs about future events and other statements that do not relate strictly to historical or current facts. These statements are based on currently available operating, financial, economic and other information, and are subject to a number of significant risks and uncertainties. A variety of factors in addition to those mentioned above, many of which are beyond our control, could cause actual future results to differ materially from those projected in the forward-looking statements. Other factors that might cause such a difference include, but are not limited to: risks related to completed or potential acquisitions, including the acquisition of Henkels & McCoy Group, Inc., as well as the ability to identify suitable acquisition or strategic investment opportunities, to integrate acquired businesses within expected timeframes and to achieve the revenue, cost savings and earnings levels from such acquisitions at or above the levels projected, including the risk of potential asset impairment charges and write-downs of goodwill; risks related to timely completion, or completion at all, of the Exchange Offer; risks related to the Company's ability to obtain consents under the Consent Solicitation; risks that conditions to the closing of the proposed transaction are not satisfied or waived at all or on the anticipated timeline; risks related to the impact of inflation on costs as well as economic activity, customer demand and interest rates, risks related to adverse effects of health epidemics and pandemics or other outbreaks of communicable diseases, such as the COVID-19 pandemic, including its effect on supply chain or inflationary issues, as well as, the potential effects of related health mandates and recommendations; market conditions, technological developments, regulatory or policy changes, including permitting processes and tax incentives that affect us or our customers' industries; the effect of federal, local, state, foreign or tax legislation and other regulations affecting the industries we serve and related projects and expenditures; the effect on demand for our services of changes in the amount of capital expenditures by our customers due to, among other things, economic conditions, including potential adverse effects of public health issues, such as the COVID-19 pandemic on economic activity generally, the availability and cost of financing, and customer consolidation in the industries we serve; activity in the industries we serve and the impact on our customers' expenditure levels caused by fluctuations in commodity prices, including for oil, natural gas, electricity and other energy sources; our ability to manage projects effectively and in accordance with our estimates, as well as our ability to accurately estimate the costs associated with our fixed price and other contracts, including any material changes in estimates for completion of projects and estimates of the recoverability of change orders; the timing and extent of fluctuations in operational, geographic and weather factors affecting our customers, projects and the industries in which we operate; the highly competitive nature of our industry and the ability of our customers, including our largest customers, to terminate or reduce the amount of work, or in some cases, the prices paid for services, on short or no notice under our contracts, and/or customer disputes related to our performance of services and the resolution of unapproved change orders; our dependence on a limited number of customers and our ability to replace non-recurring projects with new projects; the effect of state and federal regulatory initiatives, including costs of compliance with existing and potential future safety and environmental requirements, including with respect to climate change; risks associated with potential environmental issues and other hazards from our operations; disputes with, or failures of, our subcontractors to deliver agreed-upon supplies or services in a timely fashion, and the risk of being required to pay our subcontractors even if our customers do not pay us; risks related to our strategic arrangements, including our equity investments; any exposure resulting from system or information technology interruptions or data security breaches; any material changes in estimates for legal costs or case settlements or adverse determinations on any claim, lawsuit or proceeding; the adequacy of our insurance, legal and other reserves; the outcome of our plans for future operations, growth and services, including business development efforts, backlog, acquisitions and dispositions; our ability to maintain a workforce based upon current and anticipated workloads; our ability to attract and retain qualified personnel, key management and skilled employees, including from acquired businesses, and our ability to enforce any noncompetition agreements; fluctuations in fuel, maintenance, materials, labor and other costs; risks associated with volatility of our stock price or any dilution or stock price volatility that shareholders may experience in connection with shares we may issue as consideration for earn-out obligations or as purchase consideration in connection with past or future acquisitions, or as a result of other stock issuances; restrictions imposed by our credit facility, senior notes and any future loans or securities; our ability to obtain performance and surety bonds; risks related to our operations that employ a unionized workforce, including labor availability, productivity and relations, as well as risks associated with multiemployer union pension plans, including underfunding and withdrawal liabilities; risks associated with operating in or expanding into additional international markets, including risks from fluctuations in foreign currencies, foreign labor and general business conditions and risks from failure to comply with laws applicable to our foreign activities and/or governmental policy uncertainty; as well as a small number of our existing shareholders have the ability to influence major corporate decisions. We believe these forward-looking statements are reasonable; however, you should not place undue reliance on any forward-looking statements, which are based on current expectations. Furthermore, forward-looking statements speak only as of the date they are made. If any of these risks or uncertainties materialize, or if any of our underlying assumptions are incorrect, our actual results may differ significantly from the results that we express in, or imply by, any of our forward-looking statements. We do not undertake any obligation to publicly update or revise these forward-looking statements after the date of this press release to reflect future events or circumstances, except as required by applicable law. We qualify any and all of our forward-looking statements by these cautionary factors.
In connection with the Merger, the Company has filed a Registration Statement on Form S-4, which was declared effective by the SEC on September 8, 2022, and a prospectus pursuant to Rule 424(b)(3) with respect to the shares of its common stock to be issued in the Merger. Such prospectus also includes a definitive proxy statement of IEA with respect to the Merger.
INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.
These materials and other documents filed with the SEC may be obtained free of charge at the SEC's website, www.sec.gov. Copies of documents filed with the SEC by the Company may be obtained free of charge at MasTec's website at MasTec.com or (305) 406-1815. Copies of documents filed with the SEC by IEA may be obtained free of charge on IEA's website at iea.net or (765) 828-2653.
View original content:
SOURCE MasTec, Inc.
|
https://www.dakotanewsnow.com/prnewswire/2022/09/12/mastec-inc-announces-amendment-exchange-offer-consent-solicitation/
| 2022-09-12T11:25:12Z
|
https://www.dakotanewsnow.com/prnewswire/2022/09/12/mastec-inc-announces-amendment-exchange-offer-consent-solicitation/
| false
|
TEL AVIV, Israel, Sept. 12, 2022 /PRNewswire/ -- SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-Government, IoT, and Cybersecurity sectors, today announced that President and CEO Ordan Trabelsi will present a corporate overview at the three-day H.C. Wainwright Annual Global Investment Conference. The conference is a hybrid conference being held both virtually and in New York City on September 12-14, 2022.
SuperCom's CEO will host one-on-one and virtual meetings on September 12 and 13th. The Company's presentation will be available beginning at 7:00 a.m. ET on September 12, 2022. Investors who would like to listen to the Company's presentation or participate in a one-on-one with SuperCom's management, please register on the following link www.hcwevents.com/annualconference. The presentation will also be posted on SuperCom's website www.supercom.com
About SuperCom
Since 1988, SuperCom has been a global provider of traditional and digital identity solutions, providing advanced safety, identification, and security solutions to governments and organizations, both private and public, worldwide. Through its proprietary e-Government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has inspired governments and national agencies to design and issue secure Multi-ID documents and robust digital identity solutions to its citizens and visitors. SuperCom offers a unique all-in-one field-proven RFID & mobile technology and product suite, accompanied by advanced complementary services for various industries, including healthcare and homecare, security and safety, community public safety, law enforcement, electronic monitoring, livestock monitoring, and building and access automation. For more information, please visit SuperCom's website, www.supercom.com
Logo - https://mma.prnewswire.com/media/1717536/SuperCom_Logo.jpg
SuperCom Investor Relations:
ir@supercom.com
Kirin Smith
PCG Advisory
ksmith@pcgadvisory.com
View original content:
SOURCE SuperCom Ltd.
|
https://www.dakotanewsnow.com/prnewswire/2022/09/12/supercom-participate-hc-wainwright-annual-global-investment-conference/
| 2022-09-12T11:26:43Z
|
https://www.dakotanewsnow.com/prnewswire/2022/09/12/supercom-participate-hc-wainwright-annual-global-investment-conference/
| true
|
WA Seattle WA Zone Forecast for Sunday, September 11, 2022
_____
114 FPUS56 KSEW 120953
ZFPSEW
Zone Forecast Product for Washington
National Weather Service Seattle WA
253 AM PDT Mon Sep 12 2022
Spot temperatures and probabilities of measurable precipitation
are for .TONIGHT THROUGH TODAY..., Tuesday, Tuesday night, and
Wednesday.
WAZ558-122300-
Seattle and Vicinity-
Including the cities of Seattle, Shoreline, Federal Way, and Kent
253 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy then becoming partly sunny in the late
morning and early afternoon then becoming sunny. A slight chance
of showers. Highs in the mid 70s. South wind to 10 mph becoming
southwest in the afternoon.
.TONIGHT...Mostly clear in the evening then becoming mostly
cloudy. Lows in the upper 50s. Southwest wind around 10 mph
becoming south to 10 mph after midnight.
.TUESDAY...Mostly cloudy. A slight chance of showers in the
afternoon. Highs in the upper 60s. Light wind.
.TUESDAY NIGHT...Mostly cloudy. A slight chance of showers in the
evening. Lows in the mid 50s. Light wind becoming north to 10 mph
after midnight.
.WEDNESDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs in the upper 60s. Light wind.
.WEDNESDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows in the mid 50s.
.THURSDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs around 70.
.THURSDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows in the lower 50s.
.FRIDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs around 70.
.FRIDAY NIGHT...Mostly cloudy. Lows in the lower 50s.
.SATURDAY...Mostly cloudy with a slight chance of showers. Highs
around 70.
.SATURDAY NIGHT...Mostly cloudy. A slight chance of showers in
the evening, then a chance of showers after midnight. Lows in the
mid 50s.
.SUNDAY...Mostly cloudy in the morning then becoming partly
sunny. A chance of showers. Highs in the upper 60s.
TEMPERATURE / PRECIPITATION
Seattle 75 57 69 / 20 10 20
$$
WAZ559-122300-
Bremerton and Vicinity-
Including the cities of Bremerton and Silverdale
253 AM PDT Mon Sep 12 2022
.TODAY...Haze in the morning. Partly sunny with a slight chance
of showers in the morning, then sunny in the afternoon. Highs in
the lower 70s. Southwest wind to 10 mph becoming south in the
afternoon.
.TONIGHT...Mostly clear in the evening then becoming mostly
cloudy. Lows in the mid 50s. Southwest wind to 10 mph becoming
south after midnight.
.TUESDAY...Mostly cloudy in the morning, then partly sunny with a
slight chance of showers in the afternoon. Highs in the upper
60s. Light wind becoming south to 10 mph in the afternoon.
.TUESDAY NIGHT...Mostly cloudy in the evening then becoming
partly cloudy. Lows in the lower 50s. Northeast wind to 10 mph
becoming north after midnight.
.WEDNESDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs in the upper 60s. Light wind.
.WEDNESDAY NIGHT...Partly cloudy. Lows in the lower 50s.
.THURSDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs around 70.
.THURSDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows in the lower 50s.
.FRIDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs around 70.
.FRIDAY NIGHT...Mostly cloudy. Lows in the lower 50s.
.SATURDAY...Mostly cloudy in the morning then becoming partly
sunny. A slight chance of showers. Highs around 70.
.SATURDAY NIGHT...Mostly cloudy. A slight chance of showers in
the evening, then a chance of showers after midnight. Lows in the
lower 50s.
.SUNDAY...Mostly cloudy in the morning then becoming partly
sunny. A chance of showers. Highs around 70.
TEMPERATURE / PRECIPITATION
Bremerton 76 53 70 / 20 10 10
$$
WAZ507-122300-
Everett and Vicinity-
Including the cities of Everett, Edmonds, Lynnwood, Marysville,
and Arlington
253 AM PDT Mon Sep 12 2022
.TODAY...Mostly sunny. A slight chance of showers in the morning.
Haze in the morning. Highs in the mid 70s. Southeast wind to
10 mph becoming southwest in the afternoon.
.TONIGHT...Partly cloudy in the evening then becoming mostly
cloudy. Lows in the mid 50s. West wind to 10 mph becoming north
after midnight.
.TUESDAY...Mostly cloudy. A slight chance of showers in the
afternoon. Highs in the upper 60s. Light wind becoming west to
10 mph in the afternoon.
.TUESDAY NIGHT...Partly cloudy. A slight chance of showers in the
evening. Lows in the lower 50s. Northwest wind to 10 mph in the
evening becoming light and variable.
.WEDNESDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs in the upper 60s. Light wind.
.WEDNESDAY NIGHT...Partly cloudy. Lows in the lower 50s.
.THURSDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs around 70.
.THURSDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows in the lower 50s.
.FRIDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs around 70.
.FRIDAY NIGHT...Mostly cloudy. Lows in the lower 50s.
.SATURDAY...Mostly cloudy with a slight chance of showers. Highs
around 70.
.SATURDAY NIGHT...Mostly cloudy with a slight chance of showers.
Lows in the lower 50s.
.SUNDAY...Mostly cloudy in the morning then becoming partly
sunny. A chance of showers. Highs around 70.
TEMPERATURE / PRECIPITATION
Edmonds 73 57 67 / 20 10 20
Everett 74 56 68 / 20 10 20
$$
WAZ509-122300-
Tacoma Area-
Including the cities of Tacoma, Lakewood, Puyallup, and Sumner
253 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy in the morning then becoming mostly sunny.
A slight chance of showers. Highs in the mid 70s. Southwest wind
to 10 mph becoming west in the afternoon.
.TONIGHT...Partly cloudy in the evening then becoming mostly
cloudy. Lows in the mid 50s. West wind around 10 mph becoming
south to 10 mph with gusts to 20 mph after midnight.
.TUESDAY...Mostly cloudy. A slight chance of showers in the
afternoon. Highs in the upper 60s. Light wind.
.TUESDAY NIGHT...Mostly cloudy. Lows in the lower 50s. Light
wind.
.WEDNESDAY...Mostly cloudy in the morning then becoming mostly
sunny. Highs in the lower 70s. Light wind.
.WEDNESDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows in the lower 50s.
.THURSDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs around 70.
.THURSDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows in the lower 50s.
.FRIDAY...Partly sunny. Highs around 70.
.FRIDAY NIGHT...Mostly cloudy. Lows in the lower 50s.
.SATURDAY...Mostly cloudy with a slight chance of showers. Highs
around 70.
.SATURDAY NIGHT...Mostly cloudy. A slight chance of showers in
the evening, then a chance of showers after midnight. Lows in the
lower 50s.
.SUNDAY...Mostly cloudy in the morning then becoming partly
sunny. A chance of showers. Highs in the upper 60s.
TEMPERATURE / PRECIPITATION
Puyallup 77 57 70 / 30 10 10
Tacoma 75 56 69 / 30 10 10
$$
WAZ556-122300-
Bellevue and Vicinity-
Including the cities of Bellevue, Kirkland, Redmond, and Issaquah
253 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy in the morning then becoming mostly sunny.
Haze in the morning. A slight chance of showers. Highs in the
upper 70s. South wind to 10 mph in the morning becoming light and
variable.
.TONIGHT...Partly cloudy in the evening then becoming mostly
cloudy. Lows in the upper 50s. Light wind becoming east to 10 mph
after midnight.
.TUESDAY...Cloudy. A slight chance of showers in the afternoon.
Highs around 70. Light wind.
.TUESDAY NIGHT...Mostly cloudy. A slight chance of showers in the
evening. Lows in the mid 50s. Light wind.
.WEDNESDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs in the lower 70s. Light wind.
.WEDNESDAY NIGHT...Partly cloudy. Lows in the mid 50s.
.THURSDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs in the lower 70s.
.THURSDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows in the lower 50s.
.FRIDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs in the lower 70s.
.FRIDAY NIGHT...Mostly cloudy. Lows in the lower 50s.
.SATURDAY...Mostly cloudy with a slight chance of showers. Highs
around 70.
.SATURDAY NIGHT...Mostly cloudy with a slight chance of showers.
Lows in the mid 50s.
.SUNDAY...Mostly cloudy with a chance of showers. Highs around
70.
TEMPERATURE / PRECIPITATION
Bellevue 77 58 70 / 30 10 20
$$
WAZ555-122300-
East Puget Sound Lowlands-
Including the cities of Gold Bar, Enumclaw, North Bend,
and Buckley
253 AM PDT Mon Sep 12 2022
.TODAY...Haze in the morning. Mostly cloudy with a chance of
showers in the morning, then mostly sunny with a slight chance of
showers in the afternoon. Highs in the upper 70s. South wind to
10 mph in the morning becoming light and variable.
.TONIGHT...Partly cloudy in the evening then becoming mostly
cloudy. Lows in the mid 50s. West wind to 10 mph becoming north
after midnight.
.TUESDAY...Cloudy. A slight chance of showers in the afternoon.
Highs in the upper 60s. Light wind becoming west to 10 mph in the
afternoon.
.TUESDAY NIGHT...Mostly cloudy. A slight chance of showers in the
evening. Lows in the lower 50s. Light wind.
.WEDNESDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs in the lower 70s. Light wind.
.WEDNESDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows in the lower 50s.
.THURSDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs in the lower 70s.
.THURSDAY NIGHT...Mostly cloudy. Lows in the lower 50s.
.FRIDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs around 70.
.FRIDAY NIGHT...Mostly cloudy. Lows around 50.
.SATURDAY...Mostly cloudy with a slight chance of showers. Highs
around 70.
.SATURDAY NIGHT...Mostly cloudy with a slight chance of showers.
Lows in the lower 50s.
.SUNDAY...Mostly cloudy with a chance of showers. Highs in the
upper 60s.
TEMPERATURE / PRECIPITATION
Gold Bar 79 56 69 / 30 10 30
Enumclaw 75 53 66 / 30 10 20
North Bend 80 54 71 / 30 10 20
$$
WAZ503-122300-
Western Whatcom County-
Including the cities of Bellingham, Blaine, and Lynden
253 AM PDT Mon Sep 12 2022
.TODAY...Haze in the morning. Mostly sunny. Highs in the lower
70s. South wind 10 to 15 mph becoming southwest in the afternoon.
.TONIGHT...Partly cloudy. Lows in the mid 50s. Southwest wind
10 to 15 mph becoming southeast 10 to 20 mph after midnight.
.TUESDAY...Partly sunny. A slight chance of showers in the
afternoon. Highs in the upper 60s. South wind 10 to 20 mph
becoming southwest to 10 mph in the afternoon.
.TUESDAY NIGHT...Partly cloudy. A slight chance of showers in the
evening. Lows in the lower 50s. South wind 10 to 15 mph becoming
southeast after midnight.
.WEDNESDAY...Partly sunny. Highs in the upper 60s. Light wind.
.WEDNESDAY NIGHT...Mostly clear in the evening then becoming
partly cloudy. Lows in the lower 50s.
.THURSDAY...Partly sunny. Highs around 70.
.THURSDAY NIGHT...Partly cloudy. Lows in the lower 50s.
.FRIDAY...Partly sunny. A slight chance of showers in the
morning. Highs around 70.
.FRIDAY NIGHT...Partly cloudy in the evening then becoming mostly
cloudy. Lows in the lower 50s.
.SATURDAY...Partly sunny with a slight chance of showers. Highs
around 70.
.SATURDAY NIGHT...Mostly cloudy. A slight chance of showers in
the evening, then a chance of showers after midnight. Lows in the
lower 50s.
.SUNDAY...Partly sunny with a chance of showers. Highs around 70.
TEMPERATURE / PRECIPITATION
Bellingham 71 55 69 / 10 10 10
Sumas 77 54 72 / 10 10 20
$$
WAZ506-122300-
Western Skagit County-
Including the cities of Mount Vernon, Anacortes, Sedro-Woolley,
and Burlington
253 AM PDT Mon Sep 12 2022
.TODAY...Haze in the morning. Mostly sunny. Highs around 70.
South wind to 10 mph becoming southwest around 10 mph in the
afternoon.
.TONIGHT...Mostly clear in the evening then becoming partly
cloudy. Lows in the lower 50s. West wind 10 to 15 mph becoming
southeast after midnight.
.TUESDAY...Mostly cloudy in the morning, then partly sunny with a
slight chance of showers in the afternoon. Highs in the upper
60s. South wind to 10 mph becoming west in the afternoon.
.TUESDAY NIGHT...Partly cloudy. A slight chance of showers in the
evening. Lows in the lower 50s. Southwest wind 10 to 15 mph
becoming southeast after midnight.
.WEDNESDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs in the upper 60s. Light wind.
.WEDNESDAY NIGHT...Mostly clear in the evening then becoming
partly cloudy. Lows in the lower 50s.
.THURSDAY...Partly sunny. Highs around 70.
.THURSDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows in the lower 50s.
.FRIDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs around 70.
.FRIDAY NIGHT...Mostly cloudy. Lows around 50.
.SATURDAY...Mostly cloudy with a slight chance of showers. Highs
around 70.
.SATURDAY NIGHT...Mostly cloudy with a slight chance of showers.
Lows in the lower 50s.
.SUNDAY...Mostly cloudy in the morning then becoming partly
sunny. A chance of showers. Highs around 70.
TEMPERATURE / PRECIPITATION
Anacortes 71 53 69 / 20 10 20
Mount Vernon 75 55 70 / 20 10 10
$$
WAZ001-122300-
San Juan County-
Including the cities of Friday Harbor, Eastsound,
and Roche Harbor
253 AM PDT Mon Sep 12 2022
.TODAY...Haze in the morning. Mostly sunny. Highs around 70.
South wind to 10 mph.
.TONIGHT...Mostly clear. Lows in the lower 50s. South wind 10 to
15 mph becoming west after midnight.
.TUESDAY...Mostly sunny. A slight chance of showers in the
afternoon. Highs in the upper 60s. Southwest wind to 10 mph
becoming south in the afternoon.
.TUESDAY NIGHT...Partly cloudy. Lows in the lower 50s. South wind
10 to 15 mph becoming southwest after midnight.
.WEDNESDAY...Mostly sunny. Highs in the upper 60s. Light wind.
.WEDNESDAY NIGHT...Mostly clear in the evening then becoming
partly cloudy. Lows in the lower 50s.
.THURSDAY...Mostly sunny. Highs in the upper 60s.
.THURSDAY NIGHT...Partly cloudy. Lows around 50.
.FRIDAY...Partly sunny with a slight chance of showers. Highs in
the upper 60s.
.FRIDAY NIGHT...Partly cloudy in the evening, then mostly cloudy
with a slight chance of showers after midnight. Lows around 50.
.SATURDAY...Partly sunny. A slight chance of showers in the
morning, then a chance of showers in the afternoon. Highs in the
upper 60s.
.SATURDAY NIGHT...Mostly cloudy with a chance of showers. Lows
around 50.
.SUNDAY...Partly sunny with a chance of showers. Highs in the
upper 60s.
TEMPERATURE / PRECIPITATION
Friday Harbor 71 49 70 / 20 10 20
Eastsound 68 55 66 / 20 10 20
$$
WAZ510-122300-
Admiralty Inlet Area-
Including the cities of Port Townsend and Port Ludlow
253 AM PDT Mon Sep 12 2022
.TODAY...Mostly sunny. A slight chance of showers in the morning.
Haze in the morning. Highs around 70. West wind to 10 mph.
.TONIGHT...Mostly clear in the evening then becoming mostly
cloudy. Lows in the lower 50s. West wind 10 to 15 mph.
.TUESDAY...Mostly cloudy in the morning, then partly sunny with a
slight chance of showers in the afternoon. Highs in the upper
60s. South wind to 10 mph becoming west in the afternoon.
.TUESDAY NIGHT...Partly cloudy. Lows in the lower 50s. West wind
to 10 mph increasing to 10 to 15 mph with gusts to 20 mph after
midnight.
.WEDNESDAY...Mostly cloudy in the morning then becoming mostly
sunny. Highs in the upper 60s. Light wind.
.WEDNESDAY NIGHT...Mostly clear in the evening then becoming
partly cloudy. Lows around 50.
.THURSDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs in the upper 60s.
.THURSDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows around 50.
.FRIDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs in the upper 60s.
.FRIDAY NIGHT...Mostly cloudy. Lows around 50.
.SATURDAY...Mostly cloudy in the morning then becoming partly
sunny. A slight chance of showers. Highs in the mid 60s.
.SATURDAY NIGHT...Mostly cloudy. A slight chance of showers in
the evening, then a chance of showers after midnight. Lows around
50.
.SUNDAY...Mostly cloudy in the morning then becoming partly
sunny. A chance of showers. Highs in the mid 60s.
TEMPERATURE / PRECIPITATION
Oak Harbor 65 52 64 / 20 10 10
Port Townsend 68 50 66 / 20 10 10
$$
WAZ511-122300-
Hood Canal Area-
Including the cities of Hoodsport and Brinnon
253 AM PDT Mon Sep 12 2022
.TODAY...Partly sunny in the morning then becoming sunny. Haze in
the morning. Highs in the lower 70s. Southwest wind to 10 mph
increasing to 10 to 15 mph in the afternoon.
.TONIGHT...Mostly clear in the evening then becoming mostly
cloudy. Lows in the mid 50s. Southwest wind 10 to 15 mph becoming
west after midnight. Gusts to 25 mph.
.TUESDAY...Mostly cloudy in the morning, then partly sunny with a
slight chance of showers in the afternoon. Highs in the upper
60s. Northwest wind to 10 mph becoming southwest in the
afternoon.
.TUESDAY NIGHT...Mostly cloudy in the evening then becoming
partly cloudy. Lows in the lower 50s. East wind to 10 mph
becoming west with gusts to 20 mph after midnight.
.WEDNESDAY...Partly sunny. Highs around 70. Light wind.
.WEDNESDAY NIGHT...Partly cloudy. Lows around 50.
.THURSDAY...Partly sunny. Highs around 70.
.THURSDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows around 50.
.FRIDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs around 70.
.FRIDAY NIGHT...Mostly cloudy. Lows around 50.
.SATURDAY...Mostly cloudy in the morning then becoming partly
sunny. A slight chance of showers. Highs around 70.
.SATURDAY NIGHT...Mostly cloudy with a chance of showers. Lows
around 50.
.SUNDAY...Mostly cloudy in the morning then becoming partly
sunny. A chance of showers. Highs around 70.
TEMPERATURE / PRECIPITATION
Shelton 75 52 71 / 20 10 10
$$
WAZ504-122300-
Southwest Interior-
Including the cities of Olympia, Lacey, Tumwater, Centralia,
and Toledo
253 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy with a slight chance of showers in the
morning, then mostly sunny in the afternoon. Highs in the mid
70s. South wind to 10 mph becoming west in the afternoon.
.TONIGHT...Partly cloudy in the evening then becoming mostly
cloudy. Lows in the mid 50s. West wind 10 to 15 mph becoming
south with gusts to 20 mph after midnight.
.TUESDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs in the lower 70s. Light wind becoming west to 10 mph
in the afternoon.
.TUESDAY NIGHT...Mostly cloudy in the evening then becoming
partly cloudy. Lows in the lower 50s. West wind to 10 mph
becoming south after midnight, Gusts to 20 mph after midnight.
.WEDNESDAY...Mostly sunny. Highs in the mid 70s. Light wind.
.WEDNESDAY NIGHT...Partly cloudy. Lows around 50.
.THURSDAY...Partly sunny. Highs in the lower 70s.
.THURSDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows around 50.
.FRIDAY...Partly sunny. Highs in the lower 70s.
.FRIDAY NIGHT...Mostly cloudy. Lows around 50.
.SATURDAY...Mostly cloudy with a slight chance of showers. Highs
around 70.
.SATURDAY NIGHT...Mostly cloudy. A slight chance of showers in
the evening, then a chance of showers after midnight. Lows in the
lower 50s.
.SUNDAY...Mostly cloudy in the morning then becoming partly
sunny. A chance of showers. Highs around 70.
TEMPERATURE / PRECIPITATION
Chehalis 77 54 71 / 30 10
Olympia 77 52 71 / 30 10
$$
WAZ512-122300-
Lower Chehalis Valley Area-
Including the city of Montesano
253 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy in the morning then becoming mostly sunny.
Highs in the lower 70s. West wind to 10 mph.
.TONIGHT...Partly cloudy in the evening then becoming mostly
cloudy. Lows in the lower 50s. West wind to 10 mph. Gusts to
20 mph after midnight.
.TUESDAY...Mostly cloudy in the morning then becoming partly
sunny. Highs in the upper 60s. Light wind becoming west to 10 mph
in the afternoon.
.TUESDAY NIGHT...Mostly cloudy. Lows in the lower 50s. West wind
to 10 mph becoming southwest with gusts to 20 mph after midnight.
.WEDNESDAY...Partly sunny. Highs around 70. Light wind.
.WEDNESDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows around 50.
.THURSDAY...Partly sunny. Highs around 70.
.THURSDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows around 50.
.FRIDAY...Partly sunny. Highs around 70.
.FRIDAY NIGHT...Mostly cloudy. A slight chance of showers after
midnight. Lows around 50.
.SATURDAY...Partly sunny in the morning then becoming mostly
cloudy. A slight chance of showers. Highs around 70.
.SATURDAY NIGHT...Mostly cloudy with a chance of showers. Lows
around 50.
.SUNDAY...Mostly cloudy in the morning then becoming partly
sunny. A chance of showers. Highs around 70.
$$
WAZ514-122300-
Eastern Strait of Juan de Fuca-
Including the cities of Sequim and Port Angeles
253 AM PDT Mon Sep 12 2022
.TODAY...Mostly sunny. Highs in the upper 60s. Wind variable to
10 mph.
.TONIGHT...Mostly clear in the evening then becoming partly
cloudy. Lows in the lower 50s. West wind 10 to 15 mph with gusts
to 20 mph.
.TUESDAY...Partly sunny. Highs in the mid 60s. Wind variable to
10 mph.
.TUESDAY NIGHT...Partly cloudy. Lows in the upper 40s. Wind
variable to 10 mph. Gusts to 20 mph after midnight.
.WEDNESDAY...Mostly sunny. Highs in the upper 60s. Light wind.
.WEDNESDAY NIGHT...Partly cloudy. Lows around 50.
.THURSDAY...Partly sunny. Highs in the mid 60s.
.THURSDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows around 50.
.FRIDAY...Partly sunny. Highs in the mid 60s.
.FRIDAY NIGHT...Mostly cloudy. Lows around 50.
.SATURDAY...Partly sunny with a slight chance of showers. Highs
in the mid 60s.
.SATURDAY NIGHT...Mostly cloudy. A slight chance of showers in
the evening, then a chance of showers after midnight. Lows around
50.
.SUNDAY...Partly sunny with a chance of showers. Highs in the mid
60s.
TEMPERATURE / PRECIPITATION
Port Angeles 68 51 65 / 20 10 10
Sequim 70 50 67 / 20 10 10
$$
WAZ515-122300-
Western Strait of Juan De Fuca-
Including the cities of Joyce and Clallam Bay
253 AM PDT Mon Sep 12 2022
.TODAY...Mostly sunny. Highs in the mid 60s. Wind variable to
10 mph becoming northwest 10 to 15 mph in the afternoon.
.TONIGHT...Partly cloudy in the evening then becoming mostly
cloudy. Lows around 50. West wind 10 to 15 mph with gusts to
25 mph.
.TUESDAY...Partly sunny. Highs in the lower 60s. Light wind
becoming variable to 10 mph in the afternoon.
.TUESDAY NIGHT...Partly cloudy. Lows in the upper 40s. Wind
variable to 10 mph. Gusts to 20 mph after midnight.
.WEDNESDAY...Mostly sunny. Highs in the lower 60s. Light wind
becoming variable to 10 mph in the afternoon.
.WEDNESDAY NIGHT...Partly cloudy. Lows around 50.
.THURSDAY...Partly sunny. Highs in the lower 60s.
.THURSDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows around 50.
.FRIDAY...Partly sunny. Highs in the lower 60s.
.FRIDAY NIGHT...Mostly cloudy. Lows around 50.
.SATURDAY...Partly sunny with a slight chance of showers. Highs
in the lower 60s.
.SATURDAY NIGHT...Mostly cloudy with a chance of showers. Lows
around 50.
.SUNDAY...Partly sunny with a chance of showers. Highs in the
lower 60s.
TEMPERATURE / PRECIPITATION
Sekiu 64 51 62 / 20 10 20
$$
WAZ517-122300-
Central Coast-
Including the cities of Hoquiam, Aberdeen, Westport,
and Ocean Shores
253 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy until late afternoon then becoming mostly
sunny. Highs in the upper 60s. Southeast wind to 10 mph becoming
southwest around 10 mph in the afternoon.
.TONIGHT...Mostly cloudy. Lows in the mid 50s. Southwest wind
around 10 mph becoming southeast to 10 mph after midnight.
.TUESDAY...Mostly cloudy. A slight chance of showers in the
afternoon. Highs in the mid 60s. Light wind.
.TUESDAY NIGHT...Mostly cloudy. Lows in the lower 50s. West wind
to 10 mph.
.WEDNESDAY...Partly sunny. Highs in the mid 60s. Light wind
becoming west to 10 mph in the afternoon.
.WEDNESDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows around 50.
.THURSDAY...Partly sunny. Highs in the mid 60s.
.THURSDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows around 50.
.FRIDAY...Partly sunny. Highs in the mid 60s.
.FRIDAY NIGHT...Mostly cloudy. A slight chance of showers after
midnight. Lows around 50.
.SATURDAY...Partly sunny in the morning then becoming mostly
cloudy. A slight chance of showers. Highs in the mid 60s.
.SATURDAY NIGHT...Mostly cloudy with a chance of showers. Lows in
the lower 50s.
.SUNDAY...Partly sunny with a chance of showers. Highs in the mid
60s.
TEMPERATURE / PRECIPITATION
Hoquiam 65 56 64 / 20 10 20
$$
WAZ516-122300-
North Coast-
Including the cities of Neah Bay, La Push, and Forks
253 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy in the morning then becoming partly sunny.
Highs in the mid 60s. Southeast wind to 10 mph becoming southwest
in the afternoon.
.TONIGHT...Mostly cloudy. Lows in the lower 50s. Southwest wind
to 10 mph becoming southeast with gusts to 20 mph after midnight.
.TUESDAY...Mostly cloudy in the morning, then partly sunny with a
slight chance of showers in the afternoon. Highs in the mid 60s.
Light wind becoming west to 10 mph in the afternoon.
.TUESDAY NIGHT...Mostly cloudy. Lows in the lower 50s. West wind
to 10 mph becoming northeast after midnight.
.WEDNESDAY...Mostly sunny. Highs in the mid 60s. Light wind
becoming west to 10 mph in the afternoon.
.WEDNESDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Lows around 50.
.THURSDAY...Partly sunny. Highs in the mid 60s.
.THURSDAY NIGHT...Mostly cloudy. Lows around 50.
.FRIDAY...Partly sunny. Highs in the mid 60s.
.FRIDAY NIGHT...Mostly cloudy. Lows around 50.
.SATURDAY...Partly sunny with a slight chance of showers in the
morning, then mostly cloudy with a chance of showers in the
afternoon. Highs in the mid 60s.
.SATURDAY NIGHT...Mostly cloudy with a chance of showers. Lows in
the lower 50s.
.SUNDAY...Partly sunny. A chance of showers in the morning, then
a slight chance of showers in the afternoon. Highs in the mid
60s.
TEMPERATURE / PRECIPITATION
Forks 68 52 67 / 20 10 10
$$
WAZ513-122300-
Olympics-
253 AM PDT Mon Sep 12 2022
.TODAY...Haze in the morning. Sunny. Freezing level near
12500 feet.
.TONIGHT...Partly cloudy. Freezing level near 11500 feet.
.TUESDAY...Partly sunny. A slight chance of showers in the
afternoon. Snow level near 8500 feet.
.TUESDAY NIGHT...Mostly cloudy in the evening then becoming
partly cloudy. Freezing level near 11500 feet.
.WEDNESDAY...Mostly sunny. Freezing level near 11500 feet.
.WEDNESDAY NIGHT...Partly cloudy. Freezing level near 11500 feet.
.THURSDAY...Mostly sunny. Freezing level near 11000 feet.
.THURSDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Freezing level near 11000 feet.
.FRIDAY...Partly sunny. A slight chance of showers in the
afternoon. Snow level near 7000 feet.
.FRIDAY NIGHT...Mostly cloudy. A slight chance of showers after
midnight. Snow level near 7500 feet.
.SATURDAY...A slight chance of snow showers in the morning.
Partly sunny with a slight chance of showers. Snow level near
7500 feet.
.SATURDAY NIGHT...Mostly cloudy with a chance of showers. Snow
level near 8000 feet.
.SUNDAY...Partly sunny with a chance of showers. Snow level near
8000 feet.
TEMPERATURE / PRECIPITATION
Hurricane Ridge 62 46 53 / 20 10 10
$$
WAZ567-122300-
Cascades of Whatcom and Skagit Counties-
Including the cities of Marblemount and Concrete
253 AM PDT Mon Sep 12 2022
.TODAY...Partly sunny. Haze and areas of smoke in the morning. A
slight chance of showers in the morning, then a chance of showers
in the afternoon. Snow level near 11500 feet.
.TONIGHT...Partly cloudy with a slight chance of showers. Snow
level near 10500 feet.
.TUESDAY...Partly sunny. A slight chance of showers in the
morning, then a chance of showers in the afternoon. Snow level
near 9500 feet.
.TUESDAY NIGHT...Mostly cloudy. A chance of showers, snow showers
and a slight chance of thunderstorms in the evening, then a
slight chance of showers after midnight. Snow level near
9000 feet.
.WEDNESDAY...Mostly cloudy in the morning then becoming partly
sunny. A slight chance of showers. Snow level near 9000 feet.
.WEDNESDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Freezing level near 11000 feet.
.THURSDAY...Partly sunny. Freezing level near 11000 feet.
.THURSDAY NIGHT...Mostly cloudy. Freezing level near 11000 feet.
.FRIDAY...Partly sunny with a slight chance of showers. Snow
level near 8000 feet.
.FRIDAY NIGHT...Mostly cloudy with a slight chance of showers. A
slight chance of snow showers after midnight. Snow level near
8000 feet.
.SATURDAY...Partly sunny with a slight chance of showers. A
slight chance of snow showers in the morning, then a chance of
snow showers in the afternoon. Snow level near 8000 feet.
.SATURDAY NIGHT...Mostly cloudy with a chance of snow showers. A
slight chance of showers in the evening, then a chance of showers
after midnight. Snow level near 8500 feet.
.SUNDAY...Partly sunny with a chance of showers. Snow level near
8500 feet.
TEMPERATURE / PRECIPITATION
Mount Baker 67 50 57 / 20 20 30
$$
WAZ568-122300-
Cascades of Snohomish and King Counties-
Including the cities of Snoqualmie Pass, Darrington, and Index
253 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy in the morning then becoming partly sunny.
Haze and areas of smoke in the morning. A chance of showers. Snow
level near 11500 feet. Afternoon pass temperatures in the lower
70s. Light wind in the passes becoming west around 10 mph in the
afternoon.
.TONIGHT...Partly cloudy in the evening then becoming mostly
cloudy. A slight chance of showers. Snow level near 10000 feet.
Northwest wind in the passes around 10 mph in the evening
becoming light and variable.
.TUESDAY...Mostly cloudy. A slight chance of showers in the
morning, then a chance of showers and snow showers in the
afternoon. Snow level near 9500 feet. Afternoon pass temperatures
in the lower 60s. Light wind in the passes becoming west around
10 mph in the afternoon.
.TUESDAY NIGHT...Mostly cloudy with a slight chance of showers. A
chance of snow showers in the evening, then a slight chance of
snow showers after midnight. Snow level near 8500 feet. Light
wind in the passes. Gusts to 20 mph after midnight.
.WEDNESDAY...Mostly cloudy in the morning then becoming partly
sunny. A slight chance of showers. A slight chance of snow
showers in the afternoon. Snow level near 9000 feet. Afternoon
pass temperatures in the lower 60s. Light wind in the passes.
.WEDNESDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Freezing level near 11500 feet.
.THURSDAY...Partly sunny. Freezing level near 11000 feet.
.THURSDAY NIGHT...Mostly cloudy. Freezing level near 11500 feet.
.FRIDAY...Partly sunny. Freezing level near 10000 feet.
.FRIDAY NIGHT...Mostly cloudy. A slight chance of showers after
midnight. Snow level near 8000 feet.
.SATURDAY...Mostly cloudy in the morning then becoming partly
sunny. A slight chance of showers. Snow level near 8000 feet.
.SATURDAY NIGHT...Mostly cloudy with a slight chance of showers.
Snow level near 8000 feet.
.SUNDAY...Mostly cloudy with a slight chance of showers in the
morning, then partly sunny with a chance of showers in the
afternoon. Snow level near 8000 feet.
TEMPERATURE / PRECIPITATION
Snoqualmie Pass 73 50 62 / 30 20 20
Stevens Pass 71 50 60 / 40 20 40
$$
WAZ569-122300-
Cascades of Pierce and Lewis Counties-
Including the cities of Randle, Packwood, Ashford, and Morton
253 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy in the morning then becoming mostly sunny.
Haze in the morning. A chance of showers. Snow level near
11500 feet.
.TONIGHT...Partly cloudy with a slight chance of showers in the
evening, then mostly cloudy after midnight. Snow level near
9500 feet.
.TUESDAY...Mostly cloudy in the morning, then partly sunny with a
slight chance of showers in the afternoon. Snow level near
8500 feet.
.TUESDAY NIGHT...Mostly cloudy. Freezing level near 11500 feet.
.WEDNESDAY...Mostly sunny. Freezing level near 12000 feet.
.WEDNESDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Freezing level near 11500 feet.
.THURSDAY...Partly sunny. Freezing level near 11500 feet.
.THURSDAY NIGHT...Mostly cloudy. Freezing level near 11500 feet.
.FRIDAY...Partly sunny. Freezing level near 11000 feet.
.FRIDAY NIGHT...Mostly cloudy. Freezing level near 10000 feet.
.SATURDAY...Mostly cloudy with a slight chance of showers. A
slight chance of snow showers in the afternoon. Snow level near
8000 feet.
.SATURDAY NIGHT...Mostly cloudy with a slight chance of showers.
A slight chance of snow showers in the evening, then a chance of
snow showers after midnight. Snow level near 8000 feet.
.SUNDAY...Mostly cloudy in the morning then becoming partly
sunny. A chance of showers. A slight chance of snow showers in
the morning, then a chance of snow showers in the afternoon. Snow
level near 8000 feet.
$$
_____
Copyright 2022 AccuWeather
|
https://www.sfgate.com/weather/article/WA-Seattle-WA-Zone-Forecast-17435191.php
| 2022-09-12T11:29:45Z
|
https://www.sfgate.com/weather/article/WA-Seattle-WA-Zone-Forecast-17435191.php
| true
|
MIDDLETOWN, Md., Sept. 12, 2022 /PRNewswire/ -- Community Heritage Financial, Inc. (the "Company") (OTC PK: CMHF), the parent company of Middletown Valley Bank (the "Bank"), today announced the launch of a public offering of 1,500,000 shares of common stock under Regulation A, Tier 2. The public offering price is expected to be between $21.00 and $23.00 per share.
The Company is offering the shares of common stock through an underwriter, Piper Sandler & Co. The underwriter will have a 30-day option to purchase up to 225,000 additional shares of common stock.
The Company intends to use the proceeds of the offering (substantially all of which the Company intends to contribute to the capital of the Bank) to increase lending and investment activities and to expand client relationships through the ability to make additional loans with a larger legal lending limit. The Company may also use a portion of the proceeds to fund potential acquisition opportunities, and for working capital and other general corporate purposes. The Company does not have any current plans, arrangements, or understandings relating to any specific acquisitions.
The shares of common stock will be issued pursuant to an offering statement on Form 1-A (File No. 024-11920) filed by the Company with the U.S. Securities and Exchange Commission (the "SEC"), which was qualified by the SEC on September 9, 2022, and only by means of an offering circular. A preliminary offering circular related to the offering has been filed with the SEC. Prospective investors should read the preliminary offering circular, and the final offering circular, when available, and other documents the Company has filed with the SEC for more complete information about the Company and the offering. Copies of these documents are available for free by visiting EDGAR on the SEC website at www.sec.gov or may be obtained from the Piper Sandler Equity Capital Markets department at 800-747-3924.
This press release is for informational purposes only and shall not constitute an offer to sell, or the solicitation of an offer to buy, the securities, nor shall there be any offer, solicitation, or sale in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
About Community Heritage Financial, Inc.
Community Heritage Financial, Inc. is the parent company of Middletown Valley Bank. Middletown Valley Bank provides personal and business banking services, as well as mortgage lending services through its wholly owned subsidiary, Millennium Financial Services, Inc. (Mlend). Originating in Middletown, Maryland in 1908, today the Bank operates offices in the Maryland counties of Frederick, Washington, Garrett and Anne Arundel, and Franklin County, Pennsylvania. For more information, visit www.communityheritageinc.com or www.mvbbank.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements can generally be identified by the use of forward- looking terminology such as "believes," "expects," "intends," "may," "will," "should," "anticipates" or similar terminology. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, changes in interest rates, stock market liquidity, deposit flows, loan demand and real estate values, as well as changes in economic, competitive, governmental, regulatory, technological and other factors which may affect the Company specifically, its existing and target market areas or the banking industry in general. The realization or occurrence of these risks or uncertainties could cause actual results to differ materially from those addressed in the forward-looking statements. The statements in this press release are made as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or results or otherwise, except as required by law.
Investor Relations Contact:
Community Heritage Financial, Inc.
Robert E. (BJ) Goetz, Jr.
President & Chief Executive Officer
301-371-3055
View original content to download multimedia:
SOURCE Community Heritage Financial, Inc.
|
https://www.wbtv.com/prnewswire/2022/09/12/community-heritage-financial-inc-announces-public-offering-common-stock-under-regulation/
| 2022-09-12T11:30:35Z
|
https://www.wbtv.com/prnewswire/2022/09/12/community-heritage-financial-inc-announces-public-offering-common-stock-under-regulation/
| true
|
CINCINNATI (AP) — Minkah Fitzpatrick and the Pittsburgh Steelers kept kicking the door open against the Cincinnati Bengals. It took until the final whistle to finally walk on through.
Chris Boswell kicked a 53-yard field goal as time expired in overtime and the Steelers overcame T.J. Watt’s injury late in the fourth quarter to beat the Cincinnati Bengals 23-20 in a sloppy season opener for both teams Sunday.
Watt and Fitzpatrick had two of four interceptions off Joe Burrow, who rebounded from a lousy start and rallied Cincinnati from a 17-6 halftime deficit. His 6-yard touchdown pass to Ja’Marr Chase tied it at 20 with 2 seconds left in regulation
Fitzpatrick kept the Steelers alive by blocking Evan McPherson’s point-after try, sending the game to overtime.
“It’s just good to come in here in a hostile environment, man, and not blink, particularly with a number of new guys, whether they’re rookies or new to us,” Pittsburgh coach Mike Tomlin said.
McPherson and Boswell missed potential winning field goals in overtime before Steelers quarterback Mitch Trubisky completed passes of 9, 26 and 10 yards in the final 56 seconds.
“That was pretty crazy — the back-and-forth nature,” Trubisky said. “We found out a lot about this team. We battled, we stuck together. We have a lot to clean up, but we found a way in the end. Winning is fun.”
Watt, the Defensive Player of the Year, left the field and headed to the locker room shortly before the game went to overtime with a pectoral injury. Before that, he was his usual disruptive self, with a sack and a pick.
Burrow’s four interceptions were a career worst, and he was sacked seven times in front of what was supposed to be an improved offensive line.
“It’s frustrating,” Burrow said. “We came back in the second half. We finished strong. Give them credit. They had a good plan.”
Burrow didn’t play in the preseason games as he recovered from an appendectomy, and he got a rude welcome back to the field. Cam Heyward sacked him on Cincinnati’s first offensive play, and Fitzpatrick jumped Tyler Boyd’s route the next snap and returned it 31 yards for a Pick-6.
McPherson made a 59-yard field goal in the first quarter, but Watt made a leaping interception at the line on the next series. That set up Trubisky’s 2-yard TD pass to Najee Harris for a 17-3 edge.
Trubisky, the first quarterback to start for the Steelers after Ben Roethlisberger’s retirement, was 21 for 38 for 194 yards and the short TD pass to Harris as first-round pick Kenny Pickett watched from the sideline.
When asked about his offense, Tomlin said: “It was enough — we’re 1-0.”
The Bengals wasted a solid performance by the their defense, which limited the big plays and did a good job containing running back Harris, who finished with 23 yards on 10 carries before leaving late with a foot injury.
Chase had 10 catches for 129 yards for the Bengals.
JOE’S SLOW START
For much of the day, Burrow looked as if he was struggling to get back on track. He finished 33 for 53 for 338 yards and two touchdowns.
Asked if he was still trying to shake off the effects of his July surgery, he would only say, “I felt good.”
“We don’t overreact when things go well. We don’t overreact when things don’t go well,” Burrow said. “We’re even-keeled. We got into position to win the game.”
INJURIES
Steelers: CB Levi Wallace left in the second half with an ankle injury and didn’t return. … OL Mason Cole suffered an ankle injury in the second half and didn’t return. … Harris suffered a foot injury late in the game. … Tomlin said LB Robert Spillane suffered an eye injury.
Bengals: WR Tee Higgins left with a concussion from a hard hit by several Steelers. … LS Clark Harris went out with a biceps injury.
UP NEXT
Steelers: At New England next Sunday.
Bengals: At Dallas next Sunday.
__
More AP NFL coverage: https://apnews.com/hub/NFL and https://twitter.com/AP_NFL
|
https://www.pahomepage.com/sports/ap-steelers-get-late-fg-in-ot-after-watt-injured-vs-bengals/
| 2022-09-12T11:34:29Z
|
https://www.pahomepage.com/sports/ap-steelers-get-late-fg-in-ot-after-watt-injured-vs-bengals/
| true
|
Americans give health care system failing mark: AP-NORC poll
WASHINGTON (AP) — When Emmanuel Obeng-Dankwa is worried about making rent on his New York City apartment, he sometimes holds off on filling his blood pressure medication.
“If there’s no money, I prefer to skip the medication to being homeless,” said Obeng-Dankwa, a 58-year-old security guard.
He is among a majority of adults in the U.S. who say that health care is not handled well in the country, according to a new poll from The Associated Press-NORC Center for Public Affairs Research.
The poll reveals that public satisfaction with the U.S. health care system is remarkably low, with fewer than half of Americans saying it is generally handled well. Only 12% say it is handled extremely or very well. Americans have similar views about health care for older adults.
Overall, the public gives even lower marks for how prescription drug costs, the quality of care at nursing homes and mental health care are being handled, with just 6 percent or less saying those health services are done very well in the country.
“Navigating the American health care system is exceedingly frustrating,” said A. Mark Fendrick, the director of the University of Michigan Center for Value-Based Insurance Design. “The COVID pandemic has only made it worse.”
More than two years after the pandemic’s start, health care worker burnout and staffing shortages are plaguing hospitals around the country. And Americans are still having trouble getting in-person medical care after health centers introduced restrictions as COVID-19 killed and sickened millions of people around the country, Fendrick said.
In fact, the poll shows an overwhelming majority of Americans, nearly 8 in 10, say they are at least moderately concerned about getting access to quality health care when they need it.
Black and Hispanic adults in particular are resoundingly worried about health care access, with nearly 6 in 10 saying they are very or extremely concerned about getting good care. Fewer than half of white adults, 44%, expressed the same level of worry.
Racial disparities have long troubled America’s health care system. They have been abundantly clear during the COVID-19 pandemic, with Black and Hispanic people dying disproportionately from the virus. Black and Hispanic men also make up a disproportionately high rate of recent monkeypox infections.
Fifty-three percent of women said they are extremely or very concerned about obtaining quality care, compared to 42% of men.
While Americans are united in their dissatisfaction with the health care system, that agreement dissolves when it comes to solutions to fix it.
About two-thirds of adults think it is the federal government’s responsibility to make sure all Americans have health care coverage, with adults ages 18 to 49 more likely than those over 50 to hold that view. The percentage of people who believe health care coverage is a government responsibility has risen in recent years, ticking up from 57% in 2019 and 62% in 2017.
Still, there’s not consensus on how that coverage might be delivered.
About 4 in 10 Americans say they support a single-payer health care system that would require Americans to get their health insurance from a government plan. More, 58%, say they favor a government health insurance plan that anyone can purchase.
There also is broad support for policies that would help Americans pay for the costs of long-term care, including a government-administered insurance plan similar to Medicare, the federal government’s health insurance for people 65 or older.
Retired nurse Pennie Wright, of Camden, Tennessee, doesn’t like the idea of a government-run health care system.
After switching to Medicare this year, she was surprised to walk out of her annual well-woman visit, once fully covered by her private insurance plan, with a $200 bill.
She prefers the flexibility she had on her private insurance plan.
“I feel like we have the best health care system in the world, we have a choice of where we want to go,” Wright said.
A majority of Americans, roughly two-thirds, were happy to see the government step in to provide free COVID-19 testing, vaccines and treatment. Roughly 2 in 10 were neutral about the government’s response.
The government’s funding for free COVID-19 tests dried up at the beginning of the month. And while the White House says the latest batch of recommended COVID-19 boosters will be free to anyone who wants one, it doesn’t have money on hand to buy any future rounds of booster shots for every American.
Eighty percent say they support the federal government negotiating for lower drug prices. President Joe Biden this summer signed a landmark bill into law allowing Medicare to negotiate the price of prescription drugs. The move is expected to save taxpayers as much as $100 billion over the next decade.
“Medication costs should be low, to the minimum so that everyone can afford it,” said Obeng-Dankwa, the Bronx renter who has trouble paying for his medication. “Those who are poor should be able to get all the necessary health they need, in the same way someone who also has the money to pay for it.”
___
AP polling reporter Hannah Fingerhut in Washington contributed to this report.
___
The poll of 1,505 adults was conducted July 28-Aug. 1 using a sample drawn from NORC’s probability-based AmeriSpeak Panel, which is designed to be representative of the U.S. population. The margin of sampling error for all respondents is plus or minus 3.6 percentage points.
___
Follow AP’s coverage of health care costs at https://apnews.com/hub/health-care-costs.
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.wlbt.com/2022/09/12/americans-give-health-care-system-failing-mark-ap-norc-poll/
| 2022-09-12T11:35:35Z
|
https://www.wlbt.com/2022/09/12/americans-give-health-care-system-failing-mark-ap-norc-poll/
| false
|
Before freshman running back Nick Singleton got past the first line of defenders, teammate Ji’Ayir Brown knew he was going to score.
Penn State’s veteran safety bounced up and down on the sideline, pointing toward the end zone just as Singleton slipped through blocks and burst down the sideline for a 70-yard score to spark Penn State’s 46-10 over Ohio on Saturday.
Brown had seen this dash and burn from the former No. 1 recruit before.
“Once he got that edge, nobody was catching him,” Brown said. “I don’t think they were prepared for Nick’s game-breaking speed.”
The Nittany Lions (1-0) sure need it.
They’ve been one-dimensional for quite a while, having not had a 100-yard rusher since late in the 2020 season and have regularly finished among the worst rushing offenses in the country.
“He’s explosive, he’s fast, he sees it well,” quarterback Sean Clifford said. “I think it was just a matter of time.”
Singleton carried the ball 10 times for 179 yards, added a 44-yard touchdown in the third and Penn State’s defense dominated the Bobcats.
In between, Clifford and Drew Allar played clean enough and the Nittany Lion defense bore down to force eight punts, a safety and a turnover on downs.
Ohio (0-2) crossed midfield just three times.
Meanwhile, Penn State’s offense continued to blossom.
Clifford completed 19-of-27 passes for 213 yards, ran for a score and threw for another as Penn State scored on three of its first five possessions.
The sixth-year quarterback capped a 12-play opening drive with a 1-yard scoring plunge before Singleton dashed down the sideline on the Nittany Lions’ second possession to make it 14-0 late in the first quarter. Clifford threw a 7-yard touchdown pass to Mitchell Tinsley in the third before yielding to Allar.
The Nittany Lions didn’t miss a beat with the freshman running the offense, and more than 107,000 fans who packed Beaver Stadium cheered loudly when he entered.
Allar was 6 of 8 for 88 yards with touchdown passes to Omari Evans and Khalil Dinkins early in the third and fourth quarters.
Ohio broke the shutout just before halftime.
Trailing 19-0, Sieh Bangura leaned in from 1-yard out to cap an eight-play, 75-yard drive. But the Bobcats didn’t score again until Nathanial Vakos booted a 21-yard field goal with 6:50 to play.
“We came in to win the football game and it didn’t go our way,” Ohio coach Tim Albin said. “As a staff, we need to take 24 hours and get a few guys’ bumps and bruises cleaned up. Next week on the next stage we’re going to look better.”
THE TAKEAWAY
Ohio: Picked to finish in the lower half of the MAC standings by conference coaches, the Bobcats played hard on defense. They sacked Clifford three times in the first half but couldn’t hang with Penn State’s speed.
Penn State: Offensive coordinator Mike Yurcich has built a solid foundation in the first two weeks. More importantly, the running game came alive in this one as Singleton looked quick bouncing runs outside. A bonus? Fellow freshman back Kaytron Allen looked capable too with seven touches for 45 yards.
NO QB CONTROVERSY
Penn State coach James Franklin said the plan was to not only play Clifford and Allar, but third-stringer Christian Veilleux as well.
All three did play and Clifford was adamant afterwards that that was a best case scenario. He enjoyed watching both his understudies play well.
“I want to be out there with my guys as much as possible,” Clifford said. “But the one thing I will say, is if it means giving up some time to get guys prepared, I want to win more than anything. I have no ego in that. And I know how important it is to get those guys reps because if anything happens to me, I want to win games.”
UP NEXT
Ohio: Visits Iowa State on Saturday.
Penn State: Visits Auburn on Saturday.
|
https://www.fox43.com/article/sports/nick-singleton-penn-state-university-ohio-bobcats-ncaaf/521-b082fcd3-a1b0-4d5e-9ddf-7e893079e757
| 2022-09-12T11:35:50Z
|
https://www.fox43.com/article/sports/nick-singleton-penn-state-university-ohio-bobcats-ncaaf/521-b082fcd3-a1b0-4d5e-9ddf-7e893079e757
| true
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention NIO Inc. ("NIO") (NYSE: NIO) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 1, 2021 and July 11, 2022.
If you suffered a loss on your investment in NIO, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against NIO includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) NIO pulled forward revenue by selling batteries to a related party, which owned the batteries and managed users' subscriptions; (2) through the related party, NIO also recognized enormous depreciation savings; (3) as a result of the foregoing, the Company's revenue and net loss were overstated; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
DEADLINE: October 24, 2022
Aggrieved NIO investors only have until October 24, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.wlbt.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-nio-investors-lead-plaintiff-deadline-october-24-2022/
| 2022-09-12T11:37:27Z
|
https://www.wlbt.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-nio-investors-lead-plaintiff-deadline-october-24-2022/
| false
|
ENGLEWOOD CLIFFS, N.J., Sept. 12, 2022 /PRNewswire/ -- Today, Baby Dove announces how the brand's ongoing commitment to advancing superior care for Black mothers is evolving. By expanding the Black Birth Equity Fund, launching a new informative series called #DearDoula, and reinforcing existing strategic partnerships, Baby Dove further accelerates the effort to close the significant gap in care and health outcomes for Black mothers and their babies.
"As a brand that encourages all parents to care with confidence, we are committed to making care for Black moms accessible and equitable," says Neha Minj, Brand Director and Head of Operations & Engagement for Baby Dove. "Doulas can offer advocacy and support to Black birthing individuals who have not received the care they deserve. We are proud to extend our efforts and emphasize the important role they play in closing the maternal care gap, particularly with the support of our partners."
#DearDoula
In partnership with Chanel Porchia-Albert, Founder of Ancient Song Doula Services & Co-Creator of JustBirth Space, #DearDoula expands the access to doula-provided advice and recommendations directly to moms. The ongoing content series will live across social media platforms and share answers to Black parents' most common questions about pregnancy, labor & delivery, postpartum care and baby care directly from one of the country's most trusted doula experts.
"I am so excited to partner with Baby Dove to provide lifechanging positive guidance to Black women and birthing people," said Chanel. "The #DearDoula series will connect me with more moms, offer helpful information and educate them on the possibilities of doula care."
Black Birth Equity Fund
Baby Dove is doubling the investment into the Black Birth Equity Fund, for a total of $500,000. First created in August 2021, the Black Birth Equity Fund provides Black expecting mothers with immediate financial access to doula services. The Fund has offered grants to 200 moms and counting and can now reach twice as many by the end of 2022. Applications for direct, one-time grants up to $1,300 are available at BabyDove.com.
Black Maternal Health Conference 2022
This year, Baby Dove is the exclusive presenting sponsor of the Black Maternal Health Conference, the largest gathering of thought leaders, healthcare providers and doulas working to improve maternal health. Hosted by Baby Dove partner and leading advocacy group Black Mamas Matter Alliance (BMMA), the conference was created to address the most pressing conversations on the maternal care gap. As presenting sponsor, Baby Dove will host a breakout session titled "On the Front Lines," focusing on the benefits of doula care. The session will feature key speakers like Chanel, Angela D. Aina, Co-Founding Executive Director at BMMA, brand representatives and past recipients of the Black Birth Equity Fund. The conference is taking place in person and virtually in Washington, D.C. on September 17th and 18th. More information and virtual registration is available at https://blackmamasmatter.org/bmhc22/.
Expanded Availability of Baby Dove Melanin-Rich Skin and Curl Nourishment Collection
In addition to advancing care for Black moms, Baby Dove is on a mission to advance care for babies with melanin-rich skin and curly hair. Last year, Baby Dove launched the Baby Dove Melanin-Rich Skin and Curl Nourishment Collection, and we are proud to announce that the full range is now available nationwide at mass retailers for the first time. To learn more about the product line, the brand's commitment or to apply for a grant visit BabyDove.com.
About Dove
Dove started its life in 1957 in the US, with the launch of the Beauty Bar, with its patented blend of mild cleansers and ¼ moisturizing cream. Dove's heritage is based on moisturization, and it is proof not promises that enabled Dove to grow from a Beauty Bar into one of the world's most beloved beauty brands.
Women have always been our inspiration and since the beginning, we have been wholly committed to providing superior care to all women and to championing real beauty in our advertising. Dove believes that beauty is for everyone. That beauty should be a source of confidence and not anxiety. Dove's mission is to inspire women everywhere to develop a positive relationship with the way they look and realize their personal potential for beauty.
For 60 years, Dove has been committed to broadening the narrow definition of beauty in the work they do through a series of actions, including:
- Supporting diverse imagery in media and advertising via The 'Dove Real Beauty Pledge:
- Ending race-based hair discrimination via The CROWN Act:
About Baby Dove
Baby Dove entered the baby care market in 2017 – with the aim to bring something very different in terms of superior care to baby skin. Baby Dove was created from the long, trusted heritage of Dove, with the goal to bring the 60-year superior care credentials to the most delicate skin: baby skin. Baby Dove® is available nationwide in food, drug and mass outlet stores.
About Black Mamas Matter Alliance
The Black Mamas Matter Alliance (BMMA) is a national network of Black women-led organizations and multi-disciplinary professionals who work to ensure that all Black Mamas have the rights, respect, and resources to thrive before, during, and after pregnancy. BMMA honors the work and historical contributions of black women's leadership within their communities and values the need to amplify this work on a national scale. For this reason, BMMA does not have chapters. The alliance is composed of existing organizations and individuals whose work is deeply rooted in reproductive justice, birth justice, and the human rights framework.
About Unilever
Unilever is one of the world's leading suppliers of Beauty & Personal Care, Home Care, and Foods & Refreshment products, with sales in over 190 countries and products used by 3.4 billion people every day. We have 148,000 employees and generated sales of €52.4 billion in 2021. Over half of our footprint is in developing and emerging markets. We have around 400 brands found in homes all over the world – including iconic brands like Dove, Knorr, Hellmann's, Magnum, Axe, Ben & Jerry's, Degree, Seventh Generation, St. Ives, Suave, TRESemmé, and Vaseline.
Our vision is to be the global leader in sustainable business and to demonstrate how our purpose-led, future-fit business model drives superior performance. We have a long tradition of being a progressive, responsible business. It goes back to the days of our founder William Lever, who launched the world's first purposeful brand, Sunlight Soap, more than 100 years ago, and it's at the heart of how we run our company today.
The Unilever Compass, our sustainable business strategy, is set out to help us deliver superior performance and drive sustainable and responsible growth, while:
- improving the health of the planet;
- improving people's health, confidence and wellbeing; and
- contributing to a fairer and more socially inclusive world.
While there is still more to do, in the past year we're proud to have achieved sector leadership in S&P's Dow Jones Sustainability Index, 'Triple A' status in CDP's Climate, Water and Forest benchmarks, and to be named as the top ranked company in the GlobeScan/SustainAbility Sustainability Leaders survey for the eleventh consecutive year.
For more information on Unilever U.S. and its brands visit: www.unileverusa.com
For more information on Unilever Canada and its brands visit: www.unilever.ca
Contact:
Lisa Fernandez
lisa.fernandez@edelman.com
View original content to download multimedia:
SOURCE Baby Dove
|
https://www.kmvt.com/prnewswire/2022/09/12/baby-dove-continues-commitment-close-maternal-care-gap-with-deardoula-doubles-investment-black-birth-equity-fund/
| 2022-09-12T11:38:23Z
|
https://www.kmvt.com/prnewswire/2022/09/12/baby-dove-continues-commitment-close-maternal-care-gap-with-deardoula-doubles-investment-black-birth-equity-fund/
| true
|
Americans give health care system failing mark: AP-NORC poll
WASHINGTON (AP) — When Emmanuel Obeng-Dankwa is worried about making rent on his New York City apartment, he sometimes holds off on filling his blood pressure medication.
“If there’s no money, I prefer to skip the medication to being homeless,” said Obeng-Dankwa, a 58-year-old security guard.
He is among a majority of adults in the U.S. who say that health care is not handled well in the country, according to a new poll from The Associated Press-NORC Center for Public Affairs Research.
The poll reveals that public satisfaction with the U.S. health care system is remarkably low, with fewer than half of Americans saying it is generally handled well. Only 12% say it is handled extremely or very well. Americans have similar views about health care for older adults.
Overall, the public gives even lower marks for how prescription drug costs, the quality of care at nursing homes and mental health care are being handled, with just 6 percent or less saying those health services are done very well in the country.
“Navigating the American health care system is exceedingly frustrating,” said A. Mark Fendrick, the director of the University of Michigan Center for Value-Based Insurance Design. “The COVID pandemic has only made it worse.”
More than two years after the pandemic’s start, health care worker burnout and staffing shortages are plaguing hospitals around the country. And Americans are still having trouble getting in-person medical care after health centers introduced restrictions as COVID-19 killed and sickened millions of people around the country, Fendrick said.
In fact, the poll shows an overwhelming majority of Americans, nearly 8 in 10, say they are at least moderately concerned about getting access to quality health care when they need it.
Black and Hispanic adults in particular are resoundingly worried about health care access, with nearly 6 in 10 saying they are very or extremely concerned about getting good care. Fewer than half of white adults, 44%, expressed the same level of worry.
Racial disparities have long troubled America’s health care system. They have been abundantly clear during the COVID-19 pandemic, with Black and Hispanic people dying disproportionately from the virus. Black and Hispanic men also make up a disproportionately high rate of recent monkeypox infections.
Fifty-three percent of women said they are extremely or very concerned about obtaining quality care, compared to 42% of men.
While Americans are united in their dissatisfaction with the health care system, that agreement dissolves when it comes to solutions to fix it.
About two-thirds of adults think it is the federal government’s responsibility to make sure all Americans have health care coverage, with adults ages 18 to 49 more likely than those over 50 to hold that view. The percentage of people who believe health care coverage is a government responsibility has risen in recent years, ticking up from 57% in 2019 and 62% in 2017.
Still, there’s not consensus on how that coverage might be delivered.
About 4 in 10 Americans say they support a single-payer health care system that would require Americans to get their health insurance from a government plan. More, 58%, say they favor a government health insurance plan that anyone can purchase.
There also is broad support for policies that would help Americans pay for the costs of long-term care, including a government-administered insurance plan similar to Medicare, the federal government’s health insurance for people 65 or older.
Retired nurse Pennie Wright, of Camden, Tennessee, doesn’t like the idea of a government-run health care system.
After switching to Medicare this year, she was surprised to walk out of her annual well-woman visit, once fully covered by her private insurance plan, with a $200 bill.
She prefers the flexibility she had on her private insurance plan.
“I feel like we have the best health care system in the world, we have a choice of where we want to go,” Wright said.
A majority of Americans, roughly two-thirds, were happy to see the government step in to provide free COVID-19 testing, vaccines and treatment. Roughly 2 in 10 were neutral about the government’s response.
The government’s funding for free COVID-19 tests dried up at the beginning of the month. And while the White House says the latest batch of recommended COVID-19 boosters will be free to anyone who wants one, it doesn’t have money on hand to buy any future rounds of booster shots for every American.
Eighty percent say they support the federal government negotiating for lower drug prices. President Joe Biden this summer signed a landmark bill into law allowing Medicare to negotiate the price of prescription drugs. The move is expected to save taxpayers as much as $100 billion over the next decade.
“Medication costs should be low, to the minimum so that everyone can afford it,” said Obeng-Dankwa, the Bronx renter who has trouble paying for his medication. “Those who are poor should be able to get all the necessary health they need, in the same way someone who also has the money to pay for it.”
___
AP polling reporter Hannah Fingerhut in Washington contributed to this report.
___
The poll of 1,505 adults was conducted July 28-Aug. 1 using a sample drawn from NORC’s probability-based AmeriSpeak Panel, which is designed to be representative of the U.S. population. The margin of sampling error for all respondents is plus or minus 3.6 percentage points.
___
Follow AP’s coverage of health care costs at https://apnews.com/hub/health-care-costs.
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.wagmtv.com/2022/09/12/americans-give-health-care-system-failing-mark-ap-norc-poll/
| 2022-09-12T11:38:34Z
|
https://www.wagmtv.com/2022/09/12/americans-give-health-care-system-failing-mark-ap-norc-poll/
| false
|
VANCOUVER, BC, Sept. 12, 2022 /PRNewswire/ - First Mining Gold Corp. ("First Mining" or the "Company") (TSX: FF) (OTCQX: FFMGF) (FRANKFURT: FMG) is pleased to provide an updated Mineral Resource Estimate (the "MRE") on the Duparquet gold project ("Duparquet" or the "Project") located in Quebec, prepared by InnovExplo Inc. in accordance with the National Instrument 43-101 Standards of Disclosure for Mineral Projects ("NI 43-101").
The updated MRE is derived from the master database of drill data, which contains 904 holes totalling 270,119m and 173,831 sampled intervals. This MRE includes 57 drill holes totaling 9,548m not included in the previous MRE with drilling occurring after the effective date of February 28, 2013. The drilling was carried out by Clifton Star Resources Inc., Beattie Gold Mines Ltd., and 2588111 Manitoba Ltd. By incorporating these previous drill holes, Duparquet's resource increases to 3.4 Moz in the measured and indicated category, an increase of 327 koz, and to 1.6 Moz in the inferred category, an increase of 193 koz.
"First Mining is very excited to announce an updated mineral resource estimate at the Duparquet Gold Project," stated Dan Wilton, CEO of First Mining Gold. "Duparquet is an advanced stage project that has benefited from 270,000m of historical drilling and was advanced to a PFS level in 2014. This resource growth from incorporating the 2013-2018 drilling is just the beginning of what we see as immense value potential here at Duparquet. Based on the size of its current resource, Duparquet represents one of the top four undeveloped gold projects in the province of Quebec. Its above average M&I open pit grade of 1.52 g/t Au provides excellent mining flexibility and along with its size and location, make it a very versatile deposit amenable to different potential mining scenarios with good future growth potential. The project site is well located and has access to excellent infrastructure and skilled labour. First Mining intends to complete an updated economic study in the near future and to develop an exploration path to support potential resource expansion, resource classification upgrading, and discovery of new deposits in this underexplored district."
Table 1: Duparquet Gold Project Mineral Resource Estimate
Duparquet consists of four (4) contiguous mineral exploration properties: Beattie, Donchester, Central Duparquet, Dumico and the tailings from the former Beattie mine. The Project is located in the Abitibi region of the province of Quebec, approximately 50 km north of the city of Rouyn-Noranda.
The Project site has infrastructure which includes paved, provincial highways from Rouyn-Noranda to the south and LaSarre to the north, both mining communities that can provide mining infrastructure and skilled labour to develop a mine. The Project site is also proximal to Quebec's hydroelectric power grid.
Duparquet, previously comprised of 2 separate Mining Concessions (Beattie and Donchester mines), now comprises of fifty (50) map-designated claims ("CDC") covering an area of 1,079.2 ha covering a strike length of 8 km in an E-W direction.
Duparquet is geologically located in the southern portion of the Abitibi, straddling the SE trending prolific Destor-Porcupine Fault Zone (DPMFZ). Structurally the project includes numerous E-W mineralized splays off of the Destor-Porcupine Fault Zone, as well as several syenite intrusions. Surrounding host rocks include mafic to ultramafic volcanic rocks and younger Temiskaming age conglomerates.
The predominant structures on Duparquet are the E-W splays of the DPMFZ. The Beattie Fault Zone ("BFZ") is located along the north contact of the main syenite body, whereas the Donchester Fault Zone ("DFZ") is located along the south contact. The Central Duparquet Fault Zone ("CDFZ") is located along the south contact of the second smaller syenite intrusive to the east.
Figure 1: Geology of the Duparquet Project. Structural and geometric details are represented by surface projections of the relevant structural elements from the deposit-scale 3D litho-structural model
The main style of gold mineralization in the Duparquet deposit generally occurs within shears or brecciated zones along or within the adjacent intrusive syenitic masses and is associated with finely disseminated pyrite and minor arsenopyrite replacement. Sulphide content is generally low (0.5 to 4%), although it can be up to 10% in some cases. Gold is associated and hosted with the pyrite and lesser arsenopyrite and arsenian pyrite.
Gold was initially discovered in the Duparquet Township in 1910 by John Beattie. The Beattie and adjoining Donchester mines were in production from 1933 to 1956, producing upwards of 1.3 million ounces of gold. In the mid-1930's Beattie Gold Mines was the largest gold producer in Quebec. From the 1980's to 2007, very limited exploration was carried out. Clifton Star had an option on the property between 2009 and 2014. During this time a substantial amount of surface diamond drilling, channel sampling was carried out. The company also completed an environmental baseline study, environmental assessment study and numerous metallurgical studies. Mineral resource estimates were also carried out that were included in the preliminary economic assessment and a prefeasibility study. The Clifton Star option was terminated in 2014 and the property was returned to the previous owners, with Clifton Star retaining a 10% interest in the companies that held the properties.
Since the effective date of the previous mineral resource estimate (InnovExplo, Poirier et al., 2014), the Company (Clifton Star) and the previous owners (Beattie Gold Mines and 2588111 Manitoba Ltd.) had completed an additional 57 surface drill holes totalling 9,548 m, that were not included in the MRE. Significant assay results added to this new MRE include 5.65 g/t Au over 34.0 m (BD13-22) on Beattie and 5.58 g/t Au over 5.0 m (D13-18) on Donchester.
The 2022 MRE contains 904 drillholes and 892 channel samples in outcrops. It contains 173,831 sampled intervals taken from 270,119 m of drilled core and 2,371 analyses from 1,827 m of channels. The 904 DDH cover the 4.5-km strike length of the Project at a reasonably regular drill spacing of 25-50 m.
Bench-scale and pilot plant metallurgical testwork programs have been carried out for the Project. SGS carried out preliminary metallurgical testwork in 2012 to support a PEA at that time. In 2013, SGS carried out further flotation, pressure oxidation, cyanidation, rheology and environmental testwork, including a pilot plant for a PFS. Outotec was also mandated in 2013 to carry out filtration testwork.
The overall gold results from flotation concentrate, pressure oxidation (POX) and CIL circuit as well as flotation tail cyanidation for the ore resulted in an overall recovery of gold ranging from 91.9% to 95.4%.
A preliminary pilot test program investigated pressure oxidation and hot curing processing of a Duparquet flotation concentrate to render precious metals extractable by cyanidation. The recovery of gold from the pilot plant hot cure discharge ranged from 94.7% to 96.5%
Bench-scale test work was also performed on two samples of existing tailings on the Project. The test work for the flotation-POX/CIL flowsheet resulted in overall gold recoveries ranging from 83.5% to 93.3%.
The MRE update for the Project (the "2022 MRE") was prepared by Marina Iund, P.Geo. and Carl Pelletier, P.Geo., using all available information. The main objective was to update the results of InnovExplo's previous mineral resource estimate for the Project, dated June 26, 2013 (Poirier et al., 2014). The updated MRE includes new drill holes on the Beattie, Donchester and Central Duparquet properties.
The resource area has an E-W strike length of 4.5 km, a width of approximately 1 km, and a vertical extent of 1,050 m below surface.
The 2022 MRE was prepared using GEOVIA GEMS 6.8.2.2 ("GEMS") and GEOVIA Surpac 2021 ("Surpac") software. GEMS was used for updating the mineralized domains and the compositing. Surpac was used for the estimation, which consisted of 3D block modelling and the inverse distance square ("ID2") interpolation method. Statistical, capping and variography studies were completed using Snowden Supervisor v8.13 and Microsoft Excel software.
The 60 mineralized domain wireframes were created and updated by digitizing an interpretation onto sections spaced 25 m apart or 12.5 m in areas with higher drill hole density. However, if barren intervals were encountered, the mineralized zones were extended only to the mid-distance between the last known occurrence of mineralization and the barren hole. A 50-m extension around the zones was used for the secondary mineralized domains.
A dilution envelope was defined as the parts of the block model that are not included in any of the mineralized domain solids. The solid for the envelope contains "floating" gold intersects for which continuity has not yet been demonstrated or interpreted.
High-grade capping was set at 25 g/t Au for all zones, including the envelope zone. Twenty-two (22) DDH samples and one (1) channel sample were capped.
Analysis of 3,633 bulk density values and a 12 t composite drill core bulk sample from the mineralized zones, yielded 2.73 g/cm3 (mean density of the syenite) for all 60 mineralized domains and the envelope. A density of 2.00 g/cm3 was assigned to the overburden, and 1.00 g/cm3 was assigned to excavation solids (drifts and stopes) assumed to be filled with water.
The intervals defining each mineralized domain were composited to 1-m equal lengths. A grade of 0.00 g/t was assigned to missing sample intervals as it was assumed that unsampled intervals were considered to be unmineralized by the geologist in charge of the core logging.
A block model was built to enclose a sufficiently large enough volume to host an open pit. The model corresponds to a sub-blocked model in Surpac with no rotation. The user block size was defined as 5m x 5m x 5m with a minimal sub-block size of 1.25m x 1.25m x 1.25m. Block dimensions reflect the sizes of mineralized domains and plausible mining methods. All blocks with more than 50% of their volume falling within a selected solid were assigned the corresponding solid block code.
Individual zones and the envelope were estimated separately using their own search ellipsoid. The available geological and geostatistical information was used to establish the size of each search ellipsoid. Seventy-two (72) distinct mineralized domains were studied. The mean azimuth and dip of each domain were used to define 23 search ellipsoids, grouping zones of similar geometry.
Figure 2: Plan view and isometric view of the categorized mineral resources and the Whittle optimized pit-shells (blocks selection: in pit-shells or in DSO and above the respective COG)
Table 2: Cut-off grade sensitivity for the in-pit and underground portions of the Duparquet Project
InnovExplo, the authors of the MRE report concluded that:
- The database supporting the 2022 MRE is complete, valid and up to date.
- Geological and gold-grade continuity has been demonstrated for all 72 mineralized zones.
- The key parameters of the 2022 MRE (density, capping, compositing, interpolation, search ellipsoid, etc.) are supported by data and statistical and/or geostatistical analysis.
- The 2022 MRE includes measured, indicated and inferred resources for a combination of two mining scenarios: open pit and selective underground. The 2022 MRE complies with CIM Definition Standards and CIM Guidelines.
- Two cut-off grades of 0.40 and 1.50 g/t Au were used, corresponding to potential open pit and selective underground mining scenarios.
- Cut-off grades were calculated at a gold price of US$1,650 per troy ounce and an exchange rate of 1.31 USD/CAD, using reasonable mining, processing and G&A costs.
- In a combined pit and selective underground mining scenario, the Project contains an estimated M+I Resource of 65,081,200 t at 1.58 g/t Au for 3,316,100 oz of gold and an Inferred Resource of 37,371,900 t at 1.36 g/t Au for 1,636,000 oz of gold. The Project also contains the Beattie mine tailings with an estimated M+I Resource of 4,125,100 t at 0.94 g/t Au for 124,500 oz of gold.
- The results of the 2022 MRE represent a 10.5% increase in the M+I Resource and a 13.4% increase in the Inferred Resource compared to the previous 2014 MRE of Poirier et al., 2014. The increase in the M+I Resource is due to a deeper optimized shell and the updated economic parameters. The same reasons combined with the addition of 55 drill holes explain the increase in Inferred resources.
- Based on metallurgical tests, the Duparquet project appears amenable to standard gold recovery processes. A combination of flotation, pressure oxidation and cyanide leach processes has shown a gold recovery ranging from 94.7% to 96.5%.
- Additional diamond drilling on multiple zones would likely upgrade some of the Inferred Resource to the Indicated category and/or add to the Inferred Resource since most of the mineralized zones have not been fully explored at depth or close to surface infrastructures.
The effective date of the updated MRE is September 12, 2022. A NI 43-101 Technical Report prepared by InnovExplo Inc. will be filed on SEDAR within 45 days of this news release and will be available at that time on the Company website.
The independent and qualified persons for the MRE, as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects, are Marina Iund, P.Geo. and Carl Pelletier, P.Geo., both from Innovexplo. The effective date of the estimate is September 12, 2022.
Mr. Louis Martin P.Geo., (OGQ 0364), a consultant of First Mining, is a "Qualified Person" for the purposes of National Instrument 43-101 Standards of Disclosure for Mineral Projects, and he has reviewed and approved the scientific and technical disclosure contained in this news release.
First Mining is a gold developer advancing a portfolio of gold projects in Canada, with our most advanced project being the Springpole Gold Project in northwestern Ontario, which is one of the largest undeveloped gold projects in Canada, and where we have commenced a Feasibility Study and permitting activities are on-going with a draft Environmental Impact Statement ("EIS") for the project published in June 2022. First Mining also owns the Cameron, Duparquet, Duquesne and Pitt gold projects, all advanced-stage gold projects in Ontario (in the case of Cameron) and Québec. Our portfolio of gold project interests also includes the Pickle Crow gold project (being advanced in partnership with Auteco Minerals Ltd.), the Hope Brook gold project (being advanced in partnership with Big Ridge Gold Corp.), an equity interest in Treasury Metals Inc., and a portfolio of 21 gold royalties.
First Mining was established in 2015 by Mr. Keith Neumeyer, founding President and CEO of First Majestic Silver Corp.
ON BEHALF OF FIRST MINING GOLD CORP.
Daniel W. Wilton
Chief Executive Officer and Director
This news release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date of this news release. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "plans", "projects", "intends", "estimates", "envisages", "potential", "possible", "strategy", "goals", "opportunities", "objectives", or variations thereof or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions.
Forward-looking statements in this news release relate to future events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events. All forward-looking statements are based on First Mining's or its consultants' current beliefs as well as various assumptions made by them and information currently available to them. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by the respective parties, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Such factors include, without limitation the Company's business, operations and financial condition potentially being materially adversely affected by the outbreak of epidemics, pandemics or other health crises, such as COVID-19, and by reactions by government and private actors to such outbreaks; risks to employee health and safety as a result of the outbreak of epidemics, pandemics or other health crises, such as COVID-19, that may result in a slowdown or temporary suspension of operations at some or all of the Company's mineral properties as well as its head office; fluctuations in the spot and forward price of gold, silver, base metals or certain other commodities; fluctuations in the currency markets (such as the Canadian dollar versus the U.S. dollar); changes in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formations, pressures, cave-ins and flooding); the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities, indigenous populations and other stakeholders; availability and increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development; title to properties.; and the additional risks described in the Company's Annual Information Form for the year ended December 31, 2021 filed with the Canadian securities regulatory authorities under the Company's SEDAR profile at www.sedar.com, and in the Company's Annual Report on Form 40-F filed with the SEC on EDGAR.
First Mining cautions that the foregoing list of factors that may affect future results is not exhaustive. When relying on our forward-looking statements to make decisions with respect to First Mining, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. First Mining does not undertake to update any forward-looking statement, whether written or oral, that may be made from time to time by the Company or on our behalf, except as required by law.
View original content to download multimedia:
SOURCE First Mining Gold Corp.
|
https://www.wlbt.com/prnewswire/2022/09/12/first-mining-announces-updated-mineral-resource-estimate-duparquet-gold-project-quebec/
| 2022-09-12T11:38:39Z
|
https://www.wlbt.com/prnewswire/2022/09/12/first-mining-announces-updated-mineral-resource-estimate-duparquet-gold-project-quebec/
| true
|
Prince Andrew is banned from wearing military uniform for ceremonial events during mourning for the Queen... but he WILL be permitted to don armed forces outfit at Westminster Hall vigil
- Prince Andrew has been banned from wearing military uniform for ceremonial events during mourning
- But the shamed Duke of York will be permitted to don his Armed Forces outfit at the Westminster Hall vigil
- It remains unclear if Prince Harry, who is also a non-working royal, will be banned from wearing uniform
- ***Click here to follow MailOnline's liveblog as more events take place following the Queen's death***
King Charles III's shamed younger brother Prince Andrew has been banned from wearing military uniform during the period of mourning for their late mother Queen Elizabeth II, except at the final vigil for Britain's longest-serving monarch at Westminster Hall as a special mark of respect, sources said.
As a non-working member of the Royal Family, the disgraced Duke of York - who was dramatically stripped of his HRH title by the Queen and exiled from public life amid the Jeffrey Epstein scandal - will not wear his Armed Forces outfit at all bar one of this week's ceremonial events.
However, insiders revealed that Andrew, a former Royal Navy officer who served in the Falklands War and has retained his rank as a Vice Admiral, will allowed to don his uniform as a mark of respect for Elizabeth II at the final vigil in Westminster Hall.
It remains unclear if Prince Harry has also been banned from wearing his uniform after he and Meghan Markle sensationally quit frontline royal duties.
Andrew gave up his HRH status and was stripped of all his honorary military roles, including Colonel of the Grenadier Guards, over his friendship with Epstein and allegations made by one of the paedophile's 'sex slaves' Virginia Roberts that the royal sexually abused her when she was a minor under American law - claims that culminated in a bombshell US lawsuit and a multimillion-pound out of court settlement. The Duke of York has consistently denied the allegations.
Harry and Meghan were also stripped of royal titles after they quit royal duties and left the UK for California. The ensuing Megxit saga, which has seen the Duke and Duchess of Sussex make a series of astonishing allegations against The Firm including claims of racism against Meghan and her unborn son Archie by an unnamed senior royal, has sparked a civil war in the House of Windsor and plunged the monarchy into one of its most severe crises.
Working members of the Royal Family will wear uniform when present at five ceremonial events during the period of mourning the Queen.
These are the service of thanksgiving at St Giles' Cathedral in Edinburgh, the procession to Westminster Hall and service of prayer and reflection, the Vigil at Westminster Hall, and next Monday's state funeral at Westminster Abbey and the committal service at St George's Chapel in Windsor.
King Charles III's shamed brother Prince Andrew will not wear military uniform during the period of mourning for their late mother Queen Elizabeth II. It is unclear if the same applies to Prince Harry, who is also a non-working royal
The arrival of the hearse carrying Queen Elizabeth II from Balmoral to the Palace of Holyroodhouse in Edinburgh
Soldiers in the Life Guards at Wellington Barracks practice for Queen Elizabeth II's funeral procession
Vice Admiral Timothy Laurence, Prince Andrew, Princess Anne, Sophie the Countess of Wessex and Prince Edward watch as the coffin of Queen Elizabeth II, draped with the Royal Standard of Scotland, completes its journey from Balmoral to the Palace of Holyroodhouse in Edinburgh yesterday
The Prince and Princess of Wales and the Duke and Duchess of Sussex on the Long Walk at Windsor Castle on Saturday
The Duke of Sussex has paid an emotional tribute to his late grandmother the Queen as he thanked her for her 'sound advice'
Soldiers in the Life Guards at Wellington Barracks in London practise for Queen Elizabeth II's funeral procession this morning
The Duke of Sussex earlier released an emotional statement, promising to 'honour' his father as the new King.
Harry's emotional statement also paid tribute to his grandmother's 'everlasting legacy', saying: 'You are already sorely missed, not just by us, but by the world over.'
He reflected on his 'first meetings' with the Queen, including 'the first moment you met my darling wife and hugged your beloved great-grandchildren'. And in a poignant final line referencing the late Duke of Edinburgh, he said: 'We, too, smile knowing that you and grandpa are reunited now, and both together in peace.'
Harry also referenced his father, with whom his relationship is said to have been strained, saying: 'And as it comes to first meetings, we now honour my father in his new role as King Charles III.'
The duke said: 'In celebrating the life of my grandmother, Her Majesty The Queen - and in mourning her loss - we are all reminded of the guiding compass she was to so many in her commitment to service and duty.
'She was globally admired and respected. Her unwavering grace and dignity remained true throughout her life and now her everlasting legacy.
'Let us echo the words she spoke after the passing of her husband, Prince Philip, words which can bring comfort to all of us now: 'Life, of course, consists of final partings as well as first meetings.''
He added: 'Granny, while this final parting brings us great sadness, I am forever grateful for all of our first meetings-from my earliest childhood memories with you, to meeting you for the first time as my Commander-in-Chief, to the first moment you met my darling wife and hugged your beloved great-grandchildren. 'And as it comes to first meetings, we now honour my father in his new role as King Charles III. Thank you for your commitment to service. Thank you for your sound advice.
'Thank you for your infectious smile. We, too, smile knowing that you and grandpa are reunited now, and both together in peace.'
Harry's statement comes two days after the Prince and Princess of Wales put on a united front with the Duke and Duchess of Sussex as they joined forces on a walkabout at Windsor Castle over the weekend.
William and Harry have a well-documented troubled relationship but the death of their grandmother saw the rivals shelve their differences when, with their wives, they viewed floral tributes left to the late Queen.
It is understood the prince invited his brother to join them in meeting well-wishers outside the castle, and a royal source said William thought it was an 'important show of unity'. Two years have passed since William, Kate, Harry and Meghan were together side-by-side in public, during the 2020 Commonwealth Day church service on March 9, 2020.
As the couple's first engagement under their new titles, William and Kate were joined by Harry and Meghan as they inspected flowers and balloons before a walkabout at the castle on Saturday.
King Charles III was visibly emotional as MPs and peers sang the national anthem following tributes to his mother
The ceremony dates back centuries but has never been seen publicly until today
Britain's King Charles and Queen Consort Camilla stand for the national anthem
Charles said he was moved by the tributes to his mother - who he said 'set an example of selfless duty' that he said he would faithfully folllow
King Charles III and Camilla Queen Consort arrive at Houses of Parliament
A huge sea of flowers pictured at the Royal Sandringham Estate on Monday morning. Over the weekend people queued to leave tributes to the Queen at the royal residence in Norfolk
A mourner covers her face while paying respects to Queen Elizabeth II at the Green Park memorial next to Buckingham Palace on Monday, September 12
Two schoolgirls could be seen laying flowers in the central London park on Monday morning in a touching tribute to the Queen, who died 'peacefully' at Balmoral on September 8, aged 96
A royal source said the Prince of Wales asked his brother and his wife to join them in viewing the tributes.
The source said: 'The Prince of Wales invited the Duke and Duchess to join him and the Princes of Wales earlier.'
The last time William was joined in public by his brother at Windsor Castle was at the funeral of the Duke of Edinburgh in April last year.
Both couples left in the same vehicle as the engagement, which lasted more than 40 minutes, came to a close. All four were dressed in black as they walked along the gates of the castle.
The crowd was heard chatting excitedly and taking photographs as William and Kate and the Duke and Duchess of Sussex stopped to speak to each person at the front of the barriers.
The royal couples walked along separately from one another, with William and Kate speaking to people on one side of the road and Harry and Meghan speaking to people on the other side of the road.
It comes as the King promised 'faithfully to follow' the example of his mother in a speech in Westminster Hall as both Houses of Parliament gathered to express their condolence to the new monarch.
In a short response inside the hall after a formal expression of condolence from MPs and peers, the new King quoted Shakespeare as he spoke movingly of tributes and monuments to his mother inside the Palace of Westminster and spoke of feeling the 'weight of history' as he stood inside the historic room.
Speaking from a gilded lectern, Charles said: 'I am deeply grateful for the addresses of condolence.'
He said the addresses 'touchingly encompass what our late sovereign, my beloved mother the Queen, meant to us all'.
Charles once again reached for Shakespeare, after quoting from the play Hamlet in his address to the nation last week.
'As Shakespeare says of the earlier Queen Elizabeth, she was 'a pattern to all princes living'. As I stand before you today, I cannot help but feel the weight of history which surrounds us and which reminds us of the vital parliamentary traditions to which members of both Houses dedicate yourselves with such personal commitment, for the betterment of us all.'
Prime Minister Liz Truss, as well as Labour leader Sir Keir Starmer, joined MPs and peers on Monday morning under the cavernous timber roof of the ancient building in central London.
A fanfare of trumpets sounded as the King and Queen Consort, both dressed in black, arrived in Westminster Hall. The crowds in the hall stood to attention and only sat once the King had done so, before the Lord Speaker followed by the Speaker of the House of Commons made a formal address to Charles.
The King told the assembled audience that Parliament is the 'living and breathing instrument of our democracy' as he referenced the connections to 'my darling late mother'.
In reply to addresses from both Houses of Parliament, Charles said: 'Parliament is the living and breathing instrument of our democracy. That your traditions are ancient we see in the construction of this great hall and the reminders of medieval predecessors of the office to which I have been called and the tangible connections to my darling late mother we see all around us.'
Inside Westminster Hall, Speaker Sir Lindsay Hoyle extended the sympathy of MPs to the new monarch, as well as pledging loyalty to the new King.
'In 1988, we celebrated the 300th anniversary of the revolutions of 1688 to 1689,' he told the King. 'It is perhaps very British to celebrate revolutions by presenting an address to Her Majesty; but those revolutions led to our constitutional freedoms, set out the foundation for a stable monarchy, which protects liberty.'
The hearse carrying the coffin of Queen Elizabeth II, draped with the Royal Standard of Scotland, passes along Canongate towards the Royal Mile as it completes its journey from Balmoral to the Palace of Holyroodhouse in Edinburgh
The Queen's coffin is lifted out of the hearse and carried inside the Palace of Holyroodhouse in Edinburgh
The Lord Speaker also pledged his loyalty to Charles, as he praised the Queen's 'inspiring reign of deep and unparalleled devotion'.
Lord McFall read an address, unanimously agreed by peers, conveying 'the deep sympathy felt by this House in the grief Your Majesty has sustained by the death of our late beloved Queen Your Majesty's mother of blessed and glorious memory'.
In the address, he said: 'To extend to all the royal family the deep sympathy of this house in their grief which is shared by all its members. To assure Your Majesty that the example of selfless public service, which our late sovereign displayed over her reign over 70 years, her untiring endeavours for the welfare of her peoples and her fortitude in adversity will ever be held in reverent, affectionate and grateful remembrance.
'And to express to Your Majesty our loyalty to Your Majesty's royal person and our firm conviction that under the blessing of divine providence Your Majesty will throughout your reign further the happiness and protect the liberties of all your peoples in all your realms.'
The King also referenced the connections between his historic surroundings and his mother, naming the various monuments to the Queen in the parliamentary estate.
The ceremony ended with both Charles and the Queen Consort standing as the national anthem was played.
Later, the Queen will be taken from the Palace of Holyroodhouse to nearby St Giles' Cathedral where her family, and a congregation drawn from all areas of Scottish society, will attend a service of thanksgiving for her life.
Charles will lead some of the royals - expected to be the Duke of York, Earl of Wessex and the Princess Royal and her husband Vice Admiral Sir Tim Laurence - on foot, while the Queen Consort and other members of the monarchy follow in cars.
Members of the public will be able to view the coffin to pay their respects for 24 hours before it is taken to London to lie in state.
Later in the evening, the King and other members of his family, likely his siblings, will hold a vigil at the cathedral in honour of the Queen.
Crowds are expected to swell central London in the coming days, ahead of the Queen's lying in state.
People will not be allowed to camp and will be given numbered wristbands to indicate their place in the queue so they are able to leave and come back, it is understood.
New Metropolitan Police Commissioner Sir Mark Rowley called the preparations a 'massive challenge' for the force, but said it was prepared.
'There are some very diligent and determined people who have put a lot of effort into this, and indeed myself in my previous roles in the Metropolitan Police - five or six years ago I was involved in some of that planning and I have been involved in a review recently.
'But most of all I have a lot of trust and confidence in the fantastic police officers who are going to support this event and help make it safe.
'They have been working with colleagues from across Government and the Royal Household and others, as you would expect.
'We will have a safe event but we will be putting thousands of officers into this because of the level of security required and the millions of people who want to pay their respects.'
Eight days of national sorrow: From the Queen lying in state in Edinburgh and London to royal vigil by her coffin and King Charles III touring his new realm... day-by-day guide to the next week before late monarch's funeral
King Charles III will travel to Edinburgh today as the nation continues in its period of national mourning following the death of Queen Elizabeth II on Thursday in her Scottish home of Balmoral.
Today is the first opportunity for well-wishers to pay their last respects at the Queen 's coffin, as it moves from the Palace of Holyroodhouse to St Giles' Cathedral.
The nation was plunged into mourning following the Queen's death last week, with King Charles' accession being formally carried out on Saturday, before accession ceremonies were held in Scotland and Wales yesterday.
The next eight days will see a series of events, including a service of prayer and reflection for the Queen's life at St Giles' Cathedral today, which will be followed by a vigil, held by the King and attended by other members of the royal family.
Tomorrow, the Queen's coffin will be flown to London, accompanied by the Princess Royal, before being driven to Buckingham Palace. The Queen's lying in state will begin in Westminster Hall, London, on Wednesday afternoon.
Once her body has returned to London, approximately 750,000 people are expected to file past in silence as they pay their respects to the late Queen until the morning of her funeral, on Monday, September 19.
Mourners have been told to expect 'airport-style security' to be prepared to 'wait for a long time, even overnight' in order to pay their respects.
Every stage of the extraordinary journey will be closely followed by a British public coming to terms with the loss of a beloved monarch.
Her Majesty Queen Elizabeth II passed away at the age of 96 at her summer home in Balmoral, Scotland, on Thursday. Pictured is her coffin arriving at Holyroodhouse in Edinburgh yesterday
King Charles III meeting well-wishers as he returns to Clarence House from Buckingham Palace on Saturday, September 10
Princess Anne curtseys as the Queen's coffin is carried into the Palace of Holyroodhouse in Edinburgh yesterday
William and Harry could walk side by side during the Queen's funeral procession on Monday, September 19
Prince William and Kate, Prince and Princess of Wales met well-wishers in Windsor with Prince Harry and Meghan, Duchess of Sussex on Saturday, September 10
Prince William and Kate, Princess of Wales and Britain's Prince Harry and Meghan, Duchess of Sussex view the floral tributes for the late Queen Elizabeth II outside Windsor Castle
D+3 - Monday September 12
The House of Commons and the House of Lords will come together in Westminster for a Motion of Condolence, which the King will attend.
He will address MPs and peers for the first time as monarch, before flying to Edinburgh to attend Scottish Parliament later today.
At 12.45pm, the King and the Queen consort will arrive at Edinburgh Airport and travel to the Palace of Holyroodhouse where Charles III will inspect the Guard of Honour.
As is traditional when the monarch arrives in Holyrood, the Ceremony of the Keys will follow.
At 2.35pm, the procession of the Queen's coffin will be held along the Royal Mile, travelling from the Palace of Holyroodhouse to St Giles' Cathedral.
The procession will consist of a hearse, flanked by the Bearer Party of the Royal Regiment of Scotland and the detachment of The King's Body Guard in Scotland, the Royal Company of Archers.
The King and other senior members of the Royal Family will walk the 1,200 yard route on foot.
King Charles will be joined by his brothers, Prince Edward, the Earl of Wessex, Prince Andrew, the Duke of York, and his sister, the Princess Royal.
It is expected that her husband Vice Admiral Sir Tim Laurence will also join on foot - while the Queen Consort and other members of the monarchy will follow in cars.
It is not known if this will include William and Kate, the Prince and Princess of Wales, or Prince Harry and Meghan, the Duchess of Sussex.
Once laid in St Giles' Cathedral, the Crown of Scotland will be placed on the Queen's coffin.
Members of the public gather at St Giles Cathedral to view the cortege carrying Queen Elizabeth II from the Palace of Holyroodhouse today
Charles III during a reception with Realm High Commissioners and their spouses in the Bow Room at Buckingham Palace yesterday
Today members of the royal family will walk behind the Queen's coffin during a procession from the Palace of Holyroodhouse to St Giles' Cathedral, Edinburgh, at 2.35pm. Pictured, the coffin arrives in Edinburgh yesterday
Following the procession this afternoon, King Charles will hold audiences with leaders, and speak at the Scottish parliament.
This will include audiences with First Minister Nicola Sturgeon and Alison Johnstone, the Presiding Officer of the Scottish Parliament.
His journey will mark the start of tour of the nations.
At 7.20pm, the King and other family members will mount a vigil by the coffin.
Full details about the royal mourners have yet to be released but there is speculation the Duke and Duchess of Sussex and the new Prince and Princess of Wales, who on Saturday put on a united front during an appearance at Windsor Castle, will be part of the group.
The Queen will then lie at rest for 24 hours, with thousands expected to file past as they pay their respects.
After leaving England and visiting Scotland, King Charles will at some stage travel to the other countries of the UK - Wales and Northern Ireland - known as Operation Spring Tide.
People in Banchory line the street as the Queen's coffin was driven from Balmoral to Edinburgh on Sunday, September 11
Military guards march in Edinburgh prior to the arrival of the cortege carrying the coffin of the late Queen Elizabeth II
An Accession Proclamation Ceremony at Mercat Cross, Edinburgh, publicly proclaims King Charles III as the new monarch on Sunday, September 11
While the King has declared his mother's state funeral as a Bank Holiday, there is no legal requirement for employers to give staff the day off. King Charles III is pictured on Sunday as he arrives at Buckingham Palace in London
The King and Queen Consort are to fly to Northern Ireland on Tuesday to visit Hillsborough Castle (pictured)
Members of the public leave flowers at the gates following the proclamation of King Charles III at Hillsborough Castle on Sunday, September 11
D+4 - Tuesday September 13
The King and Queen Consort are to fly to Northern Ireland on Tuesday to visit Hillsborough Castle, where they will view an exhibition about the late Queen's long association with the province.
The King will then meet Northern Ireland Secretary Chris Heaton-Harris and party leaders, and receive a message of condolence led by the Speaker of the Northern Ireland Assembly.
After a short reception at Hillsborough, the King and Queen Consort will travel to St Anne's Cathedral for a service of prayer and reflection.
Before the event, King Charles will meet leaders from all the major faiths in Northern Ireland.
The royal couple will return to London later in the day, as the Queen's coffin flies into the capital.
At 5pm on Tuesday, the Queen's coffin will be taken by hearse to Edinburgh airport, where it will be met by a Guard of Honour from the Royal Regiment of Scotland.
The Royal Air Force bearer party will then carry it on to a waiting RAF aircraft, where it will be flown to London at 6pm.
She will be accompanied by Princess Anne and arrive at RAF Northolt in West London shortly before 7pm.
The coffin will then be driven to Buckingham Palace where it will be met by a Guard of Honour.
There it will rest in the Bow Room, under the watch of a rota of chaplains.
A rehearsal for the procession of the coffin from Buckingham Palace to the Palace of Westminster is also expected to take place.
Details about the route for the lying-in-state queue will be provided late on Tuesday September 13.
It is not yet known where other members of the royal family will be on Tuesday.
At 6pm on Tuesday, the Queen's coffin will be flown from Edinburgh airport to RAF Northolt in West London. Pictured, King Charles and Camilla, Queen Consort, arriving at RAF Northolt on Friday, September 9
Her body will lie in state at Westminster Hall from 5pm on Wednesday until 6.30am on the morning of her funeral on September 19. Pictured, the Queen Mother's coffin lying-in-state in Westminster Hall
Members of the public who pay their respects at Westminster will be subject to strict security checks and restrictions, including a ban on large bags, flowers and photos (Pictured mourners filing past the coffin of The Queen Mother in Westminster Hall)
Details of the route for the lying-in-state queue will be published at 10pm tomorrow. It is likely to snake for miles, all the way along the southside of the River Thames to Tower Bridge
D+5 - Wednesday September 14
The Queen's lying in state is expected to begin in Westminster Hall - Operation Marquee - following a ceremonial procession through London that will begin at 2.22pm.
The King will walk behind the gun carriage carrying his mother's coffin to Westminster Hall, in the Palace of Westminster, also known as the Houses of Parliament, marking the second time he has walked behind her in three days.
The coffin, adorned with the Imperial State Crown, be transported on a gun carriage of The King's Troop Royal Horse Artillery from Buckingham Palace.
The King, members of the royal family and senior staff of the late Queen and King's households will walk slowly behind in a dignified silence without music in a route that will take 38 minutes.
On arrival, the coffin will be placed on a raised bier where the Queen will lie in state for four full days.
The Archbishop of Canterbury will conduct a short service following the coffin's arrival.
Hundreds of thousands of people will file past the coffin on its catafalque and pay their respects, just as they did for the Queen Mother's lying in state in 2002.
Those wishing to pay their respects will be able to file solemnly past the Queen's coffin 24 hours a day from 5pm on Wednesday September 14 until 6.30am on the day of the funeral - Monday September 19.
Well-wishers have been told to expect 'very little opportunity to sit down as the queue will be continuously moving'.
Visitors will only be allowed to bring one small bag with them, smaller than 40cm x 30cm x 20cm, and have been told to dress for the weather and bring refreshments.
People are not allowed to film, take pictures or use their phones inside the Palace of Westminster.
Large crowds are expected to attend, with delays on public transport and road closures anticipated.
Details of the route for the lying-in-state queue will be published at 10pm tomorrow, with full guidance on the gov.uk website.
Security staff manning the queue route to Westminster Hall said today that crowds are expected to swell ahead of Wednesday afternoon.
They said the queue is likely to snake for miles, all the way along the southside of the River Thames to Tower Bridge.
And the Army may be drawn in to help, with 1,500 personnel available to help staff the queues.
It is understood that people will also be given wristbands so that they can temporarily leave the queue for toilet breaks.
Senior royals are also expected to pay their own moving tribute, standing guard at some stage around the coffin — the tradition known as the Vigil of the Princes.
This could include the Queen's children and grandchildren, although details have not been confirmed.
The management of the queues outside is Operation Feather.
During the Covid-19 crisis, plans included the possibility of the introduction of timed ticketing for those wanting to attend.
In Cardiff, the 3rd battalion of the Royal Welsh and The Band of the Royal Welsh arrive at Cardiff Castle accompanied by the regimental mascot during of the Welsh Proclamation of King Charles III on Sunday, September 11
Lance Corporal Shenkin IV, the regimental mascot goat, accompanies the 3rd Battalion of the Royal Welsh regiment on Sunday, September 11
Wales Herald of Arms Extraordinary, Thomas Lloyd, reads the proclamation in English at the Accession Proclamation Ceremony at Cardiff Castle on Sunday, September 11. To the left stands Wales' First Minister Mark Drakeford
On Friday, King Charles will continue his tour of the UK, travelling to Wales to receive a motion of condolence at the Welsh Parliament. Pictured, the Senedd
D+6 - Thursday September 15
Lying in state continues and a rehearsal is likely to take place for the state funeral procession.
It is not yet known where members of the royal family will be on Thursday.
D+7 - Friday September 16
On Friday, King Charles will continue his tour of the UK, travelling to Wales to receive a motion of condolence at the Welsh Parliament, and attend a service at Llandaff Cathedral, in Cardiff.
Lying in state continues at Westminster Hall.
It is not yet known where members of the royal family will be on Friday.
D+8 - Saturday September 17
The lying in state continues and heads of state will begin to arrive for the funeral.
Foreign heads of state and their spouses have been banned from using private jets and helicopters to get to the Queen's funeral – and told to take the coaches instead.
Whitehall has issued strict guidance for dignitaries arriving in the UK to pay their respects to the monarch when she is laid to rest at Westminster Abbey on Monday, September 19.
Leaked documents obtained by the Politico news website reveal the world's political elite will be banned from using their own cars to get to the abbey, and instead will be asked to park in west London and take a coach.
The UK's foreign office has also asked attendees to refrain from using private jets, and has limited spaces at the funeral to two per nation.
Elements of the plan have been met with incredulity in some quarters, with one foreign ambassador complaining: 'Can you imagine Joe Biden on the bus?'
Organisers blamed 'tight security and road restrictions', and said Heathrow is 'not available for private flight arrangements'. Helicopter transfers from airports are banned 'due to the number of flights operating at this time'.
D+9 - Sunday September 18
Heads of state will continue arriving for the funeral. An evening reception will be held for funeral guests, including prime ministers, heads of state and other dignitaries from across the world.
This may also include members of the royal family, although details have not been confirmed.
At 8pm, people will be invited to come together to 'mourn and reflect on the life and legacy of Queen Elizabeth II' during a minute's silence.
The Prime Minister's official spokesman confirmed that there will be a one-minute silence the night before the state funeral.
'The public are invited to come together and observe a national moment of reflection to mourn and reflect on the life and legacy of Queen Elizabeth II,' they said.
'The silence can be marked privately at home on your own or with friends and neighbours, out on your doorstep or street with neighbours, or at any locally arranged community events and vigils.
'We encourage local community groups, clubs and other organisations to mark this moment of reflection. And if you are overseas, people are encouraged to mark the silence at their local time.
'The shared national moment of reflection is an opportunity for everyone across the UK to mark the death of Her Majesty and we will set out details of where the Prime Minister will mark it closer to that time.'
The King will also hold an audience with the Prime Minister on Sunday.
Pictured, Britain's Prince Harry, Prince Phillip, Peter Phillips and Princess Anne walk behind the Royal coffin at the State Funeral of the Queen Mother April 9, 2002 outside Westminster Abbey in London
During the Queen's funeral, senior members of the royal family will follow behind - just like they did for the funeral of the Queen Mother. Pictured, the Duke of York, Prince Charles, Duke of Edinburgh, Princess Royal, and Earl of Wessex walk behind the Queen Mother's coffin on April 9, 2002
D+10 - Monday September 19
On Monday, there will be a national bank holiday to allow as many people as possible to watch the Queen's funeral.
Lying in state will continue until 6.30am, after which well-wishers will no longer be able to pay their respects to the Queen in Westminster Hall, with the funeral beginning in less than five hours.
The Queen's state funeral will take place at Westminster Abbey in central London at 11am.
The coffin will be taken in a grand military procession from the Palace of Westminster to Westminster Abbey for the state funeral.
The original plans are for the Queen's coffin to process on a gun carriage to the abbey, pulled by naval ratings — sailors — using ropes rather than horses.
Senior members of the family will follow behind - just like they did for the funeral of Diana, Princess of Wales and the Duke of Edinburgh.
It is not clear yet who will be involved in this, but it may include King Charles, the Princess Royal and her husband Vice Admiral Sir Tim Laurence, Prince Edward, Earl of Wessex and his wife Sophie, Countess of Wessex, and Prince Andrew, Duke of York.
It could also include the Queen's grandchildren; William, the Prince of Wales; Prince Harry, Duke of Sussex; Princess Beatrice and Eugenie, the Duke of York's daughters; Peter Phillips and Zara Tindall, the Princess Royal's children; and Lady Louise Windsor and James, Viscount Severn; Prince Edward's children.
Kate, the Princess of Wales and Meghan, Duchess of Sussex, will also be in attendance at the funeral. The Princess of Wales may play a more significant role in proceedings as spouse to the heir apparent, William, the Prince of Wales.
The military will line the streets and also join the procession.
Heads of state, prime ministers and presidents, European royals and key figures from public life will be invited to gather in the abbey, which can hold a congregation of 2,000.
The service will be televised, and a national two minutes' silence is expected to be held at midday.
After the service, the coffin will be taken in procession from Westminster Abbey to Wellington Arch and then travel to Windsor.
Once there, the hearse will travel in procession to St George's Chapel at Windsor Castle via the Long Walk, after which a televised committal service will take place in St George's Chapel.
Later in the evening, there will be a private interment service with senior members of the royal family.
The Queen's final resting place will be the King George VI memorial chapel, an annex to the main chapel - where her mother and father were buried, along with the ashes of her sister, Princess Margaret.
Philip's coffin will move from the Royal Vault to the memorial chapel to join the Queen's.
|
https://www.dailymail.co.uk/news/article-11203677/Prince-Andrew-banned-wearing-military-uniform-mourning-Queen.html?ns_mchannel=rss&ns_campaign=1490&ito=1490
| 2022-09-12T11:39:05Z
|
https://www.dailymail.co.uk/news/article-11203677/Prince-Andrew-banned-wearing-military-uniform-mourning-Queen.html?ns_mchannel=rss&ns_campaign=1490&ito=1490
| true
|
Americans give health care system failing mark: AP-NORC poll
WASHINGTON (AP) — When Emmanuel Obeng-Dankwa is worried about making rent on his New York City apartment, he sometimes holds off on filling his blood pressure medication.
“If there’s no money, I prefer to skip the medication to being homeless,” said Obeng-Dankwa, a 58-year-old security guard.
He is among a majority of adults in the U.S. who say that health care is not handled well in the country, according to a new poll from The Associated Press-NORC Center for Public Affairs Research.
The poll reveals that public satisfaction with the U.S. health care system is remarkably low, with fewer than half of Americans saying it is generally handled well. Only 12% say it is handled extremely or very well. Americans have similar views about health care for older adults.
Overall, the public gives even lower marks for how prescription drug costs, the quality of care at nursing homes and mental health care are being handled, with just 6 percent or less saying those health services are done very well in the country.
“Navigating the American health care system is exceedingly frustrating,” said A. Mark Fendrick, the director of the University of Michigan Center for Value-Based Insurance Design. “The COVID pandemic has only made it worse.”
More than two years after the pandemic’s start, health care worker burnout and staffing shortages are plaguing hospitals around the country. And Americans are still having trouble getting in-person medical care after health centers introduced restrictions as COVID-19 killed and sickened millions of people around the country, Fendrick said.
In fact, the poll shows an overwhelming majority of Americans, nearly 8 in 10, say they are at least moderately concerned about getting access to quality health care when they need it.
Black and Hispanic adults in particular are resoundingly worried about health care access, with nearly 6 in 10 saying they are very or extremely concerned about getting good care. Fewer than half of white adults, 44%, expressed the same level of worry.
Racial disparities have long troubled America’s health care system. They have been abundantly clear during the COVID-19 pandemic, with Black and Hispanic people dying disproportionately from the virus. Black and Hispanic men also make up a disproportionately high rate of recent monkeypox infections.
Fifty-three percent of women said they are extremely or very concerned about obtaining quality care, compared to 42% of men.
While Americans are united in their dissatisfaction with the health care system, that agreement dissolves when it comes to solutions to fix it.
About two-thirds of adults think it is the federal government’s responsibility to make sure all Americans have health care coverage, with adults ages 18 to 49 more likely than those over 50 to hold that view. The percentage of people who believe health care coverage is a government responsibility has risen in recent years, ticking up from 57% in 2019 and 62% in 2017.
Still, there’s not consensus on how that coverage might be delivered.
About 4 in 10 Americans say they support a single-payer health care system that would require Americans to get their health insurance from a government plan. More, 58%, say they favor a government health insurance plan that anyone can purchase.
There also is broad support for policies that would help Americans pay for the costs of long-term care, including a government-administered insurance plan similar to Medicare, the federal government’s health insurance for people 65 or older.
Retired nurse Pennie Wright, of Camden, Tennessee, doesn’t like the idea of a government-run health care system.
After switching to Medicare this year, she was surprised to walk out of her annual well-woman visit, once fully covered by her private insurance plan, with a $200 bill.
She prefers the flexibility she had on her private insurance plan.
“I feel like we have the best health care system in the world, we have a choice of where we want to go,” Wright said.
A majority of Americans, roughly two-thirds, were happy to see the government step in to provide free COVID-19 testing, vaccines and treatment. Roughly 2 in 10 were neutral about the government’s response.
The government’s funding for free COVID-19 tests dried up at the beginning of the month. And while the White House says the latest batch of recommended COVID-19 boosters will be free to anyone who wants one, it doesn’t have money on hand to buy any future rounds of booster shots for every American.
Eighty percent say they support the federal government negotiating for lower drug prices. President Joe Biden this summer signed a landmark bill into law allowing Medicare to negotiate the price of prescription drugs. The move is expected to save taxpayers as much as $100 billion over the next decade.
“Medication costs should be low, to the minimum so that everyone can afford it,” said Obeng-Dankwa, the Bronx renter who has trouble paying for his medication. “Those who are poor should be able to get all the necessary health they need, in the same way someone who also has the money to pay for it.”
___
AP polling reporter Hannah Fingerhut in Washington contributed to this report.
___
The poll of 1,505 adults was conducted July 28-Aug. 1 using a sample drawn from NORC’s probability-based AmeriSpeak Panel, which is designed to be representative of the U.S. population. The margin of sampling error for all respondents is plus or minus 3.6 percentage points.
___
Follow AP’s coverage of health care costs at https://apnews.com/hub/health-care-costs.
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.kait8.com/2022/09/12/americans-give-health-care-system-failing-mark-ap-norc-poll/
| 2022-09-12T11:39:40Z
|
https://www.kait8.com/2022/09/12/americans-give-health-care-system-failing-mark-ap-norc-poll/
| true
|
New Investor Time BioVentures Leads Round, With Risk & Return (R²) and Existing Backers
AUSTIN, Texas, Sept. 12, 2022 /PRNewswire/ -- Phantom Neuro, the first-of-its-kind neurotech startup that delivers a low power, high accuracy system for lifelike control of robotic orthopedic technologies, today announced a $6 million funding round led by new investor Time BioVentures. The round included participation from another new investor, Risk & Return (R²), an innovative venture fund focused on "capitalism for good". Support from returning investors LionBird Ventures, Draper Associates & Breakout Ventures now brings the company's total funding to $9.5M. With the financing, co-founder of Time BioVentures, D.A. Wallach, will join the company's board. The company also announced the addition of two key hires: Aurel Bouvier, PhD, Vice President of Implantable Systems and Erik Lloyd, Senior Neuroengineer.
Launched just six months ago, Phantom Neuro aims to dramatically enhance the lives of amputees and other patients with function deficits. The company's solution combines low-risk implantable sensors, AI, and enabling software to offer unparalleled control of orthopedic technologies, such as prosthetic limbs and exoskeletons.
"The field of advanced robotics has enormous potential to augment patients' daily lives, and yet we lack practical and effective commercially available devices to control these systems outside of the lab. Phantom Neuro is filling this void by creating an elegant link between biology and prosthetics that has the potential to revolutionize the standard of care for patients," says D.A. Wallach, General Partner of Time BioVentures. "Connor Glass, Phantom Neuro's founder, brings to this challenge formidable talents as a physician, inventor, and company builder. We believe he and his growing team have what it takes to deliver real solutions to patients with urgency and creativity."
Today over two million Americans live with limb loss, a number that is expected to nearly double by 2050. Over 185,000 amputations are conducted in the U.S. yearly due to trauma, increasing age, diabetes, and vascular disease; estimates of hospital charges to amputation patients in the United States total $10 billion annually. Illuminating new prosthetic technologies exist, yet modern device abandonment rates are still as high as 50%+ due to difficulty in operation, weight, and inconvenience. Phantom Neuro's answer to these obstacles is superior control of existing and next-generation orthopedic technologies. With improved patient outcomes through superior control, the incentives align for enhanced innovation in the robotic orthopedic space. Unique to Phantom's tech is also its promise of scalability - the platform has the safety and simplicity required to grow into a platform for lifelike control of virtually any wirelessly compatible device.
"We're privileged today to announce our second round of funding. I believe our rapid progress demonstrates the importance of our mission and the strength of our team. I'm thrilled to have the support of like-minded investors such as Time BioVentures and Risk & Return helping us hit our targets and work towards human trials," remarked Dr. Connor Glass, Founder and CEO of Phantom Neuro and primary inventor of Phantom's technology. "With their and returning investors' steadfast backing and advice, not to mention our growing team of experienced engineers, we're excited to achieve our next milestones."
The startup has been on an exhilarating trajectory since launch, fulfilling strategic steps leading them closer to human trials. Most recently the company announced a partnership with Blackrock Neurotech and the appointment of Dr. Geoffrey Ling, the current CEO of On Demand Pharmaceuticals and previously the Founding Director of the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office, to the board.
About Phantom Neuro
Phantom is a neurotechnology company, spun out of a lab at the Johns Hopkins University School of Medicine, that is enabling lifelike control of robotic orthopedic technologies like prosthetic limbs and exoskeletons. You can find out more at www.phantomneuro.com
About Time BioVentures
Time BioVentures is a life sciences and healthcare investment firm based in Southern California. www.TimeBioVentures.com
CONTACT
Shannon Wilsey, Public Relations | Phantom Neuro
info@phantomneuro.com
View original content to download multimedia:
SOURCE Phantom Neuro Inc.
|
https://www.wlbt.com/prnewswire/2022/09/12/phantom-neuro-raises-6m-expanded-seed-funding-company-growth-development-advanced-platform-patient-capability-restoration/
| 2022-09-12T11:40:32Z
|
https://www.wlbt.com/prnewswire/2022/09/12/phantom-neuro-raises-6m-expanded-seed-funding-company-growth-development-advanced-platform-patient-capability-restoration/
| true
|
Deal marks fourth investment from Pharos Fund IV, focused on value-based care
DALLAS and NASHVILLE, Tenn., Sept. 12, 2022 /PRNewswire/ -- Pharos Capital Group, LLC ("Pharos"), a middle-market private equity firm based in Dallas and Nashville, announced today it has made a significant investment in Renal Care 360° (or the "Company"), a comprehensive nephrology practice and chronic care management company founded by accomplished renal care entrepreneur Joe Cashia. Renal Care 360° partners with health systems, physician groups and local communities to provide enhanced community healthcare management services with a primary focus on patients in underserved, rural communities.
Pharos's investment, along with additional equity investment from the Company's founding shareholders, will be used to support continued growth of the Company's RC360° Connected Care Program, geographic expansion through acquisitions, and development of value-based care programs. Terms of the transaction were not disclosed.
Renal Care 360° has developed a unique model centered on early detection of unidentified chronic conditions using proprietary data analytics. Once medical conditions are identified, the Company offers early interventions through its affiliated physician practices with personalized education, real-time engagement, local and virtual clinic options, and dedicated care coordination to slow disease progression and improve outcomes for chronic kidney disease ("CKD"), end stage kidney disease ("ESKD"), and other co-morbidities. Renal Care 360° is also raising awareness and improving education of kidney disease in areas most impacted by inequities in access to care, enabling its health system and physician group partners to proactively engage and care for their patients.
Jim Phillips, a Partner at Pharos, said, "With the nationwide push to reform kidney care through deeper engagement of the population's most vulnerable CKD and ESKD patients, we have observed Renal Care 360°'s use of machine learning to early-identify and intervene with comprehensive, compassionate care to be a uniquely impactful model. Their specialized approach helps to slow disease progression, prevent unnecessary hospital admissions, enable physician and health system partners to continuously engage with their patients, and dramatically improve patient experiences and outcomes. We are thrilled to be partnering with a management team whose longstanding dedication to kidney care, physician practice management, home health, and population health is only rivaled by their passion to meaningfully improve and prolong the lives of many thousands of patients who may otherwise slip through the cracks."
Renal Care 360° founder Joe Cashia will continue to lead the Company as Chairman and CEO. Mr. Cashia is a 35-plus-year veteran of the healthcare industry with deep experience across the continuum of kidney care who has partnered with physicians and hospitals across the country and has created, acquired, and managed more than 1,000 healthcare centers. Previously serving as CEO of National Renal Alliance, Vivere Health, and Ascend Health Care Services and in various Board roles, Mr. Cashia has extensive experience in scaling complex healthcare service organizations with a deep appreciation for the importance of partnering with physician leaders and clinicians to drive value-based care initiatives and improve patient outcomes.
Mr. Cashia noted, "We are pleased to bring in such an experienced, healthcare-focused partner to help Renal Care 360° rapidly expand its care model to touch the lives of as many patients as possible. Pharos's dedication to bridging inequities in care, demonstrated by their proven track record guiding value-based healthcare organizations, will be invaluable as we grow our clinic footprint, scale chronic care management infrastructure to meet the overwhelming market need, and work with health systems and payors to align incentives around optimization of patient outcomes to generate transformational cost savings to the system."
This marks the fourth investment from Pharos's latest flagship fund, Pharos Capital Partners IV, L.P., investing alongside its parallel fund, Pharos Capital Partners IV-A, L.P., a licensed Rural Business Investment Company. The funds will continue Pharos's mission of lowering costs, improving outcomes, and expanding access to care, particularly within underserved rural communities.
About Renal Care 360°
Renal Care 360º is a comprehensive nephrology practice and chronic care management company partnering with health systems, physician groups and local communities to provide enhanced community healthcare management services. Renal Care 360°'s Connected Care Program partners with PCPs, nephrologists, and other physician groups to augment existing services by providing patients with a customized care coordination and education program based on the patient's health needs. In addition to contracted chronic care management services, Renal Care 360° intends to acquire nephrology practices that share a passion to transform kidney care through early detection and deep patient engagement with comprehensive care management.
For business development opportunities with Renal Care 360°, please contact Molly Braun at 985-264-4074 or mbraun@renalcare360.com.
About Pharos Capital Group
Based in Dallas and Nashville, Pharos Capital Group (www.pharosfunds.com) is a physician-founded investment firm focused on growing healthcare companies that aim to lower the total cost of care, improve patient outcomes and reduce healthcare inequalities in underserved markets, especially within urban and rural communities. Since inception, Pharos has invested in 58 companies and has over $1.2 billion of private equity assets under management as of June 30, 2022. Pharos typically invests $25-$50 million in rapidly growing middle market companies seeking later stage funding for internal growth, acquisitions, leveraged buyouts, management buyouts, or recapitalizations across healthcare sectors.
For business development opportunities with Pharos Capital Group, please contact Adam Persiani at 214-740-7003 or apersiani@pharosfunds.com.
Contact
Jennifer Hurson
845-507-0571
jhurson@lambert.com
View original content:
SOURCE Pharos Capital Group
|
https://www.wlbt.com/prnewswire/2022/09/12/pharos-capital-invests-renal-care-360-capitalizes-new-chronic-kidney-care-management-platform/
| 2022-09-12T11:40:39Z
|
https://www.wlbt.com/prnewswire/2022/09/12/pharos-capital-invests-renal-care-360-capitalizes-new-chronic-kidney-care-management-platform/
| true
|
The Clovers might be coming back to cheer once more! ET caught up with Gabrielle Union at the 2022 Daytime Beauty Awards on Sunday where she teased a possible sequel to her 2000s cult classic cheerleading film, Bring It On.
Union was joined by her longtime friend and business partner Larry Sims at the Taglyan Complex in Los Angeles where they talked all things beauty, business and told the story of how they met on the Bring It On set back in the day.
"We met on the set of Bring It On!" Union told ET's Nischelle Turner. "Yes, I used to dance for the Blaque, her cheerleading teammates," Sims added.
When asked about a rumored sequel in the works, the actress teased, "I've heard many takes over the years, but I'm hearing some really great takes from some big-name writers that are very surprising."
"Bring it On, baby, the gift the keeps on giving," Union added.
Then, Union discussed a possible storyline where her character Isis, who was the captain of the East Compton Clovers cheerleading team, is now the mother of a young cheerleader.
"Imagine if her daughter was, ya know, a high stepper from Jackson State, Hawthorne State or Hampton. There's so many forms of cheerleading that we don't get to celebrate," Union said. "The possibilities are endless," she concluded.
Last month, Union fueled buzz around a possible Bring It On sequel when she tweeted a response to a post that noted the film premiered 22 years ago. "Hmmmm so Isis might have a teenager," she wrote.
Union and Sims are co-owners of the haircare brand Flawless and were recognized as Brand of the Year at the 2022 Daytime Beauty Awards.
RELATED CONTENT:
|
https://www.wfaa.com/article/entertainment/entertainment-tonight/gabrielle-union-discusses-a-possible-bring-it-on-sequel-exclusive/603-7ec89cf1-b7b8-4077-bb74-ac4184f2add3
| 2022-09-12T11:41:16Z
|
https://www.wfaa.com/article/entertainment/entertainment-tonight/gabrielle-union-discusses-a-possible-bring-it-on-sequel-exclusive/603-7ec89cf1-b7b8-4077-bb74-ac4184f2add3
| true
|
Pope heads to Kazakh interfaith congress, without patriarch
By NICOLE WINFIELD and KOSTYA MANENKOV
Associated Press
VATICAN CITY (AP) — Pope Francis had hoped his trip to Kazakhstan this week would offer a chance to meet with the head of the Russian Orthodox Church — who has justified the war in Ukraine — and plead for peace. Patriarch Kirill bowed out a few weeks ago, but Francis is going ahead with the trip that is nevertheless being overshadowed by Russia’s seven-month war.
Francis travels to the majority-Muslim former Soviet republic on Tuesday to minister to its tiny Catholic community and participate in a Kazakh-sponsored conference of world religious leaders. The conference had as its original goal to promote interfaith dialogue in the post-pandemic world, but Russia’s invasion of Ukraine has given it a more immediate cause: for faith leaders from around the world to appeal for peace with a united voice.
“It will be an occasion to meet so many religious representatives and to dialogue as brothers, animated by the common desire for peace, the peace for which our world is thirsting,” Francis told thousands of people in St. Peter’s Square on Sunday.
In a way, Kirill’s absence will make life easier for all involved: Kazakhstan won’t have its showcase gathering of Muslim, Christian, Buddhist, Shinto and Jewish leaders from 50 countries overshadowed by a headline-grabbing photo op between the pope and the patriarch. Francis won’t have the diplomatic headache of having to explain to Ukraine why he met with an ideological supporter of Russia’s war before Francis even visited Kyiv. And Kirill will avoid the embarrassment of being present when a global congress of imams, rabbis, ministers and a pope issues a final statement largely expected to denounce war.
But for Kazakhstan’s Catholic leaders, Kirill’s absence represents something of a lost opportunity.
“Personally I am pained,” said Bishop Adelio Dell’Oro of the Kazakh diocese of Karaganda. “I think a meeting between them on the sidelines of the congress would have been a notable contribution, notable in this process of peace to clarify what religions can contribute to human coexistence in the world. So I am disappointed, but you have to accept it.”
The interfaith congress is an important triennial event for Kazakhstan, a country that borders Russia to the north, China to the east and is home to some 130 ethnic groups: It’s a showpiece of its foreign policy and a reflection of its own multicultural and multiethnic population that has long been touted as a crossroads between East and West.
“We can say that Kazakhstan is really a place where dialogue is not some formal slogan, but this is a Kazakh brand,” said Monsignor Piotr Pytlowany, spokesman for the Kazakh bishops conference. “Kazakhstan wants to share dialogue not only during this congress but also after it, offering the dialogue as one of the possible ways to resolve the various difficulties that the world now faces.”
When St. John Paul II visited in 2001, 10 years after independence, he highlighted Kazakhstan’s diversity while recalling its dark past under Stalinist repression: Entire villages of ethnic Poles were deported en masse from western Ukraine to Kazakhstan beginning in 1936, and the Soviet government deported hundreds of thousands of ethnic Germans, Chechens and other accused Nazi collaborators to Kazakhstan during World War II. Many of the deportees’ descendants remained and some of them make up the country’s Catholic community, which only numbers about 125,000 in a country of nearly 19 million.
Kazakh bishops had asked Francis to visit a former Soviet detention camp during his three-day visit, but the 85-year-old pope declined due to his strained knee ligaments, which have forced him to use a wheelchair and cane to get around.
His program has time for private meetings with religious leaders attending the congress. While the Vatican hasn’t released a list, expected participants include Sheikh Ahmed al-Tayeb, the grand imam of Al-Azhar, the seat of Sunni learning in Cairo.
One visitor not currently on his agenda: Chinese President Xi Jinping, who is expected in Kazakhstan on his first foreign trip since the coronavirus pandemic. Vatican spokesman Matteo Bruni said there were no current plans for any meeting and noted that Xi isn’t attending the religious conference. China and the Holy See haven’t had diplomatic relations for over a half-century.
Francis has repeatedly denounced Russia’s war in Ukraine as an unjust “violent aggression,” expressed solidarity with the “martyred” Ukrainian people and sent personal envoys to Ukraine to provide humanitarian and spiritual aid. At the same time, he has refrained from calling out Russia or President Vladimir Putin by name, trying to maintain a path of dialogue with Moscow in keeping with the Vatican’s diplomatic tradition of not taking sides in a conflict.
Kirill has justified Russia’s invasion of Ukraine on spiritual and ideological grounds, calling it a “metaphysical” battle with the West. He has blessed Russian soldiers going into battle and invoked the idea that Russians and Ukrainians are one people.
The Kazakh congress would have provided a neutral location and coincidental excuse for their second-ever meeting, and both Kirill and Francis had originally confirmed their presence. But Kirill pulled out last month. A former Vatican ambassador to Moscow has suggested that grumblings within the Russian Orthodox hierarchy might have factored into Kirill’s decision.
Perhaps they saw the writing on the wall. Just last week, the general assembly of the World Council of Churches, a fellowship of more than 350 churches representing more than a half-billion Christians worldwide, denounced what it called an “illegal and unjustifiable” invasion and demanded the immediate withdrawal of Russian troops from Ukraine.
The Russian Orthodox Church, which is a member of the WCC, refused to vote for the “politicized” declaration and complained about what it called “unprecedented pressure” on members to condemn Moscow and the Russian church.
Kazakhstan, for its part, has had to walk a thin line with the war. President Kassym-Jomart Tokayev has vowed to respect Western sanctions against Russia while trying to maintain close ties with Moscow, an important economic partner and ally. At the same time Tokayev refused to recognize the Russia-backed separatist “people’s republics” in Ukraine, which Moscow recognized days before invading Ukraine.
While Kazakhstan could have emerged as the mediator if Francis and Kirill had met, “maybe it’s even better that this is not happening because Kazakhstan would have looked like as a country that is getting involved in the Ukraine crisis, and this is the last thing that Kazakhstan wants to do right now,” said Temur Umarov, a Central Asia expert and fellow at the Carnegie Endowment for International Peace.
___
Manenkov reported from Nur-Sultan, Kazakhstan.
|
https://kion546.com/news/ap-national-news/2022/09/12/pope-heads-to-kazakh-interfaith-congress-without-patriarch/
| 2022-09-12T11:45:51Z
|
https://kion546.com/news/ap-national-news/2022/09/12/pope-heads-to-kazakh-interfaith-congress-without-patriarch/
| false
|
A growing number of Republican politicians are moving to penalize Wall Street investors who consider environmental, social and governance (ESG) issues when they decide where to put clients' money.
In Florida, a state board chaired by Gov. Ron DeSantis recently barred investment fund managers and advisors from considering "social, political, or ideological interests" when making decisions for Florida's retirement system. In Texas and West Virginia, GOP leaders say they will block investors from state business who they claim "boycott" the fossil fuel industry. Fifteen other states are considering similar measures. And Republicans have said that if they retake Congress in the midterms, they plan to push federal legislation to curtail investment decisions they attack as "woke."
Anti-ESG Republicans say big financial firms are abusing their power to advance a liberal agenda on issues like diversity, social justice and, especially, climate change.
Many experts disagree, saying Republicans are distorting the goals and strategies of ESG investing.
It's hard for most people to get a clear read of what ESG is amid the overheated rhetoric. Is the idea to bring about social changes that couldn't be achieved at the ballot box? And what does it mean for things like your 401K when investors follow ESG principles?
This FAQ is for anyone who wants to better understand an investing trend that is becoming core to global financial markets and a new battlefront in American politics — including, possibly, in your own state.
What is ESG?
It's probably easiest to think of this as a set of considerations that investors are using to try to understand risks and opportunities that aren't accounted for in traditional financial models.
Climate change is one of the simplest examples: Investors are trying to find out how physical risks from things like rising sea levels and worsening drought could impact a company's operations. For example, does a company rely on water to operate its factories, or to move goods in places like Europe or China where rivers have dried to a trickle this summer?
Investors also want information about "transition risk" — how companies will fare as governments enact policies aimed at cutting emissions and demand grows for things like renewable energy and batteries.
"It's about looking at a business and saying, 'Are they prepared for the climate transition that's coming?'" says Witold Henisz, faculty director of the ESG Initiative at The Wharton School of Business at the University of Pennsylvania. "Some companies are, and some companies aren't. And that tilts your portfolio, it shifts your investment strategy."
ESG is different from impact investing, where the goal is to make money by investing in companies that are trying to achieve certain social or environmental outcomes.
"In our view, ESG is more of a sort of defensive framework," says Kunal Shah, a managing director at iCapital, a financial technology company. "Whereas impact investing ... is focused on investing in companies with a clear mission to make a change to the positive."
Are ESG investors boycotting fossil fuels?
It doesn't look that way. Big banks continue to provide hundreds of billions of dollars in financing to the fossil fuel industry every year. BlackRock, the world's largest asset manager and a favorite target of anti-ESG Republicans, is one of the top shareholders in many leading oil and gas companies.
"ESG isn't about a boycott," says Henisz of the Wharton School. "It's a question of which fossil fuel company do you hold? And how long do you hold them?"
In fact, BlackRock's CEO, Larry Fink, has said he thinks selling off fossil fuel stocks — or divestment — is an ineffective way to fight climate change. Instead, Fink has advocated for engagement, urging shareholders to press fossil fuel executives to be transparent about their plans for the future.
That said, it has gotten more expensive for fossil fuel companies to borrow money in recent years, reflecting the risks those companies face from climate change, says Tensie Whelan, director of New York University's Stern Center for Sustainable Business.
"It's not so much that [lenders are] punishing the companies. They're just saying, 'Hey, there's risk. And just like we would with any other products, we need to financially assess those risks and build them into the cost of credit,'" Whalen says.
Is ESG hurting the financial performance of companies or investors?
It doesn't appear to be.
NYU's Whalen co-authored a report examining the relationship between ESG and financial performance. After reviewing more than 1,000 research papers published between 2015 and 2020, Whalen's team found that corporate sustainability initiatives often seemed to drive better financial performance. They also found that in many cases, using ESG investment strategies appeared to deliver similar or better financial results compared to conventional approaches.
That doesn't mean proponents of ESG investing think it's being done perfectly. ESG disclosures vary from company to company. Ratings agencies that assess the data use proprietary methods, making it hard for investors to know how firms reach their conclusions. And there is growing concern that some asset managers are slapping ESG labels on funds that don't deserve them.
"The problem is we don't have good data," says Henisz of the Wharton School. "And so we struggle to measure whether companies are delivering."
Why is ESG becoming a political fight now?
Observers point to two potential factors, which aren't mutually exclusive.
One is that ESG — and climate considerations more broadly — are becoming ingrained deeply enough in corporate America and financial markets to begin changing the way some industries operate, says Mindy Lubber, CEO of Ceres, a sustainability nonprofit.
Hundreds of companies and investment firms, for example, have now promised to eliminate or offset their greenhouse gas emissions. Only a few years ago, there were hardly any.
The other explanation is that Republicans are trying to score political points ahead of elections.
"Taking climate risk as investment risk is just good business," says Henisz of the Wharton School. "Now, we can argue about how we do it and who does it well and who does it poorly. That's a legitimate argument. [But] the idea that ESG is ideological and not economics is a political argument."
Copyright 2022 NPR. To see more, visit https://www.npr.org.
|
https://www.wunc.org/2022-09-12/how-esg-investing-got-tangled-up-in-americas-culture-wars
| 2022-09-12T11:46:52Z
|
https://www.wunc.org/2022-09-12/how-esg-investing-got-tangled-up-in-americas-culture-wars
| false
|
John Shepherd (Director of Secondary Education, CUSD) and Jim Hanlon (Assistant Superintendent Human Resources, CUSD) were the speakers at the Retired Public Employees Association (RPEA) Chapter 077 membership luncheon meeting on September 1 at Manzanita Place (Chico Elks Lodge). They spoke on the “Safe Schools Program with Chico Unified School District.” They reviewed various aspects of the program, including an Incident Response Team, school site safety plans, communication for safety purposes, drills/training, Code Red & Code Yellow, school resource officers, bullying and harassment, campus improvements to facilities, locking doors on campus, and other safety issues. RPEA membership luncheon meetings are held on the first Thursday of each month at 11:15 AM at Manzanita Place (Chico Elks Lodge), and additional information is available at rpeachapter77.com. (contributed)
|
https://www.chicoer.com/2022/09/12/safe-schools-snapshots/
| 2022-09-12T11:55:04Z
|
https://www.chicoer.com/2022/09/12/safe-schools-snapshots/
| false
|
Clarivate focusing on enabling corporations and law firms to innovate faster and unlock the true value of IP across patents, trademarks and copyright
MarkMonitor to strengthen Newfold Digital's enterprise domain management capabilities
LONDON and JACKSONVILLE, Fla., Sept. 12, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that Newfold Digital ("Newfold"), a leading web and commerce technology provider backed by Clearlake Capital Group, L.P. (together with its affiliates, "Clearlake") and Siris Capital Group, LLC (together with its affiliates, "Siris"), has signed a definitive agreement to purchase MarkMonitor™, an industry-leading enterprise-level provider of domain management solutions.
Under the terms of the agreement, Clarivate will receive cash proceeds of approximately $302.5 million. The transaction is expected to close in late 2022 subject to the satisfaction of regulatory approvals and other customary closing conditions.
Gordon Samson, Chief Product Officer of Clarivate, said: "Newfold is a natural fit for MarkMonitor. After the deal closes, we believe the integration of these two companies will create a rich product suite and differentiated web presence offering that brings value to businesses of all sizes. We are confident that MarkMonitor will continue to thrive and deliver even greater services to its customers under Newfold. After this transaction is closed, Clarivate will be better placed to focus even more attention and investment on our core portfolio and everything critical to IP lifecycle management."
The acquisition of MarkMonitor will underscore Newfold Digital's continued commitment to providing differentiated web presence solutions to customers across the globe. MarkMonitor, an ICANN-accredited registrar and recognized industry leader since 1999, serves the domain management needs of approximately 2,000 clients globally, with a focus on Fortune 500 companies and other large corporate clients. This will make MarkMonitor a natural extension of Newfold's portfolio of web technology brands, which includes Network Solutions, the world's first registrar, Web.com, Bluehost, Register.com and Domain.com.
"As web presence needs continue to grow and evolve, domain management and protection is becoming more important. Companies need reliable partners and solutions that deliver results, and MarkMonitor is well-known for its expertise in serving the domain portfolio needs of some of the most sophisticated digital companies in the world, making it a natural fit for our family of web technology brands," said Sharon Rowlands, CEO of Newfold Digital.
The MarkMonitor team, led by Head of Domain Management Stu Homan, will join Newfold.
"We're proud that Newfold recognizes the value of MarkMonitor's top-tier global domain management service," Homan said. "The combined capabilities of MarkMonitor and Newfold will deliver and improve on the same great services that our clients have enjoyed and relied upon for years."
"MarkMonitor will bring a rich history of industry experience and innovative solutions, and we are looking forward to welcoming the team to Newfold," said James Pade, Partner, Clearlake, and Tyler Sipprelle, Managing Director at Siris, each a director of Newfold.
MarkMonitor is currently expected to generate approximately $80 million of revenue and $35 million of EBITDA for the full year 2022.
Sidley Austin is acting as legal adviser and RBC Capital Markets and J.P. Morgan Securities LLC are acting as financial advisors to Newfold, with BNP PARIBAS Securities Corp., Deutsche Bank, Mizuho and UBS Investment Bank also providing advice. Evercore is acting as financial advisor and Blank Rome LLP is acting as legal advisor to Clarivate.
About Clarivate
Clarivate™ is a global leader in providing solutions to accelerate the pace of innovation. Our bold mission is to help customers solve some of the world's most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of Academia & Government, Life Sciences & Healthcare, Professional Services and Consumer Goods, Manufacturing & Technology. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.
About Newfold Digital
Newfold Digital is a leading web and commerce technology company serving nearly 7 million customers globally. Established in 2021 through the combination of leading web services providers Endurance Web Presence and Web.com Group, our portfolio of brands includes: Bluehost, CrazyDomains, HostGator, Network Solutions, Register.com, Web.com and many others. We help customers of all sizes build a digital presence that delivers results. With our extensive product offerings and personalized support, we take pride in collaborating with our customers to serve their online presence needs. Learn more about Newfold Digital at Newfold.com.
About Clearlake
Clearlake Capital Group, L.P. is an investment firm founded in 2006 operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with management teams by providing patient, long-term capital to businesses that can benefit from Clearlake's operational improvement approach, O.P.S.® The firm's core target sectors are technology, industrials, and consumer. Clearlake currently has over $70 billion of assets under management, and its senior investment principals have led or co-led over 400 investments. The firm is headquartered in Santa Monica, CA with affiliates in Dallas, TX, London, UK and Dublin. More information is available at www.clearlake.com and on Twitter @Clearlake.
About Siris
Siris is a leading private equity firm that invests primarily in mature technology and telecommunications companies with mission-critical products and services, facing industry changes or other significant transitions. Siris' development of proprietary research to identify opportunities and its extensive collaboration with its Executive Partners and Advisors are integral to its approach. Siris' Executive Partners and Advisors are experienced senior operating executives that actively participate in key aspects of the transaction lifecycle to help identify opportunities and drive strategic and operational value. Siris is based in New York, Silicon Valley and West Palm Beach, and has raised nearly $6 billion in cumulative capital commitments. www.siris.com.
View original content to download multimedia:
SOURCE Clarivate Plc
|
https://www.kold.com/prnewswire/2022/09/12/newfold-digital-signs-agreement-acquire-markmonitor-clarivate/
| 2022-09-12T11:56:46Z
|
https://www.kold.com/prnewswire/2022/09/12/newfold-digital-signs-agreement-acquire-markmonitor-clarivate/
| false
|
August 2022 Operational Update
- Produced approximately 301 bitcoin in August 2022, and 1,771 bitcoin for the eight months ended August 31, 2022.
- Hashrate capacity of approximately 2.4 EH/s from approximately 24,500 miners in service as of August 31, 2022.
- Approximately 5,000 older, less efficient miners representing approximately 0.3 EH/s taken offline in August to create capacity for new miners being delivered.
- Power plant uptime of 100.0% for the month of August.
FAIRFIELD, Conn., Sept. 12, 2022 /PRNewswire/ -- Greenidge Generation Holdings Inc. (NASDAQ: GREE) ("Greenidge"), a vertically integrated cryptocurrency datacenter and power generation company, today provided an operational update for the month of August 2022.
During the month of August 2022, Greenidge produced approximately 301 bitcoin, bringing the total bitcoin produced during the year to 1,771. As of August 31, 2022, Greenidge had approximately 2.4 EH/s of mining capacity online from approximately 24,500 miners. As of August 31, 2022, approximately 5,000 older, less efficient miners representing approximately 0.3 EH/s had been taken offline to create capacity for newer, more efficient miners being delivered.
The power plant located at Greenidge's facility in Dresden, NY was offline for zero hours during the month of August, representing an uptime of 100.0% for the month and 99.9% for the eight months ended August 31, 2022.
About Greenidge Generation Holdings Inc.
Greenidge Generation Holdings Inc. (NASDAQ: GREE) is a vertically integrated cryptocurrency datacenter and power generation company. Greenidge is committed to 100% carbon-neutral datacenter operations at all of its locations by utilizing low-carbon sources of energy and offsetting its carbon footprint.
For further information, please contact:
Investor Relations
investorrelations@greenidge.com
Media Inquiries
media@greenidge.com
View original content:
SOURCE Greenidge Generation Holdings Inc.
|
https://www.wbay.com/prnewswire/2022/09/12/greenidge-generation-provides-august-2022-operational-update/
| 2022-09-12T11:59:06Z
|
https://www.wbay.com/prnewswire/2022/09/12/greenidge-generation-provides-august-2022-operational-update/
| false
|
Wigan borough carer writes moving poem marking death of Queen Elizabeth II
A carer from Wigan borough has written a poem in memory of Queen Elizabeth II.
Diane Barrett, 56, is a support worker from Leigh who has enjoyed writing poems for around three years.
She regularly writes for the birthdays of clients or when a patient is dying.
These have often been included in the funeral service and Diane has even read them out in some circumstances.
Most Popular
-
1
Police step up patrols after woman walking her dog was sexually assaulted at Wigan beauty spot
-
2
REWIND: Wigan night out 20 years ago
-
3
Wigan family of seven evicted from rented property struggle to find a new home
-
4
Trial date in 2023 for Wigan man accused of making unwanted contact with woman
-
5
Creative tribute to the Queen appears outside post office in Wigan
Following the news Her Majesty had died, she saw plenty of posts on social media from people paying their respects.
This inspired Diane to write a poem in honour of her 70-year reign.
Diane said: “Obviously everyone was moved and touched about the news.
"I had seen plenty of posts and so I thought I’d do one of my poems.”
After posting it on social media, one of Diane’s friends told her she should try to share her tribute with a wider audience.
Asked about her memories of Queen Elizabeth II, Diane said: “She was all I’ve ever known in terms of a monarch, I remember her visiting Leigh all them years ago.
“We stood on the East Lancs waving our flags as her car went past.”
Diane will remember Queen Elizabeth II fondly and will celebrate not only her reign as monarch, but her life too.
She said: "She has been a remarkable leader throughout many of our lives and something special should be done to remember her.
"I hope we as a town can organise something to pay our respects.”
The poem reads:
Our Queen has gone, Our nation will mourn
We feel the loss, Our hearts are torn.
You served us well for many years,
Our eyes will overflow with tears.
Once a Princess and then Our Queen,
The longest serving Monarch there has ever been.
Dedicated your life, worked hard right to the end,
Respect, admiration and love is what we send.
You leading our country is all that most of us ever knew,
Following your life and family as we and it grew.
Although we are sad with a heavy heart,
We take comfort knowing Phillip and yourself are no longer apart.
|
https://www.wigantoday.net/news/national/wigan-borough-carer-writes-moving-poem-marking-death-of-queen-elizabeth-ii-3839670
| 2022-09-12T12:00:25Z
|
https://www.wigantoday.net/news/national/wigan-borough-carer-writes-moving-poem-marking-death-of-queen-elizabeth-ii-3839670
| false
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Shutterstock, Inc. (NYSE: SSTK) (the "Company"), a leading global creative platform for transformative brands and media companies, today announced that Sejal Amin is joining the Company's leadership team and Executive Committee as Chief Technology Officer (CTO), effective September 12, 2022.
With more than 20 years of global leadership, product and technology experience, Sejal will deliver a technology vision and strategy that transforms Shutterstock's technology platform to deliver a new and unparalleled experience to customers and contributors.
"I am thrilled to welcome Sejal to Shutterstock, as we continue our digital transformation to a full-service creative platform that democratizes creativity, pushes creative boundaries, and provides unparalleled experiences for our customers and contributors around the world," said Paul Hennessy, Chief Executive Officer at Shutterstock. "Sejal is a well-respected and revered leader with a proven track record of growth and innovation, and I am confident that she will be successful in leading Shutterstock's technology platform into its next disruptive phase."
"Shutterstock is a company that has transformed immensely from its inception almost 20 years ago, and I am honored to be the next Chief Technology Officer," said Sejal Amin. "The innovation the Company has achieved – from world class workflow applications to industry-leading proprietary technology – is tremendous, and I look forward to expanding upon the Company's vision, harnessing the potential of Shutterstock's diversified offering as we celebrate a new era for Shutterstock."
Recently, she was Chief Product and Technology Officer for Khoros, a Vista Portfolio company where she was integrating a distributed Product and Technology organization while defining a Product and Operational strategy to execute on the company's vision and growth goals. Just prior to that, she was CTO for the Thomson Reuters Tax and Accounting Tax Professionals Business. She has a wide range of technology leadership experience across several business units at Thomson Reuters managing global product development teams and portfolios of growing size and complexity for 15+ years.
With Sejal's appointment to CTO, Shutterstock now has three women on the Executive Committee, and two women leading the product development strategy, including Chief Product Officer, Meghan Schoen.
About Shutterstock, Inc.
Shutterstock, Inc. (NYSE: SSTK), is a leading global creative platform for transformative brands and media companies. Directly and through its group subsidiaries, Shutterstock's comprehensive collection includes high-quality licensed photographs, vectors, illustrations, 3D models, videos and music. Working with its growing community of over 2 million contributors, Shutterstock adds hundreds of thousands of images each week, and currently has more than 415 million images and more than 26 million video clips available.
Headquartered in New York City, Shutterstock has offices around the world and customers in more than 150 countries. The Company also owns Splash News, the world's leading entertainment news agency for newsrooms and media companies worldwide, Pond5, the world's largest video marketplace, TurboSquid, the world's largest 3D content marketplace; PicMonkey, a leading online graphic design and image editing platform; Offset, a high-end image collection; Shutterstock Studios, an end-to-end custom creative shop; PremiumBeat, a curated royalty-free music library; Shutterstock Editorial, a premier source of editorial images and videos for the world's media; Amper Music, an AI-driven music platform; and Bigstock, a value-oriented stock media offering.
For more information, please visit www.shutterstock.com and follow Shutterstock on Twitter and on Facebook.
View original content to download multimedia:
SOURCE Shutterstock, Inc.
|
https://www.wbay.com/prnewswire/2022/09/12/shutterstock-appoints-sejal-amin-chief-technology-officer/
| 2022-09-12T12:01:30Z
|
https://www.wbay.com/prnewswire/2022/09/12/shutterstock-appoints-sejal-amin-chief-technology-officer/
| false
|
DHAKA, Bangladesh (AP) — Bangladesh’s prime minister said Monday that the prolonged stay of more than 1 million Rohingya refugees in crowded camps in the country has become a serious security and stability concern.
“Apart from their own miseries, their prolonged presence is causing a serious impact on the economy, environment, security and sociopolitical stability of Bangladesh,” Prime Minister Sheikh Hasina said at the opening ceremony of a three-day meeting of military officials from 24 countries in the Indo-Pacific region.
The United States is the co-host of the gathering, called the Indo-Pacific Armies Management Seminar, along with the Bangladesh army.
While the militaries of the participating countries are discussing disaster management, transnational crime, security issues and women’s empowerment, Bangladesh is using the platform to highlight the issue of Rohingya refugees who have fled from violence in Myanmar.
Participants in the meeting, including the U.S., Canada, Australia, Japan, Indonesia, India, China and Vietnam, will visit the sprawling Rohingya refugee camps to see their plight firsthand, said Gen. S.M. Shafiuddin Ahmed, chief of Bangladesh army.
Ahmed said the military leaders are being taken to the camps in Cox’s Bazar district to give them “a clear perception” of the gravity of the refugee crisis and why their repatriation to Myanmar is necessary.
Last month, the refugees marked the fifth anniversary of a mass exodus of more than 700,000 Rohingya into Bangladesh who were fleeing a harsh crackdown by Myanmar’s military. In total, Bangladesh is hosting more than 1 million Rohingya refugees.
Hasina has said that repatriation is the only solution to the crisis, but that Bangladesh would not force them to go back to Myanmar.
Bangladeshi officials have expressed frustration after at least two attempts to repatriate the refugees failed under a bilateral agreement brokered by China. The Muslim Rohingya have said that conditions remain too dangerous in Buddhist-majority Myanmar, where they face extensive discrimination.
Charles A. Flynn, commanding general of the U.S. Army Pacific, told reporters that he could not reply to policy questions such as how militaries can help repatriate the Rohingya to Myanmar, but thanked Bangladesh for arranging the trip for the delegation to the refugee camps.
“What I will say is this. I am thankful that the chief of the Bangladesh army has found a way in the program to bring us to Cox’s Bazar and to see the magnitude of the humanitarian assistance that Bangladesh has provided for five years to that situation,” he said.
The Rohingya crisis has gone to international courts, where Myanmar has denied any wrongdoing.
Last month, U.S. Secretary of State Antony Blinken said the U.S. remains “committed to advancing justice and accountability” for Rohingya and all people of Myanmar.
|
https://www.seattletimes.com/nation-world/bangladesh-leader-prolonged-rohingya-stay-impacts-stability/?utm_source=RSS&utm_medium=Referral&utm_campaign=RSS_all
| 2022-09-12T12:04:29Z
|
https://www.seattletimes.com/nation-world/bangladesh-leader-prolonged-rohingya-stay-impacts-stability/?utm_source=RSS&utm_medium=Referral&utm_campaign=RSS_all
| false
|
DAYTONA BEACH, Fla. (AP) — A shooting scare at a central Florida high school was a “cruel prank" carried out by two groups of students who now face criminal charges and possible expulsion, police said.
Rumors, lies and conspiracy theories have been “floating around" on social media since Friday's lockdown at Mainland High School, Daytona Beach police said Sunday in a lengthy Facebook post.
“This entire incident appears to have been a cruel prank by several students that has now gotten out of control due to internet trolls, misinformed people and in some cases, people that are not even in Florida," police said.
Investigators said officials at the school became aware of a threat written on a bathroom stall Thursday. School officials and law enforcement reviewed video and interviewed two students who had entered the bathroom around the time the graffiti was discovered.
The students denied involvement and it was determined that no threat existed, police said.
On Friday, two groups of students in the cafeteria “decided to capitalize on the threat" and “appear to collaborate with each other to create a panic," police said.
They were seen on video “getting into specific positions and locations within the cafeteria, timing their actions" and several female students told an administrator someone had a gun.
At the same time, a male student ran from the building “causing a large crowd to follow him."
Video showed that no one appeared to have a gun at any time, police said.
Detectives have identified students involved in the incident and interviewed most of them. Stories have changed from seeing someone with a gun to “they just heard there was one," the report said.
The agency planned to have an extra presence on campus Monday to “ensure that everything goes smoothly."
Second-degree felony charges for making a false report concerning the use of firearms in a violent manner are pending for those involved, the statement said. Detectives are also recommending that everyone involved be expelled from school.
|
https://www.timesunion.com/news/article/Cruel-prank-led-to-panic-lockdown-at-Florida-17435294.php
| 2022-09-12T12:05:22Z
|
https://www.timesunion.com/news/article/Cruel-prank-led-to-panic-lockdown-at-Florida-17435294.php
| false
|
NEW YORK (AP) — Inflation isn’t only costing small businesses money. It’s costing them customers as well.
At the Bushwick Grind Cafe in Brooklyn, New York, Kymme Williams-Davis has raised prices and switched to different types of goods to keep up with the rising costs of milk, coffee, paper goods and plastic, as well as shortages of items such as paper cups and plastic lids. She hasn’t experienced anything like this since opening in 2015.
Williams-Davis says she has lost nearly half of her regular customers. Some have traded down and are buying coffee for $1 at the McDonald’s or bodega on either side of the café instead of paying the $3 she charges.
“If (customers) can get it for a dollar for not that notable of a difference, they’re going next door.”
One customer who had been coming in for years stopped in to tell Williams-Davis he bought himself a coffeemaker.
“He said I’m going to start making coffee at home, I need to budget, so I won’t be coming in here every day,” she said. “I feel like I’ve been on a goodbye campaign.”
Inflation has been rising at nearly the fastest pace in 40 years, driven up by strong consumer spending and higher costs for food, rent, medical care, and other necessities.
On Tuesday, the government is expected to report that price increases slowed in August compared with a year ago, largely because of a steady drop in the cost of gas. Prices for other items, particularly food, are likely to keep rising quickly. Overall, economists forecast consumer prices rose 8.1% in August, compared with a year ago, down from 8.5% in July, according to data provider FactSet.
For much of the pandemic, small business customers were largely tolerant of price increases and kept on spending. But now owners say they’re seeing some pushback.
Ninety-seven percent of small business owners say inflationary pressure is the same or worse than it was three months ago, according to a survey of more than 1,500 small businesses by Goldman Sachs 10,000 Small Business Voices. Sixty-five percent have raised prices to offset higher costs. And 38% say they’ve seen a decline in customer demand due to price increases.
Nicole Miskelley, who manages PMR, an auto and diesel repair shop in Marion, Illinois, said she has seen customers delay repairs that aren’t urgent such as scheduled maintenance or getting new tires.
At the beginning of the year, Miskelley’s labor costs rose 12% and the cost of towing cars to the shop went up due to higher gas prices. Parts are more expensive too. Last year, an air conditioner processor would cost her $200, but this year she can’t find one for under $400. So, she’s had to raise her average price for a repair by 30% to 40%.
Her customers have noticed.
“Typically, I am able to joke about how drastically different things are now and most agree with me,” she said. “On occasion, I deal with push back,” including the rare bout of yelling or cursing by a customer.
“Among a lot of my older customers, who are on restricted income like Social Security, they say they have to cut back,” she said. “They say, ‘I know I need these tires, but I need to make a couple more rounds (of Social Security) to save up.’”
She says she’s a little worried but hopes people can adjust to inflation.
“Right now , it kind of sucks because costs increased faster than I could catch up with. In time, I hope people budget better and their incomes change to reflect the economy.”
The pullback is more dramatic among consumers with less discretionary income. Walmart says its customers, who tend to have lower incomes, are spending more on food and less on other items. Small business owners are seeing much of the same.
Kim Shanahan operates the online store Gifts Fulfilled in Berlin, Maryland, which sells gift baskets and care packages and employs people with disabilities.
“Last year has been challenging to say the least,” she said. “All prices across the board have gone up.” Everything from cardboard, containers and the food that she includes in the baskets have become more expensive.
She implemented a 5% increase to cover some costs. After she raised the price of her most popular get-well gift basket called “One Tough Cookie,” from $27.50 to $28.95, sales went down, she said.
Less expensive baskets, such as those with gifts and candy that sell for $25 and under, have been the most affected, with unit sales down about 50% in 2022 compared with last year. “The whole segment of the market is gone for us,” she said.
“We are a ‘want to-’ not ‘have to-’ have item in our primary categories,” Shanahan said. “What we sort of see is people maybe buying a $50 gift dropping down to $35. And the whole lower tier aren’t even buying at all, they don’t have the discretionary funds.”
Schuyler Northstrom of Uinta Mattress, a mattress maker in Salt Lake City, Utah, says he’s raised his prices by 15% since 2020. A mattress that used to sell for $289 wholesale is now $330.
The increase doesn’t fully cover Uinta’s higher costs. Raw materials such as springs and foam have increased by 40%. But Northstrom fears that raising prices any higher could cause his customers to drop him.
“The pushback from retailers is pretty strong there,” he said. His retail partners include John Paras mattress stores and 2Brothers Mattress, both in Utah. “Sometimes we’re displaced by some of the larger guys with a lower cost product because of their volume.”
To adapt, Northstrom is redesigning the mattress to cut down on costs, and taking less profit, which isn’t sustainable in the long term, he said. He’s also focusing more on the higher end, mattresses that cost up to $1,200, which hasn’t been hit as hard.
“We’re feeling it, we’re not a necessary purchase, people buy food and gas,” he said.
___
This story has been edited to correct the name of the survey group to Goldman Sachs 10,000 Small Business Voices, not Goldman Sachs 10,000 Small Businesses.
___
AP Business Writer Christopher Rugaber in Washington contributed to this report.
|
https://wreg.com/business/ap-business/ap-as-small-businesses-raise-prices-some-customers-push-back/
| 2022-09-12T12:06:29Z
|
https://wreg.com/business/ap-business/ap-as-small-businesses-raise-prices-some-customers-push-back/
| false
|
LONDON (AP) -- King Charles landed in Edinburgh on Monday to accompany his late mother's coffin on an emotion-charged procession through the historic heart of the Scottish capital to a cathedral where it will lie for 24 hours to allow the public to pay their last respects.
Charles flew to Scotland after earlier receiving condolences at Parliament and telling lawmakers he would follow his late mother's example of "selfless duty."
Earlier, Queen Elizabeth II's grandson Prince Harry hailed her as a "guiding compass" and praised her "unwavering grace and dignity."
The government, meanwhile, announced that the nation will observe a minute of silence on Sunday, the evening before the queen's funeral. The "moment of reflection" will take place at 8 p.m. (1900 GMT). People were encouraged to mark the silence at home or at community events.
Hundreds of lawmakers crowded into the 1,000-year-old Westminster Hall at the Houses of Parliament for the service, rich in pageantry, in which Parliament offered its condolences to the king, and he replied.
A trumpet fanfare greeted the king and his wife Camilla, the queen consort, as they entered the hall, which was packed with hundreds of legislators.
Charles told members of the House of Commons and House of Lords that he would follow his late mother Queen Elizabeth II in upholding "the precious principles of constitutional governance" that underpin the U.K.'s political system.
He paid tribute to his mother, saying: "As Shakespeare said of the earlier Queen Elizabeth, she was a pattern to all princes living."
The hall, with its magnificent hammer-beam roof, is the oldest part of the parliamentary complex -- a remnant of the medieval Palace of Westminster that once stood on the site.
"As I stand before you today, I cannot help but feel the weight of history which surrounds us and which reminds us of the vital parliamentary traditions to which members of both Houses dedicate yourselves, with such personal commitment for the betterment of us all," Charles said.
The ceremony was held in Westminster Hall because monarchs are not allowed inside the House of Commons. That rule dates from the 17th century, when King Charles I tried to enter and arrest lawmakers. That confrontation between crown and Parliament led to a civil war which ended with the king being beheaded in 1649.
Earlier Monday, a personal statement posted on Harry and his wife Meghan's Archwell website said he cherished their times together "from my earliest childhood memories with you, to meeting you for the first time as my Commander-in-Chief, to the first moment you met my darling wife and hugged your beloved greatgrandchildren."
Amid acrimony in the House of Windsor, Harry quit as a senior royal and moved to the U.S. two years ago. On Saturday, there was a possible sign of a reconciliation as Harry and Meghan joined his brother Prince William and sister-in-law Catherine in meeting mourners outside Windsor Castle.
The national outpouring of grief continued Sunday as thousands of people lined streets and roadsides as the oak coffin was borne from the late queen's beloved Balmoral Castle summer retreat, where she died on Thursday, to Edinburgh.
In Edinburgh, the king will walk behind his mother's coffin as it is slowly transported from Holyroodhouse to St. Giles' Cathedral, where the crown of Scotland will be placed on the coffin ahead of a service of prayer and reflection on the life and 70-year reign of the widely cherished monarch.
The queen's coffin will lie at the cathedral for 24 hours, giving members of the public a chance to file past and pay their respects. On Tuesday, it will be flown to London where the coffin will lie in state at the Houses of Parliament Palace from Wednesday afternoon until the morning of the funeral on Sept. 19.
Authorities already have issued rules and guidelines for people wanting to pay their respects in London, with a long queue expected.
After visiting Scotland, Charles embarks on a tour of the other nations that make up the United Kingdom -- he visits the Northern Ireland capital, Belfast, on Tuesday and Wales on Friday.
Harry's statement ended on a poignant note alluding to the death last year of his grandfather, Prince Philip, saying that "We, too, smile knowing that you and grandpa are reunited now, and both together in peace."
|
https://www.cp24.com/world/charles-iii-arrives-in-edinburgh-for-queen-coffin-procession-1.6064630
| 2022-09-12T12:08:30Z
|
https://www.cp24.com/world/charles-iii-arrives-in-edinburgh-for-queen-coffin-procession-1.6064630
| false
|
TORONTO, Sept. 12, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company") (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce it has successfully launched KetaMD in Florida. KetaMD onboarded new patients and completed initial ketamine treatments. Eligible patients, as determined by one of KetaMD's licensed Florida healthcare practitioners, received medically supervised treatments, guided virtually by registered nurses with mental health expertise, while in the comfort of their home.
KetaMD, Inc. ("KetaMD"), a wholly owned subsidiary of Braxia Scientific, is an innovative end-to-end telemedicine platform, that provides access to safe, affordable, reliable and potentially life-changing at-home ketamine treatments for people suffering from mental health disorders such as depression, bipolar disorder, anxiety and post-traumatic stress disorder (PTSD).
In multiple studies, ketamine has also been shown to have rapid and persistent benefits for acute care in suicidal patients who often suffer from mental health challenges. As National Suicide Awareness month kicks off, KetaMD has ramped up operations and session availability to provide additional support to Florida residents in need of treatment.
Dr. Roger McIntyre commented, "We are incredibly proud to have treated our first patients in the U.S. through our KetaMD platform. KetaMD solves considerable issues by increasing access to innovative ketamine treatments for patients suffering from mental health disorders who don't live close to a care provider, have difficulty accessing care, or are unable to go to the doctor because of circumstances like COVID-19."
Warren Gumpel, CEO of KetaMD commented, "We started building the model for KetaMD more than five years ago with the goal of deploying the latest technology to improve people's lives and to empower those living with depression and other mental health conditions to take steps necessary to seek and receive safe, high quality, affordable, reliable care. We are working on scaling KetaMD beyond Florida across the U.S. opening up the opportunity for people to receive care anytime, from the comfort of their own homes."
For those interested in qualifying for KetaMD are encouraged to visit www.KetaMD.com.
KetaMD is a HIPAA-compliant telemedicine platform providing affordable and potentially life-changing at-home medical ketamine treatments. Prescribed by medical professionals and guided by registered nurses via our secure platform, KetaMD is a safe and effective alternative for the millions of adults that currently rely on conventional mental health treatments to relieve depression, anxiety, and related mental health challenges. Our mission is to make this treatment safely accessible to those who need it across the United States. Through KetaMD's program, adults who receive a qualifying diagnosis from one of our licensed medical prescribers may participate in our fully virtual program. For more information, visit www.ketamd.com.
Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine and psilocybin treatments for people with depression and related disorders. Braxia also launched its U.S. based end-to-end telemedicine platform KetaMD utilizing leading technology to provide access to safe, affordable, and potentially life-changing at-home ketamine treatments for people living with depression and related mental health conditions. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatments in-person and virtually for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, Braxia Health (formerly the Canadian Rapid Treatment Center of Excellence Inc.), operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Kitchener-Waterloo, Ottawa, and Montreal.
ON BEHALF OF THE BOARD
"Dr. Roger S. McIntyre"
Dr. Roger S. McIntyre
Chairman & CEO
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are "forward-looking statements."
Forward-looking statements include statements about the intended promise of ketamine-based treatments for depression, the potential for ketamine or other psychedelics to treat other mental health conditions, the integration plans for Braxia and KetaMD, the intention to conduct further clinical trials, the expected growth of at-home telemedicine, the expected benefit and synergies of Braxia and KetaMD and the expectation to expand to areas other than Florida. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the failure of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and engaging in activities that could be later determined to be illegal under domestic or international laws. Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the "CDSA") and it is a criminal offence to possess such substances under the CDSA without a prescription or a legal exemption. Health Canada has not approved psilocybin as a drug for any indication, however ketamine is a legally permissible medication for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without a prescription.
These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.
Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, including the Amended and Restated Listing Statement dated April 15, 2021 and its most recent MD&A, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.
Website: www.braxiascientific.com
View original content to download multimedia:
SOURCE Braxia Scientific Corp.
|
https://www.kalb.com/prnewswire/2022/09/12/braxia-scientific-launches-ketamd-florida-first-patients-complete-initial-virtual-ketamine-treatments-at-home/
| 2022-09-12T12:08:37Z
|
https://www.kalb.com/prnewswire/2022/09/12/braxia-scientific-launches-ketamd-florida-first-patients-complete-initial-virtual-ketamine-treatments-at-home/
| true
|
In the spring of 2012, portrait artist Ralph Heimans stood on the Cosmati pavement of Westminster Abbey and awaited the subject of his latest commission, Queen Elizabeth II. When she approached, he says, it was an extraordinary moment.
“She was wearing her Robe of State, with four footmen holding it, and as she came down the long corridor it was a very theatrical kind of entrance,” Heimans said soon after he had learned that the queen had died Thursday at age 96.
After spending an hour the queen, “discussing niceties,” he came away with “a sense of how thoughtful she was, almost a sense of shyness, an introspective quality.” In his oil painting, which hangs in Westminster, he drew her as a solitary, even brooding figure, her eyes cast down, with the vastness of Westminster behind her like so much weight from the past — and present.
“I wanted to show her in this private moment, with a certain gravity about her,” he says.
Over the past 70 years, authors, filmmakers, playwrights, songwriters and painters have responded to the queen as both symbol and human being, whether commenting on the heights of her position or attempting to tease out the inner life of a woman who spoke infrequently in public and avoided personal revelations. The dual qualities, majesty and mystery, found her imagined in settings ranging from the sobriety of royal art to the rage of punk music to the varied characterizations of film and television.
“I think because she was a constant presence who didn’t say very much, it allowed people to project on her in different ways,” says Elizabeth Holmes, whose “HRH: So Many Thoughts on Royal Style” was published in 2020. “Also, you can very easily make people look like the Queen. You can take that as a starting point and run.”
On film, the queen has been fictionalized in everything from Helen Mirren’s Oscar-winning portrayal in “The Queen” to the farcical “Naked Gun” movies and the grim “Spencer,” with Kristen Stewart as Princess Diana and Stella Gonet as Elizabeth. But she has been dramatized most fully in the Emmy-winning Netflix series “The Crown,” which follows her life from the beginning of her reign to recent times — and whose production was suspended Friday after her death.
When played by Claire Foy as a young and glamorous monarch, she is seen as finding her way in her new life, trying to maintain a happy relationship with her husband, Prince Philip. while approaching her royal duties with the sobriety of someone years older. Olivia Colman takes over as Elizabeth ages and becomes more mature and prickly, and flawed, failing initially to travel to the scene of a devastating mining tragedy in Wales and comfort the townspeople, and proving unsympathetic to Diana’s troubles with her son Prince Charles.
“I emote. The queen is not meant to,” Colman told Vanity Fair in 2018. “She’s got to be a rock for everyone, and has been trained not to (emote).”
The queen herself didn’t comment on works about her or always seem aware of cultural trends: Greeting Led Zeppelin guitarist Jimmy Page at a 2005 palace reception, she seemed unsure of who he was and what instrument he played. But she sensed her place in world and had enough savvy to appear with Daniel Craig, in character as James Bond, for a 2012 Olympics video, and enough good humor to allow herself to be pictured as parachuting from a helicopter with him (the former was really her, the latter a stunt double).
Fiction writers enjoyed setting the queen off on unusual adventures. In Emma Tennant’s “The Autobiography of the Queen,” the monarch flees to St. Lucia in the Caribbean. S.J. Bennett worked from the premise “What if the queen solved crimes?” in writing the mystery novels “The Windsor Knot” and “A Three Dog Problem.”
“She had such a unique perspective on the world. She was always looking out when everyone else was looking at her, so she must see a lot of things the rest of us don’t see,” Bennett, the daughter of a military veteran who had met the Queen, told The Associated Press.
“It was her character that fascinated me, not her position as a symbol,” she added. “She was intelligent, frequently underestimated because she wasn’t traditionally educated, and endlessly curious about people. In the books I have her eagerly looking out of the windows of Buckingham Palace while being painted for a portrait, to see what was going on outside, because that’s what she really did. She had a very wry sense of humor and a huge instinct for fun, but equally an almost supernatural instinct for diplomacy, and a world-class sense of duty.”
Musicians have paid tribute, condemned her and invoked her name for a quick laugh.
For punk and New Wave artists, she was a monument to be torn down. The Smiths’ “The Queen Is Dead” mocks the royal family and the succession to power: “I say, Charles, don’t you ever crave/To appear on the front of the Daily Mail/Dressed in your Mother’s bridal veil?” The Sex Pistols helped define the punk movement in 1976 with ”God Save the Queen,” in which Johnny Rotten (now Lydon) declares “No future” as he snarls out some of the most scathing, nihilistic lyrics ever to top the British charts:
God save the queen
The fascist regime
They made you a moron
A potential H bomb
God save the queen
She’s not a human being …
Songwriters otherwise responded with affection. Duke Ellington met her in the late 1950s and found her “so inspiring” he soon collaborated with Billy Strayhorn on the pensive “The Queen’s Suite,” for which he arranged a single gold pressing just for her. In the late 1960s, Paul McCartney dashed off the acoustic, 23-second “Her Majesty,” with its cheeky refrain, “Her Majesty’s a pretty nice girl/But she doesn’t have a lot to say,” and the Beatles tacked it onto the end of “Abbey Road.”
As he explained in “Paul McCartney: The Lyrics,” published in 2021, he wrote the song in part because the queen really didn’t offer many public statements, beyond her annual Christmas address and the opening of Parliament. McCartney would meet the queen numerous times, as a Beatle and a solo performer, and even played the song for her. But, he reaffirmed in his book: “She didn’t have a lot to say.”
____
AP National Writer Jocelyn Noveck contributed to this report.
|
https://wreg.com/entertainment-news/ap-entertainment/ap-the-queen-as-imagined-from-punk-rock-to-mystery-novels/
| 2022-09-12T12:08:48Z
|
https://wreg.com/entertainment-news/ap-entertainment/ap-the-queen-as-imagined-from-punk-rock-to-mystery-novels/
| true
|
DUBAI, United Arab Emirates (AP) — A Dubai court ruled on Monday that a British man suspected of masterminding a $1.7 billion tax scheme cannot be extradited to Denmark to face charges.
The decision in the high-profile case grants the hedge fund trader, Sanjay Shah, a victory against Danish authorities who sought him for his role in one of the country’s largest-ever fraud cases. Monday’s court ruling, which judges delivered without explanation, can be appealed by prosecutors within 30 days.
The elaborate tax scheme, which ran for three years beginning in 2012, allegedly involved foreign businesses pretending to own shares in Danish companies and claiming tax refunds for which they were not eligible.
“Of course we will try to get him (out) on bail now immediately,” Shah’s lawyer, Ali al-Zarooni, told The Associated Press from the Dubai courthouse.
Prosecutors in Copenhagen did not immediately respond to request for comment.
The 52-year-old financier has maintained his innocence in past interviews with journalists but never appeared in Denmark to answer accusations. Al-Zarooni had contested the extradition, arguing in past closed-door hearings that Denmark had “breached” the rules of international extradition treaties in unspecified ways. He declined to elaborate on Monday.
Shah’s lifestyle on Dubai’s luxurious palm-shaped island over the past few years had sparked outrage in Denmark. After Danish authorities signed an extradition agreement with the UAE, Dubai police arrested Shah in June. Shah is one of several suspects in the tax scheme sought by Danish authorities.
During his time in Dubai, the hedge fund manager ran a center for autistic children that shut down in 2020 as Denmark tried to extradite him. He also oversaw a British-based charity, Autism Rocks, which raised funds through concerts and performances.
His arrest comes as pressure grows on Dubai, the region’s financial hub, over its alleged weaknesses in combating illicit finance. The UAE, a federation of seven emirates, has long invited the wealthy, including disgraced public figures, to invest in the country without questioning where they made their money. Scrutiny of Dubai has intensified as the flashy city-state becomes a haven for Russian money amid Moscow’s war on Ukraine.
In recent months, however, the UAE has arrested several suspects wanted for major crimes, including two of the Gupta brothers from South Africa, accused of facilitating vast public corruption and draining state resources with former President Jacob Zuma. An Emirati official also recently became president of Interpol, the international police agency.
___
Associated Press writer Isabel DeBre in Dubai contributed to this report.
|
https://www.ksn.com/news/national-world/ap-international/ap-dubai-court-rejects-danish-extradition-request-for-financier/
| 2022-09-12T12:12:04Z
|
https://www.ksn.com/news/national-world/ap-international/ap-dubai-court-rejects-danish-extradition-request-for-financier/
| true
|
LONDON (AP) — Queen Elizabeth II’s grandson Prince Harry hailed her Monday as a “guiding compass” and praised her “unwavering grace and dignity,” as members of the public were to get the chance to pay their respects to the monarch when her coffin lies at rest at St. Giles’ Cathedral in Edinburgh.
The personal statement, posted on Harry and his wife Meghan’s Archwell website, said he cherished their times together “from my earliest childhood memories with you, to meeting you for the first time as my Commander-in-Chief, to the first moment you met my darling wife and hugged your beloved greatgrandchildren.”
Amid acrimony in the House of Windsor, Harry quit as a senior royal and moved to the U.S. two years ago. On Saturday, there was a possible sign of a reconciliation as Harry and Meghan joined his brother Prince William and sister-in-law Catherine in meeting mourners outside Windsor Castle.
Harry’s statement came at the start of another day steeped in the historic pageantry and pomp that follows the death of a British sovereign.
King Charles III was starting the day speaking to lawmakers at Parliament in London before flying to Scotland.
Hundreds of lawmakers crowded into the 1,000-year-old Westminster Hall at the Houses of Parliament for a service in which Parliament will offer its condolences to the king, and he will reply.
A trumpet fanfare greeted the king and his wife Camilla, the Queen Consort, as they entered the hall, which was packed with hundreds of legislators.
The Speakers of the House of Commons and House of Lords were offering condolences on the death of Queen Elizabeth II, and Charles will make a speech in reply.
The hall, with its magnificent hammer-beam roof, is the oldest part of the parliamentary complex — a remnant of the medieval Palace of Westminster that once stood on the site.
The ceremony was being held in Westminster Hall because monarchs are not allowed inside the House of Commons. That rule dates from the 17th century, when King Charles I tried to enter and arrest lawmakers. That confrontation between crown and Parliament led to a civil war which ended with the king being beheaded in 1649.
On Sunday, thousands of people lined streets and roadsides as the oak coffin was borne from the late queen’s beloved Balmoral Castle summer retreat, where she died on Thursday, to Edinburgh.
The new king will fly to Edingburgh later and will walk behind his mother’s coffin as it is slowly transported from Holyroodhouse to St. Giles’ Cathedral, where the crown of Scotland will be placed on the coffin ahead of a service of prayer and reflection on the life and 70-year reign of the widely cherished monarch.
The queen’s coffin will lie at the cathedral for 24 hours, giving members of the public a chance to file past and pay their respects. On Tuesday, it will be flown to London where the coffin will lie in state at the Houses of Parliament Palace from Wednesday afternoon until the morning of the funeral on Sept. 19.
Authorities already have issued rules and guidelines for people wanting to pay their respects in London, with a long queue expected.
After visiting Scotland, Charles embarks on a tour of the other nations that make up the United Kingdom — he visits the Northern Ireland capital, Belfast, on Tuesday and Wales on Friday.
Harry’s statement ended on a poignant note alluding to the death last year of his grandfather, Prince Philip, saying that “We, too, smile knowing that you and grandpa are reunited now, and both together in peace.”
|
https://www.ksn.com/news/national-world/public-gets-chance-to-view-queens-coffin-in-edinburgh/
| 2022-09-12T12:13:09Z
|
https://www.ksn.com/news/national-world/public-gets-chance-to-view-queens-coffin-in-edinburgh/
| true
|
Crowds in Scotland gathered along the route to watch the coffin holding Queen Elizabeth II's body travel to Edinburgh, where it will be on public view before being flown to London on Tuesday.
Copyright 2022 NPR
Crowds in Scotland gathered along the route to watch the coffin holding Queen Elizabeth II's body travel to Edinburgh, where it will be on public view before being flown to London on Tuesday.
Copyright 2022 NPR
|
https://www.nprillinois.org/2022-09-12/britain-continues-to-mourn-the-death-of-queen-elizabeth-ii
| 2022-09-12T12:13:21Z
|
https://www.nprillinois.org/2022-09-12/britain-continues-to-mourn-the-death-of-queen-elizabeth-ii
| false
|
King Charles III pledged Monday to follow his late mother’s example of “selfless duty” as he addressed lawmakers from both houses of parliament in London before he boarded a plane to Edinburgh to be with the late queen's coffin as it lies at rest in the Scottish capital.
Earlier, Queen Elizabeth II's grandson Prince Harry hailed her as a “guiding compass” and praised her “unwavering grace and dignity."
The government, meanwhile, announced that the nation will observe a minute of silence on Sunday, the evening before the queen's funeral. The “moment of reflection” will take place at 8 p.m. (1900 GMT). People were encouraged to mark the silence at home or at community events.
Hundreds of lawmakers crowded into the 1,000-year-old Westminster Hall at the Houses of Parliament for the service, rich in pageantry, in which Parliament offered its condolences to the king, and he replied.
A trumpet fanfare greeted the king and his wife Camilla, the queen consort, as they entered the hall, which was packed with hundreds of legislators.
Charles told members of the House of Commons and House of Lords that he would follow his late mother Queen Elizabeth II in upholding “the precious principles of constitutional governance” that underpin the U.K.’s political system.
He paid tribute to his mother, saying: “As Shakespeare said of the earlier Queen Elizabeth, she was a pattern to all princes living.”
The hall, with its magnificent hammer-beam roof, is the oldest part of the parliamentary complex — a remnant of the medieval Palace of Westminster that once stood on the site.
“As I stand before you today, I cannot help but feel the weight of history which surrounds us and which reminds us of the vital parliamentary traditions to which members of both Houses dedicate yourselves, with such personal commitment for the betterment of us all,” Charles said.
The ceremony was held in Westminster Hall because monarchs are not allowed inside the House of Commons. That rule dates from the 17th century, when King Charles I tried to enter and arrest lawmakers. That confrontation between crown and Parliament led to a civil war which ended with the king being beheaded in 1649.
Earlier Monday, a personal statement posted on Harry and his wife Meghan’s Archwell website said he cherished their times together “from my earliest childhood memories with you, to meeting you for the first time as my Commander-in-Chief, to the first moment you met my darling wife and hugged your beloved greatgrandchildren.”
Amid acrimony in the House of Windsor, Harry quit as a senior royal and moved to the U.S. two years ago. On Saturday, there was a possible sign of a reconciliation as Harry and Meghan joined his brother Prince William and sister-in-law Catherine in meeting mourners outside Windsor Castle.
The national outpouring of grief continued Sunday as thousands of people lined streets and roadsides as the oak coffin was borne from the late queen's beloved Balmoral Castle summer retreat, where she died on Thursday, to Edinburgh.
Later Monday in Edinburgh, the king will walk behind his mother's coffin as it is slowly transported from Holyroodhouse to St. Giles' Cathedral, where the crown of Scotland will be placed on the coffin ahead of a service of prayer and reflection on the life and 70-year reign of the widely cherished monarch.
The queen's coffin will lie at the cathedral for 24 hours, giving members of the public a chance to file past and pay their respects. On Tuesday, it will be flown to London where the coffin will lie in state at the Houses of Parliament Palace from Wednesday afternoon until the morning of the funeral on Sept. 19.
Authorities already have issued rules and guidelines for people wanting to pay their respects in London, with a long queue expected.
After visiting Scotland, Charles embarks on a tour of the other nations that make up the United Kingdom — he visits the Northern Ireland capital, Belfast, on Tuesday and Wales on Friday.
|
https://www.kivitv.com/news/world/charles-addresses-parliament-vows-to-follow-queens-example-of-selfless-duty
| 2022-09-12T12:14:09Z
|
https://www.kivitv.com/news/world/charles-addresses-parliament-vows-to-follow-queens-example-of-selfless-duty
| false
|
TSX: EQX
NYSE-A: EQX
VANCOUVER, BC, Sept. 12, 2022 /PRNewswire/ - Equinox Gold Corp. (TSX: EQX) (NYSE American: EQX) ("Equinox Gold" or the "Company") reports that, following an initial meeting with Mezcala community leaders, the blockade at the Company's Los Filos Mine in Mexico was removed and the mine resumed operations on September 10th.
The Company will continue to engage with Mezcala and other community leaders to strengthen relationships and foster long-term, stable operations at the Los Filos Mine.
Greg Smith, President & Chief Executive Officer
Rhylin Bailie, Vice President, Investor Relations
Tel: +1 604-558-0560
Email: ir@equinoxgold.com
Equinox Gold is a Canadian mining company operating entirely in the Americas, with six operating gold mines, a mine in commissioning, and a clear path to achieve more than one million ounces of annual gold production from a pipeline of development and expansion projects. Equinox Gold's common shares are listed on the TSX and the NYSE American under the trading symbol EQX. Further information about Equinox Gold's portfolio of assets and long-term growth strategy is available at www.equinoxgold.com or by email at ir@equinoxgold.com.
This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation and may include future-oriented financial information. Forward-looking statements and forward-looking information in this news release relate to, among other things: Equinox Gold's relationship with the communities at Los Filos, Equinox Gold's ability to achieve long-term stable operations at Los Filos, and the strategic vision for Equinox Gold and expectations regarding the Company's growth strategy and future production capabilities. Forward-looking statements or information generally identified by the use of the words "will", "continue", "achieve", "long-term", "strengthen" and similar expressions and phrases or statements that certain actions, events or results "may", "could", or "should", or the negative connotation of such terms, are intended to identify forward-looking statements and information. Although Equinox Gold believes that the expectations reflected in such forward-looking statements and information are reasonable, undue reliance should not be placed on forward-looking statements since Equinox Gold can give no assurance that such expectations will prove to be correct. The Company has based these forward-looking statements and information on Equinox Gold's current expectations and projections about future events and these assumptions include: the Company's previous working history with the communities around Los Filos; discussions with the Mezcala community; discussions with other communities around Los Filos; and the Company's working history with the workers and unions at Los Filos.
While Equinox Gold considers these assumptions to be reasonable based on information currently available, they may prove to be incorrect. Accordingly, readers are cautioned not to put undue reliance on the forward-looking statements or information contained in this news release. The Company cautions that forward-looking statements and information involve known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements and information contained in this presentation and Equinox Gold has made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: employee relations; relationships with, and claims by, local communities and indigenous populations; no other labour-related disruptions and no unplanned delays or interruptions in scheduled construction, development and production, including by blockade or industrial action; operational risks and hazards inherent with the business of mining (including environmental accidents and hazards, industrial accidents, equipment breakdown, unusual or unexpected geological or structural formations, cave-ins, flooding and severe weather); fluctuations in gold prices; fluctuations in prices for energy inputs, labour, materials, supplies and services; fluctuations in currency markets; inadequate insurance, or inability to obtain insurance to cover these risks and hazards; the Company's ability to obtain all necessary permits, licenses and regulatory approvals in a timely manner or at all; changes in laws, regulations and government practices, including environmental and export and import laws and regulations; the Company's ability to comply with all environmental, health and safety laws and other regulatory requirements legal restrictions relating to mining including those imposed in connection with COVID-19; and those factors identified in the section titled "Risks and Uncertainties" in Equinox Gold's MD&A dated March 23, 2022 for the year ended December 31, 2021, and in the section titled "Risks Related to the Business" in Equinox Gold's Annual Information Form dated March 24, 2022 for the year ended December 31, 2021, both of which are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar. Forward-looking statements and information are designed to help readers understand management's views as of that time with respect to future events and speak only as of the date they are made. Except as required by applicable law, Equinox Gold assumes no obligation to update or to publicly announce the results of any change to any forward-looking statement or information contained or incorporated by reference to reflect actual results, future events or developments, changes in assumptions or changes in other factors affecting the forward-looking statements and information. If Equinox Gold updates any one or more forward-looking statements, no inference should be drawn that Equinox Gold will make additional updates with respect to those or other forward-looking statements. All forward-looking statements and information contained in this news release are expressly qualified in their entirety by this cautionary statement.
View original content:
SOURCE Equinox Gold Corp.
|
https://www.kxii.com/prnewswire/2022/09/12/equinox-gold-resumes-operations-its-los-filos-mine/
| 2022-09-12T12:14:19Z
|
https://www.kxii.com/prnewswire/2022/09/12/equinox-gold-resumes-operations-its-los-filos-mine/
| false
|
STOCKHOLM, Sept. 12, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the company will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022.
The presentation is now available on Medivirs website; www.medivir.com.
For additional information, please contact
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Medivir
|
https://www.kxii.com/prnewswire/2022/09/12/medivir-present-hc-wainwright-24th-annual-global-investment-conference/
| 2022-09-12T12:15:38Z
|
https://www.kxii.com/prnewswire/2022/09/12/medivir-present-hc-wainwright-24th-annual-global-investment-conference/
| true
|
SEATTLE, Sept. 12, 2022 /PRNewswire/ -- Kineta, Inc. ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference. The conference is being held as a hybrid event on September 12-14, 2022. The in-person venue for the event is the Lotte New York Palace Hotel in New York City. Virtual participation will be staged simultaneously with over 500 company presentations scheduled as live feed or available on-demand.
Shawn Iadonato, Ph.D., Kineta's Chief Executive Officer, will provide a corporate update and overview of KVA12.1, Kineta's IND-ready VISTA blocking immunotherapy that is scheduled to initiate a Phase 1 clinical trial in the fourth quarter of 2022.
Event: H.C. Wainwright 24th Annual Global Investment Conference (Hybrid Conference)
Date: September 12-14, 2022
Time: 7:00 A.M. Eastern Time
Location: Virtual webcast to start on-demand on September 12, 2022 at 7:00 A.M. Eastern Time
Participants may access the webcast of the event through the following link:
https://journey.ct.events/view/54d1d52b-9a16-453d-a34a-010235061f02
The webcast can also be accessed in the Investors section of the Kineta website at www.kinetabio.com. The webcast replay will be available shortly after the conclusion of the event for 30 days.
Kineta is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. Kineta has leveraged its expertise in innate immunity with an intent to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy. For more information on Kineta, please visit www.kinetabio.com, and follow Kineta on Twitter, LinkedIn and Facebook.
PiiONEER™ Platform is focused on developing fully human monoclonal antibodies that target novel innate immune pathways. It was designed for the discovery and development of first or best-in-class immunotherapies that address the major challenges with cancer immune resistance to current therapies. Utilization of the PiiONEER™ Platform results in novel, well-characterized lead antibody therapeutics that can be efficiently advanced into formal IND-enabling and clinical studies.
KVA12.1 is a potential best-in-class VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope. KVA12.1 may be an effective immunotherapy for many types of cancer including NSCLC (lung), colorectal, renal cell carcinoma, head and neck, and ovarian. These initial target indications represent a significant unmet medical need with a large worldwide commercial opportunity for KVA12.1.
Anti-CD27 mAb program: Kineta has developed a diverse set of anti-CD27 agonist antibodies. They are fully human monoclonal antibodies (mAbs) that demonstrate low nanomolar (nM) binding affinity to CD27 in humans. In preclinical studies, Kineta's selected lead anti-CD27 agonist mAbs induce T cell proliferation and secretion of cytokines involved in T cell priming and recruitment, demonstrating the ability to potentiate new anti-tumor responses.
This press release may be deemed to be solicitation material with respect to the proposed transactions between Yumanity Therapeutics, Inc. ("Yumanity") and Kineta and between Yumanity and Janssen Pharmaceutica NV ("Janssen"). In connection with the proposed transactions, Yumanity filed with the U.S. Securities and Exchange Commission (the "SEC") on August 29, 2022 a registration statement on Form S-4 ("the Registration Statement"), which contains a preliminary proxy statement and prospectus. The Registration Statement has not yet become effective. Yumanity will mail the definitive proxy statement/prospectus to the Yumanity securityholders, and the securities may not be sold or exchanged until the Registration Statement becomes effective. Investors and securityholders of Yumanity and Kineta are urged to read these materials when they become available because they will contain important information about Yumanity, Kineta and the proposed transactions. This press release is not a substitute for the Registration Statement, definitive proxy statement/prospectus or any other documents that Yumanity may file with the SEC or send to securityholders in connection with the proposed transactions.
Investors and securityholders may obtain free copies of the documents filed with the SEC, once available, on Yumanity's website at www.yumanity.com, on the SEC's website at www.sec.gov or by directing a request to Yumanity's Investor Relations at (212) 213-0006 ext. 331.
This press release shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Each of Yumanity, Kineta and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Yumanity in connection with the proposed transactions. Information about the executive officers and directors of Yumanity is set forth in Yumanity's Definitive Proxy Statement on Schedule 14A relating to the 2022 Annual Meeting of Stockholders, filed with the SEC on April 25, 2022. Other information regarding the interests of such individuals, who may be deemed to be participants in the solicitation of proxies for the stockholders of Yumanity, is set forth in the preliminary proxy statement/prospectus included in the Registration Statement and will be set forth in the definitive proxy statement/prospectus and any other relevant documents to be filed with the SEC. You may obtain free copies of these documents as described above.
This press release contains certain forward-looking statements, including, without limitation, statements regarding Kineta's plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects; statements regarding the proposed merger between Yumanity and Kineta and the proposed asset sale to Janssen, including whether and when the transactions will be consummated; statements about the structure, timing and completion of the proposed transactions; and other statements that are not historical in nature. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta's business which could significantly affect expected results, including, without limitation, progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs and legislative, fiscal and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement. Except as required by law, Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
View original content to download multimedia:
SOURCE Kineta, Inc.
|
https://www.valleynewslive.com/prnewswire/2022/09/12/kineta-announces-participation-hc-wainwright-24th-annual-global-healthcare-conference/
| 2022-09-12T12:20:50Z
|
https://www.valleynewslive.com/prnewswire/2022/09/12/kineta-announces-participation-hc-wainwright-24th-annual-global-healthcare-conference/
| false
|
There are a few takeaways from the first week of the new Times area girls soccer season, but the one that is probably the most accurate is, Morgan Kotch and Riley Hayes are going to score A LOT of goals in 2022.
The two combined for 11 goals, and helped lead their teams to an impressive opening two games.
Kotch helped Pennington outscore two teams 14-3, while Hayes was pivotal as Hun won two games by a combined 13-2 score.
The two teams will meet on September 27 for the first of what could be three games this season: that regular season contest, a potential Mercer County Tournament matchup (hopefully in a final, if the coaches seed the teams properly), and then in a rematch of the epic 2021 Prep A final, won by Hun 4-3 in overtime.
In the Colonial Valley Conference, the power looks to be in the Colonial, with NJ.com No. 18 Princeton, Hightstown, and Steinert all off to 2-0 starts.
What will happen this week? Read on, after a recap of the opening four days of action.
CVC
Hightstown 4-1 Hopewell Valley: it did not take long for the Rams to make a huge statement in the 2022 season, as they found the net four times in the second half to stun the Bulldogs. Hightstown is 2-0 heading into a big week of action.
Allentown 1-0 Notre Dame: the Redbirds have played 160 minutes without allowing a goal, which is something that should lead to a lot of wins. Lindsey Hines got the winner for Allentown.
Steinert 4-1 Robbinsville: Spartans got two goals from Adriana Ryder to knock off neighbors Robbinsville. Ryder should score a lot of goals in CVC play.
BCSL
Bordentown 5-2 Collingswood: the lone win from the five area BCSL teams (along with Florence, New Egypt, Northern Burlington, and STEMCivics) came over the weekend. Victoria Wheeler and Julie Wojcik each had a pair of goals in the victory.
SKYLAND
Manville 1-0 South Hunterdon: slim loss for the Eagles, who have to bounce back this week.
PREP
Hun 3-2 Mercersburg: the Raiders went to the Mainline Jamboree and won their first game 10-0, thane came back on Saturday and pulled out a big win over a tough opponent. Riley Hayes had two goals in the win over Mercersburg, and will be pivotal to the team all season.
Pennington 6-1 Archbishop Ryan (PA): opening night was a nice one for the Red Hawks against one of the Philadelphia Catholic League powerhouses. Morgan Kotch had four goals on the evening.
BEST GAMES OF THE UPCOMING WEEK
Tuesday, Sept. 13
Pennington (2-0) at Lawrenceville (0-1-1), 4:30 p.m.: Red Hawks head on the road for the first time.
Hun (2-0) at Episcopal (PA), 4 p.m.: Hun heads back to the Philadelphia area to take on the INTERAC power.
Thursday, Sept. 15
Robbinsville (1-1) at Allentown (2-0), 4 p.m.: Redbirds and Ravens meet, with Allentown looking to keep perfect start going.
Friday, Sept. 16
Cinnaminson (0-1) at Northern Burlington (0-1), 3:45 p.m.: key BCSL Liberty battle.
Saturday, Sept. 17
Allentown (2-0) at Steinert (2-0), 10 a.m.: test for both CVC teams.
TIMES AREA GREAT EIGHT
1. Pennington (2-0)
2. Hun (2-0)
3. Princeton Day School (1-0)
4. Steinert (2-0)
5. Princeton (2-0)
6. Hightstown (2-0)
7. Allentown (2-0)
8. Lawrence (2-0)
AREA PLAYER OF THE WEEK
Morgan Kotch, F, Pennington, Jr.: six goals in two big wins for the No. 18 ranked team in the country, and she has also been a facilitator for the offense. If she is on the pitch, this Pennington team is going to be very tough to beat.
AREA PLAYER OF THE YEAR WATCH: WEEK 1
1. Morgan Kotch, F, Pennington, Jr.: six goals in two games, and there will be many more.
2. Riley Hayes, F, Hun, Sr.: she is right behind Kotch with five goals so far in two games, and should go head-to-head for the area scoring title in 2022.
3. Reagan Amberson, CB, Pennington, Sr.: when the games get tougher, Amberson is going to be at the center of the defense for the Red Hawks cleaning up and starting attacks.
4. Olivia Spektor, MF, Hun, Jr.: she led the team in assists last year in the Prep A title run, and will be a pivotal player for Jennifer Barrett in 2022.
5. Sophia Murphy, CDM, Pennington, Jr.: she has settled perfectly into the six, and will be key in front of Amberson, Lina Ballman, and Ava Glass.
AREA TEAM OF THE WEEK
Hightstown (2-0): the Rams have been dominant in two wins, with the 4-1 victory over Hopewell Valley an eye-opener around the CVC. Charlotte Garcia and Abby Shwom both have four goals in the early part of the year.
The N.J. High School Sports newsletter now appearing in mailboxes 5 days a week. Sign up now and be among the first to get all the boys and girls sports you care about, straight to your inbox each weekday. To add your name, click here.
|
https://www.nj.com/highschoolsports/2022/09/times-girls-soccer-notes-morgan-kotch-riley-hayes-off-to-hot-starts.html
| 2022-09-12T12:23:04Z
|
https://www.nj.com/highschoolsports/2022/09/times-girls-soccer-notes-morgan-kotch-riley-hayes-off-to-hot-starts.html
| false
|
Baird equity research analyst Ben Kallo initiated coverage with a price target of $8
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Swvl Holdings Corp ("Swvl" or the "Company") (NASDAQ: SWVL), a global provider of transformative tech-enabled mass transit solutions, today announced that Baird has initiated coverage on the Company with "Outperform" Rating and price target substantially higher than Swvl's current trading price.
Copies of the full analyst report can be obtained directly from Baird.
Mostafa Kandil, Swvl Founder and CEO, said, "We are grateful to see institutional research analysts take notice of what we believe to be another record-breaking quarter in Q2 where we grew revenues 3.4x year on year while improving profitability in line with our expectation to turn cash flow positive in 2023 and we achieved multiple strategic milestones including organic SaaS launches in Kuwait and Brazil and completed our acquisitions of Urbvan, Volt Lines and door2door."
Youssef Salem, Swvl CFO, said, "With a well-capitalized balance sheet after raising $29m in early Q3, a clear roadmap to cashflow generation next year, the completion of several recent acquisitions, integrated and significant revenue and cost synergies being realized, continued month-on-month organic growth, lock-up agreements extended by 31 shareholders and executives and now additional equity research initiation, we believe that we are at an inflection point in our shareholder value maximization journey. We look forward to additional research coverage initiation soon."
All reports on Swvl prepared by analysts represent the views of such analysts and are not necessarily those of Swvl. Swvl is not responsible for the content, accuracy or timelines provided by analysts. Swvl does not expressly or by implication warrant or assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, assumption, data, forecast, price target, estimate or projection contained in the reports or industry notes provided by analysts, and the dissemination of such reports or industry notes does not necessarily constitute or imply the Company's endorsement or recommendation.
About Swvl
Swvl is a global provider of transformative tech-enabled mass transit solutions, offering intercity, intracity, B2B and B2G transportation across > 20 countries. The Company's platform provides complimentary semi-private alternatives to public transportation for individuals who cannot access or afford private options. Every day, Swvl's parallel mass transit systems are empowering individuals to go where they want, when they want – making mobility safer, more efficient, accessible, and environmentally friendly. Customers can book their rides on an easy-to-use proprietary app with varied payment options and 24 / 7 access to high-quality private buses and vans.
Swvl was co-founded by Mostafa Kandil, who began his career at Rocket Internet, where he launched the car sales platform Carmudi in the Philippines, which became the largest car classifieds company in the country in just six months. He then served as Rocket Internet's Head of Operations. In 2016, Kandil joined Careem, a ride-sharing company and the first unicorn in the Middle East. He supported the platform's expansion into multiple new markets.
For additional information about Swvl, please visit www.swvl.com.
Forward-Looking Statements
Certain statements made herein are not historical facts but are forward-looking statements. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events and other statements that are not historical facts.
These statements are based on the current expectations of Swvl's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Swvl. These statements are subject to a number of risks and uncertainties regarding Swvl's business, and actual results may differ materially. These risks and uncertainties include, but are not limited to: general economic, political and business conditions, including but not limited to the economic and operational disruptions and other effects of the COVID-19 pandemic; the ability of Swvl to execute its growth strategy, manage growth profitably and retain its key employees; competition with other companies in the mobility industry; Swvl's limited operating history and lack of experience as a public company; recent implementation of certain policies and procedures to ensure compliance with applicable laws and regulations, including with respect to anti-bribery, anti-corruption, and cyber protection; the risk that Swvl is not able to execute its portfolio optimization plan; the risk that Swvl is unable to attract and retain consumers and qualified drivers and other high quality personnel; the risk that Swvl is unable to protect and enforce its intellectual property rights; the risk that Swvl is unable to determine rider demand to develop new offerings on its platform; the difficulty of obtaining required registrations, licenses, permits or approvals in jurisdictions in which Swvl currently operates or may in the future operate; the fact that Swvl currently operates in and intends to expand into jurisdictions that are, or have been, characterized by political instability, may have inadequate or limited regulatory and legal frameworks and may have limited, if any, treaties or other arrangements in place to protect foreign investment or involvement; the risk that Swvl's drivers could be classified as employees, workers or quasi-employees in the jurisdictions they operate; the fact that Swvl has operations in countries known to experience high levels of corruption and is subject to territorial anti-corruption laws in these jurisdictions; the ability of Swvl to maintain the listing of its securities on Nasdaq; Swvl's acquisitions may not be beneficial to Swvl as a result of the cost of integrating geographically disparate operations and the diversion of management's attention from its existing business, among other things; and other risks that will be detailed from time to time in filings with the U.S. Securities and Exchange Commission. The foregoing list of risk factors is not exhaustive. There may be additional risks that Swvl presently does not know or that Swvl currently believes are immaterial that could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide Swvl's expectations, plans or forecasts of future events and views as of the date of this communication. Swvl anticipates that subsequent events and developments will cause Swvl's assessments and projections to change. However, while Swvl may elect to update these forward-looking statements in the future, Swvl specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Swvl's assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor Contact
Youssef Salem
Swvl CFO
Investor.relations@swvl.com
View original content:
SOURCE Swvl Holdings Corp
|
https://www.valleynewslive.com/prnewswire/2022/09/12/swvl-announces-initiation-equity-analyst-coverage-by-baird-with-outperform-rating/
| 2022-09-12T12:24:29Z
|
https://www.valleynewslive.com/prnewswire/2022/09/12/swvl-announces-initiation-equity-analyst-coverage-by-baird-with-outperform-rating/
| true
|
Trial’s opening statements to begin for slaying of 8 family members
PIKE COUNTY, Ohio (WXIX/Gray News) - The first trial in the 2016 execution-style shooting deaths of eight members of the Rhoden family will resume Monday with opening statements after a weeklong delay because of the illness of the special prosecutor, court records show.
The murder trial of George Wagner IV is being held in Pike County Common Pleas Court in Waverly, Ohio, about 99 miles east of downtown Cincinnati. Pike County Common Pleas Court Judge Randy Deering is presiding.
The slayings are considered the state’s biggest and most complex homicide investigation to date, resulting in more than 1,000 tips, hundreds of people interviewed and dozens of search warrants.
Pike County massacre: Complete trial coverage
Wagner IV, 30, is the first member of his family of four who was all charged in the case to go on trial.
He is accused of killing Christopher Rhoden, 40; his older brother, Kenneth Rhoden, 44; his cousin, Gary Rhoden; his former wife, Dana Lynn Rhoden, 37, and their children: Clarence “Frankie” Rhoden, 20, Hanna Mae Rhoden, 19, Christopher Rhoden Jr., 16, and Frankie’s fiancé, Hannah Gilley, 20.
The victims were found fatally shot in the head, some while sleeping, in mobile homes and a camper on April 22, 2016.
Wagner IV was indicted and arrested along with three other members of his family in November 2018 on a total of 22 charges, including eight counts of aggravated murder.
He’s also charged with conspiracy to commit aggravated murder, four counts of aggravated burglary, three counts of tampering with evidence, one count each of forgery, unauthorized use of property, interception of wire, oral or electronic communications, obstructing justice, and engaging in a pattern of corrupt activity.
The trial began late last month with the final selection of jurors, who then toured key locations in the case.
With more than 250 people on the potential witness list, attorneys have told the jury to expect the trial to last anywhere from six to eight weeks.
Depending on how long opening statements take, the prosecution could call their first witnesses on Monday.
Wagner IV has pleaded not guilty, and his lawyers have argued the confessions of his brother and mother last year prove he didn’t shoot and kill anyone.
Special Prosecutor Angela Canepa agreed in a December 2021 hearing that Wagner IV didn’t kill anyone.
In the state of Ohio, however, someone can be sentenced to death for an aggravated murder conviction if they help plan it or cover it up.
The judge denied a motion from Wagner IV’s lawyers during that hearing to dismiss the eight aggravated murder charges.
[Eldest Wagner son didn’t kill anyone in Pike County massacre: court docs]
[Pike County Massacre: Judge allows shoe expert to testify]
Two key witnesses for both the prosecution and defense will be George’s younger brother, Edward “Jake” Wagner, and his mother, Angela Wagner.
Both pleaded guilty last year for their roles.
Jake Wagner, 28, was charged with eight counts of murder and 15 other charges including gun specifications, conspiracy, burglary, possession of dangerous ordnance and tampering with evidence.
He admitted to killing five members of the Rhoden family, shooting a sixth, and spying on the family before the killings, tampering with evidence, and obstructing the yearslong search for the killers.
In exchange, prosecutors say they will drop the possibility of the death penalty for his entire family, and he agreed to serve eight life sentences without parole.
His lawyer said Jake Wagner “knows he’s going to die in prison without any judicial relief.”
He is held at the Franklin County Jail.
Jake was the ex-boyfriend of one of the victims, Hanna Mae Rhoden.
Authorities have said the motive of the slayings stemmed in part over a custody dispute between a young daughter Jake Wagner and Hanna Rhoden had together.
Jake was also charged with unlawful sexual conduct with a minor for having sexual contact with Hanna Mae Rhoden when she was 15 and he was 20 years old.
The couple split up, and a bitter custody dispute ensued over their daughter, with Hanna Mae Rhoden refusing to sign shared custody papers, according to prosecutors.
“They will have to kill me first,” she wrote in a 2015 Facebook message, prosecutors have said.
Jake Wagner also was upset she was seeing another man and became pregnant with that man’s child and was exposing their daughter to people he felt she should not be.
That compelled the Wagner family to plot the killings, buying supplies such as ammunition, magazines, clips and parts to build gun silencers, according to prosecutors.
His mother pleaded to conspiracy to commit aggravated murder, several counts of aggravated burglary, tampering with evidence, and other charges as part of a plea deal.
The remaining eight counts of aggravated murder were dismissed.
The prosecution is recommending the 51-year-old woman serve 30 years in prison with no possibility of the death penalty. She currently is held at the jail in Delaware County.
The other Wagner still facing trial and accused of actually shooting and killing anyone is the family patriarch, George “Billy” Wagner III, 50.
He has pleaded not guilty and remains locked up at the Butler County Jail.
He is charged with eight counts of aggravated murder, four counts of aggravated burglary, three counts of tampering with evidence, two counts of unlawful possession of dangerous ordnance and single counts of conspiracy, forgery, unauthorized use of computer or telecommunications, interception of wire, oral or electronic communication, obstructing justice and engaging in a pattern of corrupt activity.
Copyright 2022 WXIX via Gray Media Group, Inc. All rights reserved.
|
https://www.wistv.com/2022/09/12/trials-opening-statements-begin-slaying-8-family-members/
| 2022-09-12T12:27:34Z
|
https://www.wistv.com/2022/09/12/trials-opening-statements-begin-slaying-8-family-members/
| false
|
First-time fathers' brains SHRINK by up to 2% after the birth of their baby - but it can actually help them connect with their child, study finds
- Previous studies show motherhood can change the structure of women's brains
- Researchers set out to see if this was also the case for first-time fathers
- They performed MRI scans on 40 first-time dads in Spain and the US
- On average, men lost 1-2% of cortical volume after their child was born
Many women experience cognitive struggles during pregnancy and after birth, in what is often referred to as 'baby brain.'
Now, a new study suggests that men may experience brain changes following the birth of their first child too.
Researchers from Carlos III Health Institute in Madrid found that first-time fathers lose a percentage or two of cortical volume after their child is born.
While the reason for this remains unclear, the researchers suggest that the change may make it easier for fathers to connect with their child.
A new study suggests that men may experience brain changes following the birth of their first child too
Previous studies have shown that motherhood can change the structure of women's brains.
In particular, women can experience changes in their limbic subcortical networks – the part of the brain associated with pregnancy hormones.
However, researchers have not been able to reach a consensus or whether parenthood also has an effect on fathers' brains.
'Studying fathers offers a unique opportunity to explore how parenting experience can shape the human brain when pregnancy is not directly experienced,' the researchers, led by Magdalena Martinez-Garcia, wrote in their study, published in Cerebral Cortex.
In the study, the researchers used magnetic resonance imaging (MRI) to assess the brains of 40 heterosexual first-time fathers.
Half of the fathers were based in Spain, and participated in brain scans before their partners' pregnancies and then again a few months after birth.
The other half were based in the US, and participated in brain scans during the mid-to-late stages of their partners' pregnancy, and then again seven to eight months after birth.
Meanwhile, 17 men without children in Spain also had their brains scanned as a control group.
While the reason for the findings remains unclear, the researchers suggest that the change may make it easier for fathers to connect with their child
Using the scans, the researchers measured the volume, thickness, and structural properties of the men's brains.
The results revealed that the men did not experience changes to their limbic subcortical networks, like women.
However, they did show signs of brain changes in their cortical grey matter – the area of the brain involved in social understanding.
They also showed reductions in the volume of their visual system.
'These findings may suggest a unique role of the visual system in helping fathers to recognize their infants and respond accordingly, a hypothesis to be confirmed by future studies,' the researchers said.
'Understanding how the structural changes associated with fatherhood translate into parenting and child outcomes is a largely unexplored topic, providing exciting avenues for future research.'
|
https://www.dailymail.co.uk/sciencetech/article-11203615/First-time-fathers-experience-brain-SHRINKAGE-birth-child-study-finds.html?ns_mchannel=rss&ito=1490&ns_campaign=1490
| 2022-09-12T12:28:21Z
|
https://www.dailymail.co.uk/sciencetech/article-11203615/First-time-fathers-experience-brain-SHRINKAGE-birth-child-study-finds.html?ns_mchannel=rss&ito=1490&ns_campaign=1490
| false
|
TSX.V: EU
OTCQB:ENCUF
www.encoreuranium.com
CORPUS CHRISTI, Texas, Sept. 12, 2022 /PRNewswire/ - enCore Energy Corp. ("enCore" or the "Company") (TSXV: EU) (OTCQB: ENCUF) today announced that in connection with the application to list its common shares on The Nasdaq Stock Market LLC ("Nasdaq"), it will consolidate its common shares on a one (1) post-consolidation share for every three (3) current shares basis (the "Share Consolidation"). The common shares will trade on the TSX Venture Exchange on a post-consolidated basis effective at the open of markets on September 14, 2022.
Highlights include:
- Uplisting from OTC to Nasdaq provides growth-oriented companies greater exposure to the largest capital market in the world;
- The resulting smaller share count and higher share price is more palatable to U.S. institutional investors. The revised capital structure and resulting higher share price may provide increased ability for U.S. institutional investors to become shareholders of enCore;
- Target date of September 14, 2022 for share consolidation noting the Company is actively working to complete the Nasdaq listing.
enCore's Executive Chairman William M. Sheriff said, "The decision to list on the Nasdaq will provide enCore with greater visibility through a leading capital market trading platform that is suited for growth-oriented companies like enCore. With the commissioning of the Rosita Uranium Processing Plant to be completed in 2022 and planned production in 2023, increased exposure to the largest market in the world coincides with 2023 cash flow. enCore is well positioned to provide a reliable, low carbon and domestic supply of fuel for the growing nuclear energy sector. This marks another important step in enCore's growth as it continues its work to become a leading United States ISR uranium development company."
The Company currently has 322,822,741 common shares issued and outstanding. Following the Share Consolidation, the Company will have approximately 107,607,580 common shares issued and outstanding prior to rounding for fractional shares. The Share Consolidation was approved by the board of directors of the Company as part of the Nasdaq listing process
The exercise price and the number of common shares issuable under any of the Company's outstanding warrants, stock options or other convertible securities will be proportionately adjusted upon the Consolidation. No fractional shares will be issued as a result of the Share Consolidation. All fractions of common shares will be rounded up or down to the nearest whole number. No cash consideration will be paid in respect of fractional shares.
Upon completion of the Share Consolidation, a letter of transmittal will be sent by mail to registered shareholders advising that the Share Consolidation has taken effect. The letter of transmittal will contain instructions on how registered shareholders can exchange their share certificates or DRS statements evidencing their pre-consolidated common shares for new share certificates or new DRS statements representing the number of post-consolidated common shares to which they are entitled. No action is required by non-registered shareholders (shareholders who hold their shares through an intermediary) to effect the Share Consolidation.
While the Company has applied for listing on Nasdaq, completion of a listing is subject to final regulatory approvals and the satisfaction of applicable listing requirements. There can be no assurance that a listing will be completed. When a listing is completed it is contemplated that the common shares of the Company would be dually listed and continue to trade in Canada on the TSX Venture Exchange under the symbol EU.
With approximately 90 million pounds of U3O8 estimated in the measured and indicated categories and 9 million pounds of U3O8 estimated in the inferred category1, enCore is the most diversified in-situ recovery uranium development company in the United States. enCore is focused on becoming the next uranium producer from its licensed and past-producing South Texas Rosita Processing Plant by 2023. The South Dakota-based Dewey Burdock project and the Wyoming Gas Hills project offer mid-term production opportunities, with significant New Mexico uranium resource endowments providing long-term opportunities. The enCore team is led by industry experts with extensive knowledge and experience in all aspects of ISR uranium operations and the nuclear fuel cycle. enCore is committed to engaging and working with local communities and indigenous governments to create positive impact from corporate developments.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements relating to the prospects of listing on the Nasdaq and associated benefits. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with the completion of the Nasdaq listing process and meeting related listing requirements, in addition to risks related to the advancement of our business, including general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access additional capital; the ability of enCore to implement its business strategies; and other risks. Readers are cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
View original content to download multimedia:
SOURCE enCore Energy Corp.
|
https://www.wistv.com/prnewswire/2022/09/12/encore-energy-announces-share-consolidation-connection-with-proposed-listing-nasdaq/
| 2022-09-12T12:30:14Z
|
https://www.wistv.com/prnewswire/2022/09/12/encore-energy-announces-share-consolidation-connection-with-proposed-listing-nasdaq/
| true
|
– Researchers will now be able to access rich clinical data on patients with rare neurological disease –
SAN FRANCISCO, Sept. 12, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a collaboration with Simons Searchlight, an international research program with a goal of accelerating research and improving lives for people with rare genetic neurodevelopmental disorders. This partnership will connect two sets of data – the longitudinal clinical data extracted from medical records through Invitae's Ciitizen, a patient-consented, digital natural history data platform and patient reported outcomes and biospecimens collected by Simons Searchlight. The partnership breaks down data silos and provides a rich and deep dataset that will help accelerate research for rare neurodevelopmental diseases.
"We are excited about this collaboration that will allow researchers to get deep, rich longitudinal data on rare disease patients," said Farid Vij, president and general manager of data for Invitae. "This is intended to help improve treatment, with a goal of ultimately finding a cure for these rare diseases."
Rare disease patients and caregivers are often asked to participate in many different stand- alone studies to help advance research. Through the combined clinical and patient-reported data in these two datasets, researchers get a deeper understanding of the etiology and progression of disease, sparing additional time, effort and data collection from the patient.
"Joining forces with Invitae is incredibly powerful for patients with rare diseases," said Jennifer Tjernagel, M.S., senior project manager at Simons Searchlight, Simons Foundation. "Our partnership and the resulting datasets will help improve understanding, diagnosis and treatment of neurodevelopmental disorders, such as STXBP1, SYNGAP1 and others. Having the support of Invitae's Ciitizen platform will help pair patient-reported data with clinical information for in depth data analysis."
Charlene Son Rigby, president and co-founder of STXBP1 Foundation shared, "We are thrilled to partner with Invitae and Simons Searchlight on this initiative. We believe in the power of data and how important sharing that data can be in the journey to finding a cure for STXBP1 Disorder. Having this kind of collaboration in our toolkit is opening up an entirely new approach for our foundation and our patient community. The combination of Invitae's existing clinical data which will be transitioned into a readily usable format, and Simons' deep information from patients and caregivers, will provide doctors and scientists with an innovative way to accelerate understanding of natural history, while allowing patients and their loved ones to focus on what's most important - their health."
Mike Graglia, Managing Director and Co-Founder of the SynGAP Research Fund stated, "Invitae's Ciitizen is a powerful digital natural history study data platform in the rare disease space. The technology, execution and clinical expertise behind it are exceptional. Simons Searchlight is the most established clinician-led registry in autism and related disorders. The accomplishment of connecting these two platforms is a testament to their collective focus on helping patients. Every single patient who has access to Invitae's Ciitizen platform and Searchlight should consent to join their profiles now."
This agreement expands upon a partnership that was originally launched as a pilot for STXBP1 patients and the STXBP1 Foundation. The relationship allowed consenting patients to link their de-identified Invitae Ciitizen data with the Simons Searchlight database to accelerate understanding of patients with STXBP1 disorder. By expanding focus to additional rare neurological disorders, such as SYNGAP1, SCN2A, SLC6A1 and more, researchers are one step closer to finding the needle in the haystack for patients with these conditions. To learn more about Invitae's Ciitizen data platform and request access to the consented dataset for research, email partners@invitae.com.
Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time and lower prices. For more information, visit the company's website at invitae.com.
Simons Searchlight collects medical, developmental, and behavioral data on people living with rare developmental disorders. Participants and their families share this valuable information and experiences so that scientists around the world may increase understanding of these medical conditions and ultimately improve lives. For more information, visit simonssearchlight.org
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the availability, features and potential impact of the company's products; the company's belief that it is the first and only laboratory to offer this comprehensive suite of tests for neurodevelopmental disorders in an easily accessible format; the company's belief that its NDD package is affordable and fast; and the company's belief that its NDD package will inform care decisions and treatment plans for patients. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2021. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.
Contact: Renee Kelley
pr@invitae.com
(628) 213-3283
View original content to download multimedia:
SOURCE Invitae Corporation
|
https://www.wistv.com/prnewswire/2022/09/12/invitae-simons-searchlight-partner-accelerate-research-through-data-sharing/
| 2022-09-12T12:31:51Z
|
https://www.wistv.com/prnewswire/2022/09/12/invitae-simons-searchlight-partner-accelerate-research-through-data-sharing/
| false
|
20% constant exchange rate revenue growth in H1: Demand for Abcam In-house Products Increases
CAMBRIDGE, England and WALTHAM, Mass., Sept. 12, 2022 /PRNewswire/ -- Abcam plc (NASDAQ: ABCM) (AIM: ABC) ('Abcam', the 'Group' or the 'Company'), a global leader in the supply of life science research tools, today announces its interim results for the six-month period ended 30 June 2022 (the 'period').
* Excludes the amortisation of the fair value of assets relating to the inventory acquired in connection with the acquisition of BioVision.
** Adjusted figures exclude systems and process improvement costs, acquisition costs, amortisation of fair value adjustments, integration and reorganisation costs, amortisation of acquisition intangibles, share-based payments and employer tax contributions thereon, and the tax effect of adjusting items. Such excluded items are described as "adjusting items." Further information on these items is shown in note 4 to the consolidated interim financial statements. Share-based payments have been included in adjusting items from the period ended 30 June 2022; the prior period has been re-presented to be in line with the current period.
*** Net (debt) / cash comprises cash and cash equivalents less borrowings.
FINANCIAL HIGHLIGHTS1
- 20% constant exchange rate ('CER') revenue growth (23% reported revenue growth), driven by in-house product sales and the inclusion of BioVision
- Adjusted gross margin increased 420 basis points aided by in-house product mix, including the accretive impact from the inclusion of BioVision
- Adjusted operating cost increases were primarily driven by higher selling, general & administrative expenses for personnel, IT expenses for our digital strategy, and the inclusion of BioVision. Adjusted operating profit margin expanded 540 bps to 23% driven by favourable product mix and operating leverage. Reported operating profit decreased by £1.0m to £9.3m (H1 2021: £10.3m)
- Adjusted diluted earnings per share were 14.0p up 97% (H1 2021: 7.1p)
- In-house new product development and sales experienced gains. Total in-house revenue (including CP&L and BioVision) now represents 67% of total revenue (H1 2021: 58%)
- The Company's net debt position is a result of the BioVision acquisition but improved as compared to 31 December 2021 (£24.1m)
STRATEGIC & OPERATIONAL HIGHLIGHTS1
- Academic and Research customers returned to their labs, although China continued to be impacted by COVID lockdowns
- Pharmaceutical customers continue their efforts to understand disease-specific biomarkers
- BioVision integration activities on track
- Consistent key performance indicators2
- Product satisfaction rates H1 2022 99.0% (H1 2021: 98.8%)
- Customer transactional Net Promoter Score ('tNPS') H1 2022 +55 (H1 2021: +58) - Ongoing digital and physical infrastructure investments including Waltham expansion, and new Singapore office
- Installation of High Throughput Cell-Engineering Platform for edited cell lines
- H1 2022 New Product Development of over 1,800 products
- Recognised as the company with most CiteAb awards
- Following a positive shareholder response, Board to seek General Meeting before the end of the year to approve the cancellation of its listing on AIM
Commenting on the performance, Alan Hirzel, Abcam's Chief Executive Officer, said:
"I am proud of our team's effort to support our global customers and the results those efforts generated in our first half of 2022. We achieved 20% constant exchange rate revenue growth, 23% reported revenue growth, driven by our multi-year dedication to increasing in-house innovation at Abcam. These investments in innovation and in our broader strategy, have sustained growth and expanded gross margin in the period. As we move into the next phase of our five-year strategic plan, we are moderating investment levels and working toward higher operating leverage and adjusted operating margin expansion. Looking ahead, we are confident in our growth trajectory and committed to delivering our CY2022 plan and CY2024 goals."
CY2022 GUIDANCE
For the full year ending December 2022, we currently estimate total revenue to increase approximately 20% CER including the impact from the acquisition of BioVision, with organic CER growth of mid-teens. We expect the contribution from the sale of higher margin in-house products and the full year effect of BioVision to contribute to a continuing increase in adjusted operating margins.
SHARE TRADING, LIQUIDITY AND LISTING
Having consulted shareholders on its proposal to cancel the admission of the Company's ordinary shares to trading on AIM, leaving it with a listing solely on NASDAQ, and having received positive responses from all consulted, in the coming weeks the Board will issue a circular to convene an extraordinary general meeting to seek shareholder approval for the cancellation of the admission of the Company's shares to trading on AIM.
The circular will contain full details of the proposal, what action shareholders will be required to take and information on the impact of those holding ordinary shares.
Analyst and investor meeting and webcast:
Abcam will host a conference call and webcast for analysts and investors today at 13:00 BST/ 08:00 EDT. For details, and to register, please visit corporate.abcam.com/investors/reports-presentations
For further details please contact FTI Consulting at abcam@fticonsulting.com
A recording of the webcast will be made available on Abcam's website, corporate.abcam.com/investors
Notes:
- Throughout this report, 'H1 2021' and 'H1 2022' refer to the six month periods ended 30 June 2021 and 30 June 2022, respectively.
- Key performance indicators are based on a rolling 12-month average.
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
For further information please contact:
This announcement shall not constitute an offer to sell or solicitation of an offer to buy any securities.
This announcement is not an offer of securities for sale in the United States, and the securities referred to herein may not be offered or sold in the United States absent registration except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act of 1933, as amended. Any public offering of such securities to be made in the United States will be made by means of a prospectus that may be obtained from the issuer, which would contain detailed information about the company and management, as well as financial statements.
Forward Looking Statements
This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this announcement that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation statements of targets, plans, objectives or goals for future operations, including those related to Abcam's products, product research, product development, product introductions and sales forecasts; statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures; statements regarding future economic and financial performance; statements regarding the scheduling and holding of general meetings and AGMs; statements regarding the assumptions underlying or relating to such statements; statements about Abcam's portfolio and ambitions, as well as statements that include the words "expect," "intend," "plan," "believe," "project," "forecast," "estimate," "may," "should," "anticipate" and similar statements of a future or forward-looking nature. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation: a regional or global health pandemic, including the novel coronavirus ("COVID-19"), which has adversely affected elements of our business, could severely affect our business, including due to impacts on our operations and supply chains; challenges in implementing our strategies for revenue growth in light of competitive challenges; developing new products and enhancing existing products, adapting to significant technological change and responding to the introduction of new products by competitors to remain competitive; failing to successfully identify or integrate acquired businesses or assets into our operations or fully recognise the anticipated benefits of businesses or assets that we acquire; if our customers discontinue or spend less on research, development, production or other scientific endeavours; failing to successfully use, access and maintain information systems and implement new systems to handle our changing needs; cyber security risks and any failure to maintain the confidentiality, integrity and availability of our computer hardware, software and internet applications and related tools and functions; failing to successfully manage our current and potential future growth; any significant interruptions in our operations; if our products fail to satisfy applicable quality criteria, specifications and performance standards; failing to maintain our brand and reputation; our dependence upon management and highly skilled employees and our ability to attract and retain these highly skilled employees; and the important factors discussed under the caption "Risk Factors" in Abcam's prospectus pursuant to Rule 424(b) filed with the U.S. Securities and Exchange Commission ("SEC") on 22 October 2020, which is on file with the SEC and is available on the SEC website at www.sec.gov, as such factors may be updated from time to time in Abcam's other filings with the SEC. Any forward-looking statements contained in this announcement speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. Abcam disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.
Interim management report
Introduction
We are pleased with the steady progress of our business over the past six months despite ongoing difficulties from COVID-19 related lockdowns in China. As the pandemic continues to present isolated challenges, we have focused on meeting the needs of our customers driven by the resilience of both our employees and our business, as well as the role Abcam and its customers have in advancing critical life science research. We are convinced more than ever that by continuing to invest in our technologies, people, capabilities, and customer needs, we can extend our market leadership, sustain durable growth, and become an increasingly influential partner within our industry.
Demand for our products, and particularly Abcam's in-house developed products, increased during the period. Whilst the global pandemic situation continues to be fluid – and the risk of further outbreaks and new variants remains – we estimate that overall lab activity is now approaching pre-COVID levels in most of our markets.
Having reached the halfway point in our 2024 Vision strategy, we remain on track to achieve our guided revenues, adjusted operating profit margin, and return on capital employed. As the multi-year period of growth investments moderates, we expect to achieve operating efficiencies resulting in adjusted operating profit margin expansion consistent with the Board's expectations. We are proud of our colleagues and teams around the world who have shown audacity, agility, and dedication in the delivery of our plans – they are fundamental to the Group's future success.
Underpinning our continued progress is our balance sheet and financial position, which enables us to invest in attractive organic and inorganic growth opportunities to accelerate Abcam's strategic execution and focus on in-house innovation and products. We continue to be pleased with the integration of BioVision, a leading innovator of biochemical and cell-based assays.
Looking forward, with our expanding capabilities, financial position and market opportunities for growth, the Company is well-positioned to sustain long-term value creation.
* Revenues for Hong Kong have been reclassified from Rest of Asia to China for the period ended 30 June 2022. The value attributable to Hong Kong for the six months ended 30 June 2022 is £0.8m (30 June 2021: £0.7m). The comparatives presented for the six months ended 30 June 2021 have not been updated for this change due to immateriality.
REVENUE
Revenue of £185.2 million (H1 2021: £150.2m) represents approximately 20% CER growth over the prior period. Regionally, growth was driven in the Americas with broad customer strength. In the current period, BioVision's sales (previously reported as third-party sales) have been treated as in-house from the date of acquisition, resulting in 37% CER revenue growth. Product revenue growth continues to be driven by growth in antibodies, assays, proteins, and cell engineering sales.
GROSS MARGIN
Adjusted gross profit of £140.0 million (H1 2021: £107.2m) equates to adjusted gross margin of 75.6% (H1 2021: 71.4%). Adjusted gross margin expansion was benefitted from favourable product mix from in-house products, including the accretive impact of BioVision. Reported gross profit of £137.3 million (H1 2021: £107.2m) equates to reported gross margin of 74.1% (H1 2021: 71.4%). Adjusted gross profit differs from reported gross profit by £2.7 million impacted by the amortisation of the fair value of assets relating to the inventory acquired in connection with the acquisition of BioVision.
Adjusted operating costs of £97.4 million (H1 2021: £80.7m) represents approximately 21% growth over the prior period. Excluding BioVision, underlying growth was approximately 17% primarily driven by higher selling, general and administrative expenses reflecting increased investments in personnel as we build out our in-house supply chain & logistics, and manufacturing capabilities, as well as planned investments made during the period in our platform to support the Company's growth. On a reported basis, total reported costs were £128.0 million (H1 2021: £96.9m) increased by £31.1 million or 32% reflecting the adjusting items noted below.
ADJUSTING ITEMS
Total reported expenses include the following adjusting items:
- £2.6 million relating to the Oracle Cloud ERP project (H1 2021: £2.0m)
- £6.0 million from acquisition, integration, and reorganisation charges (H1 2021: £3.5m)
- £9.0 million relating to the amortisation of acquired intangibles (H1 2021: £4.0m)
- £13.0 million in charges for share-based payments (H1 2021: £6.7m)
Note 4 in the notes to the interim financial statements provides further detail on adjusting items and a reconciliation between reported and adjusted profit measures.
NET PROFIT
Adjusted net profit was £32.2 million (H1 2021: £16.2m) driven by revenue growth, favourable product mix enabling gross margin expansion and modest cost growth. Reported net profit was £5.8 million (H1 2021 £2.9m).
CASH
Cash of £109.6 million (period ended 31 December 2021: £95.1m) increased by £14.5 million. The reported change is driven by operating activities impacted by ongoing investments in working capital and reduced by moderating investing, and financing activities. The Company has outstanding borrowings net of fees of £119.4 million, resulting from our acquisition of BioVision, resulting in net debt of £9.8 million.
Notes:
- Custom Products & Licensing (CP&L) revenue comprises custom service revenue, revenue from the supply of IVD products and royalty and licence income.
- Sales from our acquisition of BioVision have been treated as in-house from the date of acquisition impacting comparability.
Looking forward
We are achieving good momentum across the business as market activity continues to recover. Investments we have made, and that we continue to make, are enabling the business to sustain growth and we remain committed to generating revenue of £450 – 525m for the year ending 31 December 2024 (calculated at the average exchange rates for the 12 months ended June 2021).
In the more immediate term, uncertainty around the COVID-19 pandemic remains, yet laboratory activity and demand continue to recover in most regions and trading performance year to date, in spite of headwinds in China, is in line with the Board's expectations.
The business' cash generation and financial position continue to provide a foundation from which to pursue opportunities, including innovation, acquisitions, and partnerships. We will continue to invest in our business to enable Abcam to provide innovative, trusted, and improved solutions for our customers. While the rate of investment is moderating from recent levels as we pass the peak for this 2019-2024 strategy implementation, we have a continuing appetite to invest in growing Abcam sustainably for the long term.
Supported by a clear purpose and strategy, and thanks to the efforts of all our employees and partners, we believe that Abcam is well positioned to continue delivering long-term value for our shareholders.
Alan Hirzel
Chief Executive Officer
Michael S Baldock
Chief Financial Officer
12 September 2022
Forward Looking Statements
This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this announcement that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation statements of targets, plans, objectives or goals for future operations, including those related to Abcam's products, product research, product development, product introductions and sales forecasts; statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures; statements regarding future economic and financial performance; statements regarding the scheduling and holding of general meetings and AGMs; statements regarding the assumptions underlying or relating to such statements; statements about Abcam's portfolio and ambitions, as well as statements that include the words "expect," "intend," "plan," "believe," "project," "forecast," "estimate," "may," "should," "anticipate" and similar statements of a future or forward-looking nature. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation: a regional or global health pandemic, including the novel coronavirus ("COVID-19"), which has adversely affected elements of our business, could severely affect our business, including due to impacts on our operations and supply chains; challenges in implementing our strategies for revenue growth in light of competitive challenges; developing new products and enhancing existing products, adapting to significant technological change and responding to the introduction of new products by competitors to remain competitive; failing to successfully identify or integrate acquired businesses or assets into our operations or fully recognise the anticipated benefits of businesses or assets that we acquire; if our customers discontinue or spend less on research, development, production or other scientific endeavours; failing to successfully use, access and maintain information systems and implement new systems to handle our changing needs; cyber security risks and any failure to maintain the confidentiality, integrity and availability of our computer hardware, software and internet applications and related tools and functions; failing to successfully manage our current and potential future growth; any significant interruptions in our operations; if our products fail to satisfy applicable quality criteria, specifications and performance standards; failing to maintain our brand and reputation; our dependence upon management and highly skilled employees and our ability to attract and retain these highly skilled employees; and the important factors discussed under the caption "Risk Factors" in Abcam's prospectus pursuant to Rule 424(b) filed with the U.S. Securities and Exchange Commission ("SEC") on 22 October 2020, which is on file with the SEC and is available on the SEC website at www.sec.gov, as such factors may be updated from time to time in Abcam's other filings with the SEC. Any forward-looking statements contained in this announcement speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. Abcam disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.
Responsibility statement
We confirm to the best of our knowledge:
- the interim financial statements have been prepared in accordance with IAS 34;
- the Financial and Operational highlights, Interim Management Report and Interim Financial statements include a fair review of the information required by the Financial Statements Disclosure and Transparency Rules (DTR) 4.2.7R, being an indication of important events that have occurred during the first six months of the financial period and a description of the principal risks and uncertainties for the remaining six months of the period; and
- the Financial and Operational highlights and Interim Management Report include a fair review of the information required by DTR 4.2.8R, being related party transactions that have taken place in the first six months of the current financial period and that have materially affected the financial position or performance of the entity during the period and also any changes in the related party transactions described in the last Annual Report that could do so.
At the date of this statement, the Directors are those listed in the Annual Report and Accounts 2021 and there were no further changes.
By order of the Board
Alan Hirzel
Chief Executive Officer
Michael S Baldock
Chief Financial Officer
Independent review report to Abcam plc
Report on the condensed consolidated interim financial statements
Our conclusion
We have reviewed Abcam plc's condensed consolidated interim financial statements (the "interim financial statements") in the interim report of Abcam plc for the 6 month period ended 30 June 2022 (the "period").
Based on our review, nothing has come to our attention that causes us to believe that the interim financial statements are not prepared, in all material respects, in accordance with UK adopted International Accounting Standard 34, 'Interim Financial Reporting' and the AIM Rules for Companies.
The interim financial statements comprise:
- the condensed consolidated balance sheet as at 30 June 2022;
- the condensed consolidated income statement and condensed consolidated statement of comprehensive income for the period then ended;
- the condensed consolidated cash flow statement for the period then ended;
- the condensed consolidated statement of changes in equity for the period then ended; and
- the explanatory notes to the interim financial statements.
The interim financial statements included in the interim report of Abcam plc have been prepared in accordance with UK adopted International Accounting Standard 34, 'Interim Financial Reporting' and the AIM Rules for Companies.
Basis for conclusion
We conducted our review in accordance with International Standard on Review Engagements (UK) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Financial Reporting Council for use in the United Kingdom. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures.
A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK) and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We have read the other information contained in the interim report and considered whether it contains any apparent misstatements or material inconsistencies with the information in the interim financial statements.
Conclusions relating to going concern
Based on our review procedures, which are less extensive than those performed in an audit as described in the Basis for conclusion section of this report, nothing has come to our attention to suggest that the directors have inappropriately adopted the going concern basis of accounting or that the directors have identified material uncertainties relating to going concern that are not appropriately disclosed. This conclusion is based on the review procedures performed in accordance with this ISRE. However, future events or conditions may cause the group to cease to continue as a going concern.
Responsibilities for the interim financial statements and the review
Our responsibilities and those of the directors
The interim report, including the interim financial statements, is the responsibility of, and has been approved by the directors. The directors are responsible for preparing the interim report in accordance with the AIM Rules for Companies which require that the financial information must be presented and prepared in a form consistent with that which will be adopted in the company's annual financial statements. In preparing the interim report, including the interim financial statements, the directors are responsible for assessing the group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or to cease operations, or have no realistic alternative but to do so.
Our responsibility is to express a conclusion on the interim financial statements in the interim report based on our review. Our conclusion, including our Conclusions relating to going concern, is based on procedures that are less extensive than audit procedures, as described in the Basis for conclusion paragraph of this report. This report, including the conclusion, has been prepared for and only for the company for the purpose of complying with the AIM Rules for Companies and for no other purpose. We do not, in giving this conclusion, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.
PricewaterhouseCoopers LLP
Chartered Accountants
Cambridge
12 September 2022
* During the period ended 30 June 2022, share-based payment charges and employer tax contributions thereon have been included in adjusting items. The prior period has been re-presented to be in line with the current period.
Adjusted figures exclude system and process improvement costs, acquisition costs, amortisation of fair value adjustments, integration and reorganisation costs, amortisation of acquisition intangible assets, share-based payments and employer tax contributions thereon, and the tax effect of adjusting items. Such excluded items are described as "adjusting items". Further information on these items is shown in note 4.
* See note 2 for details of the prior period restatement.
Approved by the Board of directors and authorised for issue on 12 September 2022.
* See note 2 for details of the prior period restatement.
(i) Within cash and cash equivalents is £nil (30 June 2021: £1.6m) of cash relating to employee contributions to the Group's share scheme 'AbShare', which is reserved for the purpose of purchasing shares upon vesting.
(ii) Free cash flow comprises net cash generated from operating activities less net capital expenditure, reimbursement of leasehold improvement costs, transfer of cash from/(to) escrow in respect of future capital expenditure, and the principal and interest elements of lease obligations.
Notes to the condensed consolidated interim financial statements
For the six month period ended 30 June 2022
1. General information
The condensed consolidated interim financial statements for the six month period ended 30 June 2022 are unaudited and do not comprise statutory accounts within the meaning of section 434 of the Companies Act 2006, but have been reviewed by the auditor. They do not include all of the information required in annual financial statements in accordance with IFRS, and should be read in conjunction with the consolidated financial statements for the 18 month period ended 31 December 2021. The financial information for the period ended 31 December 2021 does not constitute the Company's statutory accounts for that period, but has been extracted from those accounts, which were approved by the Board of Directors on 14 March 2022 and have been delivered to the Registrar of Companies. The auditor has reported on those accounts, their opinion was unqualified, did not draw attention to any matters by way of emphasis and did not contain any statement under section 498(2) or (3) of the Companies Act 2006.
2. Basis of preparation
The condensed interim financial statements for the six month period ended 30 June 2022 included in this interim financial report have been prepared in accordance with UK adopted International Accounting Standard 34, 'Interim Financial Reporting' and the AIM Rules for Companies, and have been prepared on a going concern basis as described further below.
a. Accounting policies
The accounting policies adopted in the preparation of the condensed consolidated interim financial statements are those as set out in the Group's financial statements for the period ended 31 December 2021, except for the following:
Assets held for sale
Assets are classified as assets held for sale when their carrying amount is to be recovered principally through a sale transaction rather than through continuing use, and a sale is considered highly probable. They are measured at the lower of their carrying amount and fair value less costs to sell. Non-current assets are not depreciated or amortised while they are classified as held for sale. Assets classified as held for sale and the associated liabilities are presented separately from other assets and liabilities on the condensed consolidated balance sheet.
Tax
Taxes on income in the interim periods are accrued using the tax rate that would be applicable to the expected total annual profit. This is described in note 5.
New accounting standards and interpretations
There have not been any new standards or interpretations adopted in the period which would have a material financial impact on, or disclosure requirement for, the Group's interim report.
b. Critical accounting judgements and sources of estimation uncertainty
Judgements and estimates are the same as those as set out in the Group's financial statements for the period ended 31 December 2021, except for the following:
Assets held for sale
Judgement, which is subject to change as new information becomes available, can be required in determining when as asset is classified as held for sale, as described in the accounting policies section. A change in that judgement could result in an impairment charge, depending on whether classification requires a write-down of the asset to its fair value less costs to sell.
c. Going concern
The directors have prepared the interim financial statements on a going concern basis. In considering going concern, the directors have considered the Group's forecasts and projections, taking account of reasonably possible changes in trading performance. These show that the Group is expected to operate within the limits of its available resources.
Accordingly, the directors have a reasonable expectation that the Group has adequate resources to continue in operation for the foreseeable future and a period of not less than twelve months from the date of this report. Accordingly, the going concern basis has been adopted in preparing the interim financial report.
d. Adjusted performance measures
Adjusted performance measures are used by the Directors and management to monitor business performance internally and exclude certain cash and non-cash items which they believe are not reflective of the normal day-to-day operating activities of the Group. The Directors believe that disclosing such non-IFRS measures enables a reader to isolate and evaluate the impact of such items on results and allows for a fuller understanding of performance from period to period. Adjusted performance measures may not be directly comparable with other similarly titled measures used by other companies. A detailed reconciliation between reported and adjusted measures is presented in note 4.
For the period ended 30 June 2022, charges associated with share-based payment schemes have been included as adjusting items. The income statement for the period ended 30 June 2021 has been re-presented to reflect these charges within adjusting items. Although share-based compensation is an important aspect of the compensation of our employees and executives, management believes it is useful to exclude share-based compensation expenses from adjusted profit measures to better understand the long-term performance of our core business. Share-based compensation expenses are non-cash charges and are determined using several factors, including expectations surrounding future performance, employee forfeiture rates and, for employee payroll-related tax items, the share price. These factors are beyond the Group's direct control and generally unrelated to operational decisions and performance in any particular period. Further, share-based compensation expenses are not reflective of the value ultimately received by the recipients of the awards.
e. Restatement of prior period results – Software as a Service ('SaaS') arrangements
In March 2021, The IFRS Interpretations Committee ('IFRIC') published an agenda decision on how an entity should account for costs of configuring or customising application software in a Cloud Computing or Software as a Service ('SaaS') arrangement.
Previously, internal and external costs incurred in connection with the various phases of the Group's ERP implementation and other projects, have been capitalised as an intangible asset in line with IAS 38 'Intangible Assets'. During the period ended 31 December 2021, following an internal review of the impact of adoption of the IFRIC, the Group identified some SaaS costs had previously been capitalised, that should have been expensed.
This change in accounting policy led to adjustments amounting to a £2.7m reduction in the intangible assets, and a £0.5m reduction in the deferred tax liability recognised in the 30 June 2021 balance sheet.
The following tables show the impact of the change in accounting policy on previously reported financial results:
3. Operating segments
The Directors consider that there is only one core business activity and there are no separately identifiable business segments which are engaged in providing individual products or services or a group of related products and services which are subject to separate risks and returns. The information reported to the Group's Chief Executive Officer, who is considered the chief operating decision maker, for the purposes of resource allocation and assessment of performance, is based wholly on the overall activities of the Group. The Group has therefore determined that it has only one reportable segment under IFRS 8 Operating Segments, which is 'sales of antibodies and related products'. The Group's revenue and assets for this one reportable segment can be determined by reference to the Group's income statement and balance sheet.
Geographical information
Revenues are attributed to regions based primarily on customers' location. The Group's revenue from external customers is set out below:
(i) Revenues for Hong Kong have been reclassified from Rest of Asia to China for the period ended 30 June 2022. The value attributable to Hong Kong for the six months ended 30 June 2022 is £0.8m (30 June 2021: £0.7m). The comparatives presented for the six months ended 30 June 2021 have not been updated for this change due to immateriality.
Revenue by type is shown below:
4. Adjusted performance measures
A reconciliation of the Group's adjusted performance measures to reported IFRS measures is presented below:
* During the period ended 30 June 2022, share-based payment charges and employer tax contributions thereon have been included in adjusting items. The prior period has been re-presented to be in line with the current period.
An analysis of adjusting items is presented below:
* During the period ended 30 June 2022, share-based payment charges and employer tax contributions thereon have been included in adjusting items. The prior period has been re-presented to be in line with the current period.
(i) Comprises amortisation of fair value adjustments relating to the acquisition of BioVision. Following the acquisition, the Group recognised a fair value uplift of £6.0m to inventory carried on the Group's balance sheet. This adjustment was amortised over 4 months from November 2021 and are now fully amortised. Such costs are included within cost of sales.
(ii) Comprises costs of the strategic ERP implementation which do not qualify for capitalisation. Such costs are included within selling, general and administrative expenses.
(iii) Comprises legal and other professional fees associated with the acquisition of BioVision. Such costs are included within selling, general and administrative expenses.
(iv) Six months ended 30 June 2022: integration and reorganisation costs relate primarily to the integration of BioVision (comprising mainly retention and severance costs, employee backfill costs for those involved in the integration, settlement costs and professional fees) and footprint costs. Six months ended 30 June 2021: integration and reorganisation costs relate to the reorganisation and property related costs in respect of the alignment of the Group's operating structure and geographic footprint to its strategic goals. These costs are included in selling, general and administrative expenses.
(v) For the six month period ended 30 June 2022, £7.6m (30 June 2021: £3.0m) of amortisation of acquisition intangibles is included in research and development expenses, with the remaining £1.4m (30 June 2021: £1.0m) included in selling, general and administrative expenses.
(vi) Comprises share-based payment charges and employer's tax contributions thereon for all the Group's equity- and cash-settled schemes. Charges of £1.4m (30 June 2021: £0.1m) are included in research and development expenses, with the remaining £11.6m (30 June 2021: £6.6m) included within selling, general and administrative expenses.
5. Income tax
The major components of the income tax charge in the income statement are as follows:
* During the period ended 30 June 2022, share-based payment charges and employer tax contributions thereon have been included in adjusting items. The prior period has been re-presented to be in line with the current period.
(i) Adjusted income tax charge excludes the tax effects of adjusting items as set out in note 4.
The Group reported a net tax charge of £1.6m (30 June 2021: £6.3m). The tax charge for the six months ended 30 June 2021 was higher due to a restatement of certain deferred tax balances in line with the enactment of the change in UK corporation tax rates to 25% with effect from 1 April 2023.
The UK Corporation Tax rate for the six months ended 30 June 2022 was 19% (30 June 2021: 19%). Taxation for other jurisdictions is calculated at the rate prevailing in the relevant jurisdictions.
Effective tax rates represent management's best estimate of the average annual effective tax rate on reported or adjusted profits with these rates being applied to the six months results.
The estimated effective rate of tax on the reported profit for the six months ended 30 June 2022 is approximately 21.6% (30 June 2021: 68.5%), which represents management's best estimate of the average annual effective tax rate on profits expected for the six month period.
The estimated effective rate of tax on adjusted profits for the six months ended 30 June 2022 is approximately 20.9% (30 June 2021: 36.2%).
6. Earnings per share
The calculation of earnings per ordinary share (EPS) and adjusted earnings per ordinary share (adjusted EPS) are based on profit after tax, and adjusted profit after tax, respectively, attributable to owners of the parent and the weighted number of shares in issue during the period.
Adjusted EPS figures have been calculated based on earnings before adjusting items which are considered significant in nature or value and which are described in note 4.
Basic EPS and adjusted EPS are calculated by dividing the earnings attributable to the equity shareholders of the parent by the weighted average number of shares outstanding during the period. Diluted EPS and adjusted diluted EPS are calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all potentially dilutive ordinary shares. Such potentially dilutive ordinary shares comprise share options and awards granted to employees where the exercise price is less than the average market price of the Company's ordinary shares during the period and any unvested shares which have met, or are expected to meet, the performance conditions at the end of the reporting period.
* During the period ended 30 June 2022, share-based payment charges and employer tax contributions thereon have been included in adjusting items. The prior period has been re-presented to be in line with the current period.
7. Notes to the cash flow statement
8. Financial instruments and risk management
The Group's activities expose it to a variety of financial risks that include currency risk, interest rate risk, credit risk and liquidity risk.
The condensed interim financial statements do not include all financial risk management information and disclosures required in the annual financial statements; accordingly, they should be read in conjunction with the Group's financial statements for the period ended 31 December 2021. There have been no changes to the risk management policies since the period ended 31 December 2021.
The table below analyses financial instruments carried at fair value by valuation method. The different levels have been defined as follows:
- Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable market inputs).
The following table presents the Group's assets and liabilities carried at fair value by valuation method.
There were no transfers between levels during the period.
The Group's Level 2 financial instruments consist of forward foreign exchange contracts fair valued using forward exchange rates that are quoted in an active market.
The Group continues to generate significant amounts of US Dollars, Euros, Japanese Yen and Chinese Renminbi in excess of payments in these currencies and has hedging arrangements in place to reduce its exposure to currency fluctuations.
The following table details the forward contracts outstanding as at the period end:
The Group's Level 3 financial instruments consist of unlisted equity shares.
The fair value of the unquoted equity shares can be determined as management monitors the ongoing performance of the investment.
9. Goodwill
* The beginning of the period is 1 January 2022, 30 June 2020 and 1 January 2021 respectively for the periods presented in the table.
During the six months ended 30 June 2022, there was a cash receipt of £1.2m ($1.5m) relating to a successful claim lodged in relation to the acquisition of NKY Biotech US, Inc and its one wholly owned subsidiary, BioVision, Inc (collectively 'BioVision'). The cash consideration for BioVision was adjustable for certain net working capital balances, for which an estimate was provided on the close date. Subsequent to completing the acquisition balance sheet, it was noted that the actual net working capital balance fell short of the estimated balance and a claim was submitted. The corresponding adjustment to the consideration was recognised on the balance sheet as at 31 December 2021.
There have not been any adjustments to the provisional goodwill balance relating to BioVision in the six months ended 30 June 2022 and the goodwill balance remains provisional as at 30 June 2022. Adjustments to either the consideration paid or the acquired net assets may be recognised during the 12 month post acquisition measurement period, where it has been identified that the adjustment relates to events and circumstances prior to the acquisition.
10. Assets held for sale
Assets held for sale relate to assets and liabilities associated with the group's Fireplex multiplex and assay business. The major classes of assets and liabilities held for sale are Goodwill (£1.6m), Intangible assets (£15.3m), Property, plant and equipment (£0.8m), Inventory (£0.6m) and Deferred tax liabilities (£3.9m).
11. Capital commitments
As at 30 June 2022, the Group had capital commitments of £7.9m (30 June 2021: £8.9m) relating to the acquisition of property, plant and equipment and intangible assets.
Risks and uncertainties
The principal risks and uncertainties which the Group faces in the undertaking of its day-to-day operations and in pursuit of its longer-term objectives are set out in the Annual Report and Accounts 2021 on pages 63 to 67 and in note 4 to the consolidated financial statements. Information on financial risk management is set out in note 26 to the consolidated financial statements. A copy of the Annual Report and Accounts is available on the Group's website www.abcamplc.com/investors/reports-presentations/.
The principal risks and risk profile of the Group have not changed over the interim period and are not expected to change over the next six months.
The principal risks remain as:
Logo: https://mma.prnewswire.com/media/1670705/Abcam_Logo.jpg
View original content:
SOURCE Abcam plc
|
https://www.wkyt.com/prnewswire/2022/09/12/abcam-plc-interim-results-six-month-period-ended-30-june-2022/
| 2022-09-12T12:36:04Z
|
https://www.wkyt.com/prnewswire/2022/09/12/abcam-plc-interim-results-six-month-period-ended-30-june-2022/
| true
|
Show to honor cancer survivors and those battling the disease in program's return to air following loss of late executive producer
FORT LAUDERDALE, Fla., Sept. 12, 2022 /PRNewswire/ -- In honor of cancer survivors and those battling the disease, AutoNation, Inc. (NYSE:AN), America's most admired automotive retailer, is partnering with CBS' Daytime Emmy Award-Winning talk show @TheTalkCBS (weekdays 1 PM PT/2 PM ET) #TheTalk for the show's Season 13 Premiere airing today.
With a studio audience filled with cancer fighters and survivors, the Season 13 Premiere will honor the show's late Executive Producer Heather Gray's memory. It will represent the first time The Talk returns to the air since Gray lost her battle with cancer.
AutoNation will provide each audience member with a DRVPNK "Totes for Hope" cancer comfort bag and a $250 gift card.
"Through our singularly-focused philanthropic mission to end cancer, AutoNation Customers, Associates and communities from coast to coast together have raised and donated millions of dollars to drive out cancer," said Marc Cannon, Executive Vice President and Chief Customer Experience Officer at AutoNation. "All of us at AutoNation are honored to be a part of this special Season 13 premier Of CBS' The Talk honoring the memory of Heather Gray and all of the survivors and fighters in the studio and TV viewing audience."
Recognized for "turning the auto industry pink," AutoNation, America's most admired automotive retailer, decided nearly a decade ago to direct its charitable initiatives towards fighting cancer. In 2015, the company launched DRVPNK and began its race to beat cancer, driving toward raising $35 million to fund critical research and treatment through partnerships with cancer charities from coast to coast.
AutoNation kicks off its 8th annual DRVPNK Across America initiative on October 11 during Breast Cancer Awareness Month. On that day, thousands of AutoNation Associates from coast to coast will deliver "Totes For Hope" to patients undergoing cancer treatment. The company will also raise funds for the Breast Cancer Research Foundation. For more information about DRVPNK visit https://www.autonation.com/our-purpose/drive-pink.
About AutoNation, Inc.
AutoNation, a provider of personalized transportation services, is driven by innovation and transformation. As one of America's most admired companies, AutoNation delivers a peerless Customer experience recognized by data-driven consumer insight leaders, Reputation and J.D. Power. Through its bold leadership and brand affinity, the AutoNation Brand is synonymous with "DRVPNK" and "What Drives You, Drives Us." AutoNation has a singular focus on personalized transportation services that are easy, transparent, and Customer-centric.
Please visit www.autonation.com, www.investors.autonation.com, and www.twitter.com/AutoNation, where AutoNation discloses additional information about the Company, its business, and its results of operations. Please also visit www.autonationdrive.com, AutoNation's automotive blog, for information regarding the AutoNation community, the automotive industry, and current automotive news and trends.
View original content to download multimedia:
SOURCE AutoNation, Inc.
|
https://www.wkyt.com/prnewswire/2022/09/12/autonation-drvpnk-be-featured-season-13-premier-cbs-daytime-emmy-award-winning-talk-show-talk/
| 2022-09-12T12:36:18Z
|
https://www.wkyt.com/prnewswire/2022/09/12/autonation-drvpnk-be-featured-season-13-premier-cbs-daytime-emmy-award-winning-talk-show-talk/
| true
|
Ms. Henderson is joining the Vesttoo team after having served on the company's Advisory Board. She has 18 years of experience in reinsurance at the highest levels and was named one of the Most Influential Women in Re/Insurance by Intelligent Insurer Magazine.
TEL AVIV, Israel, Sept. 12, 2022 /PRNewswire/ -- Vesttoo, a leading insurance risk transfer and investment platform, announced today that it has hired well-known portfolio manager and risk strategist Julia Henderson as Chief Commercial Officer.
Ms. Henderson has worked in the reinsurance sector since 2004. She has been highly regarded as a prominent figure in the industry, having held executive roles at PartnerRe, Brit Insurance, Peak Capital, and Stable. She holds an MBA in Finance from the Wharton School at the University of Pennsylvania. Before joining Vesttoo as a CCO, Ms. Henderson served as a member of Vesttoo's advisory board, as well as the President and Head of Portfolio Management at Stable.
"Julia knows the reinsurance industry inside and out, and there can be no one more fitting to bring Vesttoo's vision to fruition," said Yaniv Bertele, CEO and co-founder of Vesttoo. "Our advisory board has already benefited much from her knowledge and experience, and now she is stepping into a more active role in Vesttoo's business plan and will help to keep our momentum going as we expand globally."
"Vesttoo is providing new streams of reinsurance capacity when the industry needs it most," said Vesttoo Chief Commercial Officer Julia Henderson. "Vesttoo's solutions are already increasing the flow of capital from the capital markets to the insurance markets. I have been an active proponent of enabling and smoothing this process since I began my career, and Vesttoo's technology and platform is the ultimate articulation of this flow. I am very excited to be a part of this talented team."
As Vesttoo's CCO, Ms. Henderson will oversee the commercial strategy and development of the business through marketing, sales, revenue operations, and client relationship activities to drive business growth and exceed targets. She will take a leading role in seeing the company reach its goals while maintaining a good relationship between internal departments and external clients.
Vesttoo has actively expanded its operations since the beginning of the year, announcing new offices in London, Hong Kong, Dubai, Seoul and most recently Tokyo, in addition to its established bases in Tel Aviv and New York. The company leverages its proprietary AI, its expert team of data scientists, insurance and finance professionals to build insurance-linked investment products that connect these two essential markets. It provides insurers with additional sources of capacity and investors with access to uncorrelated investment opportunities, offering a sustainable vision for the future of the industry.
About Vesttoo
Vesttoo connects the insurance industry and the capital markets by combining AI-powered technology with expertise in data science, insurance, and finance so that insurers have the capacity they need, and investors have opportunities to diversify with uncorrelated, low volatility insurance-linked assets. Among the company's partners are well-established global insurers, financial institutions, and large multinational brokers.
For more information, visit https://vesttoo.com.
Media Contact: Liran Grunhaus, media@vesttoo.com
Related Links
Logo - https://mma.prnewswire.com/media/1607508/Vesttoo_logo.jpg
View original content:
SOURCE Vesttoo
|
https://www.wistv.com/prnewswire/2022/09/12/vesttoo-appoints-reinsurance-ils-expert-julia-henderson-its-chief-commercial-officer/
| 2022-09-12T12:36:40Z
|
https://www.wistv.com/prnewswire/2022/09/12/vesttoo-appoints-reinsurance-ils-expert-julia-henderson-its-chief-commercial-officer/
| false
|
Michael Janiak is Co-Founder and Executive Creative Director at Pattern: A Digital Design & eCommerce Agency.
Your product research has paid off. Your brand tagline is testing well. You've created a killer funnel. Your ads are working. People are visiting your site in droves. Excitement! Momentum! Financial rewards!
Except ... your conversion rate is low. Really low. So now, to make up for it, you need a whole lot more traffic, which means you're going to be paying way more for customer acquisition than you thought you'd be. And adding insult to injury, with every missed sale, you're missing out not only on the immediate revenue but on the ongoing customer relationships and the multitude of long-tail opportunities that come with them, such as email marketing, SMS marketing, subscriptions, loyalty, upsells, add-ons and category expansions.
Why? Because you made the common-but-maddening mistake that too many brands still make: neglecting to treat your user experience (UX) as a critical brand and business differentiator.
Think about it for a second. The bar to entry to starting an e-commerce business has dropped through the floor. Whether it's dropshipping, Amazon or viral product hacking on TikTok, it's easy to get started and even make a little profit. But what happens when you want to build value in something bigger than a product? You need a brand. And to build a successful, valuable brand over the long term, you need great UX design that serves double-duty as a way to differentiate yourself from the noise while serving as the crucial final step in getting your potential customers to convert into paying ones.
So what does "investing in UX design" look like in practice?
Investing in UX design means telling your story in the context of consumer needs.
They've seen your ad. They've decided your product is worth considering. They've clicked or tapped to get to your site. Now what? If all you have to offer is a free shipping countdown timer and a templated, overly salesy product page, you've failed. Why? Because you neglected the human context of your customers' needs.
Let's take a shoe brand as an example. There are tens of thousands of choices across thousands of retailers and direct-to-consumer brands selling shoes. Most are competing on price and style selection, and yet the most successful brands aren't competing on that at all. They're differentiating themselves by attaching a higher-level purpose to their offering so that customers are not only "buying" a product, they're "buying in" to a deeper connection. They're building brand value by selling a vision, a feeling and a community through their products. And they're doing this by investing in thoughtfully crafted UX that combines the context of their brand purpose with the tactical aspects of selling.
Your site is your canvas for telling people why you exist, why your product is better and knocking down objections so you can make the sale. Great UX enables you to do this seamlessly and authentically without gimmicks or high-pressure tactics.
Investing in UX design also means clearing away as much friction as possible so that your odds of converting customers go up significantly.
E-commerce is a game of numbers. The more intuitive and supportive an experience is, the more likely a potential customer is to give your product a shot. This is especially true on lower-funnel digital touchpoints like the product detail page on an e-commerce site.
Many times, the product page is the first page a potential customer lands—especially when they find your brand via social. In other words, your "product page" is your "homepage" for a huge subset of your potential customers. So treat it like one! Create a product page experience where intuitive shopping UX (like product, color and size selection) meshes seamlessly with the unique benefits, story, differentiation and social proof of what you're selling. We've seen time and again that this approach does wonders for driving increased cart-to-detail rates which, in turn—you guessed it—gets more people into your checkout and raises your chances that they complete their purchase.
Investing in UX design is a great way to mitigate the rising costs of customer acquisition, particularly via social media channels.
Rising CAC (customer acquisition cost) is on the tip of every marketer and business owner's tongue, and for good reason—the halcyon days are over.
When brands invest in UX design, they're making a commitment to do the upfront hard work of partnering with experts to figure out the friction points and blockers in their user journeys. Through this work, they can redesign those journeys for an optimal customer experience—a customer experience that will pay dividends in the form of higher conversions, higher revenues and a much better return on ad spend. All of these things contribute significantly toward lowering the cost of acquiring customers over the long term.
Investing in your digital experience—and how that experience drives home the promise of your brand and the value of your products—is one of the most powerful and high-impact ways to grow your brand, amplify your revenue, and drive sales and customer loyalty over the long term. Don't make the mistake of waiting too long to do this. Your competitors certainly won't.
Forbes Agency Council is an invitation-only community for executives in successful public relations, media strategy, creative and advertising agencies. Do I qualify?
|
https://www.forbes.com/sites/forbesagencycouncil/2022/09/12/ux-design-is-the-differentiator/
| 2022-09-12T12:36:53Z
|
https://www.forbes.com/sites/forbesagencycouncil/2022/09/12/ux-design-is-the-differentiator/
| false
|
Cape Town – In the midst of the drought that has affected more than half of Somalia’s population, Special Presidential Envoy for Drought Response for the Federal Republic of Somalia, Abdirahman Abdishakur, travels to the US in aid of assistance.
Abdishakur posted a tweet on Sunday saying he was “travelling to New York to raise awareness on the drought” that is edging Somalia closer to a humanitarian disaster.
Today, I am travelling to New York to raise awareness on the drought that is edging #Somalia closer to #famine. At #UNGA77 I will lobby for an enhanced humanitarian response & for increased investment in our country's resilience.
— Abdirahman Abdishakur (@AAbdishakur) September 11, 2022
#PreventFamine #SDGs #SomaliDiaspora pic.twitter.com/3ZlSA0ZGkD
“At #UNGA77 I will lobby for an enhanced humanitarian response & for increased investment in our country’s resilience,” said Abdishakur.
He added in an official statement that during his trip to the 77th Session of the UN General Assembly that he would also meet North American and European diaspora to discuss their role in crisis relief for his country.
“I will not only raise awareness… I will seek partnerships with governments, financial institutions, private sector, diaspora groups and climate change experts to take action to avert the worst outcomes in the current crisis,” he said.
While the country is in the midst of an emergency, Abdishakur said they needed to look to the future as rains were set to fail for at least two more seasons.
Meanwhile, Xinhua News Agency reported last week that China urged the international community to make an effort to prevent a humanitarian disaster in Somalia due to risks of famine and malnutrition.
“We also welcome the implementation of the highly indebted poor country’s initiative for Somalia by the International Monetary Fund and World Bank, which helps the country tide over its difficulties through resistance and debt relief,” said Dai Bing, China’s deputy permanent representative to the UN.
“China feels deeply for the current difficulties of the people in Somalia.
“We will accelerate the assistance process, and do everything we can to help Somalia respond to the drought and jointly discuss lasting solutions to prevent and mitigate disasters,” he said.
IOL
|
https://www.iol.co.za/news/world/somali-official-travels-to-us-for-assistance-on-drought-ff12c7e8-9dd1-4c72-a334-8bf074e05910
| 2022-09-12T12:37:14Z
|
https://www.iol.co.za/news/world/somali-official-travels-to-us-for-assistance-on-drought-ff12c7e8-9dd1-4c72-a334-8bf074e05910
| false
|
Filthy wards. Unlicensed doctors. Forced labor. Outdated treatments, or no treatment at all. For nearly a century after the Civil War, Black patients in segregated state psychiatric facilities in the South endured unthinkable conditions for no reason other than the color of their skin.
Medical historian Kylie Smith, an associate professor at Emory University, has spent years studying the history of racial segregation in psychiatric hospitals, particularly in Alabama, Georgia and Mississippi.
In her lecture, “James H. Cassedy Lecture in the History of Medicine: Jim Crow in the Asylum: Psychiatry and Civil Rights in the American South,” she’ll share her research, such as the racist mentality that providers used to justify their treatment of Black patients and the ways post-Civil War segregation still affects psychiatric care throughout the South.
Most patients in these facilities were forcibly committed and couldn’t effectively contest their confinement in court. Instead, they were required to perform hard labor, disciplined harshly and denied evidence-based treatment in plantation-like conditions.
Psychiatric segregation didn’t end with the passage of the 1964 Civil Rights Act, which prohibited racial discrimination in facilities that receive federal funding. It took a long legal battle and inspections that revealed the appalling treatment of patients whose health was overshadowed by racist assumptions and fears of intermixing between Black and White people.
Smith sees those hospitals as battlegrounds for a society in flux, drawing connections between the ways Black patients were treated and an avalanche of modern disparities in health care. Even now, Black patients are less likely to receive treatment for mental health disorders and receive poorer mental health care.
Black patients are less likely to be offered talk therapy or evidence-based medication than the general population, according to the American Psychiatric Association. They are also more likely to be diagnosed with schizophrenia and less likely to be diagnosed with mood disorders than their White counterparts, the APA says. And in one study, older White people in the South were nearly twice as likely to use mental health services than older Black people.
Presented by the National Library of Medicine, the hour-long lecture will also be archived on the NLM’s videocast website. Tune in at VideoCast.nih.gov.
|
https://www.washingtonpost.com/health/2022/09/12/racism-psychiatric-hospitals-lecture/
| 2022-09-12T12:38:49Z
|
https://www.washingtonpost.com/health/2022/09/12/racism-psychiatric-hospitals-lecture/
| false
|
CEO of Acumatica, a fast-growing cloud ERP company. John has nearly 30 years of industry leadership in cloud services.
In the current market, business risks are plentiful. From ongoing issues with the supply chain to rising inflation to the “Great Resignation,” business leaders must evaluate how they will prepare for and respond to these ongoing challenges. They also need to be ready for future issues.
The issues posed by the previously mentioned risks can be damaging—and potentially catastrophic. By not adequately preparing for and responding to business risks, the health of an organization is at stake. There may be a business that did not prepare for the loss of employees quitting and now must operate with a much leaner staff. Or there could be a business that relies on a particular material to produce its inventory that’s at a standstill because of supply chain issues. The list of situations goes on and on.
The Impact Of Real-Time Visibility
So, what should a business leader be doing at this time to combat risks? One effective method is to harness business data for real-time visibility.
Getting data in real time is a necessity nowadays as it has become important for businesses to keep up with today’s unpredictable environment. Real-time data visibility has a slew of advantages for organizations, such as increasing efficiency—which enhances agility in the supply chain and elevates responsiveness. Here are some of the top ways real-time data can help businesses.
Inventory Management: Real-time data visibility provides immediate and highly accurate information about a business’s operations, including the movement and location of a good at any given time. Real-time data visibility includes information on the location of a good and its condition. Businesses can achieve insight into real-time data through the utilization of IoT devices as well as cloud monitoring tools. Together, these technologies allow companies to monitor goods via GPS, alerts and advanced notifications about potential delays. Even when there are delays, because businesses are notified ahead of time, they can proactively communicate timely updates to customers. Timely updates mean enterprises are better equipped to handle customers’ critical needs.
In Kenco’s State of Supply Chain Innovation Survey, a total of 47% of supply chain professionals surveyed said that inventory levels and availability visibility were the most essential part of e-commerce operations. When there are inventory changes, critical information must be relayed quickly so businesses can better prepare for or respond to any disruptions or delays. Having real-time data visibility fills this void in a significant way.
Productivity: In addition to aiding inventory operations, just what impact can real-time visibility have on an organization and its productivity? Consider a recent report from Sixfold and Transporeon. According to the study, real-time visibility could reduce loading times by over 20%. On top of this, the report stated that real-time visibility could improve warehouse productivity by up to 30% while trimming inventory reduction by 10%. The study credited this to improved predictability, strong communications, on-time delivery and visibility.
Cross-Connected Awareness: It is also important to stress that real-time visibility fosters cross-connected awareness in an organization. Everyone within an organization can gain access to up-to-date and accurate information to navigate whatever issue they are or might face. For instance, an e-commerce business can adapt on the fly as it monitors delays regarding a specific material it needs for production and synthesizes the information across departments (e.g., sales, marketing, finance, etc.). This access to real-time data is crucial, as it allows businesses to become more agile, resilient and prepared for what may come.
Though real-time visibility is crucial to managing business risks efficiently and effectively, it’s difficult to realize overnight. A common barrier to achieving real-time visibility is data silos.
Historically, most companies have used a wide variety of on-premises applications to run their businesses. These applications generally don’t talk to each other unless users build (or purchase) integrations between them. As a result, employees waste time exporting data from one system and uploading it to another (sometimes creating redundancies or conflicting information). Hosted solutions (e.g., the cloud) also don’t talk to each other unless users tell them to.
To meet various needs, businesses often subscribe to a wide range of cloud solutions, creating a multicloud environment. Before a business moves a significant portion of its operations to the cloud to achieve real-time visibility, leaders must take the time to create a master integration plan. Otherwise, the organization will be building new data siloes in the cloud.
A Solution For Organizations: For organizations to effectively capitalize on real-time visibility, they need to zero in on how business operations interconnect, allowing for workflow continuity and the ability to adapt to the unexpected. Business leaders can use a cloud-based business management system to gain a centralized one-stop shop that handles the most vital aspects of day-to-day operations and snapshots the real-time health of the organization.
Business risks are not going anywhere. Consider the ongoing pandemic, for example. Since the beginning of 2020, Covid-19 has changed how many businesses operate. It singlehandedly caused economic, health and operational crises, which led to many disruptions for companies.
Ultimately, though business risks are undoubtedly prevalent, real-time visibility provides a way to protect an organization’s overall operations. In just the past two years, real-time visibility has proven to be a must-have. Whether a business is looking to mitigate future potential loss or find a way to adapt to rapid changes in the current climate, real-time visibility remains an ideal solution.
Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
|
https://www.forbes.com/sites/forbestechcouncil/2022/09/12/the-essential-role-of-data-in-managing-business-risks/
| 2022-09-12T12:39:37Z
|
https://www.forbes.com/sites/forbestechcouncil/2022/09/12/the-essential-role-of-data-in-managing-business-risks/
| true
|
BEIRUT — An international human rights group called Monday on the United Nations to ensure that countries hosting its climate conference commit to meeting human rights standards after it documented instances of repression against environmental groups in Egypt, the host of COP27 later this year.
Egypt’s government has engaged in a widespread crackdown on dissent in recent years that has detained thousands, many without trial, according to rights groups. Under President Abdel Fattah el-Sissi, Egypt has also intimidated activists and new laws have practically barred many civil society organizations from operating.
“The world needs more climate activism, not less, and there can be no such effective activism when the government treats civic groups as a threat, not an asset,” said Richard Pearshouse, environment director at Human Rights Watch, in the report. “The UN Framework Convention member states and the Secretariat should press the Egyptian government to make sure environmental groups feel it is safe to engage in and beyond the COP.”
Egypt’s human rights record is coming under scrutiny as the country prepares to host the international conference aimed at slowing climate change through coordinated global action.
In July, several dozen organizations called on Egypt to end its crackdown and allow people to exercise freedom of expression ahead of the summit.
In a joint statement signed by 36 groups, including Amnesty International and Human Rights Watch, they expressed concern that Egypt will largely keep in place its prohibition on protests during the conference in November.
Egyptian Foreign Minister Sameh Shoukry, who is also the president-designate of the next annual Conference of the Parties, told The Associated Press in a May interview that a facility is being developed next to the conference venue where demonstrations can take place. He also said activists would be given access, as is customary, to negotiations in the Red Sea resort town of Sharm el-Sheikh. He did not elaborate on whether protests would be allowed elsewhere.
An Egyptian government media officer did not immediately respond to a request for comment on the Monday report from Human Rights Watch. The UN office responsible for overseeing the climate conference, the United Nations Framework Convention on Climate Change, also did not immediately respond to a request for comment on the right’s group’s call.
All of those interviewed for the report spoke on the condition of anonymity for fear of reprisal, the group said, and six declined to speak at all. Those who spoke described harassment by authorities, obstruction, and a “general atmosphere of fear” in the country and said they were wary of voicing opinions that could be seen as critical even during the UN-led conference.
Some described a partial opening in government policy for environmental campaigns in the run-up to the summit, but only for initiatives deemed to be compatible with authorities’ aims, like trash collection. They said speaking up about the country’s use of coal, and mega-infrastructure projects such as the construction of a new administrative capital, are deemed too risky of issues to tackle.
Some expressed hope that this year’s conference could be a chance to try to raise awareness of the free-speech environment that has existed inside Egypt for years.
“There can be no improvement in the environmental situation without improvement in freedom of expression and the overall human rights situation,” one person was quoted as saying in the HRW report.
|
https://www.washingtonpost.com/world/rights-group-egypt-stifles-environmental-work-ahead-of-cop/2022/09/12/6df4ae5a-328c-11ed-a0d6-415299bfebd5_story.html
| 2022-09-12T12:40:03Z
|
https://www.washingtonpost.com/world/rights-group-egypt-stifles-environmental-work-ahead-of-cop/2022/09/12/6df4ae5a-328c-11ed-a0d6-415299bfebd5_story.html
| true
|
BRUSSELS — More than six years after the deadliest peacetime attack on Belgian soil, the trial of 10 men accused over the suicide bombings at Brussels airport and an underground metro station opened Monday amid high security.
The 10 face charges including murder, attempted murder and membership of, or participation in, the activities of “a terrorist group” over the morning rush hour attacks at Belgium’s main airport and on a central commuter line. If convicted, some of them could be sentenced to terms of up to 30 years in prison.
Abdeslam, who was sentenced to life in prison without parole over the atrocities in Paris, was at the Brussels court on Monday but refused to take part, saying it was “unfair” that he should have to watch proceedings from inside a reinforced glass cubicle.
Sebastien Courtoy, a lawyer for another suspect, Smail Farisi, also complained about conditions. He said his client was “put on display like an animal in a cage. I want — I demand — to see the sick person who designed these cages to ask what kind of pleasure that person gets from this.”
For those who were hurt or lost loved ones, the trial will revive painful memories, but it also offers an opportunity for them to take a fresh step in their long recovery.
“It was a long wait for the victims, six years is very long. I think that on March 22, 2016, a very dark page started and the chapter is not finished today. But this is an important step for their recovery,” said Guillaume Lys, a lawyer for the V-Europe association representing the victims.
No images of the defendants in Monday’s trial proceedings were made public. Even a sketch artist who was allowed into the court room to work was advised not to release his drawings after the accused and their lawyers said they did not want the images published.
The hearing in what is one of the biggest jury trials ever held in Belgium was chiefly aimed at resolving technical and practical issues.
The court — located at the former headquarters of NATO on the outskirts of the Belgian capital — is due to sit again on Oct. 10 to pick a jury, with the trial proper starting on Oct. 13. More than 300 witnesses could be heard during the trial, which is expected to run for six to nine months.
___
Lorne Cook in Brussels contributed to this report.
|
https://www.washingtonpost.com/world/trial-opens-of-10-accused-over-2016-brussels-suicide-attacks/2022/09/12/4017b55c-3293-11ed-a0d6-415299bfebd5_story.html
| 2022-09-12T12:40:09Z
|
https://www.washingtonpost.com/world/trial-opens-of-10-accused-over-2016-brussels-suicide-attacks/2022/09/12/4017b55c-3293-11ed-a0d6-415299bfebd5_story.html
| false
|
Endorsement: Flavored tobacco products kill. Vote yes on Proposition 31
In 2020, the California Legislature approved a ban on sales of most flavored tobacco products, including menthol cigarettes. But the law has been on hold ever since because tobacco interests immediately spent millions of dollars qualifying a ballot referendum to overturn it, allowing the industry to reap two more years of profit from these dangerous products.
Voters now have a chance to strike back at Big Tobacco and clear the way for the new law to take effect by voting yes on Proposition 31 on the Nov. 8 ballot. And they absolutely should.
The law that would be upheld by the ballot measure, Senate Bill 793, was a good idea in 2020, and it still is. Flavors in tobacco products are uniquely harmful because they mask the unappealingly harsh taste of tobacco and can lure in new and often young users and get them hooked. Studies have shown year after year that the vast majority of tobacco users under 18 first tried flavored tobacco products. That’s why the Food and Drug Administration in 2009 banned flavors except for menthol from combustible cigarettes, and is now considering expanding flavor bans to vapes and menthol cigarettes.
It’s also why dozens of cities, including San Francisco and San Jose, have enacted bans on flavored tobacco; Los Angeles’ ban is set to go into effect next year.
The L.A. Times’ editorial board endorsements for statewide ballot measures, elected offices in Los Angeles city and county, L.A. Unified School District board, L.A. county superior court, statewide offices, the state Legislature and U.S. House and Senate seats.
Proposition 31 doesn’t criminalize flavored tobacco, as opponents suggest. It prohibits stores and vending machines from selling flavored vapes, cigarillos and menthol cigarettes and levies fines on retailers who ignore the ban, but use or possession would not be prohibited. (The sales prohibition does not apply to flavored loose-leaf and hookah tobacco and certain cigars.) And tobacco users determined to continue their habit can switch to non-flavored tobacco or buy their products from out of state.
The “no” campaign, on which tobacco companies have spent more than $20 million so far, can’t counter the evidence that flavored tobacco harms people and hooks kids, so it has resorted to blowing hot air in a different direction. The opponents’ main argument is that tobacco products are already illegal for people under 21 to buy in California, and this would only deprive users of legal age. Yes, that law exists, but age limits haven’t stopped teens from getting their hands on tobacco products, especially flavored products.
All kids deserve the quality arts education that California promises but has failed to deliver at many of its public schools.
The other arguments against Proposition 31 are just as weak: That the ban would be bad for the state budget because it would reduce revenue from the tobacco tax, which amounted to about $2 billion last year, most of which is directed into programs supporting healthcare, tobacco control and early childhood development. (This argument suggests that even tobacco companies realize Proposition 31 would reduce tobacco sales, and therefore use.
The state’s nonpartisan legislative analyst estimates the loss could be between tens of millions and $100 million a year. But it’s revenue we’d be happy to lose if it reduces nicotine addiction and the costly health problems associated with tobacco use. Previous estimates have indicated this ban could eventually save up to $13 billion in healthcare costs every year.
Opponents also argue that it might drive some small retailers out of business, though they offer no evidence. It’s more likely their real concern is the effect a ban in California will have on their own bottom lines. Don’t be fooled by the tobacco industry’s smoke screen. Vote yes on Proposition 31 to allow a good law to go into effect.
Get Group Therapy
Life is stressful. Our weekly mental wellness newsletter can help.
You may occasionally receive promotional content from the Los Angeles Times.
|
https://www.latimes.com/opinion/story/2022-09-12/flavored-tobacco-products-kill-vote-yes-on-proposition-31
| 2022-09-12T12:41:14Z
|
https://www.latimes.com/opinion/story/2022-09-12/flavored-tobacco-products-kill-vote-yes-on-proposition-31
| true
|
KANSAS CITY, Mo., Sept. 12, 2022 /PRNewswire/ -- BioMed Valley Discoveries (BVD) announced that the first patient has been dosed in a phase II clinical trial of ulixertinib (BVD-523) in combination with hydroxychloroquine (HCQ). Ulixertinib is a first-in-class and best-in-class ERK inhibitor, with this clinical trial focusing on patients with advanced gastrointestinal malignancies and mutations in the MAPK pathway. This study builds upon the finding of the phase I study of the combination, which was completed at Huntsman Cancer Institute at the University of Utah.
"Combining an ERK inhibitor with an autophagy inhibitor is anticipated to take advantage of the finding that tumors may become addicted to autophagy for survival in context of MAPK inhibition" said Brent Kreider, Ph.D., President of BioMed Valley Discoveries. "Given the favorable safety profile and efficacy seen with ulixertinib monotherapy, we believe that the combination with hydroxychloroquine has the potential to provide significant benefit to patients with advanced gastrointestinal malignancies."
The Phase II efforts build on a successful Phase Ib evaluating ulixertinib monotherapy as a novel targeted cancer treatment in cohorts of patients with genetic alterations that result in aberrant MAPK pathway signaling. Results from phase Ib demonstrated ulixertinib has an acceptable safety profile and early evidence of clinical activity against a wide range of RAS/MAPK pathway-driven cancers, including atypical alterations in BRAF.
In addition to targeting the terminal node of the RAS/MAPK pathway, ulixertinib's highly selective kinase inhibition profile is expected to provide potential impact across a number of tumor types in both monotherapy and combination. Previous efforts have also established a recommended phase 2 dose in combination with palbociclib, with additional combination efforts ongoing.
About ulixertinib (BVD-523): Ulixertinib is a first-in class and best-in class small molecule inhibitor of extracellular signal-regulated kinase (ERK) family kinases (ERK1 and ERK2) that is being developed as a novel anti-cancer drug. ERK kinases are downstream components of the mitogen-activated protein kinase (MAPK) signaling cascade (RAS-RAF-MEK-ERK). Ulixertinib has demonstrated promising early efficacy for patients with tumors harboring alterations in the MAPK pathway.
About the study: This is an open-label, multicenter, prospective phase II basket trial assessing the efficacy of ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies. All patients recruited must have a mitogen-activated protein kinase (MAPK) activating mutation to be deemed eligible for trial participation. Each disease-based basket will open to enrollment in two-stages and includes pancreatic, colorectal, esophageal, gastric and cholangiocarcinomas . (Clinicaltrials.gov Number NCT05221320).
About BioMed Valley Discoveries (BVD): BioMed Valley Discoveries is a clinical stage biotechnology company focused on addressing unmet medical needs in a variety of therapeutic and diagnostic areas. In addition to the ERK inhibitor, BVD's portfolio includes an oncolytic bacteria that has completed enrollment for a Phase I study, and two early-stage antibodies targeting the tumor microenvironment.
Operating since 2007, BioMed Valley Discoveries was established by Jim Stowers Jr., founder of the asset management firm American Century Investments, and his wife Virginia, to advance new medical innovations to improve the lives of patients with difficult-to-treat diseases. BVD is owned by a supporting organization of the Stowers Institute for Medical Research, a non-profit, basic biomedical research organization. Since 2000, the endowment of the Stowers Institute has received over $1.7 billion in dividend payments from American Century. The Institute has invested a portion of its endowment in BVD, whose profits accrue to the benefit of the Institute. For more information, visit www.biomed-valley.com.
Media Contact
Joe Chiodo, Head of Media Relations
724-462-8529
Joe.chiodo@stowers.org
View original content:
SOURCE BioMed Valley Discoveries
|
https://www.wcjb.com/prnewswire/2022/09/12/biomed-valley-discoveries-announces-first-patient-dosed-phase-ii-combination-trial-with-ulixertinib-bvd-523-its-first-in-class-best-in-class-erk-inhibitor-combination-with-hydroxychloroquine/
| 2022-09-12T12:41:59Z
|
https://www.wcjb.com/prnewswire/2022/09/12/biomed-valley-discoveries-announces-first-patient-dosed-phase-ii-combination-trial-with-ulixertinib-bvd-523-its-first-in-class-best-in-class-erk-inhibitor-combination-with-hydroxychloroquine/
| true
|
Cyprus politicians face trial in 'golden passport' scandal
Cypriots protest against corruption, including within the 'golden passport' scheme
Politicians and a lawyer accused of selling Cyprus passports to dubious investors, exposed by a sting operation that ended the citizenship-for-investment scheme, are to stand trial next month, a court ruled Monday.
Nicosia Criminal Court said the trial of former parliament speaker Demetris Syllouris, ex-MP Christakis Giovani, a senior manager of his real estate firm, Antonis Antoniou, and lawyer Andreas Pittadjis would open on October 26.
The charges against the four men include conspiracy to subvert the Republic, bribery and corruption, according to the official Cyprus News Agency.
They were released on conditional bail ranging from EUR50,000 ($50,000) to EUR30,000 each.
In August 2020, broadcaster Al Jazeera charged that high-ranking officials were ready to help a fictitious Chinese investor with a criminal past obtain a Cyprus passport through investment.
Parliament speaker Syllouris and opposition communist party AKEL MP Giovani were secretly filmed trying to facilitate a passport for the fugitive investor.
Prominent lawyer Pittadjis also featured in the video and others linked to Giovani´s property development company.
Syllouris -- who held the most senior political post after the president in Cyprus -- and Giovani later resigned, although both insisted they were innocent of any wrongdoing, saying the videos had been illegally recorded.
Until then, despite earlier criticism from Brussels, the government fiercely defended the passport scheme but abruptly had to scrap it in November 2020.
Following the damaging fallout, the government commissioned a public inquiry by former judge Myron Nicolatos following the Al Jazeera broadcast.
The inquiry found the government broke the law countless times to grant citizenship to over 6,700 people from 2007 to 2020.
The damning report said that 53% of the 6,779 passports granted were done so illegally, encouraged by a due diligence vacuum or insufficient background checks.
Cyprus´ passport scheme generated over EUR8 billion during its lifespan.
A member of the European Union, Cyprus began offering citizenship in exchange for substantial investment as early as 2007; the scheme was stepped up following the Mediterranean island´s 2013 economic crisis.
The Qatar-based broadcaster reported that dozens of those who applied for the so-called "golden passports" were under criminal investigation, international sanctions, or serving prison sentences.
Under the scheme, the government granted a passport for an investment of EUR2.5 million.
|
https://www.dailymail.co.uk/wires/afp/article-11203791/Cyprus-politicians-face-trial-golden-passport-scandal.html?ns_mchannel=rss&ns_campaign=1490&ito=1490
| 2022-09-12T12:44:24Z
|
https://www.dailymail.co.uk/wires/afp/article-11203791/Cyprus-politicians-face-trial-golden-passport-scandal.html?ns_mchannel=rss&ns_campaign=1490&ito=1490
| false
|
Sarah Hunter: Record-chasing England `want to be defined by winning trophies´
England Women captain Sarah Hunter says that the record-chasing Red Roses “want to be defined by winning trophies”.
Hunter’s side will become the first Test team – male or female – to win 25 successive international matches if they beat Wales in Bristol on Wednesday.
The game is England’s final warm-up fixture before the World Cup in New Zealand next month, when Hunter and company will arrive as clear tournament favourites.
The Red Roses, currently ranked number one in the world by a distance, have not lost since New Zealand defeated them in July 2019.
“While it is in the background, knowing the milestones and recognising them, it is about performance,” Hunter said.
“Hopefully, by living up to the performance that we want to achieve week on week, it helps to get these records.
“They (records) are not the be-all and end-all, but there is something pretty special about this team, and to be remembered you have to be part of history.
“For us, the ultimate will be if we can go down to New Zealand and we can get that World Cup trophy, and then I think it will make all the records even more special.
“At times, it is hard as a player when you are living in the moment to reflect on what you are achieving. Our ultimate focus is how good we can be, how we can keep improving our performance.
“We want to be defined by winning trophies, and there is a pretty big trophy to go to New Zealand and try to win in what I think will be the most competitive World Cup that there has ever been.”
Hunter returns to skipper a much-changed side against Wales, with switches including a new front-row of Vickii Cornborough, Lark Davies and Sarah Bern.
England forward Zoe Aldcroft will line up against Wales (David Davies/PA)
Zoe Aldcroft, meanwhile, moves from back-row to lock, and scrum-half Lucy Packer is handed only her second Red Roses start.
England head coach Simon Middleton added: “We are a team that wants to be remembered, and to do that you have to make history and do special things.
“The group of players and staff are fantastic. It is hugely competitive. It is a very difficult squad to get into, and that is why we have been as successful as we have been.
Red Roses head coach Simon Middleton (Mike Egerton/PA)
“To win 25 on the trot would be absolutely fantastic.
“We know there is a bigger picture we are working towards. Hopefully, results will follow, and if that makes more history, then fantastic.”
Team: E Kildunne; L Thompson, E Scarratt, H Rowland, S McKenna; Z Harrison, L Packer; V Cornborough, L Davies, S Bern, Z Aldcroft, A Ward, A Matthews, M Packer, S Hunter (capt).
Replacements: A Cokayne, H Botterman, M Muir, M Talling, P Cleall, C MacDonald, A Reed, H Aitchison.
|
https://www.dailymail.co.uk/wires/pa/article-11203701/Sarah-Hunter-Record-chasing-England-want-defined-winning-trophies.html?ns_mchannel=rss&ns_campaign=1490&ito=1490
| 2022-09-12T12:44:33Z
|
https://www.dailymail.co.uk/wires/pa/article-11203701/Sarah-Hunter-Record-chasing-England-want-defined-winning-trophies.html?ns_mchannel=rss&ns_campaign=1490&ito=1490
| true
|
King appears to smile after Commons Speaker mentions Glorious Revolution
The King appeared to break into a smile after Commons Speaker Sir Lindsay Hoyle mentioned the Glorious Revolution in his address to the monarch.
On Monday, Charles, accompanied by the Queen Consort, attended the Palace of Westminster to receive addresses from both Houses of Parliament in Westminster Hall.
The addresses were presented by the Speakers of each House and the King replied afterwards.
Sir Lindsay, who has served as Commons Speaker since 2019, offered “our heartfelt sympathy” to Charles and the royal family in his speech, before recalling the many occasions in which the Queen visited Westminster Hall.
Speaker of the House of Commons Sir Lindsay Hoyle walks past King Charles III and the Queen Consort at Westminster Hall, London (Ben Stansall/PA)
In particular, the Commons Speaker recounted the time the Queen visited the oldest building in Parliament to celebrate the 300th anniversary of the Glorious Revolution, before joking: “It is perhaps very British to celebrate revolutions by presenting an address to Her Majesty.”
The Glorious Revolution permanently established Parliament as the ruling power of England and, later, the United Kingdom, representing a shift from an absolute monarchy to a constitutional monarchy.
Charles, who was sat on a throne next to his wife, the Queen Consort, appeared to smile after the mention of the events which led to the deposition of James II.
The Commons Speaker told Westminster Hall: “On other occasions, our late Queen was here to mark the historic moments, such as the 50th anniversary of the Second World War, a war in which she herself served in the armed forces.
“And in 1988, we celebrated the 300th anniversary of the revolutions of 1688 to 1689.
“It is perhaps very British to celebrate revolutions by presenting an address to Her Majesty.
“But those revolutions led to our constitutional freedoms, set out the foundation for a stable monarchy, which protects liberty.”
Sir Lindsay also told the King he has taken on “weighty responsibilities”.
King Charles III presents a copy of his address to Commons Speaker Sir Lindsay Hoyle at Westminster Hall (Joe Giddens/PA)
He went on: “We know you hold the greatest respect, the precious traditions, the freedoms, and responsibilities over our unique history and our system of parliamentary government.
“We know that you will bear those responsibilities which fall to you with the fortitude, dignity, demonstrated by Her late Majesty.”
Lord Speaker Lord McFall of Alcluith also delivered an address to Charles, in which he paid tribute to the Queen’s “inspiring reign of deep and unparalleled devotion” and pledged loyalty to him on behalf of the House of Lords.
He said: “Her late Majesty, our treasured Queen and your beloved and deeply missed mother came here to Westminster Hall many times to receive the congratulations of her loyal subjects in the two Houses of Parliament and to celebrate with them historic landmarks and her long life of dedicated public service.
“She was both a leader to and a servant of her people. Her humility and integrity commanded the respect and captured the imagination of peoples and nations across the globe.”
At the end of their speeches, both Speakers delivered a humble address, unanimously agreed by MPs and peers, which conveyed “deep sympathy” to the King and his family for their loss, paid tribute to the late Queen for her “unstinting dedication” and “untiring endeavours”, and expressed the Houses’ “loyalty” to the King.
|
https://www.dailymail.co.uk/wires/pa/article-11203741/King-appears-smile-Commons-Speaker-mentions-Glorious-Revolution.html?ns_mchannel=rss&ns_campaign=1490&ito=1490
| 2022-09-12T12:45:13Z
|
https://www.dailymail.co.uk/wires/pa/article-11203741/King-appears-smile-Commons-Speaker-mentions-Glorious-Revolution.html?ns_mchannel=rss&ns_campaign=1490&ito=1490
| true
|
GOTHENBURG, Sweden, Sept. 12, 2022 /PRNewswire/ -- In accordance with a resolution taken at the Annual General Meeting of AB SKF, this is to announce the representatives of the four largest shareholders by number of votes, who, together with the Chairman of the Board, Hans Stråberg, constitute the Nomination Committee in preparation of the Annual General Meeting 2023.
Representatives:
Marcus Wallenberg, FAM
Anders Algotsson, AFA Försäkring
Christer Gardell, Cevian Capital
Anders Jonsson, Skandia
The Annual General Meeting of AB SKF will be held in Gothenburg on Thursday, 23 March 2023.
Shareholders who wish to submit proposals on members of the AB SKF Board, Board Chairman, Board fees, Chairman of the Annual General Meeting 2023 or amendments to the instruction for the Nomination Committee, may, at the latest two months before the Annual General Meeting 2023, contact the Chairman of the Board of AB SKF on e-mail: chairman@skf.com
Aktiebolaget SKF
(publ)
For further information, please contact:
PRESS: Carl Bjernstam, Group Communication
tel: 46 31-337 2517; mobile: 46 722-201 893; e-mail: carl.bjernstam@skf.com
INVESTOR RELATIONS: Patrik Stenberg, Head of Investor Relations
tel: 46 31-337 2104; mobile: 46 705-472 104; patrik.stenberg@skf.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE SKF
|
https://www.weau.com/prnewswire/2022/09/12/nomination-committee-ab-skf-annual-general-meeting-2023/
| 2022-09-12T12:45:23Z
|
https://www.weau.com/prnewswire/2022/09/12/nomination-committee-ab-skf-annual-general-meeting-2023/
| true
|
SEATTLE, Sept. 12, 2022 /PRNewswire/ -- Kineta, Inc. ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference. The conference is being held as a hybrid event on September 12-14, 2022. The in-person venue for the event is the Lotte New York Palace Hotel in New York City. Virtual participation will be staged simultaneously with over 500 company presentations scheduled as live feed or available on-demand.
Shawn Iadonato, Ph.D., Kineta's Chief Executive Officer, will provide a corporate update and overview of KVA12.1, Kineta's IND-ready VISTA blocking immunotherapy that is scheduled to initiate a Phase 1 clinical trial in the fourth quarter of 2022.
Event: H.C. Wainwright 24th Annual Global Investment Conference (Hybrid Conference)
Date: September 12-14, 2022
Time: 7:00 A.M. Eastern Time
Location: Virtual webcast to start on-demand on September 12, 2022 at 7:00 A.M. Eastern Time
Participants may access the webcast of the event through the following link:
https://journey.ct.events/view/54d1d52b-9a16-453d-a34a-010235061f02
The webcast can also be accessed in the Investors section of the Kineta website at www.kinetabio.com. The webcast replay will be available shortly after the conclusion of the event for 30 days.
Kineta is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. Kineta has leveraged its expertise in innate immunity with an intent to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy. For more information on Kineta, please visit www.kinetabio.com, and follow Kineta on Twitter, LinkedIn and Facebook.
PiiONEER™ Platform is focused on developing fully human monoclonal antibodies that target novel innate immune pathways. It was designed for the discovery and development of first or best-in-class immunotherapies that address the major challenges with cancer immune resistance to current therapies. Utilization of the PiiONEER™ Platform results in novel, well-characterized lead antibody therapeutics that can be efficiently advanced into formal IND-enabling and clinical studies.
KVA12.1 is a potential best-in-class VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope. KVA12.1 may be an effective immunotherapy for many types of cancer including NSCLC (lung), colorectal, renal cell carcinoma, head and neck, and ovarian. These initial target indications represent a significant unmet medical need with a large worldwide commercial opportunity for KVA12.1.
Anti-CD27 mAb program: Kineta has developed a diverse set of anti-CD27 agonist antibodies. They are fully human monoclonal antibodies (mAbs) that demonstrate low nanomolar (nM) binding affinity to CD27 in humans. In preclinical studies, Kineta's selected lead anti-CD27 agonist mAbs induce T cell proliferation and secretion of cytokines involved in T cell priming and recruitment, demonstrating the ability to potentiate new anti-tumor responses.
This press release may be deemed to be solicitation material with respect to the proposed transactions between Yumanity Therapeutics, Inc. ("Yumanity") and Kineta and between Yumanity and Janssen Pharmaceutica NV ("Janssen"). In connection with the proposed transactions, Yumanity filed with the U.S. Securities and Exchange Commission (the "SEC") on August 29, 2022 a registration statement on Form S-4 ("the Registration Statement"), which contains a preliminary proxy statement and prospectus. The Registration Statement has not yet become effective. Yumanity will mail the definitive proxy statement/prospectus to the Yumanity securityholders, and the securities may not be sold or exchanged until the Registration Statement becomes effective. Investors and securityholders of Yumanity and Kineta are urged to read these materials when they become available because they will contain important information about Yumanity, Kineta and the proposed transactions. This press release is not a substitute for the Registration Statement, definitive proxy statement/prospectus or any other documents that Yumanity may file with the SEC or send to securityholders in connection with the proposed transactions.
Investors and securityholders may obtain free copies of the documents filed with the SEC, once available, on Yumanity's website at www.yumanity.com, on the SEC's website at www.sec.gov or by directing a request to Yumanity's Investor Relations at (212) 213-0006 ext. 331.
This press release shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Each of Yumanity, Kineta and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Yumanity in connection with the proposed transactions. Information about the executive officers and directors of Yumanity is set forth in Yumanity's Definitive Proxy Statement on Schedule 14A relating to the 2022 Annual Meeting of Stockholders, filed with the SEC on April 25, 2022. Other information regarding the interests of such individuals, who may be deemed to be participants in the solicitation of proxies for the stockholders of Yumanity, is set forth in the preliminary proxy statement/prospectus included in the Registration Statement and will be set forth in the definitive proxy statement/prospectus and any other relevant documents to be filed with the SEC. You may obtain free copies of these documents as described above.
This press release contains certain forward-looking statements, including, without limitation, statements regarding Kineta's plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects; statements regarding the proposed merger between Yumanity and Kineta and the proposed asset sale to Janssen, including whether and when the transactions will be consummated; statements about the structure, timing and completion of the proposed transactions; and other statements that are not historical in nature. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta's business which could significantly affect expected results, including, without limitation, progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs and legislative, fiscal and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement. Except as required by law, Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
View original content to download multimedia:
SOURCE Kineta, Inc.
|
https://www.wibw.com/prnewswire/2022/09/12/kineta-announces-participation-hc-wainwright-24th-annual-global-healthcare-conference/
| 2022-09-12T12:45:27Z
|
https://www.wibw.com/prnewswire/2022/09/12/kineta-announces-participation-hc-wainwright-24th-annual-global-healthcare-conference/
| false
|
STERLING, Va., Sept. 12, 2022 /PRNewswire/ -- ADG-REI Technology Ventures, a collaboration between REI Systems of Sterling, VA, and ADG Tech Consulting of Herndon, VA, today announced that it has been awarded a joint venture (JV) contract by the U.S. Department of Homeland Security (DHS), U.S. Citizenship and Immigration Services (USCIS) worth $110M. Under a three-year contract, ADG-REI Technology Ventures will provide Agile DevSecOps services for mission-critical immigration systems.
The contract is part of the USCIS Outcome-Based Delivery and Development Operations (DevOps) Services (ODOS) III program. ADG-REI Technology Ventures provides leading-edge DevSecOps and User Experience Design (UXD) services to frequently deploy cost-effective and high-quality code supporting the USCIS mission—overseeing lawful immigration to the United States. The team will leverage an open-source technology stack, microservices architecture, and human-centered design practices in an Agile environment to deliver new business functionalities daily. The JV's technical experts will be responsible for developing high-quality business functionality to work within customer-centric architectures and processes.
"For nearly 20 years, REI Systems has partnered with the Department of Homeland Security to honor its mission of safeguarding the American people. We have a proven track record delivering innovative software solutions that cross many of the markets we serve," said Samidha Manu, Vice President of Federal Civilian Services. "Expanding our Agile DevSecOps presence within DHS further demonstrates our past successes and ability to deliver fully tested rapidly operational capabilities into our customers' hands."
REI Systems provides reliable, effective, and innovative technology solutions that advance federal, state, local, and nonprofit missions. Our technologists and consultants are passionate about solving complex challenges that impact millions of lives. We take a Mindful Modernization® approach in delivering our application modernization, grants management systems, government data analytics, and advisory services. Mindful Modernization is the REI Way of delivering mission impact by aligning our government customers' strategic objectives to measurable outcomes through people, processes, and technology. For more information, visit REIsystems.com.
ADG Tech Consulting is an IT and software development consulting provider with 12 years of international and domestic professional experience. ADG provides 24 hours, seven days a week support. Its consultants specialize in leading-edge technology to efficiently meet our clients' existing and ever-changing needs. For more information, visit adgtech.net.
Media & Public Relations
Marketing@reisystems.com
View original content to download multimedia:
SOURCE REI Systems
|
https://www.weau.com/prnewswire/2022/09/12/rei-systems-awarded-contract-provide-devsecops-citizenship-immigration-services-joint-venture-with-adg-tech-consulting/
| 2022-09-12T12:46:48Z
|
https://www.weau.com/prnewswire/2022/09/12/rei-systems-awarded-contract-provide-devsecops-citizenship-immigration-services-joint-venture-with-adg-tech-consulting/
| false
|
NIAGARA FALLS, N.Y. (WIVB) — There was a time when Niagara Falls Coach Lines had 80 drivers to bus the Niagara Falls City School District students; So many, they had people on standby. But that luxury is gone.
At this point, the company has a little over 40 drivers, about two-thirds of what they need for a full complement of drivers.
So, how are they making do with getting your kids to and from school? A temporary fix is staggered start times for students.
President of Niagara Falls Coach Lines Michael Dowd says, “We can now stagger some of the runs, and kids aren’t waiting as long as they were. The other strategy is we now find ourselves doubling up the number of students that we might otherwise have had. So some of our runs are quite full, which is frustrating to everybody. Parents, because they’re worried about the kids, our drivers because they are, frankly, under a lot of pressure because now they’ve got 60 kids instead of 30.”
Dowd says this all exacerbates the problem with driver retention. But to help, last year there was an increase in wages more than they were supposed to with the union contracts last year. This happened in hope of attracting and retaining drivers.
But how are they going to handle when people call out or there is bad weather when they have an already-short staff? Dowd says the solution is dispatchers.
“They’re there to try and figure out what other bus we can get those kids on. So, while I think we might see some more weather delays and that sort of thing during the winter, we will still handle it. And the district is good about notifying the parents where there’s going to be delays. And we’re hopeful that with some pay increases we’re going to start attracting more drivers,” Dowd said.
At this point, Niagara Falls Coach Lines has a number of drivers that are finished with training and waiting for the DMV to approve them to drive, but the goal is to have 60 drivers by the end of the year. If you would like to put in an application to become a driver, you can do so here.
People who apply and go through the licensing program are paid for their time to come in and take the course. All of the requirements, such as background checks, fingerprinting, and courses are paid for by Niagara Falls Coach Lines. But even if 10 people signed up tomorrow, Dowd says it would still be a month and a half, at least, for them to get their license and be on the road.
Latest Posts
- ‘Give me my bike!’ Scuffle over bicycle in California caught on video
- Former MLB player who became a cop dies in crash on the way to 9/11 event
- NY’s average gas price drops below $4
- Uninvited guest: Bear crashes Conn. birthday party, eats cupcakes
- How Niagara Falls CSD is handling bus driver shortages
Chelsea Lovell is a traffic anchor and reporter from Queens who joined the News 4 team in 2022. See more of her work here and follow her on Twitter.
|
https://www.wivb.com/news/local-news/niagara-county/niagara-falls/how-niagara-falls-csd-is-handling-bus-driver-shortages/
| 2022-09-12T12:47:34Z
|
https://www.wivb.com/news/local-news/niagara-county/niagara-falls/how-niagara-falls-csd-is-handling-bus-driver-shortages/
| true
|
SAN JOSE, Calif., Sept. 12, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the inventor of its ovarian cancer CAR-T technology, Dr. Jose Conejo-Garcia, Senior Member of the Immunology Department at Moffitt Cancer Center, will be speaking at the Rivkin Center and American Association for Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium. The symposium will include a seminar on immuno-oncology on Wednesday, September 28, 2022, at which Dr. Conejo-Garcia is an invited lecturer.
During the presentation, Dr. Conejo-Garcia will discuss the CAR-T technology, which is an autologous cell therapy comprised of engineered T-cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone receptor, and the target-binding domain is derived from its natural ligand, this technology is also known as CER-T (Chimeric Endocrine Receptor T-cell) therapy, a new type of CAR-T. Dr. Conejo-Garcia will also discuss the ongoing Phase 1 clinical trial of this technology.
"I am excited to discuss our novel FSHR-mediated CAR-T technology at this seminar series and to share ideas and advance the field of ovarian cancer research," stated Dr. Conejo-Garcia. "Moffitt and Anixa have been working together to advance this ovarian cancer therapy and we are thrilled to have treated the first patient in our ongoing clinical trial. If this therapeutic approach is successful, this could enable a major shift in the overall treatment paradigm for ovarian cancer."
More information about the event may be found at: https://rivkin.org/symposia/ocrs/.
Anixa is a clinical-stage biotechnology company with a number of programs addressing cancer and infectious disease. Anixa's portfolio of therapeutics includes a cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and, with partner MolGenie GmbH, a COVID-19 program focused on compounds targeting the Mpro enzyme of SARS-CoV-2, which is largely conserved across all recently identified variants. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn and Facebook.
Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:
SOURCE Anixa Biosciences, Inc.
|
https://www.wsaz.com/prnewswire/2022/09/12/anixa-biosciences-ovarian-cancer-car-t-therapy-be-presented-rivkin-center-amp-american-association-cancer-research-aacr-14th-biennial-ovarian-cancer-research-symposium/
| 2022-09-12T12:47:52Z
|
https://www.wsaz.com/prnewswire/2022/09/12/anixa-biosciences-ovarian-cancer-car-t-therapy-be-presented-rivkin-center-amp-american-association-cancer-research-aacr-14th-biennial-ovarian-cancer-research-symposium/
| true
|
New Album "Mission Peace" Dropped Friday August 26, 2022
ASPEN, Colo., Sept. 12, 2022 /PRNewswire/ -- It is Midterms Season! Staunch Moderates' Midterms Strategy is: 1) the recent dropping of our sophomore R & B hip hop album, "Mission Peace," available NOW on all major music streaming platforms, including Spotify, Apple Music, Amazon Music, Pandora, and SoundCloud, along with an additional 54 outlets globally; 2) the completion of our 90 Minutes Documentary Film and beginning of its marketing and distribution, and finally 3) the continued distribution of our BIGFOOTS FOOTBALL six-episode music video series, which started August 1st up to the kickoff of the NFL football season September 8th, a la HBO's Ballers distribution style, on Staunch Moderates News' YouTube Channel.
Staunch Moderates own Biggie Smalls, Casanova Ace, a former WWE wrestling star and current rapper is featured on our album, Mission Peace," along with special guest artists Jefferey Skunk Baxter of the Doobie Brothers & founding member of Steely Dan, plus CJ Vanston (Tears for Fears, Dali Lama, Joe Cocker, Ringo Star), E.P. Gregory T. Simmons. Our new band name that all members seem to dig is, "DJ Staunch & the Bigfoots."
When asked, "Who are our inspirations?" we like to say: Frank Sinatra, The Rat Pack, Ramsey Lewis, The Jacksons, Quincy Jones, Steelie Dan, and the Doobie Brothers. We hope you hear them in our tunes!
The complete track listing for Mission Peace is as follows:
Track Title Time
Love 6:05
Bali Girl 5:35
Bigfoots Football 4:23
Olympics & Peace 3:14
Bill Maher 2:48
SMN Remix 3:05
Elon Musk 6:12
DC Aliens 3:21
Peace 2:47
Genres of music within our music are: R&B, jazz, hip hop, rock n roll, classical, gospel, Olympics and Hawaiian.
2021 "The First Realm" Album: (Soundcloud link here)
2022 "Mission Peace" Album: (Soundcloud link here)
Many ask, "what's the rationale behind our Bigfoot Mascot, "Staunch?" Think of it, the "Bigfoot-print" of our country, say at least an 80 percentile all Moderates, the silent majority! Also, we Staunch Moderates are in the paradigm shifting business: from the most terrifying folklore character to the coolest beings on the planet, not human but Bigfoot. Well this is a paradigm shifting analogy to what we are really trying to do to change our socio-political Divide, from anger, aggression, and hate to love, moderation and peace through our music and various different forms of entertainment. It's a tall order, but we are trying!
We currently have over 38 million views and streams of our tracks and other content on our Old MTV-like, Staunch Moderates News YouTube Channel. That's roughly 10% of the U.S. population.
A Staunch Moderates quote we feel worth to remember: "Set our differences aside, find common middle ground, reach across the aisle, tell a joke, evaluate, negotiate, compromise and decide the most equitable solutions humanly possible, like in the 1787 drafting of our Constitution and many other democratic constitutions around the world like it. Checks and balances rather than winner take all!!!"
The pitch: Hey, have you heard of the Staunch Moderates? They're this hip, cool, trending Intellectual Movement of 2022 about addressing the Divide & to strive for National & World Peace, basically an intellectual movement about peace. They've got Bigfoots! They've got Bigfoots Football. They've got Bigfoots Baseball. They've got Staunch Moderates News! Last year they made a 14 track hip hop album, "The First Realm." Just now, they just dropped their second album, "Mission Peace." Listen in & join the Movement. You too can take part in addressing the Divide and striving for National and World Peace. The unthinkable has become the thinkable, because of the platform the Staunch Moderates are bringing to you, again a way that you can address the Divide and strive for National and World Peace. Tune in, tell your friends and dig the music. Peace!
Staunch Moderates are an Intellectual Movement that addresses our country's current intellectual and political divide and strives for both national and world peace. Formed in December of 2019, the Movement hit the ground running, campaigning for their messages throughout the 2020 Election Year. They actively campaigned at sixteen different state Primaries by hosting 35 vital societal issue forums and conducted polls and produced several interviews with different political celebrities during the conventions and debates. With Casanova Ace rapping, the team even hosted a live Election Day Show with a panel of ten of their closest political celebrity friends, including former Congressman Barry Goldwater, former bodybuilding champion Lou Ferrigno, Olympian Maggie Connor and former White House press office Edward P. Lozzi, among others. For fans, constituents and the curious, check it all out at StaunchModerates.org or any of their social media channels.
Website: http://www.staunchmoderates.org/ www.StaunchModerates.org
Facebook: Facebook.com/staunchmoderates
Instagram: staunch_moderates
Twitter: @SModerates
YouTube: Staunch Moderates News
Vimeo: https://vimeo.com/staunchmoderates
View original content:
SOURCE Staunch Moderates
|
https://www.weau.com/prnewswire/2022/09/12/staunch-moderates-intellectual-movements-midterm-strategy-rapper-casanova-ace-dj-staunch-release-sophomore-album-mission-peace-doubling-down-movements-intellectual-political-philosophy-moderation-over-extremism/
| 2022-09-12T12:47:58Z
|
https://www.weau.com/prnewswire/2022/09/12/staunch-moderates-intellectual-movements-midterm-strategy-rapper-casanova-ace-dj-staunch-release-sophomore-album-mission-peace-doubling-down-movements-intellectual-political-philosophy-moderation-over-extremism/
| true
|
STERLING, Va., Sept. 12, 2022 /PRNewswire/ -- ADG-REI Technology Ventures, a collaboration between REI Systems of Sterling, VA, and ADG Tech Consulting of Herndon, VA, today announced that it has been awarded a joint venture (JV) contract by the U.S. Department of Homeland Security (DHS), U.S. Citizenship and Immigration Services (USCIS) worth $110M. Under a three-year contract, ADG-REI Technology Ventures will provide Agile DevSecOps services for mission-critical immigration systems.
The contract is part of the USCIS Outcome-Based Delivery and Development Operations (DevOps) Services (ODOS) III program. ADG-REI Technology Ventures provides leading-edge DevSecOps and User Experience Design (UXD) services to frequently deploy cost-effective and high-quality code supporting the USCIS mission—overseeing lawful immigration to the United States. The team will leverage an open-source technology stack, microservices architecture, and human-centered design practices in an Agile environment to deliver new business functionalities daily. The JV's technical experts will be responsible for developing high-quality business functionality to work within customer-centric architectures and processes.
"For nearly 20 years, REI Systems has partnered with the Department of Homeland Security to honor its mission of safeguarding the American people. We have a proven track record delivering innovative software solutions that cross many of the markets we serve," said Samidha Manu, Vice President of Federal Civilian Services. "Expanding our Agile DevSecOps presence within DHS further demonstrates our past successes and ability to deliver fully tested rapidly operational capabilities into our customers' hands."
REI Systems provides reliable, effective, and innovative technology solutions that advance federal, state, local, and nonprofit missions. Our technologists and consultants are passionate about solving complex challenges that impact millions of lives. We take a Mindful Modernization® approach in delivering our application modernization, grants management systems, government data analytics, and advisory services. Mindful Modernization is the REI Way of delivering mission impact by aligning our government customers' strategic objectives to measurable outcomes through people, processes, and technology. For more information, visit REIsystems.com.
ADG Tech Consulting is an IT and software development consulting provider with 12 years of international and domestic professional experience. ADG provides 24 hours, seven days a week support. Its consultants specialize in leading-edge technology to efficiently meet our clients' existing and ever-changing needs. For more information, visit adgtech.net.
Media & Public Relations
Marketing@reisystems.com
View original content to download multimedia:
SOURCE REI Systems
|
https://www.wcjb.com/prnewswire/2022/09/12/rei-systems-awarded-contract-provide-devsecops-citizenship-immigration-services-joint-venture-with-adg-tech-consulting/
| 2022-09-12T12:48:12Z
|
https://www.wcjb.com/prnewswire/2022/09/12/rei-systems-awarded-contract-provide-devsecops-citizenship-immigration-services-joint-venture-with-adg-tech-consulting/
| true
|
346th board meeting of Shahjalal Islami Bank held
The 346th meeting of the Board of Directors of Shahjalal Islami Bank Limited (SJIBL) was held recently at Corporate Head Office of the bank by maintaining proper hygiene and social distance.
On the other hand, a number of directors of the bank participated in this meeting through digital platform.
The meeting was presided over by the Chairman of the Board of Directors Mohammed Younus, reads a press release.
The board approved a number of investment proposals and reviewed various issues related to policy of the bank.
Among others, Vice-Chairman of the Board Mohiuddin Ahmed, Directors Dr Anwer Hossain Khan, MP, Sanaullah Shahid, Abdul Karim, Abdul Halim, Akkas Uddin Mollah, Khandaker Shakib Ahmed, Engr Md Towhidur Rahman, AK Azad, Md Nasir Uddin Khan, Fakir Akhtaruzzaman, Md Moshiur Rahman Chamak, Jabun Nahar and Fakir Mashrikuzzaman; Independent Directors Ekramul Haque and Nasir Uddin Ahmed; Managing Director & CEO M Shahidul Islam and Company Secretary of the bank Md Abul Bashar were also present in the meeting.
|
https://www.tbsnews.net/economy/corporates/346th-board-meeting-shahjalal-islami-bank-held-494910
| 2022-09-12T12:54:06Z
|
https://www.tbsnews.net/economy/corporates/346th-board-meeting-shahjalal-islami-bank-held-494910
| false
|
Provides a business update on deployments and progress of its upcoming listing on NASDAQ
TEL AVIV, Israel, Sept. 12, 2022 /PRNewswire/ -- HUB Cyber Security (Israel) Limited (TASE: HUB), a developer of Confidential Computing cybersecurity solutions and services ("HUB" or the "Company"), is updating its shareholders today on the following progress:
- Progressing as planned following the recent F-4 registration statement submission to the SEC, with an anticipated listing before year-end 2022.
- A tender contract was won with the Israeli Department of Defense for the provisioning of NIS 4.2 million worth of HUB's products and services over the next 3 years.
- Receipt of first orders to deploy HUB's Confidential Computing solutions for a Swiss corporation in the total expected amount of USD 18 million over 3 years (in context with TASE report Ref#: 2022-01-061507).
About HUB Cyber Security (Israel) Limited
HUB Cyber Security (Israel) Limited ("HUB") was established in 2017 by veterans of the 8200 and 81 elite intelligence units of the Israeli Defense Forces. The company specializes in unique Cyber Security solutions protecting sensitive commercial and government information. The company debuted an advanced encrypted computing solution aimed at preventing hostile intrusions at the hardware level while introducing a novel set of data theft prevention solutions. HUB operates in over 30 countries and provides innovative cybersecurity computing appliances as well as a wide range of cybersecurity services worldwide.
About Mount Rainier Acquisition Corp.
Mount Rainier Acquisition Corp. is a blank check company sponsored by DC Rainier SPV LLC, a Delaware limited liability company managed by Dominion Capital LLC, whose business purpose is to effect a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
Forward-Looking Statements
Certain statements included in this press release are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or HUB's or RNER's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "would", "seem", "expect", "intend", "will", "estimate", "anticipate", "believe", "future", "predict", "potential," "forecast" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward looking statements.
These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by HUB and its management, and RNER and its management, as the case may be, are inherently uncertain. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of HUB or RNER. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) expectations regarding HUB's strategies and future financial performance, including its future business plans or objectives, prospective performance and opportunities and competitors, revenues, products and services, pricing, operating expenses, market trends, liquidity, cash flows and uses of cash, capital expenditures, and HUB's ability to invest in growth initiatives and pursue acquisition opportunities; (ii) the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any subsequent definitive agreements with respect to the proposed transactions; (iii) the outcome of any legal proceedings that may be instituted against RNER, HUB, the Combined Company or others following the announcement of the proposed transactions and any definitive agreements with respect thereto; (iv) the inability to complete the proposed transactions due to, among other things, the failure to obtain approval of the stockholders of RNER or HUB, to obtain certain governmental and regulatory approvals or to satisfy other conditions to closing, including delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals or complete regulatory reviews required to complete the proposed transactions; (v) the inability to obtain the financing necessary to consummate the proposed transactions; (vi) changes to the proposed structure of the proposed transactions that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the proposed transactions; (vii) the ability to meet stock exchange listing standards following the consummation of the proposed transactions; (viii) the risk that the announcement and consummation of the proposed transactions disrupts HUB's current plans and operations; (ix) the lack of a third party valuation in determining whether or not to pursue the proposed transactions; (x) the ability to recognize the anticipated benefits of the proposed transactions, which may be affected by, among other things, competition, the ability of the Combined Company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (xi) costs related to the proposed transactions; (xii) the amount of any redemptions by existing holders of RNER's common stock being greater than expected; (xiii) limited liquidity and trading of RNER's and HUB's securities; (xiv) geopolitical risk, including military action and related sanctions, and changes in applicable laws or regulations; (xv) geopolitical risk, including military action and related sanctions, and changes in applicable laws or regulations; (xvi) the possibility that RNER, HUB or the Combined Company may be adversely affected by other economic, business, and/or competitive factors; (xvii) inaccuracies for any reason in the estimates of expenses and profitability and projected financial information for HUB; and (xviii) other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in RNER's final prospectus relating to its initial public offering dated October 4, 2021.
Forward-looking statements speak only as of the date they are made. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Neither HUB nor RNER undertakes any duty to update these forward-looking statements.
Additional Information About the Transaction and Where to Find It
In connection with the proposed transaction, HUB has filed with the SEC a registration statement on Form F-4 containing a proxy statement/prospectus, and after the registration statement is declared effective by the SEC, RNER will mail a definitive proxy statement/prospectus relating to the Proposed Business Combination to its stockholders. This press release does not contain all the information that should be considered concerning the proposed transaction and is not intended to form the basis of any investment decision or any other decision in respect of the proposed transaction. This press release is not a substitute for any registration statement or for any other document that HUB or RNER may file with the SEC in connection with the proposed transaction. Investors and security holders are advised to read, when available, the preliminary proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed transaction, as these materials will contain important information about HUB, RNER and the proposed transaction.
When available, the definitive proxy statement/prospectus and other relevant materials for the proposed transaction will be mailed to stockholders of RNER as of a record date to be established for voting on the proposed transaction. Stockholders will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other documents filed with the SEC, without charge, once available, through the website maintained by the SEC at www.sec.gov.
INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
Logo - https://mma.prnewswire.com/media/1710726/HUB_Security_Logo.jpg
View original content:
SOURCE HUB Security
|
https://www.dakotanewsnow.com/prnewswire/2022/09/12/hub-security-wins-nis-42-million-tender-israeli-department-defense/
| 2022-09-12T12:54:46Z
|
https://www.dakotanewsnow.com/prnewswire/2022/09/12/hub-security-wins-nis-42-million-tender-israeli-department-defense/
| true
|
Case Study Concludes Better SharePoint, M365 Utilization Is An Administrative Gamechanger
WHITE PLAINS, N.Y., Sept. 12, 2022 /PRNewswire/ -- Collaborative project information management (PIM) software provider ProjectReady shared how its unique approach to SharePoint provisioning and management, in conjunction with improved deployment of the entire Microsoft 365 tech stack, has helped AECOM Canada reduce time spent on project team governance and management by up to 80 percent. The new case study, which features AECOM Canada Director of Digital Transformation Jeff Walter, details how the company is using ProjectReady to effectively manage roles and permissions across the lifecycle of projects, at scale.
"The ability to create a repeatable process that's accurate, reliable, and easy to use makes so much sense and saves so much time," said Walter. "An added bonus is that when the architecture and taxonomy are set up for reporting via ProjectReady, it provides access to information and the SQL database, which has certainly advanced our ability to report on projects."
Walters shares that, prior to ProjectReady, SharePoint provisioning was traditionally managed by AECOM's IT department while requests for changes and new sites flowed through the company's intranet. Not only did this process create bottlenecks, but it also resulted in poor SharePoint adoption due to the end-user being cut out of the equation.
In 2019, Walter attended an Autodesk University presentation, "Bringing SharePoint and BIM360 Together," given by Shaili Modi-Oza, ProjectReady's director of development, where he discovered that his team at AECOM Canada could use the ProjectReady solution to drive improved efficiency and, ultimately, greater value from the company's existing M365 investment.
"It's a true governance tool over the core solutions we use [SharePoint and Teams] within the Microsoft platform," said Walter. "I can use the SharePoint list with confidence instead of a spreadsheet and, with it, I can control who can see what, who has access to what libraries, folders, and documents. I couldn't do that before."
To read more about Walter's experience with ProjectReady and how AECOM Canada is using the collaborative project information management solution to improve efficiency, drive value, and drive SharePoint adoption, visit https://project-ready.com/home/case-study-aecom to download the case study. To learn more about ProjectReady, visit www.project-ready.com.
AECOM Canada is a subsidiary of AECOM, a Fortune 500 company and one of the largest infrastructure consulting firms in the world.
ProjectReady helps organizations apply process over the platforms they use every day to create simple, repeatable, and governed user workflows to improve efficiency, accuracy, and accountability.
View original content to download multimedia:
SOURCE ProjectReady
|
https://www.wflx.com/prnewswire/2022/09/12/aecom-canada-uses-projectready-streamline-construction-project-team-governance-improves-efficiency-by-80-percent/
| 2022-09-12T12:55:46Z
|
https://www.wflx.com/prnewswire/2022/09/12/aecom-canada-uses-projectready-streamline-construction-project-team-governance-improves-efficiency-by-80-percent/
| false
|
Maroš Šefčovič says physical checks across Irish Sea could be cut
- Published
The EU's chief Brexit negotiator has said physical checks on goods travelling across the Irish Sea could be cut to a "couple of lorries a day".
Customs checks would only be made when there was reasonable suspicion of illegality or dangerous goods, Maroš Šefčovič told the Financial Times.
The EU is ready to work in a "open and constructive" way with the UK, he said.
Prime Minister Liz Truss has said she is hoping for a negotiated solution to issues surrounding the NI Protocol.
However, she said any solution must contain all of the policies within the government's Northern Ireland Protocol Bill.
It cleared the House of Commons in July and goes to the Lords in the autumn.
The bill would give ministers the power to scrap parts of the EU-UK post-Brexit deal.
The protocol is designed to prevent a hard border on the island of Ireland but it is unpopular with unionists because it has introduced new trade barriers in the Irish Sea.
'Invisible border'
Mr Šefčovič said he was "encouraged" by Ms Truss's recent remarks.
He argued the trade border would be "invisible" under the EU's plans, with goods processed remotely while making their way to Northern Ireland, as long as the UK provides real-time data on their movements.
Last week, Taoiseach (Irish prime minister) Micheál Martin said a "pathway" to resolving the issues could be found "if there is a will", and that his government would work with the UK and the EU "to do the practical and sensible thing".
He said a strong partnership between the two governments was "vital" to underpin the Good Friday Agreement.
What is in the Northern Ireland Protocol bill?
The UK government published plans for the bill in June. At the centre of the proposal is the concept of green lanes and red lanes for trade.
This would mean:
- Goods coming from Great Britain into Northern Ireland and which are staying would use the green lane. This means there would be no checks and paperwork would be minimal
- GB goods moving through NI into Ireland or the wider European Union would use the red lane and continue to be checked at NI ports
London also wants any trade disputes resolved by "independent arbitration" and not by the European Court of Justice, and for Northern Ireland to benefit from the same tax breaks as elsewhere in the UK.
Last week, the White House warned again that dismantling the Northern Ireland Protocol would "not create a conducive environment" for US-UK trade talks.
US President Joe Biden's press secretary, Karine Jean-Pierre, said such actions could harm the Good Friday Agreement.
The warning came as the Northern Ireland secretary said he wanted to "negotiate a solution" with the EU.
However, Chris Heaton-Harris told MPs the government would still legislate if this did not happen.
The impasse between the UK and the EU over the Northern Ireland Protocol is one of the most serious and immediate issues facing the new prime minister in her relations with the US.
As foreign secretary, Liz Truss was at the forefront of UK government threats to unilaterally rewrite the protocol, something opposed by the EU and Washington.
- 2 September
|
https://www.bbc.co.uk/news/uk-northern-ireland-62876492
| 2022-09-12T12:56:49Z
|
https://www.bbc.co.uk/news/uk-northern-ireland-62876492
| false
|
LONDON (AP) — When the hearse carrying Queen Elizabeth II’s body pulled out of the gates of Balmoral Castle on Sunday, it marked the monarch’s final departure from a personal sanctuary where she could shed the straitjacket of protocol and ceremony for a few weeks every year.
The sprawling estate in the Scottish Highlands west of Aberdeen was a place where Elizabeth rode her beloved horses, picnicked, and pushed her children around the grounds on tricycles and wagons, setting aside the formality of Buckingham Palace.
“When … she goes through those (Balmoral) gates, I believe the royal part of her stays mostly outside,’’ said the Rev. David Barr, of Glenmuick Church in nearby Ballater. “And as she goes in, she was able to be a wife, a loving wife, a loving mum, a loving gran and then later on a loving great gran — and aunty — and be normal.’’
It was a transformation that took place every summer, when the royal family would spend much of August and September at the estate that has been a royal bolt-hole since 1852, when Prince Albert bought it for his wife, Queen Victoria.
Balmoral is the family’s “private wilderness,” where a fleet of immaculate Land Rovers would pick up guests each morning during the shooting and stalking season, Jonathan Dimbleby wrote in his 1994 biography of Prince Charles, who became King Charles III upon his mother’s death.
But there were other attractions, too.
“In the stables, the Queen’s horses were again at the ready, coats groomed, saddles and bridles soaped and stirrups polished,’’ Dimbleby wrote. “The household servants, trained in discretion, appeared only when required, aware that to be seen or heard without a purpose would be to intrude.”
At Balmoral, a woman most remembered for being clad in robes and crowns or grandmotherly dresses and wide-brimmed hats could tie a scarf around her head, snuggle into a warm jacket and tug on a pair of boots to explore a domain covered with heather and pine forests and populated by deer, bees and butterflies.
That sense of informality could bring out the queen’s mischievous side.
A former royal protection officer, Richard Griffin, remembered accompanying the queen on a picnic when they met two American hikers. The tourists didn’t recognize Elizabeth and asked how long she had been visiting the area. When she replied “over 80 years,” they asked if she had ever met the queen.
“As quick as a flash she says, ‘Well, I haven’t, but Dickie here meets her regularly’,” Griffin told Sky News earlier this year during events marking the monarch’s 70 years on the throne.
One of the hikers then turned to Griffin and asked what the queen was like. He replied: “She can be very cantankerous at times, but she’s got a lovely sense of humor.”
After posing for a picture with the queen, the unsuspecting hikers waved good-bye and they continued their trek.
“And then Her Majesty said to me, ‘I’d love to be a fly on the wall when he shows those photographs to friends in America. Hopefully, someone tells him who I am,’” Griffin recalled.
The queen’s love of Balmoral underscored the royal family’s close links to Scotland, which began with her great, great-grandmother Queen Victoria, who began the royal tradition of wearing the tartan.
During the 2014 referendum on Scottish independence, the queen was said to be hoping for a “no” vote, though she couldn’t express her view publicly. Former Prime Minister David Cameron later confirmed this, telling how her husband, the late Prince Philip, sought to keep the peace at Balmoral by trying to hide the morning papers on the day a poll was published suggesting the Scots might vote in favor of leaving the U.K.
“But, of course, when she got the result he said that she purred like a cat with satisfaction when she heard her United Kingdom was going to remain united,” royal historian Robert Lacey told the BBC on Friday.
But at its heart, Balmoral was a family home for the queen.
Freed temporarily from the affairs of state, Elizabeth and Philip spent more time with their children while at Balmoral.
Home movies shared with the BBC for a documentary on the queen’s 90th birthday showed the couple playing with Charles and his sister, Anne, on the lawn outside Balmoral Castle, with Philip careening down a grassy slope on a little red wagon before toppling over, his kilt flying in the breeze.
In later years, Charles played ping-pong and football in the yard and was even allowed to cycle to the village shop by himself, albeit with a police officer trailing behind, Dimbleby wrote.
It’s “very significant” that the queen died in Scotland, Lacey told The Associated Press.
“Because apart from her love of that particular country, it was the countryside, the way it brought her into contact with nature,” he said.
___
For more AP coverage of the death of Queen Elizabeth II and Britain’s royal family: https://apnews.com/hub/queen-elizabeth-ii
|
https://pix11.com/news/ap-general/ap-beloved-balmoral-elizabeth-leaves-highlands-for-last-time/
| 2022-09-12T12:58:13Z
|
https://pix11.com/news/ap-general/ap-beloved-balmoral-elizabeth-leaves-highlands-for-last-time/
| false
|
Initial Order delivery of over $7 million and Domestic Violence Monitoring Program Go-Live is expected by October 1st, 2022
TEL AVIV, Israel, Sept. 12, 2022 /PRNewswire/ -- SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-Government, IoT, and Cybersecurity sectors, is pleased to announce that, together with its local partner, it has executed the contract and launched the over $33 million project with Romania's Ministry of Interior, following the award announced on August 24th. The project will include the deployment of SuperCom's PureSecurity Electronic Monitoring (EM) Suite for Domestic Violence monitoring, GPS Tracking of offenders, and a home detention monitoring program.
SuperCom's PureSecurity Suite is a best-of-breed electronic monitoring and tracking platform with a comprehensive set of innovative features, including advanced anti-tamper mechanisms, multi-factor biometrics, the newest location technologies and sensors, practically limitless historic data, seamless 3rd party API integration, and an ultra-lightweight ankle-bracelet with proprietary energy efficiency algorithms.
This is Romania's first EM project, linking it with a long list of nations choosing SuperCom's EM solutions and further expanding SuperCom's footprint into an additional country in the EU. The nationwide program is expected to encompass all EM offender programs within the country, up to 15,000 enrollees simultaneously, and include a unique integration of multiple offender tracking sub-programs.
The awarded value of the contract based on the government's internal budgeting is over $33 million. The budget is based mainly on monitoring software, EM products, and complimentary services spread over four years, plus an additional three years of continued services. Initial Order delivery of over $7 million is expected by October 1st, 2022.
"We are excited with the execution of this contract; it further validates our strategy to scale up operations to accelerate growth and improve public safety in more nations worldwide. We look forward to supporting Romania's public safety efforts and bringing them the many benefits of SuperCom's proprietary EM technology. It is an honor to take part in this national initiative by building the necessary infrastructure and deploying Romania's first EM program," commented Ordan Trabelsi, President & CEO of SuperCom.
"This competitive tender process that just concluded is the first of several tenders for large-scale national European EM projects expected to be concluded in 2022 and 2023, with a total estimated value of over $200 million. With this meaningful win and contract execution, SuperCom is once again signaling, after more than 10 other recent national European EM project wins, the superiority of its value offering in the European EM space. We believe our growing reputation as a leading global EM solution provider will drive additional wins in the future," concluded Mr. Trabelsi.
This contract execution follows the award announced on August 24th, which was won through a formal bid process, with over 8 international companies participating in the bidding process. The process included several rounds of negotiations and several demonstrations and system tests by the contracting authority.
About SuperCom
Since 1988, SuperCom has been a global provider of traditional and digital identity solutions, providing advanced safety, identification, and security solutions to governments and organizations, both private and public, throughout the world. Through its proprietary e-Government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance and border control services, SuperCom has inspired governments and national agencies to design and issue secure Multi-ID documents and robust digital identity solutions to its citizens and visitors. SuperCom offers a unique all-in-one field-proven RFID & mobile technology and product suite, accompanied by advanced complementary services for various industries including healthcare and homecare, security and safety, community public safety, law enforcement, electronic monitoring, livestock monitoring, and building and access automation. For more information, please visit SuperCom's website, www.supercom.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded or followed by or that otherwise include the words "believes", "expects", "anticipates", "intends", "projects", "estimates", "plans", and similar expressions or future or conditional verbs such as "will", "should", "would", "may" and "could" are generally forward-looking in nature and not historical or current facts. These forward-looking statements are subject to risks and uncertainties that could cause our actual results to differ materially from the statements made. Examples of these statements include, but are not limited to, statements regarding business and economic trends, the anticipated effects of the COVID-19 outbreak on travel and physical locations, the levels of consumer, business and economic confidence generally, the duration of the COVID-19 outbreak and severity of such outbreak, the pace of recovery following the COVID-19 outbreak, status of contractual awards and related commitments and contingencies, the effect on our supply chain, our ability to implement cost containment and business recovery strategies and resulting anticipated impact of such outbreak on our business, financial condition and results of operations, the adverse effects of the COVID-19 outbreak on our business or the market price of our ordinary shares, and other risks and uncertainties described in the forward looking statements and in the section captioned "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2021, filed with the U.S. Securities and Exchange Commission (the "SEC") on April 4, 2022, our reports on Form 6-K filed from time to time with the SEC and our other filings with the SEC. Except as required by law, we not undertake any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
SuperCom Investor Relations:
Kirin Smith
PCG Advisory
ksmith@pcgadvisory.com
Logo: https://mma.prnewswire.com/media/1717536/SuperCom_Logo.jpg
View original content:
SOURCE SuperCom Ltd.
|
https://www.dakotanewsnow.com/prnewswire/2022/09/12/supercom-launches-33-million-national-electronic-monitoring-project-romania/
| 2022-09-12T12:59:03Z
|
https://www.dakotanewsnow.com/prnewswire/2022/09/12/supercom-launches-33-million-national-electronic-monitoring-project-romania/
| true
|
BIARRITZ, France, Sept. 12, 2022 /PRNewswire/ -- Founded by Christophe Buée and Pierre-Nicolas Lebas in 2013 in France, Winback designs, manufactures, and distributes cutting-edge medical devices based on non-invasive technologies.
Winback has always been inspired by therapists and it led it to become the world leader of Tecartherapy in rehabilitation and pain management by re-inventing the use of currents to combine them with established therapeutic approaches such as manual therapy, cryotherapy and compression.
Praised worldwide by physiotherapists, 10 000 devices are used every day to perform treatments. The bottom line for Winback's success is: innovation thanks to R&D teams in France and South Korea, consumer-centricity and a powerful global community of experts activating the online & offline Winback Academy.
In 2021, Winback has reached a turnover of over 30 million dollars across the globe with 7 offices operating in 55 countries. The success story does not end there since Winback is now expanding its expertise in the Beauty market with the acquisition of Bloomea:
Bloomea's genesis started in France in 1999 with its patented innovation "Modeling Bloomea" initially developed for scars management post cosmetic surgeries. Officially launched in 2015, Bloomea with its "La Fontaine" device obtained the Pierantoni prize and the French Cosmetic Award in Hong Kong.
With such a growth rate, Bloomea is today a start-up of 20 people with an international footprint, developing a holistic range of devices including radio frequency technologies & skincare products for premium institutes. Long term partner with Winback, Bloomea is now joining the Group to pursue its strong growth serving world's best beauty brands and salons.
Contact: Arnaud Dutilh, Global marketing director at Winback, arnaud@winback.com
View original content to download multimedia:
SOURCE WINBACK
|
https://www.dakotanewsnow.com/prnewswire/2022/09/12/winback-world-leader-tecar-therapy-high-frequency-electrotherapy-physiotherapy-expands-its-expertise-beauty-market-with-acquisition-bloomea/
| 2022-09-12T13:00:08Z
|
https://www.dakotanewsnow.com/prnewswire/2022/09/12/winback-world-leader-tecar-therapy-high-frequency-electrotherapy-physiotherapy-expands-its-expertise-beauty-market-with-acquisition-bloomea/
| false
|
LOVELAND, Colo., Sept. 12, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, announced today that the Company has entered a definitive agreement to acquire 100% of the share capital of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics ("LightDeck"), a pioneer in innovative planar waveguide fluorescence immunoassay diagnostics with strong manufacturing and specialized production capabilities (the "Acquisition").
Founded in 2009 and headquartered in Boulder, Colorado, LightDeck has developed a scalable and innovative platform for rapid and accurate point of care diagnostics. LightDeck's 80-member team includes industry veterans, engineers, and scientists, with deep technical expertise in assay development, manufacturing, and software development, who have collaborated with commercial, academic, and government partners worldwide to build an extensive intellectual property portfolio of 16 US patents and 15 international patents with broad applications, including in veterinary diagnostics, water testing, and human in-vitro diagnostics use. LightDeck's planar waveguide technology optimizes laser activated fluorescence and microfluidics to provide point of care cartridge-based testing without compromise, enabling reference lab-quality results in minutes with inexpensive, quantitative, and easy-to-use functionality. LightDeck's current Boulder location includes fully equipped laboratories for assay development and controlled manufacturing capabilities that support its new, state-of-the-art, highly automated facility in Longmont, Colorado, anticipated to go online in 2023 to dramatically scale-up capacity, production, and research and development.
"We are thrilled to welcome the entire LightDeck team to Heska. We have known and closely followed their success for years and we are happy to fully join with them today as one team focused on supercharging their great work. LightDeck brings to Heska best-in-breed, highly scalable manufacturing and world-class assay development to help drive our strategies for winning at innovation and winning at scale," commented Kevin Wilson, Heska's Chief Executive Officer and President. "LightDeck was central in developing Heska's leading immunodiagnostic platform, Element i+®, including its current menu of Total T4, cTSH, Cortisol, and Progesterone. Having proven our capability, we now take this next important step as we aim to drive production of Element i+® analyzers and cartridges at scale and to accelerate key test menu expansion, such as our recently announced Nu.Q® Vet Cancer Screen, cCRP, SDMA, infectious diseases, and more, in single and multi-plex formats that are substantially better than the competition. We expect to drive gross margin improvement with new manufacturing capabilities and scaling across the business. The addition of LightDeck is a great strategic, financial, and cultural fit with Heska as we continue our march to the top of the innovation and manufacturing competition for the most valuable diagnostics," concluded Mr. Wilson.
Nick Traggis, LightDeck's Chief Executive Officer commented, "This is a terrific outcome for LightDeck and Heska and their shareholders, employees and commercial partners. We have known and worked with Heska for years and we greatly admire the Heska organization. Since its founding in 2009, LightDeck has been dedicated to revolutionizing testing at the point of care- for faster, more accurate, less expensive, multi-plex testing of the most important diagnostic tests. We have developed one of the most innovative and technologically-advanced assay platforms in the world, which has led to our recent addition to Fast Company's Annual List of the World's 50 Most Innovative Companies for 2022. I am very proud of the work our team has accomplished over the last 13 years." LightDeck's Co-Founder and Chief Technology Officer, Mike Lochhead, went on to say, "We are excited to now enter this next phase with Heska to dramatically expand our reach and scale. What we do at LightDeck matters a great deal. With Heska, we go confidently into our next commercial, manufacturing, and development chapters, strongly engaged, highly supported, and clearly set-up for long-term success and growth."
Transaction Details
Heska will purchase LightDeck for a purchase price of $38.7 million. The transaction is expected to close in the first half of 2023, subject to customary closing conditions.
Mr. Wilson and Company management will discuss this announcement and other Company updates on Heska's Third Quarter 2022 earnings conference call early November 2022. To access the event, please visit https://ir.heska.com/events/.
About Heska
Heska Corporation (NASDAQ: HSKA) manufactures, develops and sells advanced veterinary diagnostics, informatics, and specialty healthcare solutions through its two business segments: North America and International. Both segments include Point of Care Lab testing instruments and consumables, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The North America segment also includes private label vaccine and pharmaceutical production for third-parties, primarily for herd animal health. For more information, please visit www.heska.com.
About LightDeck Diagnostics
LightDeck Diagnostics believes in a new approach to healthcare, where quick and accurate diagnostic tests will be run wherever and whenever they are needed. The company's proprietary LightDeck® platform combines an advanced laser waveguide with novel materials and patented manufacturing techniques to deliver lab-quality results anywhere, in minutes. The LightDeck platform is achieving success in veterinary diagnostics and for environmental testing. LightDeck is also developing a portfolio of in vitro diagnostic panels. The company is based in Boulder, Colorado, and is recognized as Colorado BioScience Association's Company of the Year, 2021.
Forward-Looking Statements
This document contains forward-looking information related to the Company. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "believes," "plans," "anticipates," "aims," "expects," "intends," "strategy," "future," "opportunity," "may," "will," "should," "could," "potential," or similar expressions. All of the statements in this document, other than historical facts, are forward-looking statements and are based on a number of assumptions that could ultimately prove inaccurate and cause actual results to materially deviate from forward-looking statements. Forward-looking statements in this document include, among other things, statements with respect to future financial and operating results and strategic goals, the expected timing of the Acquisition and its anticipated benefits. Such statements are subject to risks and uncertainties, including, but not limited to, risks and the closing of the Acquisition; the ability to achieve the anticipated benefits of the Acquisition; any product's ability to perform and be recognized as anticipated, in particular when such product is under development; Heska's ability to sell and market its products and services in an economically sustainable fashion, including related to varying customs, cultures, languages and sales cycles; foreign political and economic climates; the Company's ability to integrate the acquired LightDeck business within its existing operations; and new product development and release schedules. Other factors that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements are set forth under "Risk Factors" in the Company's most recent annual report on Form 10-K.
View original content to download multimedia:
SOURCE Heska Corporation
|
https://www.kfyrtv.com/prnewswire/2022/09/12/heska-acquire-lightdeck-diagnostics-invest-manufacturing-capabilities-accelerate-research-development-efforts/
| 2022-09-12T13:00:14Z
|
https://www.kfyrtv.com/prnewswire/2022/09/12/heska-acquire-lightdeck-diagnostics-invest-manufacturing-capabilities-accelerate-research-development-efforts/
| true
|
LONDON (AP) — Queen Elizabeth II’s grandson Prince Harry hailed her Monday as a “guiding compass” and praised her “unwavering grace and dignity,” as members of the public were to get the chance to pay their respects to the monarch when her coffin lies at rest at St. Giles’ Cathedral in Edinburgh.
The personal statement, posted on Harry and his wife Meghan’s Archwell website, said he cherished their times together “from my earliest childhood memories with you, to meeting you for the first time as my Commander-in-Chief, to the first moment you met my darling wife and hugged your beloved greatgrandchildren.”
Amid acrimony in the House of Windsor, Harry quit as a senior royal and moved to the U.S. two years ago. On Saturday, there was a possible sign of a reconciliation as Harry and Meghan joined his brother Prince William and sister-in-law Catherine in meeting mourners outside Windsor Castle.
Harry’s statement came at the start of another day steeped in the historic pageantry and pomp that follows the death of a British sovereign.
King Charles III was starting the day speaking to lawmakers at Parliament in London before flying to Scotland.
Hundreds of lawmakers crowded into the 1,000-year-old Westminster Hall at the Houses of Parliament for a service in which Parliament will offer its condolences to the king, and he will reply.
A trumpet fanfare greeted the king and his wife Camilla, the Queen Consort, as they entered the hall, which was packed with hundreds of legislators.
The Speakers of the House of Commons and House of Lords were offering condolences on the death of Queen Elizabeth II, and Charles will make a speech in reply.
The hall, with its magnificent hammer-beam roof, is the oldest part of the parliamentary complex — a remnant of the medieval Palace of Westminster that once stood on the site.
The ceremony was being held in Westminster Hall because monarchs are not allowed inside the House of Commons. That rule dates from the 17th century, when King Charles I tried to enter and arrest lawmakers. That confrontation between crown and Parliament led to a civil war which ended with the king being beheaded in 1649.
On Sunday, thousands of people lined streets and roadsides as the oak coffin was borne from the late queen’s beloved Balmoral Castle summer retreat, where she died on Thursday, to Edinburgh.
The new king will fly to Edingburgh later and will walk behind his mother’s coffin as it is slowly transported from Holyroodhouse to St. Giles’ Cathedral, where the crown of Scotland will be placed on the coffin ahead of a service of prayer and reflection on the life and 70-year reign of the widely cherished monarch.
The queen’s coffin will lie at the cathedral for 24 hours, giving members of the public a chance to file past and pay their respects. On Tuesday, it will be flown to London where the coffin will lie in state at the Houses of Parliament Palace from Wednesday afternoon until the morning of the funeral on Sept. 19.
Authorities already have issued rules and guidelines for people wanting to pay their respects in London, with a long queue expected.
After visiting Scotland, Charles embarks on a tour of the other nations that make up the United Kingdom — he visits the Northern Ireland capital, Belfast, on Tuesday and Wales on Friday.
Harry’s statement ended on a poignant note alluding to the death last year of his grandfather, Prince Philip, saying that “We, too, smile knowing that you and grandpa are reunited now, and both together in peace.”
|
https://www.wdtn.com/news/u-s-world/public-gets-chance-to-view-queens-coffin-in-edinburgh/
| 2022-09-12T13:00:58Z
|
https://www.wdtn.com/news/u-s-world/public-gets-chance-to-view-queens-coffin-in-edinburgh/
| true
|
Company's spend management platform technology will be used to facilitate payments for resources to offset education disruptions caused by COVID-19
MIAMI and OLYMPIA, Wash., Sept. 12, 2022 /PRNewswire/ -- Washington State has selected ClassWallet to help it track, report and facilitate the distribution of $3.8 million in federal Emergency Assistance for Non-public Schools (EANS II) program funds for the purchase of resources to offset education disruptions caused by COVID-19.
The ClassWallet spend management platform will enable eligible schools to streamline the purchasing and accounting processes associated with the acquisition of products and services related to sanitization, personal protective equipment, COVID testing, education technology and connectivity. It allows school administrators to quickly upload invoices and receipts, make payments and manage purchasing with automated record keeping and broad transparency. The one-year contract covers the 2022-23 school year beginning September 1.
T.J. Kelly, the chief financial officer of the Washington State Office of Superintendent of Public Instruction (OSPI), said, "Our hope is that utilizing ClassWallet platform will enable our non-public schools to efficiently purchase the COVID-related products and services they need to continue the delivery of in-person instruction throughout the 2022-23 school year."
"COVID-19 put a lot of added strain on school administrators and the ClassWallet platform virtually eliminates the burdensome accounting side of managing these much needed EANS II funds," said Jamie Rosenberg, CEO, ClassWallet. "In addition to automated reporting and comprehensive oversight, our platform enables the Washington State Department of Education to determine the parameters for approved purchases to avoid the misappropriation of funds."
For more information about ClassWallet, send an email to info@classwallet.com or call 877-969-5536.
Founded in 2014, ClassWallet (www.classwallet.com) is the leading digital wallet and automated accounts payable platform for federal, state and district education. Saving valuable time and overhead costs to track, pay and report on decentralized purchases, ClassWallet is used in 27 states and by 19 state agencies, across 6,200 schools serving 4.1 million students. ClassWallet's integrated marketplace of leading suppliers and learning curricula includes top retailers like Amazon, Office Depot, Staples, Scholastic, School Specialty, Lakeshore Learning and more. Headquartered in Miami, ClassWallet has been ranked number 779 on the prestigious Inc. 5000 list of the fastest-growing private companies in the U.S. in 2022 and the 56th fastest growing financial services company in the nation.
CONTACTS:
Doug Wright / Ashley Blas / Liz Savery
Feintuch Communications
646-753-5711 / 646-753-5713 / 917-805-4581
classwallet@feintuchpr.com
Media room
View original content to download multimedia:
SOURCE ClassWallet
|
https://www.wbtv.com/prnewswire/2022/09/12/classwallet-awarded-contract-washington-state-assist-distribution-federal-eans-ii-program-funds-non-public-schools/
| 2022-09-12T13:01:18Z
|
https://www.wbtv.com/prnewswire/2022/09/12/classwallet-awarded-contract-washington-state-assist-distribution-federal-eans-ii-program-funds-non-public-schools/
| true
|
STOCKHOLM, Sept. 12, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the company will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022.
The presentation is now available on Medivirs website; www.medivir.com.
For additional information, please contact
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Medivir
|
https://www.kfyrtv.com/prnewswire/2022/09/12/medivir-present-hc-wainwright-24th-annual-global-investment-conference/
| 2022-09-12T13:01:32Z
|
https://www.kfyrtv.com/prnewswire/2022/09/12/medivir-present-hc-wainwright-24th-annual-global-investment-conference/
| true
|
BERLIN (AP) — The German government said Monday that it can't stop a shipment of Russian uranium destined for French nuclear plants from being processed at a site in Germany because atomic fuel isn't covered by European Union sanctions on Russia.
Environmentalists have called on Germany and the Netherlands to block the shipment of uranium aboard the Russian ship Mikhail Dudin in the English Channel from being transported to a processing plant in Lingen, close to the German-Dutch border.
“We have no legal grounds to prevent the transport of uranium from Russia, because the sanctions imposed by the EU due to the Russian invasion of Ukraine exempt the import of nuclear fuel, like Russian gas, to the EU from import bans," said a spokesman for Germany's Environment Ministry, Andreas Kuebler.
Safety requirements for the shipment had been examined and found to meet requirements, meaning German authorities had to approve it, he added.
“You can imagine that we view such uranium shipments very critically due to the Russian invasion, but also because of Germany's exit from nuclear in general,” Kuebler told reporters in Berlin, noting that the government has worked to close the processing plant in Lingen and a second in nearby Gronau.
The plant in Lingen is operated by Framatome, which is majority-owned by French utility giant EDF. The French government has a majority stake in EDF, which manages all of France's nuclear power plants.
Environmental groups including the Russian organization Ecodefense urged European countries to end all uranium procurement from Russia, and cited the British government's recent decision to block the Mikhail Dudin from offloading nuclear waste near Liverpool for processing there.
Government spokeswoman Christiane Hoffmann said Germany continually reviews whether sanctions need to be expanded, but declined to say whether there were concrete plans to get the EU to block nuclear fuel imports.
Environment Ministry spokesman Kuebler noted that Russia is not the only supplier of uranium.
“Canada would be another possibility, for example,” he said.
___
Follow all AP stories on the impact of the war in Ukraine at https://apnews.com/hub/russia-ukraine.
|
https://www.milfordmirror.com/news/article/Germany-No-option-but-to-permit-Russian-uranium-17435325.php
| 2022-09-12T13:04:17Z
|
https://www.milfordmirror.com/news/article/Germany-No-option-but-to-permit-Russian-uranium-17435325.php
| true
|
DHAKA, Bangladesh (AP) — Bangladesh’s prime minister said Monday that the prolonged stay of more than 1 million Rohingya refugees in crowded camps in the country has become a serious security and stability concern.
“Apart from their own miseries, their prolonged presence is causing a serious impact on the economy, environment, security and sociopolitical stability of Bangladesh,” Prime Minister Sheikh Hasina said at the opening ceremony of a three-day meeting of military officials from 24 countries in the Indo-Pacific region.
The United States is the co-host of the gathering, called the Indo-Pacific Armies Management Seminar, along with the Bangladesh army.
While the militaries of the participating countries are discussing disaster management, transnational crime, security issues and women's empowerment, Bangladesh is using the platform to highlight the issue of Rohingya refugees who have fled from violence in Myanmar.
Participants in the meeting, including the U.S., Canada, Australia, Japan, Indonesia, India, China and Vietnam, will visit the sprawling Rohingya refugee camps to see their plight firsthand, said Gen. S.M. Shafiuddin Ahmed, chief of Bangladesh army.
Ahmed said the military leaders are being taken to the camps in Cox’s Bazar district to give them “a clear perception” of the gravity of the refugee crisis and why their repatriation to Myanmar is necessary.
Last month, the refugees marked the fifth anniversary of a mass exodus of more than 700,000 Rohingya into Bangladesh who were fleeing a harsh crackdown by Myanmar’s military. In total, Bangladesh is hosting more than 1 million Rohingya refugees.
Hasina has said that repatriation is the only solution to the crisis, but that Bangladesh would not force them to go back to Myanmar.
Bangladeshi officials have expressed frustration after at least two attempts to repatriate the refugees failed under a bilateral agreement brokered by China. The Muslim Rohingya have said that conditions remain too dangerous in Buddhist-majority Myanmar, where they face extensive discrimination.
Charles A. Flynn, commanding general of the U.S. Army Pacific, told reporters that he could not reply to policy questions such as how militaries can help repatriate the Rohingya to Myanmar, but thanked Bangladesh for arranging the trip for the delegation to the refugee camps.
“What I will say is this. I am thankful that the chief of the Bangladesh army has found a way in the program to bring us to Cox’s Bazar and to see the magnitude of the humanitarian assistance that Bangladesh has provided for five years to that situation,” he said.
The Rohingya crisis has gone to international courts, where Myanmar has denied any wrongdoing.
Last month, U.S. Secretary of State Antony Blinken said the U.S. remains “committed to advancing justice and accountability” for Rohingya and all people of Myanmar.
|
https://www.mrt.com/news/article/Bangladesh-leader-Prolonged-Rohingya-stay-17435285.php
| 2022-09-12T13:04:40Z
|
https://www.mrt.com/news/article/Bangladesh-leader-Prolonged-Rohingya-stay-17435285.php
| false
|
NEW YORK (AP) — Three children died after being found on a New York City beach early Monday and police believe they may have been drowned by their mother.
The 7-year-old boy, a 4-year-old girl and a 3-month-old girl were found on Brooklyn's Coney Island beach shortly after 4:30 a.m. and taken to a nearby hospital, Chief of Department Kenneth Corey said. All three were pronounced dead there.
The children's 30-year-old mother had been picked up earlier about 2 miles (3.2 kilometers) away, Corey said. She was being questioned at the local stationhouse.
Police first got a call at about 1:40 a.m. from a concerned relative of the mother who “indicated she was concerned that her family member may have harmed her three small children,” Corey said at a news conference near where the children were found.
Officers went to the woman's apartment building in the Coney Island neighborhood, where a man identified as the father of one of the children said he was similarly concerned.
Officers canvassed the area and found the woman about 90 minutes later, barefoot and soaking wet. She was still being questioned by detectives later Monday morning. “So far, she’s not said anything," Corey said.
The search intensified and police located the three children on the beach. Efforts to revive them failed, Corey said.
|
https://www.mrt.com/news/article/Police-believe-3-children-drowned-by-mother-at-17435296.php
| 2022-09-12T13:05:13Z
|
https://www.mrt.com/news/article/Police-believe-3-children-drowned-by-mother-at-17435296.php
| false
|
Class XI, XII marksheet distribution
The Directorate of Government Examinations has announced that the original marksheets for students who took up Class XII and XI public exams in May will be distributed from September 15.
Students can go to the institutions where they studied and get the marksheets. Private candidates can obtain their marksheets through the centres where they wrote the examinations. For details, candidates can visit www.dge.tn.gov.in
|
https://www.thehindu.com/news/cities/chennai/class-xi-xii-marksheet-distribution/article65882334.ece
| 2022-09-12T13:07:15Z
|
https://www.thehindu.com/news/cities/chennai/class-xi-xii-marksheet-distribution/article65882334.ece
| true
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VTYX, ATER, ADTX, RMED, and SPPI.
To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.
- VTYX: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=VTYX&prnumber=091220221
- ATER: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=ATER&prnumber=091220221
- ADTX: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=ADTX&prnumber=091220221
- RMED: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=RMED&prnumber=091220221
- SPPI: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=SPPI&prnumber=091220221
(Note: You may have to copy this link into your browser then press the [ENTER] key.)
InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
View original content to download multimedia:
SOURCE InvestorsObserver
|
https://www.wbtv.com/prnewswire/2022/09/12/thinking-about-buying-stock-ventyx-biosciences-aterian-aditxt-ra-medical-systems-or-spectrum-pharmaceuticals/
| 2022-09-12T13:08:03Z
|
https://www.wbtv.com/prnewswire/2022/09/12/thinking-about-buying-stock-ventyx-biosciences-aterian-aditxt-ra-medical-systems-or-spectrum-pharmaceuticals/
| false
|
FORT MYERS, Fla., Sept. 12, 2022 /PRNewswire/ -- Chico's FAS, Inc. (NYSE: CHS) (the "Company" or "Chico's FAS") today announced it will be participating in the Wells Fargo 5th Annual Consumer Conference, to be held in Dana Point, CA.
Molly Langenstein, Chief Executive Officer and President, and Patrick J. Guido, Executive Vice President – Chief Financial Officer, are scheduled to participate in a fireside chat on Wednesday, September 21, 2022, at 8:40 AM PDT, which will be webcast live and available following the event in the Investor Relations section of the Company's website at www.chicosfas.com.
ABOUT CHICO'S FAS, INC.
Chico's FAS is a Florida-based fashion company founded in 1983 on Sanibel Island, Fla. The Company reinvented the fashion retail experience by creating fashion communities anchored by service, which put the customer at the center of everything we do. As one of the leading fashion retailers in North America, Chico's FAS is a company of three unique brands - Chico's, White House Black Market and Soma - each thriving in their own white space, founded by women, led by women, providing solutions that millions of women say give them confidence and joy.
Our Company has a passion for fashion, and each day, we provide clothing, shoes and accessories, intimate apparel and expert styling in our brick-and-mortar boutiques, digital online boutiques and through StyleConnect®, the Company's customized, branded, digital styling tool that enables customers to conveniently shop wherever, whenever and however they prefer.
As of July 30, 2022, the Company operated 1,258 stores in the U.S. and sold merchandise through 58 international franchise locations in Mexico and 2 domestic franchise airport locations. The Company's merchandise is also available at www.chicos.com, www.chicosofftherack.com, www.whbm.com and www.soma.com.
To learn more about Chico's FAS, please visit our corporate website at www.chicosfas.com. The information on our corporate website is not, and shall not be deemed to be, a part of this press release or incorporated into our federal securities law filings.
Investor Relations Contact:
Michelle Miller
Director, Investor Relations
Chico's FAS, Inc.
(239) 346-3156
View original content to download multimedia:
SOURCE Chico's FAS, Inc.
|
https://www.kmvt.com/prnewswire/2022/09/12/chicos-fas-inc-participate-wells-fargo-5th-annual-consumer-conference/
| 2022-09-12T13:10:36Z
|
https://www.kmvt.com/prnewswire/2022/09/12/chicos-fas-inc-participate-wells-fargo-5th-annual-consumer-conference/
| true
|
Hundreds of people lined the streets of Plattsburgh on Saturday for the annual parade to mark the 1814 Battle of Plattsburgh.
“This is one of the pivotal battles in [the war of 1812], and it really defined us as a nation,” said Plattsburgh Mayor Chris Rosenquest.
“The British had more than 10,000 troops coming down form Canada marching towards Plattsburgh. Plattsburgh had maybe 1500 regular militia,” says Tom Donahue, President of 1914 Commemoration Inc.
“I think a lot of the time, Plattsburgh’s history gets overlooked even locally so it was really important that our children know the local history as well,” said resident Ruth Baker.
Despite the disparity, Commodore Thomas Macdonough defeated British troops on Lake Champlain.
“If that hadn’t happened, we might not be speaking English here, we might have a little British accent today,” Donahue says.
Parade goers came dressed for the occasion. “It’s the battle of Plattsburgh, [so] you’re going to have to come dressed a little bit period,” Rosenquest says.
Peru resident Norm Lavigne said he found his attire on the internet. “I think I’m a George Washington knockoff, he said. “And he’s a colonial general.”
Plattsburgh resident Agin Mark said he enjoyed this year’s parade.
“From bag pipes, to quills the basketball team — it’s awesome,” he said. “I almost wish I went to college in Plattsburgh.”
SUNY Plattsburgh students were in attendance as well.
“This is a great way for the college to build up that good relationship between the town and the gown,” says Plattsburgh student Michael Casey.
Bagpipe players were happy to see large crowds.
“Even as a little kid, when I heard bagpipes, it elicited emotions from people,” says Plattsburgh Police Pipes and Drums player Chris Ford. “It’s great with any musical when you have people around. [When] people are excited, it adds to the whole thing and makes us feel more important.”
|
https://www.mychamplainvalley.com/news/new-york/battle-of-plattsburgh-anniversary-parade-draws-large-crowds/
| 2022-09-12T13:10:45Z
|
https://www.mychamplainvalley.com/news/new-york/battle-of-plattsburgh-anniversary-parade-draws-large-crowds/
| true
|
(KTLA) — A man in California is without a bicycle after another man took the bike he claimed was his in a violent altercation Sunday.
In video shared with KTLA, one man can be seen riding a bike around midday and pulling a cart loaded down with luggage in an alley in Venice.
As the cyclist hears another man yell, “Give me my bike!” he slows down and stops to refute the other man’s assertion.
As the cyclist begins to make his case, the other man, who is armed with what appears to be a stick or pipe, strikes the luggage with his weapon.
As the armed man repeatedly shouts “Give me my bike!” along with profanities, he grabs at the bike’s handlebars, causing the cyclist to fall to the ground.
The man with the weapon then pulls the bike away from the cyclist and begins to walk away with it as passersby try to intervene on behalf of the man on the ground.
As the confrontation exits the screen, the cyclist remains lying on the ground, appearing confused.
It remains unclear if the cyclist got the bicycle back or if the second man was correct in asserting that the bike was his.
The Los Angeles Police Department did not have any information to share on the incident.
|
https://wgntv.com/news/nexstar-media-wire/give-me-my-bike-scuffle-over-bicycle-in-california-caught-on-video/
| 2022-09-12T13:12:53Z
|
https://wgntv.com/news/nexstar-media-wire/give-me-my-bike-scuffle-over-bicycle-in-california-caught-on-video/
| true
|
(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.)
Gina Woodall, Arizona State University
(THE CONVERSATION) Two years after the 2020 presidential election, Donald Trump’s resentment over losing continues to energize his supporters in Arizona.
That resentment played out during the Aug. 13, 2022, Republican primaries that saw Trump-endorsed candidates for U.S. Senate, governor, secretary of state and state attorney general sweep the GOP ticket.
While each of the candidates made Trump’s false claims that he won the presidential contest a central part of their campaigns, it’s unclear whether that message will resonate among Arizona’s increasingly diverse registered voters in the general election on Nov. 8, 2022.
Trump-endorsed Blake Masters beat his Republican challengers and faces incumbent Sen. Mark Kelly. In the governor’s race, Kari Lake, the former television anchor endorsed by Trump, is facing Democrat Katie Hobbes, the sitting Arizona secretary of state, for the governor’s office.
In the state’s attorney general’s race, GOP candidate and another 2020 election denier Abraham Hamadeh, faces Democrat Kris Mayes.
Most disconcerting to Democrats was the primary win of Arizona state Rep. Mark Finchem, a 2020 election denier who won the Republican nomination for secretary of state over a more moderate Republican. If he beats Democrat Adrian Fontes in the November general election, Finchem would oversee the state’s elections.
That possibility has Democrats fearing repeats of political acts such as the Republican-backed review of the 2020 presidential election in Arizona’s largest county that ended without producing proof to support Trump’s false claims of a stolen election.
Changing demographics favor Democrats
As a native Arizonan who has studied Arizona politics for the past 20 years, I have seen the rise of political extremism in my home state.
The victories of extremist GOP candidates and open support of baseless conspiracy theories have added a volatile ingredient to the politics of Arizona, where a historically conservative electorate is undergoing dramatic political shifts due to changing demographics.
Over the past 10 years, residents who identify solely as white saw their numbers shrink from 73% in 2010 to 60% in 2020. At the same time, the number of residents who identified as more than one race grew from 3.4% in 2010 to nearly 14% in 2020.
In all, Arizona has close to 7.5 million residents, and over 30% of them identify as Latino. Over the past decade, the state’s Latino population grew from 1.9 million to 2.2 million. By some estimates, Latinos could make up as much as 50% of the state’s population by 2050.
If national statistics are any indication, Latino voters tend to support Democrats. In a March 2022 poll, about 48% of Latinos nationwide considered themselves Democrats, and only 23% identified as Republican.
In Arizona, the numbers are similar.
According to a 2022 study, Latinos are more likely to be Democrats than non-Latinos are, with 45% of Latinos affiliating with the Democratic Party, compared with 28% of non-Latinos. Less than 15% of Latinos are registered as Republicans, the report found, and 40% are registered as “other” and are not affiliated with either major party.
The growth of Latino voters in Arizona contributed to Joe Biden’s win in 2020 – and also the elections of Democrats Mark Kelly and Kyrsten Sinema to the U.S. Senate.
MAGA state?
For the past 70 years, Arizona has been a reliable state for Republican presidential politicians. Bill Clinton was the only Democratic candidate to win a presidential race there since the election of Dwight D. Eisenhower in 1952.
That changed in 2020 with Biden’s surprising win over Trump. Though the election saw a record turnout of about 3.4 million voters, it was ultimately decided by a mere 10,457 votes.
Since then, Republican leaders in Arizona and around the nation have taken a hard right.
The party that was once dominated by conservative leader Barry Goldwater and John McCain, a moderate Republican who believed in fighting against climate change, has been taken over by leaders who support the notion that Trump somehow won the state and the last presidential election.
Given the increase in Latino voters in the state, it is no surprise that tightening immigration laws is an issue among the GOP, especially among Trump supporters.
In fact, Lake wasted little time after her primary win to use incendiary language in proclaiming her first goal if elected governor in November.
“Day 1,” she wrote on Twitter. “I take my hand off the Bible, give the Oath of Office and we Declare an Invasion on our Southern Border …”
As part of her campaign, Lake has attempted to paint Hobbes as someone who would be ineffective on border security. It’s unclear whether that strategy will work in a state with a fast-growing Latino population.
While Lake is fully embracing her MAGA support, Masters is doing the opposite in the U.S. Senate race against the incumbent Kelly. In one of the most competitive U.S. Senate races in the country, Kelly, a moderate Democrat, is favored to win. As a result, Masters has started moderating his image and toning down his extremist rhetoric after beating his GOP rivals.
On abortion, for instance, Masters has gone as far as scrubbing his own website of previous hard-line, anti-abortion stances and support for Trump’s false claims that the 2020 election was stolen from him.
“We need to get serious about election integrity,” Masters posted on his site in August. “The 2020 election was a rotten mess – if we had had a free and fair election, President Trump would be sitting in the Oval Office today and America would be so much better off.”
After the primary, Masters’ site only says, “We need to get serious about election integrity.”
Counting the political numbers
Heading into November, one thing is clear: The 2022 midterm elections in Arizona cannot be won by one party alone, but requires a combination of Republicans, Democrats and independent voters to win in this evenly divided state.
Among registered voters, the GOP has about 1.5 million residents, or 35%. Nearly 1.3 million voters are registered as Democrats, while about 1.4 million, or about 34%, registered as other or independent.
With such an equal split among political parties, election outcomes rely more on voter turnout. In the past two presidential elections, the number of registered voters who cast ballots jumped from about 2.6 million, or 74%, in 2016 to 3.4 million, or nearly 80%, in 2020.
The state GOP is counting on President Biden’s low approval ratings, high inflation and the typical midterm referendum on the incumbent’s party to get its voters out on Election Day.
The Democrats are focusing on get-out-the-vote efforts, particularly among young Latinos, and painting the Trump-endorsed candidates as too extreme for Arizonans.
Given the changing demographics in Arizona, that strategy may appeal to not only independent voters but also mainstream Republicans disillusioned with the extreme wing of their party.
This article is republished from The Conversation under a Creative Commons license. Read the original article here: https://theconversation.com/arizonas-latino-voters-and-political-independents-could-spell-midterm-defeats-for-maga-candidates-188512.
|
https://www.ourmidland.com/news/article/Arizona-s-Latino-voters-and-political-17435371.php
| 2022-09-12T13:14:07Z
|
https://www.ourmidland.com/news/article/Arizona-s-Latino-voters-and-political-17435371.php
| false
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Mudrick Capital Management, L.P., an institutional investment firm focused on event-driven and special-situation investing in the global credit markets, today announced that Thomas Bachner has joined the firm as its President. Mr. Bachner previously was Global Head of Institutional Partnerships and Distribution at Bridgewater Associates, the asset management firm he joined in 2003.
As Mudrick's President, Mr. Bachner will be responsible for managing the non-investment functions of the firm.
"We are excited that Tom Bachner has joined the Mudrick team at this important point in our firm's evolution," said Jason Mudrick, Founder and Chief Investment Officer of Mudrick Capital Management, L.P. "His extensive experience and deep understanding of the institutional business development and client services facets of a firm like ours will be invaluable as we move forward, particularly as the opportunity set in event-driven and special-situation investing in the global credit markets expands."
"I look forward to working with the extraordinarily nimble and entrepreneurial Mudrick team, which has established a strong reputation in the special situation and deep-value, event-driven investing space – especially for its ability to identify attractive, alpha-generating investment opportunities," said Tom Bachner. "Jason Mudrick is a special investor and I am thrilled to contribute to the firm's success."
Prior to Mudrick, Mr. Bachner spent 19 years at Bridgewater Associates most recently as Global Head of Institutional Partnerships, responsible for all third-party distribution as well as a group of Bridgewater's strategic relationships. Throughout his tenure, Mr. Bachner also held a variety of roles including Head of Client Advisors, in which he was responsible for ensuring excellent client service.
Before Bridgewater, Mr. Bachner served 10 years in the U.S. government in a variety of intelligence-related roles. He served three tours in Eastern Europe, including two years in Bosnia as part of the NATO peacekeeping mission. After leaving government service and earning an MBA from the University of Texas-Austin, Mr. Bachner was a strategy consultant for Arthur D. Little, focused on corporate financial strategy. He received a BA in political science with a focus on Soviet-American relations from Yale College, where he was a member of the varsity hockey team for three years.
Mudrick Capital Management, L.P. is an institutional investment firm with a focus on event-driven and special-situation investing in the global credit markets. Mudrick manages approximately $3.4 billion as of August 31, 2022 on behalf of a diverse group of sophisticated global institutional investors. The firm has offices in New York and London.
View original content:
SOURCE Mudrick Capital Management, L.P.
|
https://www.kmvt.com/prnewswire/2022/09/12/mudrick-capital-management-names-tom-bachner-president/
| 2022-09-12T13:14:40Z
|
https://www.kmvt.com/prnewswire/2022/09/12/mudrick-capital-management-names-tom-bachner-president/
| true
|
STERLING, Va., Sept. 12, 2022 /PRNewswire/ -- ADG-REI Technology Ventures, a collaboration between REI Systems of Sterling, VA, and ADG Tech Consulting of Herndon, VA, today announced that it has been awarded a joint venture (JV) contract by the U.S. Department of Homeland Security (DHS), U.S. Citizenship and Immigration Services (USCIS) worth $110M. Under a three-year contract, ADG-REI Technology Ventures will provide Agile DevSecOps services for mission-critical immigration systems.
The contract is part of the USCIS Outcome-Based Delivery and Development Operations (DevOps) Services (ODOS) III program. ADG-REI Technology Ventures provides leading-edge DevSecOps and User Experience Design (UXD) services to frequently deploy cost-effective and high-quality code supporting the USCIS mission—overseeing lawful immigration to the United States. The team will leverage an open-source technology stack, microservices architecture, and human-centered design practices in an Agile environment to deliver new business functionalities daily. The JV's technical experts will be responsible for developing high-quality business functionality to work within customer-centric architectures and processes.
"For nearly 20 years, REI Systems has partnered with the Department of Homeland Security to honor its mission of safeguarding the American people. We have a proven track record delivering innovative software solutions that cross many of the markets we serve," said Samidha Manu, Vice President of Federal Civilian Services. "Expanding our Agile DevSecOps presence within DHS further demonstrates our past successes and ability to deliver fully tested rapidly operational capabilities into our customers' hands."
REI Systems provides reliable, effective, and innovative technology solutions that advance federal, state, local, and nonprofit missions. Our technologists and consultants are passionate about solving complex challenges that impact millions of lives. We take a Mindful Modernization® approach in delivering our application modernization, grants management systems, government data analytics, and advisory services. Mindful Modernization is the REI Way of delivering mission impact by aligning our government customers' strategic objectives to measurable outcomes through people, processes, and technology. For more information, visit REIsystems.com.
ADG Tech Consulting is an IT and software development consulting provider with 12 years of international and domestic professional experience. ADG provides 24 hours, seven days a week support. Its consultants specialize in leading-edge technology to efficiently meet our clients' existing and ever-changing needs. For more information, visit adgtech.net.
Media & Public Relations
Marketing@reisystems.com
View original content to download multimedia:
SOURCE REI Systems
|
https://www.kmvt.com/prnewswire/2022/09/12/rei-systems-awarded-contract-provide-devsecops-citizenship-immigration-services-joint-venture-with-adg-tech-consulting/
| 2022-09-12T13:16:20Z
|
https://www.kmvt.com/prnewswire/2022/09/12/rei-systems-awarded-contract-provide-devsecops-citizenship-immigration-services-joint-venture-with-adg-tech-consulting/
| true
|
CA Eureka CA Zone Forecast for Sunday, September 11, 2022
_____
117 FPUS56 KEKA 121137
ZFPEKA
Zone Forecast Product for California
National Weather Service Eureka CA
437 AM PDT Mon Sep 12 2022
This is an average forecast over a large and geographically diverse
area. For a specific forecast for your location...please refer to
the point and click forecast on our webpage at:
Spot temperatures and probabilities of measurable precipitation
are for today, tonight, and Tuesday.
CAZ101-130245-
Coastal Del Norte-
437 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy. Patchy drizzle and areas of dense fog in
the morning. Highs 62 to 72. Northwest wind around 5 mph.
.TONIGHT...Mostly cloudy. Lows 46 to 56. West wind around 5 mph
in the evening becoming light.
.TUESDAY...Mostly cloudy. Highs 59 to 69. Light winds becoming
west around 5 mph in the afternoon.
.TUESDAY NIGHT...Cloudy. Lows 46 to 56. Northeast wind around
5 mph.
.WEDNESDAY...Cloudy. Highs 58 to 68. Northwest wind around
10 mph.
.WEDNESDAY NIGHT THROUGH FRIDAY NIGHT...Mostly cloudy. Lows 45 to
55. Highs 58 to 70.
.SATURDAY THROUGH SUNDAY...Mostly cloudy. Slight chance of rain.
Highs 59 to 70. Lows 44 to 54.
TEMPERATURE / PRECIPITATION
Crescent City 65 54 64 / 20 10 10
Klamath 69 50 67 / 20
$$
CAZ102-130245-
Del Norte Interior-
437 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy early in the morning then becoming mostly
sunny. Chance of rain showers in the morning. Highs 63 to 77.
.TONIGHT...Partly cloudy. Lows 45 to 55.
.TUESDAY...Partly cloudy. Highs 61 to 74.
.TUESDAY NIGHT...Mostly cloudy. Lows 46 to 56.
.WEDNESDAY...Mostly cloudy. Highs 60 to 72.
.WEDNESDAY NIGHT...Mostly cloudy. Lows 46 to 56.
.THURSDAY THROUGH FRIDAY...Partly cloudy. Highs 62 to 76. Lows
47 to 57.
.FRIDAY NIGHT...Mostly cloudy. Lows 47 to 57.
.SATURDAY THROUGH SUNDAY...Mostly cloudy. Slight chance of rain.
Highs 61 to 76. Lows 46 to 56.
TEMPERATURE / PRECIPITATION
Gasquet 75 48 73 / 10
$$
CAZ103-130245-
Northern Humboldt Coast-
437 AM PDT Mon Sep 12 2022
.TODAY...Cloudy until early afternoon then becoming partly
cloudy. Patchy drizzle and areas of dense fog in the morning.
Highs 62 to 72. Northwest wind around 10 mph.
.TONIGHT...Partly cloudy in the evening then becoming mostly
cloudy. Lows 47 to 57. Northwest wind around 10 mph.
.TUESDAY...Mostly cloudy. Highs 60 to 70. Northwest wind around
10 mph.
.TUESDAY NIGHT...Mostly cloudy. Lows 46 to 56. Northeast wind
around 10 mph.
.WEDNESDAY...Mostly cloudy. Highs 61 to 71. Northwest wind around
10 mph.
.WEDNESDAY NIGHT THROUGH FRIDAY NIGHT...Mostly cloudy. Lows 46 to
56. Highs 60 to 71.
.SATURDAY...Mostly cloudy. Slight chance of rain. Highs 60 to 70.
.SATURDAY NIGHT...Mostly cloudy. Lows 45 to 55.
.SUNDAY...Mostly cloudy. Slight chance of rain. Highs 61 to 71.
TEMPERATURE / PRECIPITATION
McKinleyville 66 52 63 / 20 10
Arcata 69 51 65 / 20
Eureka 66 52 64 / 20 10
Fortuna 67 52 66 / 20
$$
CAZ104-130245-
Southwestern Humboldt-
437 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy early in the morning then clearing. Patchy
drizzle and fog in the morning. Highs 70 to 85. North wind 5 to
15 mph.
.TONIGHT...Partly cloudy. Lows 48 to 58. North wind 5 to 15 mph.
.TUESDAY...Mostly sunny. Highs 66 to 81. Northwest wind up to
10 mph.
.TUESDAY NIGHT...Partly cloudy. Lows 48 to 58. North wind around
10 mph.
.WEDNESDAY...Partly cloudy. Highs 65 to 80. Northwest wind around
10 mph.
.WEDNESDAY NIGHT THROUGH SATURDAY NIGHT...Partly cloudy. Lows
48 to 58. Highs 67 to 82.
.SUNDAY...Partly cloudy. Slight chance of rain. Highs 66 to 81.
TEMPERATURE / PRECIPITATION
Honeydew 80 51 78 /
$$
CAZ105-130245-
Northern Humboldt Interior-
437 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy in the morning then clearing. Patchy
valley fog in the morning. Highs 72 to 87.
.TONIGHT...Partly cloudy. Lows 46 to 56.
.TUESDAY...Partly cloudy. Highs 68 to 83.
.TUESDAY NIGHT...Mostly cloudy. Lows 46 to 56.
.WEDNESDAY...Mostly cloudy. Highs 67 to 82.
.WEDNESDAY NIGHT THROUGH THURSDAY NIGHT...Partly cloudy. Lows
47 to 57. Highs 69 to 84.
.FRIDAY AND FRIDAY NIGHT...Mostly cloudy. Highs 68 to 83. Lows
47 to 57.
.SATURDAY...Mostly cloudy in the morning then becoming partly
cloudy. Slight chance of rain. Highs 67 to 82.
.SATURDAY NIGHT...Partly cloudy in the evening then becoming
mostly cloudy. Slight chance of rain. Lows 45 to 55.
.SUNDAY...Partly cloudy in the morning then becoming mostly
cloudy. Slight chance of rain. Highs 67 to 82.
TEMPERATURE / PRECIPITATION
Orleans 87 49 82 / 10
Hoopa 84 49 81 / 10
Willow Creek 86 48 82 / 10
$$
CAZ106-130245-
Southern Humboldt Interior-
437 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy in the morning then clearing. Highs 72 to
87.
.TONIGHT...Partly cloudy. Lows 44 to 54.
.TUESDAY...Mostly sunny. Highs 66 to 81.
.TUESDAY NIGHT...Partly cloudy. Lows 44 to 54.
.WEDNESDAY...Mostly cloudy. Highs 63 to 78.
.WEDNESDAY NIGHT THROUGH THURSDAY NIGHT...Partly cloudy. Lows
46 to 56. Highs 67 to 82.
.FRIDAY AND FRIDAY NIGHT...Mostly cloudy. Highs 67 to 82. Lows
46 to 56.
.SATURDAY THROUGH SUNDAY...Partly cloudy. Slight chance of rain.
Highs 66 to 81. Lows 45 to 55.
TEMPERATURE / PRECIPITATION
Garberville 84 47 79 /
$$
CAZ107-130245-
Northern Trinity-
437 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy then becoming partly cloudy early in the
afternoon then becoming sunny. Chance of rain showers in the
morning. Highs 83 to 98.
.TONIGHT...Mostly clear. Lows 47 to 57.
.TUESDAY...Sunny. Highs 78 to 93.
.TUESDAY NIGHT...Partly cloudy. Lows 45 to 55.
.WEDNESDAY...Partly cloudy. Highs 74 to 89.
.WEDNESDAY NIGHT...Partly cloudy. Lows 44 to 54.
.THURSDAY...Sunny. Highs 76 to 91.
.THURSDAY NIGHT THROUGH FRIDAY NIGHT...Partly cloudy. Lows 46 to
56. Highs 76 to 91.
.SATURDAY...Partly cloudy. Slight chance of rain. Highs 71 to 86.
.SATURDAY NIGHT...Partly cloudy. Lows 43 to 53.
.SUNDAY...Partly cloudy. Slight chance of rain. Highs 71 to 86.
TEMPERATURE / PRECIPITATION
Trinity Center 84 51 81 / 10
Weaverville 91 51 86 / 10
$$
CAZ108-130245-
Southern Trinity-
437 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy then becoming partly cloudy early in the
afternoon then becoming sunny. Chance of rain showers in the
morning. Highs 76 to 91.
.TONIGHT...Mostly clear. Lows 44 to 54.
.TUESDAY...Sunny. Highs 71 to 86.
.TUESDAY NIGHT...Partly cloudy. Lows 43 to 53.
.WEDNESDAY...Partly cloudy. Highs 66 to 81.
.WEDNESDAY NIGHT...Partly cloudy. Lows 43 to 53.
.THURSDAY...Sunny. Highs 68 to 83.
.THURSDAY NIGHT THROUGH SATURDAY NIGHT...Partly cloudy. Lows
43 to 53. Highs 68 to 83.
.SUNDAY...Partly cloudy. Slight chance of rain. Highs 64 to 79.
TEMPERATURE / PRECIPITATION
Hayfork 91 43 86 / 10
Ruth 82 45 78 / 10
$$
CAZ109-130245-
Mendocino Coast-
437 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy in the morning then becoming partly
cloudy. Highs 67 to 82. Northwest wind 5 to 15 mph.
.TONIGHT...Partly cloudy. Lows 45 to 55. Northwest wind 5 to
15 mph.
.TUESDAY...Partly cloudy. Highs 60 to 74. Northwest wind up to
10 mph.
.TUESDAY NIGHT...Partly cloudy. Lows 45 to 55. Northwest wind
around 10 mph.
.WEDNESDAY...Partly cloudy. Highs 60 to 73. Northwest wind around
10 mph.
.WEDNESDAY NIGHT THROUGH SATURDAY NIGHT...Partly cloudy. Lows
44 to 54. Highs 61 to 76.
.SUNDAY...Partly cloudy. Slight chance of rain. Highs 62 to 76.
TEMPERATURE / PRECIPITATION
Fort Bragg 67 51 62 / 10
Point Arena 63 53 59 / 10
$$
CAZ110-130245-
Northwestern Mendocino Interior-
437 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy then becoming partly cloudy early in the
afternoon then becoming sunny. Highs 77 to 92.
.TONIGHT...Partly cloudy. Lows 44 to 54.
.TUESDAY...Sunny. Highs 69 to 84.
.TUESDAY NIGHT...Partly cloudy. Lows 43 to 53.
.WEDNESDAY...Partly cloudy. Highs 66 to 81.
.WEDNESDAY NIGHT...Partly cloudy. Lows 44 to 54.
.THURSDAY...Sunny. Highs 70 to 85.
.THURSDAY NIGHT THROUGH SATURDAY NIGHT...Partly cloudy. Lows
45 to 55. Highs 71 to 86.
.SUNDAY...Partly cloudy. Slight chance of rain. Highs 68 to 83.
TEMPERATURE / PRECIPITATION
Leggett 79 47 73 /
Laytonville 82 47 75 / 10
Willits 79 47 73 / 10
$$
CAZ111-130245-
Northeastern Mendocino Interior-
437 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy until early afternoon then clearing.
Chance of rain showers in the morning. Highs 77 to 92.
.TONIGHT...Mostly clear. Lows 46 to 56.
.TUESDAY...Sunny. Highs 70 to 85.
.TUESDAY NIGHT...Partly cloudy. Lows 43 to 53.
.WEDNESDAY...Partly cloudy. Highs 65 to 80.
.WEDNESDAY NIGHT...Partly cloudy. Lows 44 to 54.
.THURSDAY...Sunny. Highs 69 to 84.
.THURSDAY NIGHT THROUGH SUNDAY...Partly cloudy. Lows 45 to 55.
Highs 70 to 85.
TEMPERATURE / PRECIPITATION
Covelo 88 47 81 / 10
$$
CAZ112-130245-
Southwestern Mendocino Interior-
437 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy in the morning then becoming mostly sunny.
Highs 72 to 87.
.TONIGHT...Partly cloudy. Lows 47 to 57.
.TUESDAY...Partly cloudy in the morning then clearing. Highs
68 to 78.
.TUESDAY NIGHT...Partly cloudy. Lows 46 to 56.
.WEDNESDAY...Partly cloudy. Highs 67 to 78.
.WEDNESDAY NIGHT THROUGH SUNDAY...Partly cloudy. Lows 47 to 57.
Highs 67 to 82.
TEMPERATURE / PRECIPITATION
Boonville 80 49 75 /
$$
CAZ113-130245-
Southeastern Mendocino Interior-
437 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy in the morning then becoming partly
cloudy. Highs 74 to 89.
.TONIGHT...Partly cloudy. Lows 49 to 59.
.TUESDAY...Sunny. Highs 68 to 83.
.TUESDAY NIGHT...Partly cloudy. Lows 48 to 58.
.WEDNESDAY...Partly cloudy. Highs 66 to 80.
.WEDNESDAY NIGHT...Partly cloudy. Lows 48 to 58.
.THURSDAY AND THURSDAY NIGHT...Mostly clear. Highs 70 to 85. Lows
49 to 59.
.FRIDAY THROUGH SUNDAY...Partly cloudy. Highs 71 to 86. Lows
49 to 59.
TEMPERATURE / PRECIPITATION
Ukiah 87 52 80 /
$$
CAZ114-130245-
Northern Lake-
437 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy until early afternoon then becoming mostly
sunny. Highs 77 to 92.
.TONIGHT...Mostly clear. Lows 48 to 58.
.TUESDAY...Sunny. Highs 70 to 85.
.TUESDAY NIGHT...Mostly clear. Lows 44 to 54.
.WEDNESDAY...Partly cloudy. Highs 66 to 81.
.WEDNESDAY NIGHT THROUGH THURSDAY NIGHT...Mostly clear. Lows
46 to 56. Highs 69 to 84.
.FRIDAY THROUGH SUNDAY...Partly cloudy. Highs 70 to 85. Lows
47 to 57.
TEMPERATURE / PRECIPITATION
Lake Pillsbury 91 42 83 / 10
$$
CAZ115-130245-
Southern Lake-
437 AM PDT Mon Sep 12 2022
.TODAY...Mostly cloudy early in the morning then becoming partly
cloudy. Highs 80 to 92.
.TONIGHT...Mostly clear. Lows 51 to 61.
.TUESDAY...Sunny. Highs 73 to 86.
.TUESDAY NIGHT...Mostly clear. Lows 47 to 57.
.WEDNESDAY...Mostly sunny. Highs 68 to 80.
.WEDNESDAY NIGHT THROUGH THURSDAY NIGHT...Mostly clear. Lows
49 to 59. Highs 68 to 83.
.FRIDAY THROUGH SUNDAY...Partly cloudy. Highs 70 to 85. Lows
50 to 60.
TEMPERATURE / PRECIPITATION
Lakeport 86 51 78 / 10
Middletown 90 50 82 / 10
Clearlake 89 52 83 / 10
$$
_____
Copyright 2022 AccuWeather
|
https://www.sfchronicle.com/weather/article/CA-Eureka-CA-Zone-Forecast-17435298.php
| 2022-09-12T13:19:33Z
|
https://www.sfchronicle.com/weather/article/CA-Eureka-CA-Zone-Forecast-17435298.php
| false
|
Teacher shortages are real, but not for the reason you heard
BIRMINGHAM, Ala. (AP) — Everywhere, it seems, back-to-school has been shadowed by worries of a teacher shortage.
The U.S. education secretary has called for investment to keep teachers from quitting. A teachers union leader has described it as a five-alarm emergency. News coverage has warned of a crisis in teaching.
In reality, there is little evidence to suggest teacher turnover has increased nationwide or educators are leaving in droves.
Certainly, many schools have struggled to find enough educators. But the challenges are related more to hiring, especially for non-teaching staff positions. Schools flush with federal pandemic relief money are creating new positions and struggling to fill them at a time of low unemployment and stiff competition for workers of all kinds.
Since well before the COVID-19 pandemic, schools have had difficulty recruiting enough teachers in some regions, particularly in parts of the South. Fields like special education and bilingual education also have been critically short on teachers nationwide.
For some districts, shortages have meant children have fewer or less qualified instructors.
In rural Alabama’s Black Belt, there were no certified math teachers last year in Bullock County’s public middle school.
“It really impacts the children because they’re not learning what they need to learn,” said Christopher Blair, the county’s former superintendent. “When you have these uncertified, emergency or inexperienced teachers, students are in classrooms where they’re not going to get the level of rigor and classroom experiences.”
While the nation lacks vacancy data in several states, national pain points are obvious.
For starters, the pandemic kicked off the largest drop in education employment ever. According to the Bureau of Labor Statistics, the number of people employed in public schools dropped from almost 8.1 million in March 2020 to 7.3 million in May. Employment has grown back to 7.7 million since then, but that still leaves schools short around 360,000 positions.
“We’re still trying to dig out of that hole,” said Chad Aldeman, policy director at the Edunomics Lab at Georgetown University.
It’s unknown how many of those positions lost were teaching jobs, or other staff members like bus drivers — support positions that schools are having an especially hard time filling. A RAND survey of school leaders this year found that around three-fourths of school leaders say they are trying to hire more substitutes, 58% are trying to hire more bus drivers and 43% are trying to hire more tutors.
Still, the problems are not as tied to teachers quitting as many have suggested.
Teacher surveys have indicated many considered leaving their jobs. They’re under pressure to keep kids safe from guns, catch them up academically and deal with pandemic challenges with mental health and behavior.
National Education Association union leader Becky Pringle tweeted in April: “The educator shortage is a five-alarm crisis.” But a Brown University study found turnover largely unchanged among states that had data.
Quit rates in education rose slightly this year, but that’s true for the nation as a whole, and teachers remain far more likely to stay in their job than a typical worker.
Hiring has been so difficult largely because of an increase in the number of open positions. Many schools indicated plans to use federal relief money to create new jobs, in some cases looking to hire even more people than they had pre-pandemic. Some neighboring schools are competing for fewer applicants, as enrollment in teacher prep programs colleges has declined.
The Upper Darby School District in Pennsylvania has around 70 positions it is trying to fill, especially bus drivers, lunch aides and substitute teachers. But it cannot find enough applicants. The district has warned families it may have to cancel school or switch to remote learning on days when it lacks subs.
“It’s become a financial competition from district to district to do that, and that’s unfortunate for children in communities who deserve the same opportunities everywhere in the state,” Superintendent Daniel McGarry said.
The number of unfilled vacancies has led some states and school systems to ease credential requirements, in order to expand the pool of applicants. U.S. Education Secretary Miguel Cardona told reporters last week that creative approaches are needed to bring in more teachers, such as retired educators, but schools must not lower standards.
Schools in the South are more likely to struggle with teacher vacancies. A federal survey found an average of 3.4 teaching vacancies per school as of this summer; that number was lowest in the West, with 2.7 vacancies on average, and highest in the South, with 4.2 vacancies.
In Birmingham, the school district is struggling to fill around 50 teaching spots, including 15 in special education, despite $10,000 signing bonuses for special ed teachers. Jenikka Oglesby, a human resources officer for the district, says the problem owes in part to low salaries in the South that don’t always offset a lower cost of living.
The school system in Moss Point, a small town near the Gulf Coast of Mississippi, has increased wages to entice more applicants. But other districts nearby have done the same. Some teachers realized they could make $30,000 more by working 30 minutes away in Mobile, Alabama.
“I personally lost some really good teachers to Mobile County Schools,” said Tenesha Batiste, human resources director for the Moss Point district. And she also lost some not-so-great teachers, she added — people who broke their contracts and quit three days before the school year started.
“It’s the job that makes all others possible, yet they get paid once a month, and they can go to Chick-fil-A in some places and make more money,” Batiste said.
A bright spot for Moss Point this year is four student teachers from the University of Southern Mississippi. They will spend the school year working with children as part of a residency program for aspiring educators. The state has invested almost $10 million of federal relief money into residency programs, with the hope the residents will stay and become teachers in their assigned districts.
Michelle Dallas, a teacher resident in a Moss Point first-grade classroom, recently switched from a career in mental health and is confident she is meant to be a teacher.
“That’s why I’m here,” she said, “to fulfill my calling.”
___
This story is part of an Associated Press collaboration with AL.com, The Christian Science Monitor, The Dallas Morning News, The Fresno Bee in California, The Hechinger Report, The Seattle Times and The Post and Courier in Charleston, South Carolina.
___
Associated Press writers Brooke Schultz in Harrisburg, Pa., Collin Binkley in Washington, D.C., and Carolyn Thompson in Buffalo, N.Y. contributed to this report. Lurye reported from New Orleans. Schultz is a corps member for the Associated Press/Report for America Statehouse News Initiative. Report for America is a nonprofit national service program that places journalists in local newsrooms to report on undercovered issues.
___
The Associated Press education team receives support from the Carnegie Corporation of New York. The AP is solely responsible for all content.
___
For more back-to-school coverage, visit: https://apnews.com/hub/back-to-school
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.wlbt.com/2022/09/12/teacher-shortages-are-real-not-reason-you-heard/
| 2022-09-12T13:27:20Z
|
https://www.wlbt.com/2022/09/12/teacher-shortages-are-real-not-reason-you-heard/
| true
|
ARLINGTON, Texas (AP) — Dallas Cowboys quarterback Dak Prescott will need surgery for a fractured bone in his throwing hand sustained in the season opener and will miss multiple weeks.
The quarterback got hurt in the fourth quarter of the Cowboys’ 19-3 loss to the Tampa Bay Buccaneers on Sunday night. Prescott’s right hand made contact with rushing linebacker Shaquil Barrett when throwing a pass.
Prescott said he initially thought he had just jammed a finger, like he has many times before, but realized on the next play that he couldn’t grip the football.
After initially being checked on the sideline, he jogged to the locker room and had X-rays. Backup Cooper Rush finished the game.
“I’ve hit my hand on helmets or bodies a lot in my career and never had anything, maybe a jammed finger and actually thought that is what it was,” Prescott said. “Told the trainers the same thing, I can’t grip (the ball), I feel like if you yank it, I’ll be OK. Came in and got X-rays, and things are different.”
Prescott said he will see a doctor Monday and have surgery after that. He said he was told after the X-rays that the injury “was much cleaner than it could have been.”
Cowboys owner Jerry Jones said the injury is above his thumb, and behind the joint, and he pointed to an area between his own thumb and wrist.
Prescott’s 2020 season ended in the fifth week because of a gruesome ankle injury. He returned last season to throw for 4,449 yards and 37 touchdowns as the Cowboys won the NFC East before losing their first-round playoff game to San Francisco at home.
The 29-year-old Prescott said he got into the best shape of his life going into this season, his seventh in the NFL.
When there appeared to be a setback in practice last week, Prescott blamed a change in cleats for soreness in his surgically repaired ankle.
Prescott and the Cowboys are dealing with a bigger issue now, after losing the season opener without scoring a touchdown.
“To be very candid with you, all of that takes a backseat to the fact that as we go forward here for the next few weeks, we’ll be going forward without Dak,” Jones said. “That’s foremost on my mind.”
Jones reiterated that while Prescott will be out “several games,” he would not be out for the season.
Asked to characterize his emotions, Prescott said while disappointing and unfortunate, injuries are not necessarily anything he can control.
“Obviously going to miss some time and not be there for my team, and that’s what hurts more than more than anything especially after the start that we just put out there,” Prescott said. “Wanted to be able to respond and not necessarily having that opportunity for several weeks, yeah, it’s unfortunate. But I’ll do what I’ve always done any time adversity comes, take it on headfirst and I’ll give my best and I’m sure I’ll come out of this thing better.”
___
More AP NFL coverage: https://apnews.com/hub/nfl and https://twitter.com/AP_NFL
|
https://www.texomashomepage.com/sports/ap-cowboys-qb-prescott-to-miss-multiple-weeks-with-hand-injury/
| 2022-09-12T13:27:29Z
|
https://www.texomashomepage.com/sports/ap-cowboys-qb-prescott-to-miss-multiple-weeks-with-hand-injury/
| false
|
– Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab –
– Data highlighted in late-breaking presentation at the European Society for Medical Oncology (ESMO) Congress 2022 –
TOKYO and BOTHELL, Wash. and RAHWAY, N.J., Sept. 12, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), Seagen Inc. (Nasdaq:SGEN) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869) Cohort K investigating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and PADCEV alone as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible to receive cisplatin-based chemotherapy. The findings were presented today at the European Society for Medical Oncology (ESMO) Congress as part of a late-breaking abstract presentation (Abstract #LBA73).
In patients treated with enfortumab vedotin and pembrolizumab (n=76), results demonstrated a 64.5% confirmed objective response rate (ORR) (95% CI: 52.7 to 75.1) per RECIST v1.1 by blinded independent central review (BICR), the primary endpoint of Cohort K, with 10.5% of patients experiencing a complete response and 53.9% of patients experiencing a partial response. The median duration of response (DOR) per BICR was not reached (95% CI: 10.25 months to NR). All-grade treatment-related adverse events (TRAEs) of special interest for enfortumab vedotin in combination with pembrolizumab were skin reactions (67.1%), peripheral neuropathy (60.5%), ocular disorders (dry eye, blurred vision, and corneal disorders) (26.3%), hyperglycemia (14.5%), and infusion-related reactions (3.9%). Pembrolizumab adverse events of special interest were consistent with previously observed safety data from monotherapy with the exception of severe skin reactions. Overall, the results were generally consistent with previously reported efficacy and safety results of the EV-103/KEYNOTE-869 dose-escalation cohort and expansion Cohort A.1
Please see Important Safety Information at the end of this press release for both drugs, including BOXED WARNING for enfortumab vedotin and immune-mediated adverse reactions for pembrolizumab.
Cohort K also included a monotherapy arm in which patients were treated with enfortumab vedotin alone (n=73), though this study was not designed to support a formal comparison between the two arms. Results showed a 45.2% confirmed ORR (95% CI: 33.5 to 57.3) per RECIST v1.1 by BICR, with 4.1% of patients experiencing a complete response and 41.1% of patients experiencing a partial response. The median DOR was 13.2 months (95% CI: 6.14 to 15.97) per RECIST v1.1 by BICR. All-grade TRAEs of special interest for enfortumab vedotin were peripheral neuropathy (54.8%), skin reactions (45.2%), ocular disorders (dry eye, blurred vision, and corneal disorders) (28.8%), hyperglycemia (11.0%), and infusion-related reactions (5.5%).
Additional secondary endpoints in the EV-103 Cohort K trial included progression-free survival (PFS) and overall survival (OS). Among patients treated with enfortumab vedotin and pembrolizumab, median PFS was not reached (95% CI: 8.31 months to NR). Median OS was 22.3 months (95% CI: 19.09 to NR). Among patients treated with enfortumab vedotin, median PFS was 8.0 months (95% CI: 6.05 to 10.35) and median OS was 21.7 months (95% CI: 15.21 to NR).
TRAEs of any grade that occurred in more than 20% of patients treated with enfortumab vedotin alone or in combination with pembrolizumab were fatigue, peripheral sensory neuropathy, alopecia, rash maculo-papular, pruritus, dysgeusia, weight decreased, diarrhea, decreased appetite, nausea, and dry eye.
"Results from EV-103/KEYNOTE-869 Cohort K support the ongoing investigation of enfortumab vedotin and pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who are in need of treatment options, and this combination may be an important therapeutic option for these patients," said Jonathan E. Rosenberg, M.D., Chief, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology, and Enno W. Ercklentz Chair, Memorial Sloan Kettering Cancer Center and EV-103/KEYNOTE-869 Cohort K primary investigator. Dr. Rosenberg has consulting relationships with Astellas, Seagen and Merck.
"We're encouraged by these positive findings from the combination of enfortumab vedotin and pembrolizumab in people with advanced urothelial cancer who historically have had limited treatment options in the first-line setting, and we intend to discuss these results with regulatory authorities," said Ahsan Arozullah, M.D., M.P.H., Senior Vice President and Head of Development Therapeutic Areas, Astellas.
"Nearly sixty-five percent of patients who were treated with enfortumab vedotin and pembrolizumab responded to the combination, with almost eleven percent showing no detectable cancer following treatment. These study results represent an encouraging finding for people with advanced urothelial cancer who are not eligible for cisplatin treatment," said Marjorie Green, Senior Vice President and Head of Late Stage Development, Seagen.
"We're pleased that this combination provided a meaningful benefit to this group of advanced bladder cancer patients in this study, and we will continue to investigate enfortumab vedotin plus pembrolizumab through our collaboration," said Dr. Eliav Barr, Senior Vice President, Head of Global Clinical Development and Chief Medical Officer, Merck Research Laboratories.
In February 2020, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for enfortumab vedotin in combination with pembrolizumab for patients with unresectable la/mUC who are ineligible to receive cisplatin-based chemotherapy in the first-line setting. The designation is based on results from the dose-escalation cohort and expansion Cohort A of the phase 1b/2 trial, EV-103/KEYNOTE-869 (NCT03288545), evaluating patients with la/mUC who are ineligible to receive cisplatin-based chemotherapy treated in the first-line setting with enfortumab vedotin in combination with pembrolizumab.
Astellas, Seagen and Merck are further investigating enfortumab vedotin plus pembrolizumab in Phase 3 studies, including EV-302/KEYNOTE-A39 (NCT04223856), which is intended to confirm these results for the investigational treatment combination in previously untreated la/mUC and in muscle-invasive bladder cancer in EV-304/KEYNOTE-B15 (NCT04700124) and EV-303/KEYNOTE-905 (NCT03924895).
About Bladder and Urothelial Cancer
It is estimated that approximately 83,730 people in the U.S. were diagnosed with bladder cancer in 2021.2 Urothelial cancer accounts for 90% of all bladder cancers and can also be found in the renal pelvis, ureter and urethra.3 Globally, approximately 573,000 new cases of bladder cancer and 212,000 deaths are reported annually.4
About the EV-103/KEYNOTE-869 Trial (Cohort K)
The EV-103 trial (NCT03288545) is an ongoing, multi-cohort, open-label, multicenter phase 1b/2 trial of enfortumab vedotin alone or in combination with pembrolizumab and/or chemotherapy in first- or second-line settings in patients with locally advanced or metastatic urothelial cancer (la/mUC) and in patients with muscle-invasive bladder cancer.
Cohort K of the EV-103/KEYNOTE-869 trial is a randomized 1:1 cohort investigating enfortumab vedotin alone (n=73) or in combination with pembrolizumab (n=76) in adult patients with unresectable la/mUC who are ineligible for cisplatin-based chemotherapy and have received no prior treatment for la/mUC. The enfortumab vedotin monotherapy study arm is intended to characterize the activity of enfortumab vedotin alone in this patient population. The key outcome measure of EV-103/KEYNOTE-869 Cohort K is objective response rate (ORR) per blinded independent central review (BICR) using RECIST 1.1. Secondary endpoints include ORR per investigator assessment; duration of response (DOR), disease control rate (DCR) and progression-free survival (PFS) per BICR and investigator assessment; overall survival (OS); and assessment of safety.
About PADCEV
PADCEV (enfortumab vedotin-ejfv) is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.5 Nonclinical data suggest the anticancer activity of PADCEV is due to its binding to Nectin-4 expressing cells followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell, which result in the cell not reproducing (cell cycle arrest) and in programmed cell death (apoptosis).6
PADCEV (enfortumab vedotin-ejfv) U.S. Indication & Important Safety Information
BOXED WARNING: SERIOUS SKIN REACTIONS
- PADCEV can cause severe and fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which occurred predominantly during the first cycle of treatment, but may occur later.
- Closely monitor patients for skin reactions.
- Immediately withhold PADCEV and consider referral for specialized care for suspected SJS or TEN or severe skin reactions.
- Permanently discontinue PADCEV in patients with confirmed SJS or TEN; or Grade 4 or recurrent Grade 3 skin reactions.
Indication
PADCEV® is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who:
- have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or
- are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.6
Important Safety Information
Warnings and Precautions
Skin reactions Severe cutaneous adverse reactions, including fatal cases of SJS or TEN, occurred in patients treated with PADCEV. SJS and TEN occurred predominantly during the first cycle of treatment but may occur later. Skin reactions occurred in 55% of the 680 patients treated with PADCEV in clinical trials. Twenty-three percent (23%) of patients had maculo-papular rash and 33% had pruritus. Grade 3-4 skin reactions occurred in 13% of patients, including maculo-papular rash, rash erythematous, rash or drug eruption, symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), dermatitis bullous, dermatitis exfoliative, and palmar-plantar erythrodysesthesia. In clinical trials, the median time to onset of severe skin reactions was 0.6 months (range: 0.1 to 6.4). Among patients experiencing a skin reaction leading to dose interruption who then restarted PADCEV (n=59), 24% of patients restarting at the same dose and 16% of patients restarting at a reduced dose experienced recurrent severe skin reactions. Skin reactions led to discontinuation of PADCEV in 2.6% of patients. Monitor patients closely throughout treatment for skin reactions. Consider topical corticosteroids and antihistamines, as clinically indicated. Withhold PADCEV and refer for specialized care for suspected SJS or TEN or for severe (Grade 3) skin reactions. Permanently discontinue PADCEV in patients with confirmed SJS or TEN, or for Grade 4 or recurrent Grade 3 skin reactions.
Hyperglycemia and diabetic ketoacidosis (DKA), including fatal events, occurred in patients with and without pre-existing diabetes mellitus, treated with PADCEV. Patients with baseline hemoglobin A1C ≥8% were excluded from clinical trials. In clinical trials, 14% of the 680 patients treated with PADCEV developed hyperglycemia; 7% of patients developed Grade 3-4 hyperglycemia. The incidence of Grade 3-4 hyperglycemia increased consistently in patients with higher body mass index and in patients with higher baseline A1C. Five percent (5%) of patients required initiation of insulin therapy for treatment of hyperglycemia. The median time to onset of hyperglycemia was 0.6 months (range: 0.1 to 20.3). Hyperglycemia led to discontinuation of PADCEV in 0.6% of patients. Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold PADCEV.
Pneumonitis Severe, life-threatening or fatal pneumonitis occurred in patients treated with PADCEV. In clinical trials, 3.1% of the 680 patients treated with PADCEV had pneumonitis of any grade and 0.7% had Grade 3-4. In clinical trials, the median time to onset of pneumonitis was 2.9 months (range: 0.6 to 6). Monitor patients for signs and symptoms indicative of pneumonitis, such as hypoxia, cough, dyspnea or interstitial infiltrates on radiologic exams. Evaluate and exclude infectious, neoplastic and other causes for such signs and symptoms through appropriate investigations. Withhold PADCEV for patients who develop persistent or recurrent Grade 2 pneumonitis and consider dose reduction. Permanently discontinue PADCEV in all patients with Grade 3 or 4 pneumonitis.
Peripheral neuropathy (PN) occurred in 52% of the 680 patients treated with PADCEV in clinical trials, including 39% with sensory neuropathy, 7% with muscular weakness and 6% with motor neuropathy; 4% experienced Grade 3-4 reactions. PN occurred in patients treated with PADCEV with or without pre-existing PN. The median time to onset of Grade ≥2 PN was 4.6 months (range: 0.1 to 15.8 months). Neuropathy led to treatment discontinuation in 5% of patients. Monitor patients for symptoms of new or worsening peripheral neuropathy and consider dose interruption or dose reduction of PADCEV when PN occurs. Permanently discontinue PADCEV in patients who develop Grade ≥3 PN.
Ocular disorders were reported in 40% of the 384 patients treated with PADCEV in clinical trials in which ophthalmologic exams were scheduled. The majority of these events involved the cornea and included events associated with dry eye such as keratitis, blurred vision, increased lacrimation, conjunctivitis, limbal stem cell deficiency, and keratopathy. Dry eye symptoms occurred in 34% of patients, and blurred vision occurred in 13% of patients, during treatment with PADCEV. The median time to onset to symptomatic ocular disorder was 1.6 months (range: 0 to 19.1 months). Monitor patients for ocular disorders. Consider artificial tears for prophylaxis of dry eyes and ophthalmologic evaluation if ocular symptoms occur or do not resolve. Consider treatment with ophthalmic topical steroids, if indicated after an ophthalmic exam. Consider dose interruption or dose reduction of PADCEV for symptomatic ocular disorders.
Infusion site extravasation Skin and soft tissue reactions secondary to extravasation have been observed after administration of PADCEV. Of the 680 patients, 1.6% of patients experienced skin and soft tissue reactions, including 0.3% who experienced Grade 3-4 reactions. Reactions may be delayed. Erythema, swelling, increased temperature, and pain worsened until 2-7 days after extravasation and resolved within 1-4 weeks of peak. Two patients (0.3%) developed extravasation reactions with secondary cellulitis, bullae, or exfoliation. Ensure adequate venous access prior to starting PADCEV and monitor for possible extravasation during administration. If extravasation occurs, stop the infusion and monitor for adverse reactions.
Embryo-fetal toxicity PADCEV can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during PADCEV treatment and for 2 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with PADCEV and for 4 months after the last dose.
Adverse Reactions
Most Common Adverse Reactions, Including Laboratory Abnormalities (≥20%)
Rash, aspartate aminotransferase (AST) increased, glucose increased, creatinine increased, fatigue, PN, lymphocytes decreased, alopecia, decreased appetite, hemoglobin decreased, diarrhea, sodium decreased, nausea, pruritus, phosphate decreased, dysgeusia, alanine aminotransferase (ALT) increased, anemia, albumin decreased, neutrophils decreased, urate increased, lipase increased, platelets decreased, weight decreased and dry skin.
EV-301 Study: 296 patients previously treated with a PD-1/L1 inhibitor and platinum-based chemotherapy.
Serious adverse reactions occurred in 47% of patients treated with PADCEV; the most common (≥2%) were urinary tract infection, acute kidney injury (7% each) and pneumonia (5%). Fatal adverse reactions occurred in 3% of patients, including multiorgan dysfunction (1.0%), hepatic dysfunction, septic shock, hyperglycemia, pneumonitis and pelvic abscess (0.3% each). Adverse reactions leading to discontinuation occurred in 17% of patients; the most common (≥2%) were PN (5%) and rash (4%). Adverse reactions leading to dose interruption occurred in 61% of patients; the most common (≥4%) were PN (23%), rash (11%) and fatigue (9%). Adverse reactions leading to dose reduction occurred in 34% of patients; the most common (≥2%) were PN (10%), rash (8%), decreased appetite and fatigue (3% each). Clinically relevant adverse reactions (<15%) include vomiting (14%), AST increased (12%), hyperglycemia (10%), ALT increased (9%), pneumonitis (3%) and infusion site extravasation (0.7%).
EV-201, Cohort 2 Study: 89 patients previously treated with a PD-1/L1 inhibitor and not eligible for platinum-based chemotherapy.
Serious adverse reactions occurred in 39% of patients treated with PADCEV; the most common (≥3%) were pneumonia, sepsis and diarrhea (5% each). Fatal adverse reactions occurred in 8% of patients, including acute kidney injury (2.2%), metabolic acidosis, sepsis, multiorgan dysfunction, pneumonia and pneumonitis (1.1% each). Adverse reactions leading to discontinuation occurred in 20% of patients; the most common (≥2%) was PN (7%). Adverse reactions leading to dose interruption occurred in 60% of patients; the most common (≥3%) were PN (19%), rash (9%), fatigue (8%), diarrhea (5%), AST increased and hyperglycemia (3% each). Adverse reactions leading to dose reduction occurred in 49% of patients; the most common (≥3%) were PN (19%), rash (11%) and fatigue (7%). Clinically relevant adverse reactions (<15%) include vomiting (13%), AST increased (12%), lipase increased (11%), ALT increased (10%), pneumonitis (4%) and infusion site extravasation (1%).
Drug Interactions
Effects of other drugs on PADCEV (Dual P-gp and Strong CYP3A4 Inhibitors)
Concomitant use with a dual P-gp and strong CYP3A4 inhibitors may increase unconjugated monomethyl auristatin E exposure, which may increase the incidence or severity of PADCEV toxicities. Closely monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.
Specific Populations
Lactation Advise lactating women not to breastfeed during treatment with PADCEV and for at least 3 weeks after the last dose.
Hepatic impairment Avoid the use of PADCEV in patients with moderate or severe hepatic impairment.
For more information, please see the full Prescribing Information including BOXED WARNING for PADCEV here.
About KEYTRUDA® (pembrolizumab) injection, 100 mg
KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Merck has the industry's largest immuno-oncology clinical research program. There are currently more than 1,600 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.
Selected KEYTRUDA® (pembrolizumab) Indications in the U.S.
Urothelial Carcinoma
KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC):
- who are not eligible for any platinum-containing chemotherapy, or
- who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Non-muscle Invasive Bladder Cancer
KEYTRUDA is indicated for the treatment of patients with Bacillus Calmette-Guerin-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
See additional selected KEYTRUDA indications in the U.S. after the Selected Important Safety Information.
Selected Important Safety Information for KEYTRUDA
Severe and Fatal Immune-Mediated Adverse Reactions
KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to either the PD-1 or the PD-L1, blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, can affect more than one body system simultaneously, and can occur at any time after starting treatment or after discontinuation of treatment. Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Early identification and management are essential to ensure safe use of anti–PD-1/PD-L1 treatments. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. For patients with TNBC treated with KEYTRUDA in the neoadjuvant setting, monitor blood cortisol at baseline, prior to surgery, and as clinically indicated. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.
Withhold or permanently discontinue KEYTRUDA depending on severity of the immune-mediated adverse reaction. In general, if KEYTRUDA requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose adverse reactions are not controlled with corticosteroid therapy.
Immune-Mediated Pneumonitis
KEYTRUDA can cause immune-mediated pneumonitis. The incidence is higher in patients who have received prior thoracic radiation. Immune-mediated pneumonitis occurred in 3.4% (94/2799) of patients receiving KEYTRUDA, including fatal (0.1%), Grade 4 (0.3%), Grade 3 (0.9%), and Grade 2 (1.3%) reactions. Systemic corticosteroids were required in 67% (63/94) of patients. Pneumonitis led to permanent discontinuation of KEYTRUDA in 1.3% (36) and withholding in 0.9% (26) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Pneumonitis resolved in 59% of the 94 patients.
Pneumonitis occurred in 8% (31/389) of adult patients with cHL receiving KEYTRUDA as a single agent, including Grades 3-4 in 2.3% of patients. Patients received high-dose corticosteroids for a median duration of 10 days (range: 2 days to 53 months). Pneumonitis rates were similar in patients with and without prior thoracic radiation. Pneumonitis led to discontinuation of KEYTRUDA in 5.4% (21) of patients. Of the patients who developed pneumonitis, 42% interrupted KEYTRUDA, 68% discontinued KEYTRUDA, and 77% had resolution.
Immune-Mediated Colitis
KEYTRUDA can cause immune-mediated colitis, which may present with diarrhea. Cytomegalovirus infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. Immune-mediated colitis occurred in 1.7% (48/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (1.1%), and Grade 2 (0.4%) reactions. Systemic corticosteroids were required in 69% (33/48); additional immunosuppressant therapy was required in 4.2% of patients. Colitis led to permanent discontinuation of KEYTRUDA in 0.5% (15) and withholding in 0.5% (13) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Colitis resolved in 85% of the 48 patients.
Hepatotoxicity and Immune-Mediated Hepatitis
KEYTRUDA as a Single Agent
KEYTRUDA can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in 0.7% (19/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.4%), and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 68% (13/19) of patients; additional immunosuppressant therapy was required in 11% of patients. Hepatitis led to permanent discontinuation of KEYTRUDA in 0.2% (6) and withholding in 0.3% (9) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence. Hepatitis resolved in 79% of the 19 patients.
KEYTRUDA With Axitinib
KEYTRUDA in combination with axitinib can cause hepatic toxicity. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider monitoring more frequently as compared to when the drugs are administered as single agents. For elevated liver enzymes, interrupt KEYTRUDA and axitinib, and consider administering corticosteroids as needed. With the combination of KEYTRUDA and axitinib, Grades 3 and 4 increased alanine aminotransferase (ALT) (20%) and increased aspartate aminotransferase (AST) (13%) were seen at a higher frequency compared to KEYTRUDA alone. Fifty-nine percent of the patients with increased ALT received systemic corticosteroids. In patients with ALT ≥3 times upper limit of normal (ULN) (Grades 2-4, n=116), ALT resolved to Grades 0-1 in 94%. Among the 92 patients who were rechallenged with either KEYTRUDA (n=3) or axitinib (n=34) administered as a single agent or with both (n=55), recurrence of ALT ≥3 times ULN was observed in 1 patient receiving KEYTRUDA, 16 patients receiving axitinib, and 24 patients receiving both. All patients with a recurrence of ALT ≥3 ULN subsequently recovered from the event.
Immune-Mediated Endocrinopathies
Adrenal Insufficiency
KEYTRUDA can cause primary or secondary adrenal insufficiency. For Grade 2 or higher, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold KEYTRUDA depending on severity. Adrenal insufficiency occurred in 0.8% (22/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.3%), and Grade 2 (0.3%) reactions. Systemic corticosteroids were required in 77% (17/22) of patients; of these, the majority remained on systemic corticosteroids. Adrenal insufficiency led to permanent discontinuation of KEYTRUDA in <0.1% (1) and withholding in 0.3% (8) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.
Hypophysitis
KEYTRUDA can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Hypophysitis occurred in 0.6% (17/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.3%), and Grade 2 (0.2%) reactions. Systemic corticosteroids were required in 94% (16/17) of patients; of these, the majority remained on systemic corticosteroids. Hypophysitis led to permanent discontinuation of KEYTRUDA in 0.1% (4) and withholding in 0.3% (7) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.
Thyroid Disorders
KEYTRUDA can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Thyroiditis occurred in 0.6% (16/2799) of patients receiving KEYTRUDA, including Grade 2 (0.3%). None discontinued, but KEYTRUDA was withheld in <0.1% (1) of patients.
Hyperthyroidism occurred in 3.4% (96/2799) of patients receiving KEYTRUDA, including Grade 3 (0.1%) and Grade 2 (0.8%). It led to permanent discontinuation of KEYTRUDA in <0.1% (2) and withholding in 0.3% (7) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement. Hypothyroidism occurred in 8% (237/2799) of patients receiving KEYTRUDA, including Grade 3 (0.1%) and Grade 2 (6.2%). It led to permanent discontinuation of KEYTRUDA in <0.1% (1) and withholding in 0.5% (14) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement. The majority of patients with hypothyroidism required long-term thyroid hormone replacement. The incidence of new or worsening hypothyroidism was higher in 1185 patients with HNSCC, occurring in 16% of patients receiving KEYTRUDA as a single agent or in combination with platinum and FU, including Grade 3 (0.3%) hypothyroidism. The incidence of new or worsening hypothyroidism was higher in 389 adult patients with cHL (17%) receiving KEYTRUDA as a single agent, including Grade 1 (6.2%) and Grade 2 (10.8%) hypothyroidism.
Type 1 Diabetes Mellitus (DM), Which Can Present With Diabetic Ketoacidosis
Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold KEYTRUDA depending on severity. Type 1 DM occurred in 0.2% (6/2799) of patients receiving KEYTRUDA. It led to permanent discontinuation in <0.1% (1) and withholding of KEYTRUDA in <0.1% (1) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.
Immune-Mediated Nephritis With Renal Dysfunction
KEYTRUDA can cause immune-mediated nephritis. Immune-mediated nephritis occurred in 0.3% (9/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.1%), and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 89% (8/9) of patients. Nephritis led to permanent discontinuation of KEYTRUDA in 0.1% (3) and withholding in 0.1% (3) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence. Nephritis resolved in 56% of the 9 patients.
Immune-Mediated Dermatologic Adverse Reactions
KEYTRUDA can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms, and toxic epidermal necrolysis, has occurred with anti–PD-1/PD-L1 treatments. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes. Withhold or permanently discontinue KEYTRUDA depending on severity. Immune-mediated dermatologic adverse reactions occurred in 1.4% (38/2799) of patients receiving KEYTRUDA, including Grade 3 (1%) and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 40% (15/38) of patients. These reactions led to permanent discontinuation in 0.1% (2) and withholding of KEYTRUDA in 0.6% (16) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 6% had recurrence. The reactions resolved in 79% of the 38 patients.
Other Immune-Mediated Adverse Reactions
The following clinically significant immune-mediated adverse reactions occurred at an incidence of <1% (unless otherwise noted) in patients who received KEYTRUDA or were reported with the use of other anti–PD-1/PD-L1 treatments. Severe or fatal cases have been reported for some of these adverse reactions. Cardiac/Vascular: Myocarditis, pericarditis, vasculitis; Nervous System: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy; Ocular: Uveitis, iritis and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss; Gastrointestinal: Pancreatitis, to include increases in serum amylase and lipase levels, gastritis, duodenitis; Musculoskeletal and Connective Tissue: Myositis/polymyositis, rhabdomyolysis (and associated sequelae, including renal failure), arthritis (1.5%), polymyalgia rheumatica; Endocrine: Hypoparathyroidism; Hematologic/Immune: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection.
Infusion-Related Reactions
KEYTRUDA can cause severe or life-threatening infusion-related reactions, including hypersensitivity and anaphylaxis, which have been reported in 0.2% of 2799 patients receiving KEYTRUDA. Monitor for signs and symptoms of infusion-related reactions. Interrupt or slow the rate of infusion for Grade 1 or Grade 2 reactions. For Grade 3 or Grade 4 reactions, stop infusion and permanently discontinue KEYTRUDA.
Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after anti–PD-1/PD-L1 treatments. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute and chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between anti–PD-1/PD-L1 treatment and allogeneic HSCT. Follow patients closely for evidence of these complications and intervene promptly. Consider the benefit vs risks of using anti–PD-1/PD-L1 treatments prior to or after an allogeneic HSCT.
Increased Mortality in Patients With Multiple Myeloma
In trials in patients with multiple myeloma, the addition of KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of these patients with an anti–PD-1/PD-L1 treatment in this combination is not recommended outside of controlled trials.
Embryofetal Toxicity
Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. Advise women of this potential risk. In females of reproductive potential, verify pregnancy status prior to initiating KEYTRUDA and advise them to use effective contraception during treatment and for 4 months after the last dose.
Adverse Reactions
In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9% of 555 patients with advanced melanoma; adverse reactions leading to permanent discontinuation in more than one patient were colitis (1.4%), autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and cardiac failure (0.4%). The most common adverse reactions (≥20%) with KEYTRUDA were fatigue (28%), diarrhea (26%), rash (24%), and nausea (21%).
In KEYNOTE-054, when KEYTRUDA was administered as a single agent to patients with stage III melanoma, KEYTRUDA was permanently discontinued due to adverse reactions in 14% of 509 patients; the most common (≥1%) were pneumonitis (1.4%), colitis (1.2%), and diarrhea (1%). Serious adverse reactions occurred in 25% of patients receiving KEYTRUDA. The most common adverse reaction (≥20%) with KEYTRUDA was diarrhea (28%). In KEYNOTE-716, when KEYTRUDA was administered as a single agent to patients with stage IIB or IIC melanoma, adverse reactions occurring in patients with stage IIB or IIC melanoma were similar to those occurring in 1011 patients with stage III melanoma from KEYNOTE-054.
In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in 20% of 405 patients. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonitis (3%) and acute kidney injury (2%). The most common adverse reactions (≥20%) with KEYTRUDA were nausea (56%), fatigue (56%), constipation (35%), diarrhea (31%), decreased appetite (28%), rash (25%), vomiting (24%), cough (21%), dyspnea (21%), and pyrexia (20%).
In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and either paclitaxel or paclitaxel protein-bound in metastatic squamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in 15% of 101 patients. The most frequent serious adverse reactions reported in at least 2% of patients were febrile neutropenia, pneumonia, and urinary tract infection. Adverse reactions observed in KEYNOTE-407 were similar to those observed in KEYNOTE-189 with the exception that increased incidences of alopecia (47% vs 36%) and peripheral neuropathy (31% vs 25%) were observed in the KEYTRUDA and chemotherapy arm compared to the placebo and chemotherapy arm in KEYNOTE-407.
In KEYNOTE-042, KEYTRUDA was discontinued due to adverse reactions in 19% of 636 patients with advanced NSCLC; the most common were pneumonitis (3%), death due to unknown cause (1.6%), and pneumonia (1.4%). The most frequent serious adverse reactions reported in at least 2% of patients were pneumonia (7%), pneumonitis (3.9%), pulmonary embolism (2.4%), and pleural effusion (2.2%). The most common adverse reaction (≥20%) was fatigue (25%).
In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse reactions in 8% of 682 patients with metastatic NSCLC; the most common was pneumonitis (1.8%). The most common adverse reactions (≥20%) were decreased appetite (25%), fatigue (25%), dyspnea (23%), and nausea (20%).
In KEYNOTE-048, KEYTRUDA monotherapy was discontinued due to adverse events in 12% of 300 patients with HNSCC; the most common adverse reactions leading to permanent discontinuation were sepsis (1.7%) and pneumonia (1.3%). The most common adverse reactions (≥20%) were fatigue (33%), constipation (20%), and rash (20%).
In KEYNOTE-048, when KEYTRUDA was administered in combination with platinum (cisplatin or carboplatin) and FU chemotherapy, KEYTRUDA was discontinued due to adverse reactions in 16% of 276 patients with HNSCC. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonia (2.5%), pneumonitis (1.8%), and septic shock (1.4%). The most common adverse reactions (≥20%) were nausea (51%), fatigue (49%), constipation (37%), vomiting (32%), mucosal inflammation (31%), diarrhea (29%), decreased appetite (29%), stomatitis (26%), and cough (22%).
In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in 17% of 192 patients with HNSCC. Serious adverse reactions occurred in 45% of patients. The most frequent serious adverse reactions reported in at least 2% of patients were pneumonia, dyspnea, confusional state, vomiting, pleural effusion, and respiratory failure. The most common adverse reactions (≥20%) were fatigue, decreased appetite, and dyspnea. Adverse reactions occurring in patients with HNSCC were generally similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy, with the exception of increased incidences of facial edema and new or worsening hypothyroidism.
In KEYNOTE-204, KEYTRUDA was discontinued due to adverse reactions in 14% of 148 patients with cHL. Serious adverse reactions occurred in 30% of patients receiving KEYTRUDA; those ≥1% were pneumonitis, pneumonia, pyrexia, myocarditis, acute kidney injury, febrile neutropenia, and sepsis. Three patients died from causes other than disease progression: 2 from complications after allogeneic HSCT and 1 from unknown cause. The most common adverse reactions (≥20%) were upper respiratory tract infection (41%), musculoskeletal pain (32%), diarrhea (22%), and pyrexia, fatigue, rash, and cough (20% each).
In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5% of 210 patients with cHL. Serious adverse reactions occurred in 16% of patients; those ≥1% were pneumonia, pneumonitis, pyrexia, dyspnea, GVHD, and herpes zoster. Two patients died from causes other than disease progression: 1 from GVHD after subsequent allogeneic HSCT and 1 from septic shock. The most common adverse reactions (≥20%) were fatigue (26%), pyrexia (24%), cough (24%), musculoskeletal pain (21%), diarrhea (20%), and rash (20%).
In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8% of 53 patients with PMBCL. Serious adverse reactions occurred in 26% of patients and included arrhythmia (4%), cardiac tamponade (2%), myocardial infarction (2%), pericardial effusion (2%), and pericarditis (2%). Six (11%) patients died within 30 days of start of treatment. The most common adverse reactions (≥20%) were musculoskeletal pain (30%), upper respiratory tract infection and pyrexia (28% each), cough (26%), fatigue (23%), and dyspnea (21%).
In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in 11% of 370 patients with locally advanced or mUC. Serious adverse reactions occurred in 42% of patients; those ≥2% were urinary tract infection, hematuria, acute kidney injury, pneumonia, and urosepsis. The most common adverse reactions (≥20%) were fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%), constipation (21%), rash (21%), and diarrhea (20%).
In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8% of 266 patients with locally advanced or mUC. The most common adverse reaction resulting in permanent discontinuation of KEYTRUDA was pneumonitis (1.9%). Serious adverse reactions occurred in 39% of KEYTRUDA-treated patients; those ≥2% were urinary tract infection, pneumonia, anemia, and pneumonitis. The most common adverse reactions (≥20%) in patients who received KEYTRUDA were fatigue (38%), musculoskeletal pain (32%), pruritus (23%), decreased appetite (21%), nausea (21%), and rash (20%).
In KEYNOTE-057, KEYTRUDA was discontinued due to adverse reactions in 11% of 148 patients with high-risk NMIBC. The most common adverse reaction resulting in permanent discontinuation of KEYTRUDA was pneumonitis (1.4%). Serious adverse reactions occurred in 28% of patients; those ≥2% were pneumonia (3%), cardiac ischemia (2%), colitis (2%), pulmonary embolism (2%), sepsis (2%), and urinary tract infection (2%). The most common adverse reactions (≥20%) were fatigue (29%), diarrhea (24%), and rash (24%).
Adverse reactions occurring in patients with MSI-H or dMMR CRC were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy.
In KEYNOTE-811, when KEYTRUDA was administered in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, KEYTRUDA was discontinued due to adverse reactions in 6% of 217 patients with locally advanced unresectable or metastatic HER2+ gastric or GEJ adenocarcinoma. The most common adverse reaction resulting in permanent discontinuation was pneumonitis (1.4%). In the KEYTRUDA arm versus placebo, there was a difference of ≥5% incidence between patients treated with KEYTRUDA versus standard of care for diarrhea (53% vs 44%) and nausea (49% vs 44%).
The most common adverse reactions (reported in ≥20%) in patients receiving KEYTRUDA in combination with chemotherapy were fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, stomatitis, headache, weight loss, abdominal pain, arthralgia, myalgia, and insomnia.
In KEYNOTE-590, when KEYTRUDA was administered with cisplatin and fluorouracil to patients with metastatic or locally advanced esophageal or GEJ (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma who were not candidates for surgical resection or definitive chemoradiation, KEYTRUDA was discontinued due to adverse reactions in 15% of 370 patients. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA (≥1%) were pneumonitis (1.6%), acute kidney injury (1.1%), and pneumonia (1.1%). The most common adverse reactions (≥20%) with KEYTRUDA in combination with chemotherapy were nausea (67%), fatigue (57%), decreased appetite (44%), constipation (40%), diarrhea (36%), vomiting (34%), stomatitis (27%), and weight loss (24%).
Adverse reactions occurring in patients with esophageal cancer who received KEYTRUDA as a monotherapy were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy.
In KEYNOTE-826, when KEYTRUDA was administered in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab (n=307), to patients with persistent, recurrent, or first-line metastatic cervical cancer regardless of tumor PD-L1 expression who had not been treated with chemotherapy except when used concurrently as a radio-sensitizing agent, fatal adverse reactions occurred in 4.6% of patients, including 3 cases of hemorrhage, 2 cases each of sepsis and due to unknown causes, and 1 case each of acute myocardial infarction, autoimmune encephalitis, cardiac arrest, cerebrovascular accident, femur fracture with perioperative pulmonary embolus, intestinal perforation, and pelvic infection. Serious adverse reactions occurred in 50% of patients receiving KEYTRUDA in combination with chemotherapy with or without bevacizumab; those ≥3% were febrile neutropenia (6.8%), urinary tract infection (5.2%), anemia (4.6%), and acute kidney injury and sepsis (3.3% each).
KEYTRUDA was discontinued in 15% of patients due to adverse reactions. The most common adverse reaction resulting in permanent discontinuation (≥1%) was colitis (1%).
For patients treated with KEYTRUDA, chemotherapy, and bevacizumab (n=196), the most common adverse reactions (≥20%) were peripheral neuropathy (62%), alopecia (58%), anemia (55%), fatigue/asthenia (53%), nausea and neutropenia (41% each), diarrhea (39%), hypertension and thrombocytopenia (35% each), constipation and arthralgia (31% each), vomiting (30%), urinary tract infection (27%), rash (26%), leukopenia (24%), hypothyroidism (22%), and decreased appetite (21%).
For patients treated with KEYTRUDA in combination with chemotherapy with or without bevacizumab, the most common adverse reactions (≥20%) were peripheral neuropathy (58%), alopecia (56%), fatigue (47%), nausea (40%), diarrhea (36%), constipation (28%), arthralgia (27%), vomiting (26%), hypertension and urinary tract infection (24% each), and rash (22%).
In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8% of 98 patients with previously treated recurrent or metastatic cervical cancer. Serious adverse reactions occurred in 39% of patients receiving KEYTRUDA; the most frequent included anemia (7%), fistula, hemorrhage, and infections [except urinary tract infections] (4.1% each). The most common adverse reactions (≥20%) were fatigue (43%), musculoskeletal pain (27%), diarrhea (23%), pain and abdominal pain (22% each), and decreased appetite (21%).
Adverse reactions occurring in patients with HCC were generally similar to those in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy, with the exception of increased incidences of ascites (8% Grades 3-4) and immune-mediated hepatitis (2.9%). Laboratory abnormalities (Grades 3-4) that occurred at a higher incidence were elevated AST (20%), ALT (9%), and hyperbilirubinemia (10%).
Among the 50 patients with MCC enrolled in study KEYNOTE-017, adverse reactions occurring in patients with MCC were generally similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy. Laboratory abnormalities (Grades 3-4) that occurred at a higher incidence were elevated AST (11%) and hyperglycemia (19%).
In KEYNOTE-426, when KEYTRUDA was administered in combination with axitinib, fatal adverse reactions occurred in 3.3% of 429 patients. Serious adverse reactions occurred in 40% of patients, the most frequent (≥1%) were hepatotoxicity (7%), diarrhea (4.2%), acute kidney injury (2.3%), dehydration (1%), and pneumonitis (1%). Permanent discontinuation due to an adverse reaction occurred in 31% of patients; KEYTRUDA only (13%), axitinib only (13%), and the combination (8%); the most common were hepatotoxicity (13%), diarrhea/colitis (1.9%), acute kidney injury (1.6%), and cerebrovascular accident (1.2%). The most common adverse reactions (≥20%) were diarrhea (56%), fatigue/asthenia (52%), hypertension (48%), hepatotoxicity (39%), hypothyroidism (35%), decreased appetite (30%), palmar-plantar erythrodysesthesia (28%), nausea (28%), stomatitis/mucosal inflammation (27%), dysphonia (25%), rash (25%), cough (21%), and constipation (21%).
In KEYNOTE-564, when KEYTRUDA was administered as a single agent for the adjuvant treatment of renal cell carcinoma, serious adverse reactions occurred in 20% of patients receiving KEYTRUDA; the serious adverse reactions (≥1%) were acute kidney injury, adrenal insufficiency, pneumonia, colitis, and diabetic ketoacidosis (1% each). Fatal adverse reactions occurred in 0.2% including 1 case of pneumonia. Discontinuation of KEYTRUDA due to adverse reactions occurred in 21% of 488 patients; the most common (≥1%) were increased ALT (1.6%), colitis (1%), and adrenal insufficiency (1%). The most common adverse reactions (≥20%) were musculoskeletal pain (41%), fatigue (40%), rash (30%), diarrhea (27%), pruritus (23%), and hypothyroidism (21%).
Adverse reactions occurring in patients with MSI-H or dMMR endometrial carcinoma who received KEYTRUDA as a single agent were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a single agent.
Adverse reactions occurring in patients with TMB-H cancer were similar to those occurring in patients with other solid tumors who received KEYTRUDA as a single agent.
Adverse reactions occurring in patients with recurrent or metastatic cSCC or locally advanced cSCC were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy.
In KEYNOTE-522, when KEYTRUDA was administered with neoadjuvant chemotherapy (carboplatin and paclitaxel followed by doxorubicin or epirubicin and cyclophosphamide) followed by surgery and continued adjuvant treatment with KEYTRUDA as a single agent (n=778) to patients with newly diagnosed, previously untreated, high-risk early-stage TNBC, fatal adverse reactions occurred in 0.9% of patients, including 1 each of adrenal crisis, autoimmune encephalitis, hepatitis, pneumonia, pneumonitis, pulmonary embolism, and sepsis in association with multiple organ dysfunction syndrome and myocardial infarction. Serious adverse reactions occurred in 44% of patients receiving KEYTRUDA; those ≥2% were febrile neutropenia (15%), pyrexia (3.7%), anemia (2.6%), and neutropenia (2.2%). KEYTRUDA was discontinued in 20% of patients due to adverse reactions. The most common reactions (≥1%) resulting in permanent discontinuation were increased ALT (2.7%), increased AST (1.5%), and rash (1%). The most common adverse reactions (≥20%) in patients receiving KEYTRUDA were fatigue (70%), nausea (67%), alopecia (61%), rash (52%), constipation (42%), diarrhea and peripheral neuropathy (41% each), stomatitis (34%), vomiting (31%), headache (30%), arthralgia (29%), pyrexia (28%), cough (26%), abdominal pain (24%), decreased appetite (23%), insomnia (21%), and myalgia (20%).
In KEYNOTE-355, when KEYTRUDA and chemotherapy (paclitaxel, paclitaxel protein-bound, or gemcitabine and carboplatin) were administered to patients with locally recurrent unresectable or metastatic TNBC who had not been previously treated with chemotherapy in the metastatic setting (n=596), fatal adverse reactions occurred in 2.5% of patients, including cardio-respiratory arrest (0.7%) and septic shock (0.3%). Serious adverse reactions occurred in 30% of patients receiving KEYTRUDA in combination with chemotherapy; the serious reactions in ≥2% were pneumonia (2.9%), anemia (2.2%), and thrombocytopenia (2%). KEYTRUDA was discontinued in 11% of patients due to adverse reactions. The most common reactions resulting in permanent discontinuation (≥1%) were increased ALT (2.2%), increased AST (1.5%), and pneumonitis (1.2%). The most common adverse reactions (≥20%) in patients receiving KEYTRUDA in combination with chemotherapy were fatigue (48%), nausea (44%), alopecia (34%), diarrhea and constipation (28% each), vomiting and rash (26% each), cough (23%), decreased appetite (21%), and headache (20%).
Lactation
Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 4 months after the final dose.
Pediatric Use
In KEYNOTE-051, 161 pediatric patients (62 pediatric patients aged 6 months to younger than 12 years and 99 pediatric patients aged 12 years to 17 years) were administered KEYTRUDA 2 mg/kg every 3 weeks. The median duration of exposure was 2.1 months (range: 1 day to 24 months).
Adverse reactions that occurred at a ≥10% higher rate in pediatric patients when compared to adults were pyrexia (33%), vomiting (30%), leukopenia (30%), upper respiratory tract infection (29%), neutropenia (26%), headache (25%), and Grade 3 anemia (17%).
Additional Indications for KEYTRUDA in the U.S.
Melanoma
KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.
KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB, IIC, or III melanoma following complete resection.
Non-Small Cell Lung Cancer
KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.
KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:
- stage III where patients are not candidates for surgical resection or definitive chemoradiation, or
- metastatic.
KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.
Head and Neck Squamous Cell Cancer
KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).
KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.
KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
Classical Hodgkin Lymphoma
KEYTRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
KEYTRUDA is indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.
Primary Mediastinal Large B-Cell Lymphoma
KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy.
KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.
Microsatellite Instability-High or Mismatch Repair Deficient Cancer
KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.
Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer
KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test.
Gastric Cancer
KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Esophageal Cancer
KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either:
- in combination with platinum- and fluoropyrimidine-based chemotherapy, or
- as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test.
Cervical Cancer
KEYTRUDA, in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.
KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.
Hepatocellular Carcinoma
KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Merkel Cell Carcinoma
KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Renal Cell Carcinoma
KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Endometrial Carcinoma
KEYTRUDA, as a single agent, is indicated for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
Tumor Mutational Burden-High Cancer
KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.
Cutaneous Squamous Cell Carcinoma
KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation.
Triple-Negative Breast Cancer
KEYTRUDA is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved test.
Please see Prescribing Information for KEYTRUDA (pembrolizumab) at http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf and Medication Guide for KEYTRUDA at http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_mg.pdf.
About Astellas
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.
About Seagen
Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company's marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.
Merck's focus on cancer
Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck, the potential to bring new hope to people with cancer drives our purpose, and supporting accessibility to our cancer medicines is our commitment. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates with the potential to improve the treatment of advanced cancers. For more information about our oncology clinical trials, visit www.merck.com/clinicaltrials.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
About the Astellas, Seagen and Merck Collaboration
Astellas and Seagen entered a clinical collaboration agreement with Merck to evaluate the combination of Astellas' and Seagen's PADCEV® (enfortumab vedotin-ejfv) and Merck's KEYTRUDA® (pembrolizumab) in patients with previously untreated metastatic urothelial cancer. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Astellas Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development), which is included in this press release, is not intended to constitute an advertisement or medical advice.
Seagen Forward-Looking Statements
Certain statements made in this press release are forward-looking, such as those, among others, relating to the therapeutic potential of PADCEV alone or in combination, including its possible efficacy, safety and therapeutic uses; plans to discuss Cohort K results with regulatory authorities; and clinical development plans, including planned and ongoing clinical trials. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the possibility that the data from the EV-103 trial may not be sufficient to support any regulatory approval; the risk of adverse events, including the potential for newly-emerging safety signals; adverse regulatory actions; delays, setbacks or failures in clinical development activities, the submission of regulatory applications and the regulatory review process for a variety of reasons, including the inherent difficulty and uncertainty of pharmaceutical product development; possible required modifications to clinical trials; the inability to provide information and institute safety mitigation measures as may be required by the FDA or other regulatory authorities from time to time; failure to properly conduct or manage clinical trials; and failure of clinical results to support continued development or regulatory approvals. More information about the risks and uncertainties faced by Seagen is contained under the caption "Risk Factors" included in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2021 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
1 C.J. Hoimes, J.E. Rosenberg et.al. EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. Annals of Oncology 2019; 30 (Supplement 5): v356–v402.
2 American Cancer Society. Cancer Facts & Figures. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf. Accessed September 10, 2022.
3 American Society of Clinical Oncology. Bladder Cancer: Introduction (9-20). https://www.cancer.net/cancer-types/bladder-cancer/introduction. Accessed September 10, 2022.
4 International Agency for Research on Cancer. Cancer Tomorrow: Bladder. http://gco.iarc.fr/tomorrow. Accessed September 10, 2022.
5 Challita-Eid P, Satpayev D, Yang P, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res 2016;76(10):3003-13.
6 PADCEV [package insert]. Northbrook, IL: Astellas Pharma US, Inc.
View original content to download multimedia:
SOURCE Astellas Pharma Inc.
|
https://www.wbay.com/prnewswire/2022/09/12/astellas-seagen-merck-announce-results-clinical-trial-investigating-padcev-enfortumab-vedotin-ejfv-with-keytruda-pembrolizumab-padcev-monotherapy-first-line-advanced-urothelial-cancer/
| 2022-09-12T13:29:08Z
|
https://www.wbay.com/prnewswire/2022/09/12/astellas-seagen-merck-announce-results-clinical-trial-investigating-padcev-enfortumab-vedotin-ejfv-with-keytruda-pembrolizumab-padcev-monotherapy-first-line-advanced-urothelial-cancer/
| false
|
STATEN ISLAND (PIX11) — A 33-year-old man died Sunday after getting into a fight with two men he tried to rob on Staten Island, authorities said.
The armed robber approached the two men, both 29, near Pacific Avenue and St. Albans Place in Eltingville at around 2 a.m. and threatened them with a gun and demanded money, police said. A fight ensued and the two younger men were able to restrain the thief during the struggle when he became unconscious, police said.
Officials found the 33-year-old man unconscious and unresponsive at the scene and he was transported to the hospital, where he died. The other two men suffered minor injuries and were treated at an area hospital.
Police said they recovered a fake gun at the scene. There have been no arrests and the investigation is ongoing.
The identity of the deceased has not yet been released.
Anyone with information in regard to the identity of this individual is asked to call the NYPD’s Crime Stoppers Hotline at 1-800-577-TIPS (8477) or, for Spanish, 1-888-57-PISTA (74782). The public can also submit their tips by logging onto the Crime Stoppers website at WWW.NYPDCRIMESTOPPERS.COM, or on Twitter @NYPDTips.
|
https://pix11.com/news/local-news/staten-island/armed-suspect-dies-trying-to-rob-2-men-on-staten-island-police-say/
| 2022-09-12T13:30:38Z
|
https://pix11.com/news/local-news/staten-island/armed-suspect-dies-trying-to-rob-2-men-on-staten-island-police-say/
| true
|
EL PASO, Texas (AP) — U.S. Customs and Border Protection has deactivated the agency’s Twitter account for the West Texas region after it retweeted posts criticizing President Joe Biden’s border policies and liked posts that made gay slurs against U.S. Transportation Secretary Pete Buttigieg.
CBP Commissioner Chris Magnus posted a tweet late Saturday saying the agency “has become aware of unauthorized and inappropriate content” that was posted on the @CBPWestTexas Twitter account.
The agency’s Office of Professional Responsibility will investigate, Magnus said.
“This must not happen again,” his statement said.
On Saturday, the account retweeted posts by Stephen Miller that criticized Biden’s immigration policies and claimed the government was ignoring violent crime. Miller was the architect of former President Donald Trump’s hard-line immigration policies.
“The tweets do not reflect the values of this administration and our work to rebuild a humane, orderly and secure immigration system,” Magnus said in a statement.
A human rights advocate and a former immigration attorney posted tweets Saturday noting the account had retweeted Miller’s criticisms and then looked back and found other posts the account had liked.
In October 2021, it was announced that 60 Border Patrol agents had committed misconduct by participating in a private Facebook group that mocked migrants and lawmakers. Customs and Border Protection’s Discipline Review Board recommended that 24 of the agents be fired, but only two were.
The existence of the Facebook page, which had about 9,500 members, was reported in July 2019.
|
https://www.kxxv.com/hometown/texas/border-patrol-halts-tweets-from-agencys-west-texas-region
| 2022-09-12T13:30:41Z
|
https://www.kxxv.com/hometown/texas/border-patrol-halts-tweets-from-agencys-west-texas-region
| false
|
CANADA STOCKS-TSX futures rise as commodity prices gain
Sept 7 (Reuters) - Futures for Canada's main stock index rose on Monday, led by gains in crude oil and bullion prices, despite concerns over a slowdown in the Canadian economy.
Futures on the S&P/TSX index SXFc1 were up 0.6% at 7:14 a.m. ET, a day after the index closed at its highest level since Aug. 29.
Oil prices LCOc1, CLc1 gained 1% as Iranian nuclear talks appeared to hit obstacles and an embargo on Russian oil shipments loomed, with tight supply struggling to meet still robust demand. O/R
Meanwhile, gold prices XAU= rose 0.7% as the dollar fell to an over two-week low, prompting investors to buy bullion, while markets eyed U.S. inflation data due later this week for further clues on Federal Reserve rate hikes. GOL.N
Fears of a tighter monetary policy across the globe to combat surging price pressures has rattled market sentiment recently.
Official data released last week showed Canada shed jobs for a third consecutive month in August, in a sign higher interest rates may be starting to cool the overheated economy, though economists said it was unlikely to force a central bank pause.
Canada's real problem is not job losses but the rush to retirement which leaves businesses scrambling, helping push wages sharply higher and threatening to further drag down the country's sagging productivity, economists say.
Investors will be closely watching July factory sales data due on Wednesday, followed by housing starts number on Sept. 15.
The Toronto Stock Exchange's S&P/TSX composite index .GSPTSE ended 1.9% higher at 19,773.34 on Friday.
Dow e-minis 1YMcv1 were up 57 points, or 0.18%, at 7:14 a.m. ET, while S&P 500 e-minis EScv1 were up 15.75 points, or 0.39%, and Nasdaq 100 e-minis NQcv1 were up 54 points, or 0.43%. .N
(Reporting by Aniruddha Ghosh in Bengaluru; Editing by Krishna Chandra Eluri)
((Aniruddha.Ghosh@thomsonreuters.com; 91 83 83 81 2416;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
https://www.nasdaq.com/articles/canada-stocks-tsx-futures-rise-as-commodity-prices-gain-0
| 2022-09-12T13:31:31Z
|
https://www.nasdaq.com/articles/canada-stocks-tsx-futures-rise-as-commodity-prices-gain-0
| true
|
DUBAI, United Arab Emirates (AP) — A Dubai court ruled on Monday that a British man suspected of masterminding a $1.7 billion tax scheme cannot be extradited to Denmark to face charges.
The decision in the high-profile case grants the hedge fund trader, Sanjay Shah, a victory against Danish authorities who sought him for his role in one of the country’s largest-ever fraud cases. Monday’s court ruling, which judges delivered without explanation, can be appealed by prosecutors within 30 days.
The elaborate tax scheme, which ran for three years beginning in 2012, allegedly involved foreign businesses pretending to own shares in Danish companies and claiming tax refunds for which they were not eligible.
“Of course we will try to get him (out) on bail now immediately,” Shah’s lawyer, Ali al-Zarooni, told The Associated Press from the Dubai courthouse.
Prosecutors in Copenhagen did not immediately respond to request for comment.
The 52-year-old financier has maintained his innocence in past interviews with journalists but never appeared in Denmark to answer accusations. Al-Zarooni had contested the extradition, arguing in past closed-door hearings that Denmark had “breached” the rules of international extradition treaties in unspecified ways. He declined to elaborate on Monday.
Shah’s lifestyle on Dubai’s luxurious palm-shaped island over the past few years had sparked outrage in Denmark. After Danish authorities signed an extradition agreement with the UAE, Dubai police arrested Shah in June. Shah is one of several suspects in the tax scheme sought by Danish authorities.
During his time in Dubai, the hedge fund manager ran a center for autistic children that shut down in 2020 as Denmark tried to extradite him. He also oversaw a British-based charity, Autism Rocks, which raised funds through concerts and performances.
His arrest comes as pressure grows on Dubai, the region’s financial hub, over its alleged weaknesses in combating illicit finance. The UAE, a federation of seven emirates, has long invited the wealthy, including disgraced public figures, to invest in the country without questioning where they made their money. Scrutiny of Dubai has intensified as the flashy city-state becomes a haven for Russian money amid Moscow’s war on Ukraine.
In recent months, however, the UAE has arrested several suspects wanted for major crimes, including two of the Gupta brothers from South Africa, accused of facilitating vast public corruption and draining state resources with former President Jacob Zuma. An Emirati official also recently became president of Interpol, the international police agency.
___
Associated Press writer Isabel DeBre in Dubai contributed to this report.
|
https://www.wjhl.com/news/international/ap-dubai-court-rejects-danish-extradition-request-for-financier/
| 2022-09-12T13:32:07Z
|
https://www.wjhl.com/news/international/ap-dubai-court-rejects-danish-extradition-request-for-financier/
| false
|
Teacher shortages are real, but not for the reason you heard
BIRMINGHAM, Ala. (AP) — Everywhere, it seems, back-to-school has been shadowed by worries of a teacher shortage.
The U.S. education secretary has called for investment to keep teachers from quitting. A teachers union leader has described it as a five-alarm emergency. News coverage has warned of a crisis in teaching.
In reality, there is little evidence to suggest teacher turnover has increased nationwide or educators are leaving in droves.
Certainly, many schools have struggled to find enough educators. But the challenges are related more to hiring, especially for non-teaching staff positions. Schools flush with federal pandemic relief money are creating new positions and struggling to fill them at a time of low unemployment and stiff competition for workers of all kinds.
Since well before the COVID-19 pandemic, schools have had difficulty recruiting enough teachers in some regions, particularly in parts of the South. Fields like special education and bilingual education also have been critically short on teachers nationwide.
For some districts, shortages have meant children have fewer or less qualified instructors.
In rural Alabama’s Black Belt, there were no certified math teachers last year in Bullock County’s public middle school.
“It really impacts the children because they’re not learning what they need to learn,” said Christopher Blair, the county’s former superintendent. “When you have these uncertified, emergency or inexperienced teachers, students are in classrooms where they’re not going to get the level of rigor and classroom experiences.”
While the nation lacks vacancy data in several states, national pain points are obvious.
For starters, the pandemic kicked off the largest drop in education employment ever. According to the Bureau of Labor Statistics, the number of people employed in public schools dropped from almost 8.1 million in March 2020 to 7.3 million in May. Employment has grown back to 7.7 million since then, but that still leaves schools short around 360,000 positions.
“We’re still trying to dig out of that hole,” said Chad Aldeman, policy director at the Edunomics Lab at Georgetown University.
It’s unknown how many of those positions lost were teaching jobs, or other staff members like bus drivers — support positions that schools are having an especially hard time filling. A RAND survey of school leaders this year found that around three-fourths of school leaders say they are trying to hire more substitutes, 58% are trying to hire more bus drivers and 43% are trying to hire more tutors.
Still, the problems are not as tied to teachers quitting as many have suggested.
Teacher surveys have indicated many considered leaving their jobs. They’re under pressure to keep kids safe from guns, catch them up academically and deal with pandemic challenges with mental health and behavior.
National Education Association union leader Becky Pringle tweeted in April: “The educator shortage is a five-alarm crisis.” But a Brown University study found turnover largely unchanged among states that had data.
Quit rates in education rose slightly this year, but that’s true for the nation as a whole, and teachers remain far more likely to stay in their job than a typical worker.
Hiring has been so difficult largely because of an increase in the number of open positions. Many schools indicated plans to use federal relief money to create new jobs, in some cases looking to hire even more people than they had pre-pandemic. Some neighboring schools are competing for fewer applicants, as enrollment in teacher prep programs colleges has declined.
The Upper Darby School District in Pennsylvania has around 70 positions it is trying to fill, especially bus drivers, lunch aides and substitute teachers. But it cannot find enough applicants. The district has warned families it may have to cancel school or switch to remote learning on days when it lacks subs.
“It’s become a financial competition from district to district to do that, and that’s unfortunate for children in communities who deserve the same opportunities everywhere in the state,” Superintendent Daniel McGarry said.
The number of unfilled vacancies has led some states and school systems to ease credential requirements, in order to expand the pool of applicants. U.S. Education Secretary Miguel Cardona told reporters last week that creative approaches are needed to bring in more teachers, such as retired educators, but schools must not lower standards.
Schools in the South are more likely to struggle with teacher vacancies. A federal survey found an average of 3.4 teaching vacancies per school as of this summer; that number was lowest in the West, with 2.7 vacancies on average, and highest in the South, with 4.2 vacancies.
In Birmingham, the school district is struggling to fill around 50 teaching spots, including 15 in special education, despite $10,000 signing bonuses for special ed teachers. Jenikka Oglesby, a human resources officer for the district, says the problem owes in part to low salaries in the South that don’t always offset a lower cost of living.
The school system in Moss Point, a small town near the Gulf Coast of Mississippi, has increased wages to entice more applicants. But other districts nearby have done the same. Some teachers realized they could make $30,000 more by working 30 minutes away in Mobile, Alabama.
“I personally lost some really good teachers to Mobile County Schools,” said Tenesha Batiste, human resources director for the Moss Point district. And she also lost some not-so-great teachers, she added — people who broke their contracts and quit three days before the school year started.
“It’s the job that makes all others possible, yet they get paid once a month, and they can go to Chick-fil-A in some places and make more money,” Batiste said.
A bright spot for Moss Point this year is four student teachers from the University of Southern Mississippi. They will spend the school year working with children as part of a residency program for aspiring educators. The state has invested almost $10 million of federal relief money into residency programs, with the hope the residents will stay and become teachers in their assigned districts.
Michelle Dallas, a teacher resident in a Moss Point first-grade classroom, recently switched from a career in mental health and is confident she is meant to be a teacher.
“That’s why I’m here,” she said, “to fulfill my calling.”
___
This story is part of an Associated Press collaboration with AL.com, The Christian Science Monitor, The Dallas Morning News, The Fresno Bee in California, The Hechinger Report, The Seattle Times and The Post and Courier in Charleston, South Carolina.
___
Associated Press writers Brooke Schultz in Harrisburg, Pa., Collin Binkley in Washington, D.C., and Carolyn Thompson in Buffalo, N.Y. contributed to this report. Lurye reported from New Orleans. Schultz is a corps member for the Associated Press/Report for America Statehouse News Initiative. Report for America is a nonprofit national service program that places journalists in local newsrooms to report on undercovered issues.
___
The Associated Press education team receives support from the Carnegie Corporation of New York. The AP is solely responsible for all content.
___
For more back-to-school coverage, visit: https://apnews.com/hub/back-to-school
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.kalb.com/2022/09/12/teacher-shortages-are-real-not-reason-you-heard/
| 2022-09-12T13:34:55Z
|
https://www.kalb.com/2022/09/12/teacher-shortages-are-real-not-reason-you-heard/
| false
|
Process Improvements Standardize Longstanding AAA Practices, and Revise Rules to Generate Further Efficiencies and Reflect Advances in Technology
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- The American Arbitration Association-International Centre for Dispute Resolution® (AAA-ICDR®) announces that significant amendments have been made to the AAA Commercial Arbitration Rules and Mediation Procedures.
The updates to the arbitration rules, effective September 1, 2022, focus on process improvements in key areas, including technology, speed, economy, security, and privacy. The amended rules are the result of a two-year initiative by an internal AAA working group, with contributions from the AAA's case management and administrative groups, party surveys, and arbitrators, as well as the AAA-ICDR Council's Law and Practice and LLC Committees.
"The goals of our commercial arbitration rules—to ensure parties achieve a resolution to their disputes through an orderly, economical, and expeditious process—are the same as when these rules were first drafted 72 years ago," said Robert Matlin, Esq., Senior Vice President of the AAA's Commercial and Construction Divisions. "Our amended rules address the technology advancements which can make the arbitration process more streamlined and cost-effective—and standardize them, to continue to ensure the integrity, security, and confidentiality of our procedures."
The 2022 amendments to the AAA Commercial Arbitration Rules and Mediation Procedures ("the Rules") involve:
- Consolidation—The AAA has instituted its first-ever commercial rule to consolidate existing arbitrations or the joinder of additional parties.
- Confidentiality—The reinforcement of the longstanding requirements in the AAA Code of Ethics for Arbitrators, by including a commitment by AAA Staff and arbitrators to the confidentiality of arbitration in the Commercial Arbitration Rules.
- Conduct of Parties & Their Representatives—The AAA's expectations of civility and professionalism of all participants in arbitrations have been specifically incorporated into the Rules.
- Providing Arbitrators with the Authority to Interpret Awards—The AAA has drawn on the recently adopted ICDR article allowing the arbitrator to explain the award on a party's motion.
- Importance of Cybersecurity, Privacy & Data Protection—Reflecting the importance the AAA places on the safety and security of user and case information, the Rules recommend that the parties and the arbitrator discuss data protection during the preliminary hearing.
To read a more detailed explanation of the 2022 amendments to the AAA Commercial Arbitration Rules and Mediation Procedures, click here.
The not-for-profit American Arbitration Association® (AAA) is the leading provider of alternative dispute resolution (ADR) services for parties in commercial disputes, having administered more than seven million ADR cases since its founding in 1926. With 29 offices in the United States, in addition to Singapore, the AAA provides organizations of all sizes in virtually every industry with ADR services and products. For more information, visit www.adr.org.
The International Centre for Dispute Resolution® (ICDR®) is the international division of the American Arbitration Association (AAA) and the largest international provider of dispute resolution services. Established in 1996, the ICDR serves parties from over 100 countries with multilingual staff experienced in international dispute resolution proceedings, and a roster of over 725 arbitrators and mediators. For more information, visit www.icdr.org.
View original content to download multimedia:
SOURCE American Arbitration Association-International Centre for Dispute Resolution
|
https://www.mysuncoast.com/prnewswire/2022/09/12/aaa-updates-commercial-arbitration-rules-amp-mediation-procedures-uphold-aaa-standards/
| 2022-09-12T13:34:58Z
|
https://www.mysuncoast.com/prnewswire/2022/09/12/aaa-updates-commercial-arbitration-rules-amp-mediation-procedures-uphold-aaa-standards/
| true
|
TEMPE, Ariz. and PRAGUE, Sept. 12, 2022 /PRNewswire/ -- NortonLifeLock (NASDAQ: NLOK), a global leader in Cyber Safety, today announced it has completed its previously announced acquisition of Avast.
"We believe that everyone deserves the freedom to live their digital lives to the fullest," said Vincent Pilette, CEO of NortonLifeLock and the Combined Company. "Half a billion users trust us to protect and empower their digital lives, and now that NortonLifeLock and Avast have come together, we plan to redefine and reimagine Cyber Safety for consumers and small businesses around the world."
On a provisional basis, shareholders holding 36.505% of the Avast shares elected the Majority Stock Option comprising 0.1937 new NortonLifeLock shares and $2.37 in cash per Avast share, with the remaining 63.495% due to receive the Majority Cash Option comprising 0.0302 new NortonLifeLock shares and $7.61 in cash per Avast share. On a provisional basis and prior to the calculation of the amount of GBP consideration due pursuant to the currency conversion facility, the aggregate consideration due pursuant to the Merger comprises 94,201,223 new NortonLifeLock Shares and cash consideration of approximately $5,970,761,620.
With the completion of the transaction, trading in Avast shares was suspended at 7:30 a.m. BST on September 12, 2022, and the Avast shares will be delisted from the London Stock Exchange effective as of September 13, 2022, at 8:00 a.m. BST.
The Combined Company will operate as NortonLifeLock Inc. and discuss its shared financials and metrics during the fiscal year 2023 second quarter earnings release call. As it starts merging its operations, the Combined Company will soon announce a new name that reflects the forward-thinking vision and scale of its comprehensive Cyber Safety platform and trust-based solutions for consumers around the world. It will also begin trading under a new stock ticker under the new company name on NASDAQ. Until that time, the Combined Company will operate as NortonLifeLock Inc. and continue trading on NASDAQ under its current "NLOK" ticker symbol.
Advisors
Evercore is serving as financial advisor to NortonLifeLock and Kirkland & Ellis LLP and Macfarlanes LLP are serving as its legal advisors. UBS and J.P. Morgan Cazenove are serving as financial advisors to Avast and White & Case LLP is serving as its legal advisor.
For more information, please visit investor.nortonlifelock.com/offer-for-avast.
About NortonLifeLock Inc.
NortonLifeLock Inc. (NASDAQ: NLOK) is a global leader in consumer Cyber Safety, protecting and empowering people to live their digital lives safely. We are the consumer's trusted ally in an increasingly complex and connected world. Learn more about how we're transforming Cyber Safety at www.nortonlifelock.com.
About Avast
Avast is a global leader in digital security and privacy products. Avast offers products under the Avast and AVG brands that help protect people from threats on the internet and the evolving IoT threat landscape. Its threat detection network is among the most advanced in the world, using machine learning and artificial intelligence technologies to detect and stop threats in real time. Avast digital security products for Mobile, PC or Mac are top-ranked and certified by VB100, AV-Comparatives, AV-Test, SE Labs and others. Avast is a member of Coalition Against Stalkerware, No More Ransom and Internet Watch Foundation. Visit: www.avast.com.
Forward-Looking Statements
This press release contains certain forward-looking statements. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as "anticipate", "target", "expect", "estimate", "intend", "plan", "goal", "believe", "aim", "will", "may", "would", "could" or "should" or other words of similar meaning or the negative thereof. Forward-looking statements include statements relating to the following: (i) future capital expenditures, expenses, revenues, economic performance, financial conditions, dividend policy, losses and future prospects of the combined group of NortonLifeLock and Avast (the "Combined Company"); (ii) business and management strategies and the expansion and growth of the operations of the Combined Company; (iii) the effects of government regulation on the business of the Combined Company; and (iv) the time frame and the expected benefits of the Merger to the Combined Company and its respective customers, stockholders and investors, including expected growth, earnings accretion and cost savings. There are many factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such factors include, but are not limited to, general business and economic conditions globally, industry trends, competition, changes in government and other regulation, changes in political and economic stability, disruptions in business operations due to reorganization activities, interest rate and currency fluctuations, the inability of the Combined Company to realize successfully any anticipated synergy benefits when the Merger is implemented, the inability of the Combined Company to integrate successfully NortonLifeLock's and Avast's operations when the Merger is implemented, fluctuations and volatility in NortonLifeLock's stock price, the ability of NortonLifeLock to successfully execute strategic plans, the ability of the Combined Company to maintain customer and partner relationships, the timing and market acceptance of new product releases and upgrades, matters arising out of the ongoing SEC investigation and the Combined Company incurring and/or experiencing unanticipated costs and/or delays or difficulties relating to the Merger when it is implemented. Additional information concerning these and other risk factors is contained in the Risk Factors sections of NortonLifeLock's most recent reports on Form 10-K and Form 10-Q, the contents of which are not incorporated by reference into, nor do they form part of, this press release.
These forward-looking statements are based on numerous assumptions regarding the present and future business strategies of such persons and the environment in which each will operate in the future. By their nature, these forward-looking statements involve known and unknown risks, as well as uncertainties because they relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking statements in this press release may cause the actual results, performance or achievements of any such person, or industry results and developments, to be materially different from any results, performance or achievements expressed or implied by such forward-looking statements. No assurance can be given that such expectations will prove to have been correct and persons reading this press release are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this press release. All subsequent oral or written forward-looking statements attributable to NortonLifeLock, Avast or any persons acting on their behalf are expressly qualified in their entirety by the cautionary statement above. NortonLifeLock does not assume any obligation to update the forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by applicable law, regulation or stock exchange rules.
Restricted Jurisdictions
Copies of this press release and any formal documentation relating to the Merger are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in, into or from any jurisdiction where local laws or regulations may result in a significant risk of legal or regulatory exposure if information concerning the Merger were made available in that jurisdiction, or if details regarding any election that may be made in connection with the Merger is or were extended or made available in that jurisdiction, or where to do so would result in a requirement to comply with any governmental or other consent or any registration, filing or other formality which NortonLifeLock or Avast regards as unduly onerous. Any persons receiving this press release, or any such documents (including custodians, nominees and trustees), must not mail or otherwise forward, distribute or send them in or into or from any such restricted jurisdiction.
No Offer or Solicitation
The information contained in this press release is for information purposes only and is not intended to and does not constitute, or form any part of, an offer to sell or the solicitation of an offer to subscribe for an invitation to subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the Merger or otherwise, nor shall there be any sale, issuance, subscription or transfer of securities in any jurisdiction in contravention of applicable law or regulation. In particular, this press release is not an offer of securities for sale in the United States. No offer of securities shall be made in the United States absent registration under the Securities Act of 1933, as amended, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements. Any securities issued as part of the Merger are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the Securities Act. The Merger will be made solely by means of the scheme document published by Avast, or (if applicable) pursuant to an offer document to be published by NortonLifeLock, which (as applicable) would contain the full terms and conditions of the Merger. Any decision in respect of, or other response to, the Merger, should be made only on the basis of the information contained in such document(s). If NortonLifeLock ultimately seeks to implement the Merger by way of a takeover offer, that offer will be made in compliance with applicable US laws and regulations.
No profit forecasts or estimates
No statement in this press release is intended as, or is to be construed as, a profit forecast or estimate for any period and no statement in this press release should be interpreted to mean that earnings or earnings per ordinary share, for NortonLifeLock or Avast, respectively for the current or future financial years would necessarily match or exceed the historical published earnings or earnings per ordinary share for NortonLifeLock or Avast, respectively.
Publication on website
A copy of this press release will be made available (subject to certain restrictions relating to persons resident in Restricted Jurisdictions) on NortonLifeLock's website (at https://investor.nortonlifelock.com/) by no later than 12 noon London time on the business day following the date of this press release. Neither the contents of this website nor the content of any other website accessible from hyperlinks on such website is incorporated into, or forms part of, this press release.
View original content to download multimedia:
SOURCE NortonLifeLock Inc.
|
https://www.kold.com/prnewswire/2022/09/12/nortonlifelock-completes-merger-with-avast/
| 2022-09-12T13:35:05Z
|
https://www.kold.com/prnewswire/2022/09/12/nortonlifelock-completes-merger-with-avast/
| true
|
The gathering of global leaders at MDA's annual conference will be presented both in-person in Dallas, TX, and virtually, March 19-22, 2023
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- The Muscular Dystrophy Association (MDA) today announced that registration is open for the 2023 MDA Clinical & Scientific Conference being held March 19-22, 2023. MDA is the largest worldwide convener of the neuromuscular disease community of renowned researchers, clinicians, academicians, advocates, and industry leaders both in person at the Hilton Anatole in Dallas, Texas and via live stream.
The 2023 MDA Clinical & Scientific Conference will explore the latest research advancements and clinical achievement in neuromuscular disease with concurrent clinical and scientific sessions on topics highlighting:
- Advances in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth (CMT), congenital muscular dystrophy (CMD), Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophy (LGMD), myotonic dystrophy (DM), myasthenia gravis (MG), Pompe disease, spinal muscular atrophy (SMA), and many others
- Practical considerations in delivering gene therapy
- Advances in ultra-rare neuromuscular disease
- Support for diverse clinical trial participation and clinical management
- Mechanisms in repeat-mediated diseases
- Technological advances for therapy development
- Big data - digital and computational tools (MOVR data hub)
- Clinical trial updates
"MDA's 2023 Conference brings together global leaders in our field for exciting presentations and announcements, exploring all aspects of pre-clinical, translational, and clinical research and care across neuromuscular disease to support the development of breakthrough treatments and stronger futures for our community," says Donald S. Wood, PhD, President & CEO, at MDA. "MDA has made a history of doing the impossible – creating the field of neuromuscular disease medicine, spearheading efforts to discover the first gene in a human disease without knowledge of that gene's protein product, and now opening the frontiers of genetic medicine with some of the first treatments for genetic diseases in the history of medicine. What is equally important is that we convene MDA's Care Center Network of neuromuscular disease specialists, connecting them to the latest clinical trials and FDA approved treatments. They are also developing new treatments and creating the pipeline of progress that is the hallmark of today's neuromuscular disease frontier."
"This year's conference will take a particular look at emerging technologies in genetic medicine. Since the discovery of how CRISPR technology can be applied to edit genes there has been a resurgence in interest in ways that this technology can be evolved and adapted to treat neuromuscular disease," said Sharon Hesterlee, PhD, Chief Research Officer at MDA. "In addition, new gene therapy viral vectors, non-viral gene therapy vectors and the next generation of exon-skipping drugs are all progressing rapidly. The conference will feature leading experts pioneering these new techniques."
Before the conference, MDA will once again host the annual gathering of the Neuromuscular Advocacy Collaborative (NMAC). This pre-conference meeting brings together leaders from multiple neuromuscular advocacy organizations with the goal of developing a shared public policy agenda that will improve the lives of the entire neuromuscular disease community.
The abstract submission portal is also open. Oral presentations will be selected from abstracts submitted on or before October 31, 2022. For those submitting an abstract only as a poster submission the deadline is December 31, 2022.
Early bird registration ends December 31, 2022. Virtual registration will open January 2, 2022.
Members of the neuromuscular disease community who are registered with MDA are welcome to participate in the virtual conference at no-cost or may register to attend in-person at the patient/caregiver rate until allotted spaces are filled.
All COVID-19 safety precautions will be taken and enforced at the conference.
For additional information and to register, click here.
Muscular Dystrophy Association (MDA) is the #1 voluntary health organization in the United States for people living with muscular dystrophy, ALS, and related neuromuscular diseases. For over 70 years, MDA has led the way in accelerating research, advancing care, and advocating for the support of our families. MDA's mission is to empower the people we serve to live longer, more independent lives. To learn more visit mda.org and follow MDA on Instagram, Facebook, Twitter, TikTok, YouTube, and LinkedIn.
View original content to download multimedia:
SOURCE Muscular Dystrophy Association
|
https://www.kold.com/prnewswire/2022/09/12/registration-now-open-2023-mda-clinical-amp-scientific-conference-showcase-cutting-edge-research-advancements-clinical-achievements-neuromuscular-disease/
| 2022-09-12T13:36:25Z
|
https://www.kold.com/prnewswire/2022/09/12/registration-now-open-2023-mda-clinical-amp-scientific-conference-showcase-cutting-edge-research-advancements-clinical-achievements-neuromuscular-disease/
| false
|
WOLVERHAMPTON, England (AP) — Former Spain striker Diego Costa joined Wolverhampton on a free transfer on Monday, securing a surprising return to English soccer for one of the most hot-headed and confrontational players in Premier League history.
Costa is well known in England from his spell at Chelsea from 2014-17, during which he won two Premier League titles, but hasn’t played since terminating his contract at Brazilian team Atlético Mineiro in January. In between, he played for Atlético Madrid.
Wolves turned to the 33-year-old Costa after Sasa Kalajdzic, who joined in the final week of the transfer window, damaged his anterior cruciate ligament on his debut against Southampton on Sept. 3.
Costa, who has signed a deal until the end of the season, said he will need “two to three weeks to get back in shape” but feels “physically and mentally ready for this new challenge.”
“What they can expect from me,” Costa said in a message to Wolves fans, “is dedication, willingness, discipline and goals which is what I will try to bring to the team to thank for all the support and all the trust.”
Costa collected 35 yellow cards and one red card during his time at Chelsea.
Wolves chairman Jeff Shi said Costa will bring “something unique to our dressing room and on the pitch.”
___
More AP soccer: https://apnews.com/hub/soccer and https://twitter.com/AP_Sports
|
https://www.seattletimes.com/sports/striker-diego-costa-back-in-premier-league-at-wolves/?utm_source=RSS&utm_medium=Referral&utm_campaign=RSS_all
| 2022-09-12T13:37:16Z
|
https://www.seattletimes.com/sports/striker-diego-costa-back-in-premier-league-at-wolves/?utm_source=RSS&utm_medium=Referral&utm_campaign=RSS_all
| true
|
ISTANBUL, Sept. 12, 2022 /PRNewswire/ -- D-MARKET Electronic Services & Trading (d/b/a "Hepsiburada") (NASDAQ: HEPS), a leading Turkish e-commerce platform, will report its unaudited financial results for the second quarter ending June 30, 2022 before the U.S. market opens on Wednesday, September 28, 2022.
Conference Call and Webcast Details
The Company's management will host an analyst and investor conference call and live webcast to discuss its financial results at 16.00 İstanbul / 14.00 London / 9.00 a.m. New York time on Wednesday, September 28, 2022.
Live webcast can be accessed via https://87399.themediaframe.eu/links/hepsiburada220928.html
A replay will be available on the Hepsiburada Investor Relations website https://investors.hepsiburada.com following the call.
The Company's results presentation will be available at the Hepsiburada Investor Relations website https://investors.hepsiburada.com on September 28, 2022.
About Hepsiburada
Hepsiburada is a leading e-commerce technology platform in Turkey, combining a globally proven e-commerce business model with a one-stop 'Super App' to cater to our customers' everyday needs and to help make people's daily lives better. Customers can access a broad range of products and services including same-day delivery of groceries and essentials, products from international merchants, airline tickets and payment services through our embedded digital wallet, Hepsipay. As at the end of March 2022, we had seamlessly connected 44.2 million members and 82.9 thousand Active Merchants.
Founded in Istanbul in 2000, Hepsiburada was built to lead the digitalization of commerce in Turkey. As a female-founded organization, we are committed to meaningful action to empower women. Through our 'Technology Empowerment for Women Entrepreneurs' programme, we have reached over 32 thousand female entrepreneurs across Turkey to date.
Logo - https://mma.prnewswire.com/media/1686926/Hepsiburada_Logo.jpg
View original content:
SOURCE Hepsiburada
|
https://www.mysuncoast.com/prnewswire/2022/09/12/hepsiburada-announce-second-quarter-2022-results-september-28-2022/
| 2022-09-12T13:39:07Z
|
https://www.mysuncoast.com/prnewswire/2022/09/12/hepsiburada-announce-second-quarter-2022-results-september-28-2022/
| true
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.